<SEC-DOCUMENT>0001299130-23-000048.txt : 20230504
<SEC-HEADER>0001299130-23-000048.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504164232
ACCESSION NUMBER:		0001299130-23-000048
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		23889542

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pacb-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:1a1845fe-2bc6-4ddb-97ba-df0aaca6d029,g:3aa17778-fe5e-42a5-997b-9f59380cc331,d:dd15d706814f4821992e3c53513cc1e0--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pacb="http://www.pacificbiosciences.com/20230331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pacb-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF8yLTEtMS0xLTQzMDA_cc1a71b4-1c91-4335-8a6b-2ebba91416c8">0001299130</ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF8zLTEtMS0xLTQzMDA_6b761957-9e5a-4695-a7f2-cb9e0131c9b5">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF80LTEtMS0xLTQzMDA_3089336f-e498-4c33-b32f-a0c37758825f">2023</ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF81LTEtMS0xLTQzMDA_fad77b81-6014-48a9-a35b-0b7e1be9ce77">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF82LTEtMS0xLTQzMDA_f3f739e1-9f95-4ed7-9397-8fab29606c3d">false</ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="pacb:StandardProductWarrantyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80NzEvZnJhZzoxYjExODhkZjg3OTA0ZGNjOGNjYTJkMDgyNGQwMmZhNS90ZXh0cmVnaW9uOjFiMTE4OGRmODc5MDRkY2M4Y2NhMmQwODI0ZDAyZmE1XzQzOTgwNDY1MTExNTQ_2118f037-a144-4792-997d-43129fe3012f">one-year</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zNzUvZnJhZzphZGY2YzNjNzBmZWI0MmY1OGNkOTExMDQzMzIxOGVlYS90ZXh0cmVnaW9uOmFkZjZjM2M3MGZlYjQyZjU4Y2Q5MTEwNDMzMjE4ZWVhXzQzOTgwNDY1MTE2NjI_b7454d8a-5d4a-47ab-8f62-a63b3fd10e1b">0.0229885</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pacb-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422efc39545048258818ad27173590cc_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib7391dc7425a48d1a68d124321e865b5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ice0a062bee2249a4af687c1d872b4327_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1cbb2936bb243b9a6592d611b169c16_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b86da148fb47efb77eed316c399b1d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf85b8a953e446a85fd97c4f01de732_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05213693bb1c4eca878f5cc5112eeacb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c21d7954bc458d83b1ff91758a8270_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecc5bfef65744e09f272a78bcd68905_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecfc3de7424c4826b3f1731873d7f206_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e0d15efe13435583148487cd4c04ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4390a867ed4ef08906ca95ade8cd55_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie48d42565d924ff9b4097dc043825527_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e7973ed88f4dc7822e42f6f9cada08_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida601350d8e2486398e6f3e38ab85829_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6cdbbe039cb4ef9af089ecc75fdb0cf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e5013b2dc1b488db91c4bba79e8f7aa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c88663c018943f9969c82d3e25f57bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bf4cc431b7947788851e8ff3c3c2b54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39fce68f15da4941b559323699f4cc33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e3eb7fc88e14f23ab89fd860977e2c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib71260de6ee845f5827e04115b08241b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9c204295fa84994bdf6767d1c0daee1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704c53f1332c4b5e8b25ccf4893f15dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97cb8a03d16a448db1f7d245caca0d25_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if308a61785ca47938bc76410bbcfc128_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf6c8b89b524ea6a297d1dcd7650325_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82e7c77b29bc4222a75d223c5aaf47c1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232d2d8db0364677a249ba5c3d03501b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4568e4d90a544e3fa9b601fb92c24e7f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170a5ddc0ff746bfba70414d856b57e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib74a70bcb48d4df6a79ecde68ca7040d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib90fd5a838bf4898b37389a8c2bf2e1c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1f31512b50453585d88478dd9e32d0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f53c3bcf98f4143b2d656d33b41f1c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774d705431d84bc8ad8c5a09742aa5c1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25920f50c4c04d77b9d0cd22fdc09393_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae391408ebf445da076c0866d88c4bd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9967229d5414a46b6899d104fa4fcba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e1e2078c914a13a68381f4308c93a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i181aa9f4b31640dc8b14b6f82d70f240_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idae08cb548c441d3a91eba1de5219bd2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i849871cbc3cc45449d92adfe970af3c2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3125acf4ad4057b79910330fc7d13f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ab613bda3d44499a905662ecf1e971_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ec8616bd37486dbff25977da4441f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291b4bea01ad41c8963da94469fbd98f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i619b5be971f6439098c7aeac4e276a0d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49aeaa24126c489988a6ac04f57a2a00_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee96d635765436ca616328acee64b12_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d490d8a9b4c43f9b0eb01ef5372cfe7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94319df9941e4d4c9b28b64317ee7277_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d93184ef1de4f57bce4ecfe8206889f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa53ec2a0144c8dab9bfffe76c775ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8af53f30ae4b7885dc2a7228d101d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4750e8e52de64b8ab4710c73414a1095_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54541305e5464edbb7c276c8782d6c2e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf211a0be2545bcb8bb2d83516598b9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if015623b8ea744f8818948cfc6f9cec7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b6553253ca455f8645230475b2cc61_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe2a17ef15ba4c0cbedffc645c45aab6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceb62135438a477dbd091a982c13e82b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55e15ba1dd7f452d855f284c62a7103b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e23dae7b884c2d8e323afdc2202ec1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab42dea2b5104f92933733e4ae8b828c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id826230d5e794444a1100227d2df4064_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f54406977384ecdbd22b1c966005bd1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i447b3166a1894e65ad053b4aca1c8396_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2809d3f2dac4155af95932f49d85131_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf35d3b973c84f74991c106cc5541b89_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b785e7e49a249b7975eb905979aa957_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if53a52cbc7e348799f5eb8078ff67bb2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i642d2faa764c497fb709bd8f7cf545ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f0aa7e818a540b4b3800563f1640bb5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c2165a552b2406aad1c18da3e5bcba1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f0c2ed914b74450b0a466f80963c39e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bed7d66a5a240dd880c5f2e196b2fb4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6cf974ed2ad44f0b3a0fa6beaa4d15a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ceb8bb0a3b41be9d4cc3b73a38fb83_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia15d8c644eec4080836b0b62648963ed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8fbcede4404a2e8b1019f78237b47e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36c2bb89833b4cfcb9dcbf700eebd5b0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7ed9bee28b4168b9214818a5a04afc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d5823f4ed048deabd8e0c7591c429c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16bd2f0eca824f1797f501f4e0391099_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3df88f6219dc43ce83dc501b125501a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea01b3eb40349d587b12f4dca39ef4e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ff3053e324549d69983b4ab416817c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3a16d74a89a48b188694cf52ea1bf6d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22b2f234d3f44dea2cb7006091d3cfa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8484a2b1bd284e689338fd42dc179878_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3026c43f5474b3aaf648b1b685a4b02_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd1b10964904b3baf45a616d35f8e4a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe51e70a3fcd4e399fbfdbb8e358e931_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6066f8de0b274e42940b04267565bdf7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4563e98c524b29afa46ed0121d04a2_I20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b06909acc8846a687b88fb4008d393a_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87dcdd78b25e4f46a8ae756042953485_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f01855a6084151a5dd9a070e4784b3_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a09135868a48e4afb9690de6dd439c_D20210216-20210216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i742c54bedefe423c93b513816a6c3979_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib40b2b69144d46d385bf12dbac4912ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i618edbbfddab4833a48509103c51d343_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98efc311e4834a52b95558f1635f4df5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f811a83540b4cdb8df5a2ca849b6ae0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3539bf245d854192abfe418d43a09772_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0172c443e454bb9826a003845a4aa13_D20230131-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:ShelfOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756aff43669a4bee98c53b5da2ad6ad6_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6620f4b62a6245299f332889d2275280_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i638e0be2cf05429d9d48a17c3ad3afc4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9475351ae4143b49d057e49d769bac5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb8601e7bab34e959227a80dc0653b82_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557fdaad292c4b3fb9316667a1bba49e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b211de82ab46bd9b8e7ecfb559c3d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b260485f44645a2bd579bb81411474c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7d26135b95464faa9c223629b18165_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0a53ada800e4aa28d98cf54fcb50068_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8c470b6b7746deb6ce4dee0f7e41f1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425ffb2f994b48168f939e71d5ba1ad5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3065503208462293114ba3cebc247b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6e067725af44f990c3a8d3a8d5c108_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4665a48d6d14296985783f51f19db3f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197db529bcc44b64992d8392908d33c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ceb564dadd349a3923864a97aebdd11_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978408a314554860834dc737c3b1419c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f9e8f8b14e405e9c92d12a3b2a9e3c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i801b0f6773b4475bb9dd53e570abb778_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a1b740447c43f8a9ab44e87fa30129_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04cac2e649ab434a97832d035f40bb55_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c86fb9249949768d1bdd6a89aac5c5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ec828e984b4ebc8d4bd50a11327be6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb8e95a9d8854d71946cebeffe0b0fb3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib607a9972ac84fbcba2120fd9f7e766b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1641ad7927bc43fd949abadef487d0a9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1a78f0fe194bdfb72bae3a006f6e4b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4c824aaa2f49fc9e518b8402729d62_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f27eacedc494a34b10e2794baf8cdf4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf52ec5feb514b609a102b910f6fa20e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da4fe9d8e6343d5a93b936c584e420e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978f0bc925a24496b995a232807ed9bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2efc93840c24155946c8e1c76fe58de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idd15d706814f4821992e3c53513cc1e0_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTg3_fab373b2-88a0-4869-926d-0cbeec4aa942">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTkw_0efd8486-e4e5-4a53-8f29-e7f75ab081c8">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN180MTE_e9d70852-afd5-49e9-9709-2568688a6497">March 31, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Or</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTkx_419e52dd-8392-45a6-87b6-d8625fcd9cbc">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTky_912074ca-4968-46e5-a106-92bd5628fb02">001-34899</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><img src="pacb-20230331_g1.jpg" alt="Logo 1.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:260px"/></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTg4_e8e57be2-f016-4afa-8db8-2635d36735fe">Pacific Biosciences of California, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18wLTAtMS0xLTQzMDA_1c94b511-6128-4703-b3dc-df578ee1107e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18wLTEtMS0xLTQzMDA_e86fabbd-b02e-46c1-ac93-a6654417e2ed">16-1590339</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18zLTAtMS0xLTQzMDAvdGV4dHJlZ2lvbjo5ODQ4YzE1ODcyZjc0ODJkOTQ2YTc2ZjdhY2FiYTM3M180_ea75ac88-2dd6-4005-b9f6-6ff03026fe92">1305 O&#8217;Brien Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18zLTAtMS0xLTQzMDAvdGV4dHJlZ2lvbjo5ODQ4YzE1ODcyZjc0ODJkOTQ2YTc2ZjdhY2FiYTM3M183_f0b4b031-4c2f-4038-b2de-869b75da22ac">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18zLTAtMS0xLTQzMDAvdGV4dHJlZ2lvbjo5ODQ4YzE1ODcyZjc0ODJkOTQ2YTc2ZjdhY2FiYTM3M18xMQ_25c5c760-d5f7-4c32-9089-588b30481992">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18zLTEtMS0xLTQzMDA_0206dec8-4df2-4458-aa4c-c54dcf1f2999">94025</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN184ODU_7c9ab157-67e9-4125-8ceb-aaa9e947502b">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN184ODk_b0b4a437-e24b-439a-b88a-dcf8ca4d6594">521-8000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:37.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OTlmOGYyOGFhMjY3NGI0NDhhYTI5OTUyN2U0MDAxMDgvdGFibGVyYW5nZTo5OWY4ZjI4YWEyNjc0YjQ0OGFhMjk5NTI3ZTQwMDEwOF8xLTAtMS0xLTQzMDA_4b776fb1-804c-459a-9df5-bc6371434a3a">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OTlmOGYyOGFhMjY3NGI0NDhhYTI5OTUyN2U0MDAxMDgvdGFibGVyYW5nZTo5OWY4ZjI4YWEyNjc0YjQ0OGFhMjk5NTI3ZTQwMDEwOF8xLTEtMS0xLTQzMDA_0664442b-f2f7-4496-80dc-8302e45e85aa">PACB</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OTlmOGYyOGFhMjY3NGI0NDhhYTI5OTUyN2U0MDAxMDgvdGFibGVyYW5nZTo5OWY4ZjI4YWEyNjc0YjQ0OGFhMjk5NTI3ZTQwMDEwOF8xLTItMS0xLTQzMDA_6ebdd1ef-8bbe-4cac-b803-ed0e15c2a880">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTkz_cc61d577-81c4-4914-b5ec-efce8762a2cd">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTk0_9f940ed3-d95b-4722-956d-ca4c030dc34d">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6MWE3ZjdmY2I4MzA2NDlmY2IxYzUwYjFkYmM4OWRiYTQvdGFibGVyYW5nZToxYTdmN2ZjYjgzMDY0OWZjYjFjNTBiMWRiYzg5ZGJhNF8wLTAtMS0xLTQzMDA_dcda34f1-16db-45a3-b182-64c5a90bff52">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6MWE3ZjdmY2I4MzA2NDlmY2IxYzUwYjFkYmM4OWRiYTQvdGFibGVyYW5nZToxYTdmN2ZjYjgzMDY0OWZjYjFjNTBiMWRiYzg5ZGJhNF8xLTMtMS0xLTQzMDA_b493bf97-58bc-4972-9bcf-1da463501c4d">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6MWE3ZjdmY2I4MzA2NDlmY2IxYzUwYjFkYmM4OWRiYTQvdGFibGVyYW5nZToxYTdmN2ZjYjgzMDY0OWZjYjFjNTBiMWRiYzg5ZGJhNF8yLTEtMS0xLTQzMDA_57a83cce-f111-4033-b55a-534241048377">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN180Mzk4MDQ2NTEzNzI2_9c83d0c7-5c69-4140-9a8b-13821d77bcbd">x</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of shares outstanding of the issuer&#8217;s common stock as of April&#160;30, 2023: <ix:nonFraction unitRef="shares" contextRef="i422efc39545048258818ad27173590cc_I20230430" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN181NDk3NTU4MTY1MjE_4c037a88-8324-4f8b-8fd3-9207aa09c358">249,891,404</ix:nonFraction>. </span></div><div style="margin-bottom:1pt;margin-top:2pt;text-indent:25.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PAGE No.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_13">Item 1. Financial Statements (unaudited):</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_16">March 31</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_16">, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_16">3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_16"> and December 31, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_16">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_16">3</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19">Condensed Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19">Loss</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19"> for the Three </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19">Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19">March 31</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19">, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19">3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19"> and 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_19">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_19">4</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_22">Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_22">March 31</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_22">, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_22">3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_22"> and 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_22">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_22">5</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_25">Three</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_25"> Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_25">March 31</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_25">, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_25">3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_25"> and 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_25">2</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_25">6</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_28">Notes to Condensed Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_28">7</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_64">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_64">20</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_82">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_82">26</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_85">Item 4. Controls and Procedures</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_85">26</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_88">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_91">Item 1. Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_91">27</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_94">Item 1A. Risk Factors </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_94">28</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_97">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_97">63</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_100">Item 3. Default Upon Senior Securities </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_100">63</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_103">Item 4. Mine Safety Disclosures </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_103">63</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_106">Item 5. Other Information</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_106">63</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_109">Item 6. Exhibits</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd15d706814f4821992e3c53513cc1e0_109">63</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="idd15d706814f4821992e3c53513cc1e0_13"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements </span></div><div id="idd15d706814f4821992e3c53513cc1e0_16"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span id="i71fd6429d51541aca85ce707635ba737_360"></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:68.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Current assets </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMy0xLTEtMS00MzAw_3b8dccff-1567-42ac-bfe8-dad8af547ada">353,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMy0zLTEtMS00MzAw_323016d3-bd80-441e-b2d9-4584a138bbd3">325,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNC0xLTEtMS00MzAw_260c57c6-e0ce-43f0-826b-dfe87890a73b">521,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNC0zLTEtMS00MzAw_6048e26f-54a8-42ee-95bb-0f419671077f">447,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNS0xLTEtMS00MzAw_da55dafe-0611-48fa-a96e-5ddb1f398682">29,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNS0zLTEtMS00MzAw_6c32e0ba-3921-4300-896d-9994f64b031c">18,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNi0xLTEtMS00MzAw_bdf80c8e-60d7-4bad-8317-e9fd57bb2d02">61,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNi0zLTEtMS00MzAw_43fe8338-730d-41c9-aa8d-186757183c21">50,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNy0xLTEtMS00MzAw_b6d7054a-1153-4f49-996f-dc01d4ee7820">14,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNy0zLTEtMS00MzAw_7ae56e80-411b-4b3a-9f1e-30310edabc17">10,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfOC0xLTEtMS00MzAw_52a00a2f-bfbc-4a23-bffb-e4d8bc7ba264">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfOC0zLTEtMS00MzAw_86f98538-8292-438f-a1ff-4fc2d728ecdc">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total current assets </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfOS0xLTEtMS00MzAw_3d6bb2d0-76d6-48d5-ad11-57803dfecff2">981,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfOS0zLTEtMS00MzAw_2317c2a2-3fd2-41ed-8a28-b16b74d10653">852,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property and equipment, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTAtMS0xLTEtNDMwMA_6c5919b0-6098-493b-afa3-bd7e01a70c35">40,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTAtMy0xLTEtNDMwMA_039ec4b5-8610-4940-a321-7be18a69e11a">41,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTEtMS0xLTEtNDMwMA_be9d1571-3eaf-4f78-82c2-4271cbd92333">38,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTEtMy0xLTEtNDMwMA_f6d0884d-e146-41df-a982-2c16f004384b">39,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTItMS0xLTEtNDMwMA_4c36bd9a-f960-409e-ac7d-b5847eff3150">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTItMy0xLTEtNDMwMA_a9d35f60-1a28-45a3-944a-bdc257c63429">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTMtMS0xLTEtNDMwMA_468b474b-2ea6-49c6-8604-a0858dfed9a9">410,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTMtMy0xLTEtNDMwMA_a2872eb8-e421-420f-b323-6c93e3abc16a">410,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTQtMS0xLTEtNDMwMA_ad0a87b0-a44b-4ca7-bea3-155872672eaf">409,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTQtMy0xLTEtNDMwMA_7ae94569-6510-4623-8139-297168192d73">409,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other long-term assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTUtMS0xLTEtNDMwMA_6022b752-7a20-4e4a-8ee3-bce79da9a680">13,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTUtMy0xLTEtNDMwMA_351cee04-6859-41df-b448-209d8e385d2b">10,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTYtMS0xLTEtNDMwMA_ede4d93c-31ce-4b89-93f8-e86fe5a70504">1,896,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTYtMy0xLTEtNDMwMA_80acc91e-0977-48f3-b412-5f8f377b9b45">1,767,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Liabilities and Stockholders&#8217; Equity </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts payable </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTktMS0xLTEtNDMwMA_6fafa35f-f2ee-4170-8d34-4906432ff0da">17,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTktMy0xLTEtNDMwMA_9df1df0e-bf97-449c-9fc9-4602c5d9b14b">12,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjAtMS0xLTEtNDMwMA_92b43d69-5df5-4548-938b-a73e9fd9b298">19,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjAtMy0xLTEtNDMwMA_a85ea509-8639-40fa-b65e-893bf341d119">32,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred revenue, current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjEtMS0xLTEtNDMwMA_33793ddd-7830-4d15-8ee4-5cbf410737f6">30,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjEtMy0xLTEtNDMwMA_4e5936c3-23b2-4ad9-83f0-e7877159f33e">30,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjItMS0xLTEtNDMwMA_2bc09d55-55d4-4eae-9ab4-6e25731184ee">9,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjItMy0xLTEtNDMwMA_d54d7179-3cb5-441f-8d7c-dd31fea9019a">8,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other liabilities, current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjMtMS0xLTEtNDMwMA_c55b4f9b-5a8d-4dc7-915c-b9f2fe680f37">4,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjMtMy0xLTEtNDMwMA_b0229c24-2696-4211-a89c-971a29e28b4a">7,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent consideration liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjQtMS0xLTEtMTE2OTU_5fa15ce3-a0dc-4673-b4f9-d902f74b544e">184,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjQtMy0xLTEtMTE2OTU_a1044e90-7531-4791-92c7-8d138b7814d4">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total current liabilities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjQtMS0xLTEtNDMwMA_11f1e576-46d7-4fde-a267-0f9587b5845f">265,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjQtMy0xLTEtNDMwMA_ab8e3b27-a4be-45a9-88c6-8c5b1683aaa6">263,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred revenue, non-current </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjUtMS0xLTEtNDMwMA_6360faef-79e0-4ecf-8219-178ae4c9cbc0">1,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjUtMy0xLTEtNDMwMA_c59cd294-9e2a-457e-95bd-2f3e0e04d25a">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjctMS0xLTEtNDMwMA_f6616148-ce03-4a7c-ad96-310bb31f5a66">38,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjctMy0xLTEtNDMwMA_51836437-530e-4e80-ae35-b7ca51cee92c">41,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Convertible senior notes, net, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjgtMS0xLTEtNDMwMA_f3dd3991-4bf5-46d3-ada4-fff96eb03e45">896,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjgtMy0xLTEtNDMwMA_8b3c45a2-db7e-4551-9651-38dd413e10a4">896,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other liabilities, non-current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjktMS0xLTEtNDMwMA_3b5c16ca-e745-4e71-bd3b-57ad9b1f6cea">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjktMy0xLTEtNDMwMA_74322a3c-b668-4d3c-9af0-470867ebecd1">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total liabilities </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzAtMS0xLTEtNDMwMA_a1800873-209a-49fd-91f3-80dc0ebe1dc1">1,204,300</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzAtMy0xLTEtNDMwMA_8a11ae89-85fd-4013-b370-2f85ac43edee">1,204,182</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzItMS0xLTEtNDMwMA_36a5011c-8a8c-4dd1-90e4-b2abbeeb6181"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzItMy0xLTEtNDMwMA_2d4f3d7b-1a50-432e-9902-4385b9c88bd2"></ix:nonFraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzUtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjZhNmRiMGMxZDIxNTQwOGM4ODMzZmU0NTkzNGYzN2Q4XzIx_82cde825-87dc-45de-9336-bba9aea096bf"><ix:nonFraction unitRef="usdPerShare" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzUtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjZhNmRiMGMxZDIxNTQwOGM4ODMzZmU0NTkzNGYzN2Q4XzIx_ea5af7e0-16e8-456a-8e8d-77e39ea70ad9">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzE1_43caa508-c568-48a0-b862-3c4e30543f67"><ix:nonFraction unitRef="shares" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzE1_e8326259-d75c-4915-8815-f882ae85f3d8">50,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzI2_22967be3-ea50-4b7c-8874-d5a968f67263"><ix:nonFraction unitRef="shares" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzI2_ca00ae88-fcdc-4066-a6b4-043f40015619"><ix:nonFraction unitRef="shares" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzI2_e2b6b06f-de30-43be-9208-04748431c64c"><ix:nonFraction unitRef="shares" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzI2_ee17f3f1-fa5a-45d6-a137-0d8c3ba5df32">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMS0xLTEtNDMwMA_10a19777-d5f2-4370-a7b6-14ea649a910c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMy0xLTEtNDMwMA_be09306a-d0ed-4640-b545-730a82801352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzctMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmM1NjNlNDg5YTk2NDQ3NzhhMzE4ODlhMzRjNGM5YWY5XzE4_703766d5-bf18-4620-8c82-e4d9b074a09a"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzctMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmM1NjNlNDg5YTk2NDQ3NzhhMzE4ODlhMzRjNGM5YWY5XzE4_fe658025-6653-4072-81a0-e3abf4bf5ce9">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzE1_24cec4f5-1c8b-44b4-8210-bbd49921e83d"><ix:nonFraction unitRef="shares" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzE1_9afdc7fb-7313-4a54-ac9b-f8364584c71f">1,000,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzQ5_83235359-c8fb-4249-93fa-67ecd0d0db71"><ix:nonFraction unitRef="shares" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzQ5_8bc94636-474b-43c0-9249-8cdeef38da3b">249,803</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzU2_4ceb4e11-173e-4529-bbe4-df55f281110e"><ix:nonFraction unitRef="shares" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzU2_acfef713-e347-42cc-8b92-7267c0e042c3">226,505</ix:nonFraction></ix:nonFraction> shares at March&#160;31, 2023 and December&#160;31, 2022, respectively </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMS0xLTEtNDMwMA_fbaf0a74-e211-40a9-83d1-9eb706b672e8">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMy0xLTEtNDMwMA_cc619268-2722-44fd-b57d-0cfc5ae4941a">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Additional paid-in capital </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzktMS0xLTEtNDMwMA_6e74a93b-2021-4f7d-806c-512e08d1eea3">2,314,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzktMy0xLTEtNDMwMA_54509824-6191-4c76-984d-2cb8d63e71f7">2,099,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDAtMS0xLTEtNDMwMA_1c5273de-2027-42c7-a31e-e9168b54ed1f">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDAtMy0xLTEtNDMwMA_4677c20b-04dc-4069-9213-15a2170917ce">4,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accumulated deficit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDEtMS0xLTEtNDMwMA_cfc34bc8-aaa2-4b1f-b49b-b5fd7d07290a">1,620,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDEtMy0xLTEtNDMwMA_df230a6f-de97-4de0-bd7d-fb22cd8bfa64">1,532,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDItMS0xLTEtNDMwMA_794136c9-ce67-4753-b413-bd8680052956">692,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDItMy0xLTEtNDMwMA_923ee174-9652-4f7b-acfd-5b8951374200">562,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDMtMS0xLTEtNDMwMA_02871ece-620a-48d2-a65e-d87699f25aa9">1,896,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDMtMy0xLTEtNDMwMA_2950a0c7-0e82-4026-aa26-3dc1570f8a7a">1,767,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.446%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0a062bee2249a4af687c1d872b4327_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMy0xLTEtMS00MzAw_ddb8c995-460d-4bf8-bd11-c7f37b551975">34,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib1cbb2936bb243b9a6592d611b169c16_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMy0zLTEtMS00MzAw_372c70ab-74aa-416f-a374-ce015dab1cff">28,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b86da148fb47efb77eed316c399b1d_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNC0xLTEtMS00MzAw_2b82682a-d88d-4df7-b50a-3fc2a60d93de">4,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5cf85b8a953e446a85fd97c4f01de732_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNC0zLTEtMS00MzAw_22a88a47-f645-4b80-a5f1-7513b63241d1">4,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNS0xLTEtMS00MzAw_fd864fa8-d196-4c14-b888-eb7cadd3284c">38,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNS0zLTEtMS00MzAw_afb79b86-8d47-4abd-bb78-b2c8ec6e5c8c">33,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0a062bee2249a4af687c1d872b4327_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNy0xLTEtMS00MzAw_df32780d-bd14-41de-af61-06c4d95ab63d">25,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib1cbb2936bb243b9a6592d611b169c16_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNy0zLTEtMS00MzAw_9730fa64-c838-4e7f-ac16-e1c8576034c2">14,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b86da148fb47efb77eed316c399b1d_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfOC0xLTEtMS00MzAw_077bc0b5-1acf-4eed-bbca-37a1089705a7">3,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5cf85b8a953e446a85fd97c4f01de732_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfOC0zLTEtMS00MzAw_9bcc9939-39f7-4281-a601-09ea87eea5ec">4,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfOS0xLTEtMS00MzAw_a0646517-1c53-4972-89e0-b48a2b189e2a">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfOS0zLTEtMS00MzAw_589eb5f8-86be-40a8-a6aa-2f02dbf10a7f">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of revenue </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTAtMS0xLTEtNDMwMA_909a52e8-46c3-4b6f-adc1-06be01b2c47e">29,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTAtMy0xLTEtNDMwMA_520d036d-7eaf-42f4-a696-a766fd74b399">19,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTEtMS0xLTEtNDMwMA_4de561a5-d5c4-4d3d-b5e7-54927bbae443">9,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTEtMy0xLTEtNDMwMA_29802217-cb9a-4f46-83c8-1d3bf153a4f3">14,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTMtMS0xLTEtNDMwMA_e1e05540-9101-4442-b2f0-a6893b6936f5">48,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTMtMy0xLTEtNDMwMA_075f03cc-548f-4f07-9d14-4c29f67b4b6d">52,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTQtMS0xLTEtNDMwMA_3e893984-87e1-4af3-b4c0-f483e5ab7181">39,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTQtMy0xLTEtNDMwMA_77f8c815-a420-4a3c-b097-144d36c35ee0">39,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTYtMS0xLTEtNDMwMA_4b075441-c5e8-4eeb-8c41-84a6450d1bf0">12,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTYtMy0xLTEtNDMwMA_47a6a3c1-464a-43b3-86d6-1ed7109cb5fd">1,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expense </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTctMS0xLTEtNDMwMA_32eb7687-4a31-46d4-8960-812611a351fb">101,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTctMy0xLTEtNDMwMA_1811ebdf-e6ca-4752-9446-47923c3d55fa">91,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTgtMS0xLTEtNDMwMA_3415dde4-eb50-45d5-8f97-e19bcb450275">91,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTgtMy0xLTEtNDMwMA_799fc533-c4bd-4a74-bc6b-40f229751056">77,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjAtMS0xLTEtNDMwMA_9952b8b2-3067-4a06-ada6-ebc58f988cf0">3,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjAtMy0xLTEtNDMwMA_e7bc6fae-48c5-4142-8202-e87a546854c6">3,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjEtMS0xLTEtNDMwMA_7baeb22d-54c2-4dfe-93bf-fb74f18c5ac1">6,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjEtMy0xLTEtNDMwMA_8cf3815f-c207-49de-901a-e2386f5e5e98">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before expense (benefit) from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjItMS0xLTEtNDMwMA_04099700-12f7-4f19-a346-3f2a3d0e8d60">88,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjItMy0xLTEtNDMwMA_57d256eb-73fe-43f8-bec5-c6d1ff3d62a6">81,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense (benefit) from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjMtMS0xLTEtNDMwMA_8f01c3e4-fa02-4a4b-a11f-1fc9462c7a01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjMtMy0xLTEtNDMwMA_f6a4c4eb-8bf9-4c12-9cd2-a1ac771e17c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjQtMS0xLTEtNDMwMA_06953f18-ec92-4d6e-9fff-367dbdb5d2d8">88,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjQtMy0xLTEtNDMwMA_05709cf7-9337-410e-966d-b996b7879470">81,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain (loss) on investments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjYtMS0xLTEtNDMwMA_4004ac07-507e-4acd-bbcc-fa550e5b05f8">2,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjYtMy0xLTEtNDMwMA_69b4c6a7-75ca-434f-8684-50b4c396b449">2,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjctMS0xLTEtNDMwMA_1eccc67c-9540-418e-bc3e-a6512874bb25">85,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjctMy0xLTEtNDMwMA_a123948b-69d5-4f65-b323-f1f1c10fee6b">84,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjktMS0xLTEtNDMwMA_6182ba1f-b114-4c02-9ac7-7b0a8c7fc2d7">0.36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjktMy0xLTEtNDMwMA_b1d8b20f-1913-4797-bef0-1229310d1c88">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzAtMS0xLTEtNDMwMA_84d3ea7e-70f7-4a34-860c-ff006ba06a62">0.36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzAtMy0xLTEtNDMwMA_a03a3768-bd2e-4a0b-9b0f-b0f20f697030">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in calculating net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzMtMS0xLTEtNDMwMA_7f21c096-30d3-438d-8665-03d3d4f55f1c">242,032</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzMtMy0xLTEtNDMwMA_7637772b-4b1e-4d7e-adee-c031f0980950">222,289</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzQtMS0xLTEtNDMwMA_035e87a1-145b-4b4c-a618-2445d7930e02">242,032</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzQtMy0xLTEtNDMwMA_5163c46f-7ec6-42c6-8659-7efa6e6a2f45">222,289</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.573%"></td><td style="width:0.1%"></td></tr><tr style="height:28pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive <br/>(Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">For the three months ended March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i05213693bb1c4eca878f5cc5112eeacb_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy0xLTEtMS00MzAw_e895f32e-9d4c-42b4-b583-c63f38895bfc">226,505</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i05213693bb1c4eca878f5cc5112eeacb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy0zLTEtMS00MzAw_ac156ba1-7536-404b-850d-8c867336c883">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i53c21d7954bc458d83b1ff91758a8270_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy01LTEtMS00MzAw_97b56c0d-5b13-44e5-98c4-c16a98893c7d">2,099,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="idecc5bfef65744e09f272a78bcd68905_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy03LTEtMS00MzAw_6f5155a0-e9c8-45c4-a4bf-1390cb4ed5a6">4,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iecfc3de7424c4826b3f1731873d7f206_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy05LTEtMS00MzAw_723ddc28-4678-491e-9f0b-211bf03b5e96">1,532,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy0xMS0xLTEtNDMwMA_45a06ddf-7d45-4871-b815-3d828bbff286">562,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1e0d15efe13435583148487cd4c04ed_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNC05LTEtMS00MzAw_5fe709e1-6886-4515-9276-a7bae8eecd78">88,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNC0xMS0xLTEtNDMwMA_fdf00655-1a0d-4af5-8fc8-55b79ba38c5a">88,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide4390a867ed4ef08906ca95ade8cd55_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNS03LTEtMS00MzAw_a4b8c12c-ebd0-4992-a385-7eb435719161">2,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNS0xMS0xLTEtNDMwMA_facc5415-ce32-43b5-b179-2f1f75ef78c7">2,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0xLTEtMS0xMDQ1OQ_f5f3b3b4-daac-4ffe-b095-29d65169951c">20,125</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0zLTEtMS0xMDQ1OQ_8b48ae98-090c-4726-b586-a61fc885ab95">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie48d42565d924ff9b4097dc043825527_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi01LTEtMS0xMDQ1OQ_0751db7e-0b09-4330-80af-0ab18e050fd6">189,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0xMS0xLTEtMTA0NTk_b13f5a40-533e-416a-a1dc-0b1797d89753">189,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0xLTEtMS00MzAw_d2307645-009f-40e5-87e4-93463f71c022">3,173</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0zLTEtMS00MzAw_5c7c119f-be65-4a70-a616-2c7b18a40474">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie48d42565d924ff9b4097dc043825527_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi01LTEtMS00MzAw_d60c02ac-7e55-4cb4-a93e-9aaf9be598f9">7,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0xMS0xLTEtNDMwMA_e7cf0f3c-693f-427d-8d77-1ab8cf323aaa">7,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie48d42565d924ff9b4097dc043825527_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNy01LTEtMS00MzAw_0bb81167-8b3a-4469-a12c-bbc493c9e73e">17,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNy0xMS0xLTEtNDMwMA_15dca762-8b79-4590-8a2e-ba36906955b4">17,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic2e7973ed88f4dc7822e42f6f9cada08_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC0xLTEtMS00MzAw_c91ae889-bcac-4130-b3fe-d16eabd7193d">249,803</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2e7973ed88f4dc7822e42f6f9cada08_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC0zLTEtMS00MzAw_73da4f07-62aa-4334-af7e-8340ec0661e5">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ida601350d8e2486398e6f3e38ab85829_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC01LTEtMS00MzAw_eb63e0ae-7a57-40a3-b0ff-636f6a0261c1">2,314,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie6cdbbe039cb4ef9af089ecc75fdb0cf_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC03LTEtMS00MzAw_d67cd4e7-8ade-433b-9779-23a05c50b8f7">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9e5013b2dc1b488db91c4bba79e8f7aa_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC05LTEtMS00MzAw_b18190d2-a6e2-48da-be4c-3074c0dfcad5">1,620,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC0xMS0xLTEtNDMwMA_8b5a2855-a925-4d24-86c4-93fe5b297462">692,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">For the three months ended March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0c88663c018943f9969c82d3e25f57bc_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtMS0xLTEtNDMwMA_a0cd8d89-4c35-417d-8996-6b7c61a52931">220,978</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c88663c018943f9969c82d3e25f57bc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtMy0xLTEtNDMwMA_be85f10a-4b84-4745-9b90-a09adad9bb65">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6bf4cc431b7947788851e8ff3c3c2b54_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtNS0xLTEtNDMwMA_e1508e73-51d0-491e-a7a8-29e4c7635868">2,009,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i39fce68f15da4941b559323699f4cc33_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtNy0xLTEtNDMwMA_211be74f-43ef-4545-9309-28baea8b2a41">1,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6e3eb7fc88e14f23ab89fd860977e2c5_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtOS0xLTEtNDMwMA_6124670d-1b03-465e-87e3-3faa34645605">1,218,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib71260de6ee845f5827e04115b08241b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtMTEtMS0xLTQzMDA_875ef941-072a-4d6a-b168-b2fa169c6362">790,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id9c204295fa84994bdf6767d1c0daee1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTItOS0xLTEtNDMwMA_08159ae4-7a27-493a-9f0e-3364aa2039d8">81,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTItMTEtMS0xLTQzMDA_789a306a-2f8e-43c9-91ae-156f2796b8d8">81,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i704c53f1332c4b5e8b25ccf4893f15dc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTMtNy0xLTEtNDMwMA_700f64c0-a023-4e3b-90b0-8a7f1dbf97c6">2,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTMtMTEtMS0xLTQzMDA_e6a01153-9e30-4ca5-bfb5-9e6ef063d96b">2,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i97cb8a03d16a448db1f7d245caca0d25_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTQtMS0xLTEtNDMwMA_c157fae7-5aa7-48fa-8864-988f164eee06">3,351</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i97cb8a03d16a448db1f7d245caca0d25_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTQtMy0xLTEtNDMwMA_f5d6ddbd-52bc-4c44-be52-22936024eabd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if308a61785ca47938bc76410bbcfc128_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTQtNS0xLTEtNDMwMA_f0c9d9e9-6427-4f14-ac93-93b7a87f3630">5,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTQtMTEtMS0xLTQzMDA_b0dca983-92c0-44c5-ae66-794d57f73f78">5,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if308a61785ca47938bc76410bbcfc128_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTctNS0xLTEtNDMwMA_bac86a4a-b32b-4e67-878f-6f0b8d7f550d">22,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTctMTEtMS0xLTQzMDA_6c5fd260-65e1-4337-bf40-205de7185c56">22,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iddf6c8b89b524ea6a297d1dcd7650325_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtMS0xLTEtNDMwMA_f55f0a97-675d-47aa-b244-58b8f00b71ad">224,329</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iddf6c8b89b524ea6a297d1dcd7650325_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtMy0xLTEtNDMwMA_af9a094b-6044-446e-82ab-a85a51c9a549">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i82e7c77b29bc4222a75d223c5aaf47c1_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtNS0xLTEtNDMwMA_4fb1ddca-ee30-4cbe-b0f1-f0091f15a6e1">2,038,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i232d2d8db0364677a249ba5c3d03501b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtNy0xLTEtNDMwMA_8e217a8b-fc61-400d-ad25-9854980048d7">4,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4568e4d90a544e3fa9b601fb92c24e7f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtOS0xLTEtNDMwMA_24306674-d429-41fc-9ac1-c95c3ee963fa">1,299,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtMTEtMS0xLTQzMDA_3e343713-cb46-44bd-9ebd-5c15e0fe9843">734,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMy0xLTEtMS00MzAw_4f381adb-d6a8-4830-915b-ac9a412692f4">88,015</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMy0zLTEtMS00MzAw_d7cbac56-3edd-42f1-ab22-0c50dcd6aa83">81,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNi0xLTEtMS00MzAw_1097e806-b30f-4f27-87ce-e2653b99bb2f">2,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNi0zLTEtMS00MzAw_02ed4f01-9397-4bdd-b388-4436a0ec9b6b">2,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNy0xLTEtMS00MzAw_b6734583-85e5-4592-9601-ea295b49b3b3">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNy0zLTEtMS00MzAw_ffab12a0-31bd-49d9-a7e7-6ba203b2433f">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfOC0xLTEtMS00MzAw_794b4980-c3d5-468f-afdb-f7c94418571c">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfOC0zLTEtMS00MzAw_b5381c35-37a1-4434-922b-4d15d0e1e1d8">1,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of debt discount and financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfOS0xLTEtMS00MzAw_cfbb7612-63dc-4139-935b-af36b1f0597e">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfOS0zLTEtMS00MzAw_f471f133-3124-46fd-89bf-d12c4b08fce3">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTAtMS0xLTEtNDMwMA_31f782d2-f3df-4ac1-8a7f-0ab9edd57c71">17,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTAtMy0xLTEtNDMwMA_a7a7b6fc-1e55-4185-b7c9-96c6b520fc2c">22,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accretion of discount and amortization of premium on marketable securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTEtMS0xLTEtNDMwMA_862d29ae-76e0-46bc-ac7d-22689319d707">2,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTEtMy0xLTEtNDMwMA_229551ac-a3cb-43fb-85fe-25165583e9f5">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in the estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTMtMS0xLTEtNDMwMA_b2e26d91-3d08-4339-9390-fe7e94425ec8">12,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTMtMy0xLTEtNDMwMA_ea02f361-b8f5-458b-b6bc-8259a956a5b6">1,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventory provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTItMS0xLTEtMTU3ODA_4d8d584a-ad3d-49a5-9e13-5535847ac2d6">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTItMy0xLTEtMTU3ODA_35667819-e2c5-40cf-b278-6cc4cee1ca00">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Loss on disposition of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTQtMS0xLTEtNDMwMA_9083e5e4-5543-4188-990b-fafd63f84f9f">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTQtMy0xLTEtNDMwMA_8408cd34-31e6-4cc1-8c16-1c9b46d5a308">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in assets and liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTYtMS0xLTEtNDMwMA_e8222ba8-4133-423c-ad63-06135b5e223a">10,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTYtMy0xLTEtNDMwMA_c51ce9bb-d466-450d-9e06-17a3276a573d">3,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventory, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTctMS0xLTEtNDMwMA_e22daf40-87da-4c6d-9ccd-c48782a3fb4b">13,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTctMy0xLTEtNDMwMA_6e42e907-8c14-497f-bf92-57498ea1c68f">6,661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTgtMS0xLTEtNDMwMA_927accd3-217c-4a43-a374-e6dac9166ed8">6,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTgtMy0xLTEtNDMwMA_5b987294-80f1-453a-8ce2-0b27ee2e3059">1,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTktMS0xLTEtNDMwMA_d2c461e7-6e9e-4f16-b509-3ae0bc45a1b8">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTktMy0xLTEtNDMwMA_eaf366af-e6c2-4428-836a-e5c4d6121016">6,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjAtMS0xLTEtNDMwMA_cd125785-b5bc-4354-b8a3-05511c300906">13,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjAtMy0xLTEtNDMwMA_2e494476-f731-4622-8c9e-864b34e31f65">17,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjEtMS0xLTEtNDMwMA_6ba867c4-aa5b-4117-a4e3-550e856f01b9">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjEtMy0xLTEtNDMwMA_9a3da53c-08d7-450a-b213-aa23e13f469b">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjItMS0xLTEtNDMwMA_56151c3c-de61-4243-bc5b-9d758cc7e35c">1,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjItMy0xLTEtNDMwMA_cc6009ea-a138-48ec-add1-9b27e0b2c134">1,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjMtMS0xLTEtNDMwMA_9dacf042-75a3-4b4e-8966-91863b2f8a32">2,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjMtMy0xLTEtNDMwMA_1da7a06b-0940-4d36-96b9-75db1ba4ba6d">2,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in operating activities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjQtMS0xLTEtNDMwMA_f756a93b-4303-4a79-9695-d032c76427db">94,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjQtMy0xLTEtNDMwMA_a385a387-17a2-49b4-af2a-fd19e42dacd7">79,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of property and equipment </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjYtMS0xLTEtNDMwMA_3d071a97-e570-44bd-8a9b-3ccce9c2ae25">3,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjYtMy0xLTEtNDMwMA_05fee4f2-8662-4e92-b9b2-a833395f19c5">3,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of investments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjktMS0xLTEtNDMwMA_c464c446-0dd9-4b67-bb1f-aeb26fad06c7">233,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjktMy0xLTEtNDMwMA_335df0d7-df91-46c2-9ea9-62f4265110c9">76,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales of investments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzAtMS0xLTEtNDMwMA_32752973-075f-4715-803a-4f9857d6f18c">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzAtMy0xLTEtNDMwMA_348c169f-03e0-4123-b425-9394109373a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Maturities of investments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzEtMS0xLTEtNDMwMA_accf3ea0-3f4a-4b55-8d7f-e8549581e062">163,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzEtMy0xLTEtNDMwMA_a47c5af9-8aad-4381-bdfb-e7a8e8fbc458">122,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzItMS0xLTEtNDMwMA_2331fc5a-b2e5-41fa-bf38-2da3cf7bc493">72,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzItMy0xLTEtNDMwMA_bfa81e12-8ccd-4248-8329-fec61846ad55">42,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock under equity offerings, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzYtMS0xLTEtNDMwMA_9489bdf7-84fe-4ab9-be75-53134bea21db">189,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzYtMy0xLTEtNDMwMA_c6a14c2b-f4d3-4f53-9e77-f3ef5e616eac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock from equity plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzctMS0xLTEtNDMwMA_d00ac8eb-9857-473a-9911-dd50261765dd">7,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzctMy0xLTEtNDMwMA_82a27098-7fe2-4328-aab0-fcdcad9b2903">5,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes payable principal payoff</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzgtMS0xLTEtNDMwMA_7e48cb49-61ba-4636-9e05-5440d3a17e33">446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzgtMy0xLTEtNDMwMA_279ad2a3-f773-4d22-b501-2e942577044a">377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDAtMS0xLTEtNDMwMA_311418f8-af87-4b58-9f4e-b40abb9665be">195,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDAtMy0xLTEtNDMwMA_a40381e5-b8b7-4aac-904a-fc6d7143d99d">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDEtMS0xLTEtNDMwMA_cb3ba9c4-24ad-41c8-bb07-a6bc93cf304a">28,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDEtMy0xLTEtNDMwMA_5ee28d40-5f44-4a3d-9340-4116dcca7e27">31,761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at beginning of period </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDItMS0xLTEtNDMwMA_1d6748d9-9403-49e2-8a6c-e678fd09e12d">328,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib71260de6ee845f5827e04115b08241b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDItMy0xLTEtNDMwMA_e8a651bb-e3a4-44f6-bcaa-ecd2f3232a0f">465,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDMtMS0xLTEtNDMwMA_4b35734d-9f69-4a65-9dee-3a2cfae9fa80">357,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDMtMy0xLTEtNDMwMA_c85909ba-2116-43bd-a56b-7d6837a65c24">434,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of period </span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDQtMS0xLTEtNDMwMA_c8ce9941-20b1-43a7-96e4-ee4bcabd7059">353,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDQtMy0xLTEtNDMwMA_708ac36c-41b0-42ba-8535-5bdb08c8ce7e">428,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash at end of period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDUtMS0xLTEtNDMwMA_7a79132a-b043-44e5-8fe1-2d68513c04f1">3,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDUtMy0xLTEtNDMwMA_af882460-122d-41a1-8779-c1156dea9e50">5,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDYtMS0xLTEtNDMwMA_7a1ab5f4-9e09-4037-baf9-e3b12bbb7a38">357,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDYtMy0xLTEtNDMwMA_d262a2f1-0064-4c8c-b71d-4a89ed4cf202">434,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="idd15d706814f4821992e3c53513cc1e0_31"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU4MA_a7f3991a-2e5d-4576-a245-c60f64883721" continuedAt="i670444a3df6b4f40a44baf2f04100608" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i670444a3df6b4f40a44baf2f04100608" continuedAt="i21ce5c6f44e54ecdbbf0ddce495e7a05"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our existing HiFi long-read sequencing technology and our emerging short-read Sequencing by Binding (SBB</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) technology. Our products address solutions across a broad set of applications including human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU4Mg_9c4bd387-ae80-4120-9991-e9b4484b0185" escape="true">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2022 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to current period presentation.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU3OQ_06cfa062-bc03-444f-9ae5-1e7e6abe8701" escape="true">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2023. Actual results could differ materially from these estimates.</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Investments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU4Mw_cd36157f-d442-4d4e-98ab-ca40af09d79d" escape="true">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="i21ce5c6f44e54ecdbbf0ddce495e7a05"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNDM5ODA0NjU0NDc5NA_000cae07-1beb-4f58-9639-2de2148bbe52" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNDM5ODA0NjU0NDc5Mw_8fe94546-7b32-424c-b201-b7903899bd82" escape="true">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration and Other Risks </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, no customer represented 10% or greater of our total revenue during the period. For the three months ended March&#160;31, 2022, two customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="ib74a70bcb48d4df6a79ecde68ca7040d_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNTgwMw_27e7e558-1408-4728-b517-6f1ea2ef4e5a">14</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib90fd5a838bf4898b37389a8c2bf2e1c_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfODI0NjMzNzI0MzIxMA_68c65357-6fae-41bd-bfb3-86c430ebe7fc">11</ix:nonFraction>%, respectively, of total revenue during the period. No other customers exceeded 10% during those periods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, <ix:nonFraction unitRef="number" contextRef="idd1f31512b50453585d88478dd9e32d0_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNTkxNQ_04696958-8867-44bc-9616-4dcd1f0fe4d1">49</ix:nonFraction>% of our accounts receivable were from domestic customers, compared to <ix:nonFraction unitRef="number" contextRef="i3f53c3bcf98f4143b2d656d33b41f1c4_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNTk4Nw_aedb9f39-32cb-4875-bb1c-364c70a6c98b">57</ix:nonFraction>% as of December&#160;31, 2022. As of March&#160;31, 2023, no customer represented 10% or greater of our accounts receivable, while one customer represented approximately <ix:nonFraction unitRef="number" contextRef="i774d705431d84bc8ad8c5a09742aa5c1_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfMTA5OTUxMTY0OTcxOA_b3850014-f4e5-45f1-9369-0c9af146bb6a">10</ix:nonFraction>% of our net accounts receivable as of December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU4NQ_b1d60dc1-321b-482f-bfad-5115e37e74ba" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div></ix:continuation><div id="idd15d706814f4821992e3c53513cc1e0_43"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNjU5NzA2OTc3Njk3OQ_5f8f9c58-5e06-415c-b6ff-f6ab1165b8fc" continuedAt="i39c9a28e9c8b421b871ed7fcecdd7ce9" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i39c9a28e9c8b421b871ed7fcecdd7ce9" continuedAt="if31548f24e994d25b4ec7eb761351b51"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="if31548f24e994d25b4ec7eb761351b51" continuedAt="i7807b89920e845e1be6bc603bec712e3"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTExOQ_2933d98e-f7a2-4e2f-9ab6-4580558b5570" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTEyMA_02a2d488-c965-4a51-9409-0d25c8dc8962" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0xLTEtMS00MzAw_0dda0c17-d01c-4af5-b388-620e78c0f298">103,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0zLTEtMS00MzAw_3fd84e3e-bfee-4061-9566-f5b2656d4dd2">250,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy01LTEtMS00MzAw_d7578961-ab0d-4d6b-b4c5-d4b68055c5e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy03LTEtMS00MzAw_8e6c35fd-c2e4-4175-b72d-da83d7be66d2">353,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy05LTEtMS00MzAw_776331a3-f490-4288-b5f8-9290d77ebe0a">137,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0xMS0xLTEtNDMwMA_ae46ac32-cbd8-47e0-adec-bbdb6850c58b">187,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0xMy0xLTEtNDMwMA_12001456-0f3e-47e6-89f5-65440ea695df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0xNS0xLTEtNDMwMA_7de2cb93-8554-42b8-86c6-87ab9a54bf33">325,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i181aa9f4b31640dc8b14b6f82d70f240_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0xLTEtMS00MzAw_7702b825-c29a-4751-aed0-a71f95b26019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idae08cb548c441d3a91eba1de5219bd2_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0zLTEtMS00MzAw_2fcf9fb4-e272-46d0-8507-77e5b14fa572">109,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i849871cbc3cc45449d92adfe970af3c2_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS01LTEtMS00MzAw_54a71b6c-dff4-4333-aac4-46fd8f0bfea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2a3125acf4ad4057b79910330fc7d13f_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS03LTEtMS00MzAw_d564883c-f1bb-4116-93ae-f55fc645bab9">109,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65ab613bda3d44499a905662ecf1e971_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS05LTEtMS00MzAw_600acaf4-eadb-45e7-9039-92579b1aa529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69ec8616bd37486dbff25977da4441f8_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0xMS0xLTEtNDMwMA_394a6060-ebba-41ae-9f74-7d6764fa0068">127,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i291b4bea01ad41c8963da94469fbd98f_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0xMy0xLTEtNDMwMA_d7f31589-5bb8-4b85-babf-860d0b47a549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i619b5be971f6439098c7aeac4e276a0d_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0xNS0xLTEtNDMwMA_4052dde3-27ff-43f0-9ef1-9b77dc02e063">127,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i49aeaa24126c489988a6ac04f57a2a00_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0xLTEtMS00MzAw_53de9f29-202d-4874-b3f9-817fb860c136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ee96d635765436ca616328acee64b12_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0zLTEtMS00MzAw_384ed3f7-4cc9-4943-a143-4ac685816569">87,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9d490d8a9b4c43f9b0eb01ef5372cfe7_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi01LTEtMS00MzAw_63686101-787a-49da-8cc2-e8161899adf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i94319df9941e4d4c9b28b64317ee7277_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi03LTEtMS00MzAw_51acd9da-779f-40c6-bd9b-d123d0d9e181">87,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7d93184ef1de4f57bce4ecfe8206889f_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi05LTEtMS00MzAw_6c1afbe2-a838-482a-93ed-48f8a8e005de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idfa53ec2a0144c8dab9bfffe76c775ab_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0xMS0xLTEtNDMwMA_12efad5f-4214-4801-88ee-1210f999cc44">49,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a8af53f30ae4b7885dc2a7228d101d0_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0xMy0xLTEtNDMwMA_6aec199c-5418-4ca3-a29d-c506e6721947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4750e8e52de64b8ab4710c73414a1095_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0xNS0xLTEtNDMwMA_63e3e5b0-a88d-4703-ba4d-2b638ff01d26">49,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54541305e5464edbb7c276c8782d6c2e_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0xLTEtMS00MzAw_b7fc7491-7ce7-46dd-9172-6d782265b823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iebf211a0be2545bcb8bb2d83516598b9_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0zLTEtMS00MzAw_7efd3a2e-f1f6-4260-bc7b-e9f1dc7f1e0c">323,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if015623b8ea744f8818948cfc6f9cec7_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy01LTEtMS00MzAw_ddaf2c75-8614-4648-ba73-88021fdb6908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i48b6553253ca455f8645230475b2cc61_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy03LTEtMS00MzAw_4a86e2b6-23ab-49c9-9a0f-07bd4b5399f4">323,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibe2a17ef15ba4c0cbedffc645c45aab6_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy05LTEtMS00MzAw_62fd167e-85c7-49e7-9532-2886e3dd6955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iceb62135438a477dbd091a982c13e82b_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0xMS0xLTEtNDMwMA_68c384db-d8eb-447f-bcbf-ef3fa667856c">270,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55e15ba1dd7f452d855f284c62a7103b_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0xMy0xLTEtNDMwMA_33b5ea39-ac59-46f2-b77f-22049d107b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia4e23dae7b884c2d8e323afdc2202ec1_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0xNS0xLTEtNDMwMA_686fc195-4f58-4560-ba28-34c81b1a3788">270,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0xLTEtMS00MzAw_e35382d6-f980-4925-b0b8-36a278436695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0zLTEtMS00MzAw_2f3b6927-de81-4177-aa2f-99855feeec53">521,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC01LTEtMS00MzAw_5d821d88-feee-4106-ae48-86828e44d0ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC03LTEtMS00MzAw_8d0243e1-f86a-439b-a16c-4199b34928f6">521,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC05LTEtMS00MzAw_daacbaaa-e25f-4146-b803-6926d699422a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0xMS0xLTEtNDMwMA_69c47a93-2f10-43cb-99e8-5a882ba18a3d">447,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0xMy0xLTEtNDMwMA_398948bc-ea5c-46b1-84ca-8ec38ad4641e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0xNS0xLTEtNDMwMA_d891c9f9-d4ef-4362-8624-3920f471794f">447,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMS0xLTEtNDMwMA_ca5bdf7f-1e5a-4692-9a9e-6af3726ab20a">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMy0xLTEtNDMwMA_86718bab-904d-49b5-92bf-f127399b31a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtNS0xLTEtNDMwMA_db29743b-164a-483e-80ba-4fa851922dbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtNy0xLTEtNDMwMA_0435bc91-caef-4a4c-8e50-4e4f59012929">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtOS0xLTEtNDMwMA_f1d7c67e-019a-411c-adc0-1a584051f8e4">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMTEtMS0xLTQzMDA_75cc0302-1d51-4dfb-8ab6-8d9381f849f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMTMtMS0xLTQzMDA_dcfc8c48-4c70-4381-a719-d39c6b3547ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMTUtMS0xLTQzMDA_20aea589-9827-46e4-996c-6afda7481cd5">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMS0xLTEtNDMwMA_e1a60f65-5225-4d6e-82c8-44da103b35b4">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMy0xLTEtNDMwMA_1593c891-ddd4-44a0-ac9a-c1b5f0ccdcb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtNS0xLTEtNDMwMA_c1628a64-85b4-4b22-9ab4-30455cc72118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtNy0xLTEtNDMwMA_994ee833-60ca-49eb-94b6-f0019d531304">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtOS0xLTEtNDMwMA_0b9cfd5e-9dc4-4821-b862-7ac24ab8072b">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMTEtMS0xLTQzMDA_8b76cbcb-6a7a-4511-9d35-beb0def85d63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMTMtMS0xLTQzMDA_b2fd2510-bc69-4141-8d82-531a47d1e062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMTUtMS0xLTQzMDA_d165e0e2-430e-438e-b99f-4b4d2b02a98d">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMS0xLTEtNDMwMA_f3a9419f-4cb9-4197-8580-220d9aaa5878">106,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMy0xLTEtNDMwMA_3bba5e99-449a-4ec5-b8ba-a269dcbd261b">771,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItNS0xLTEtNDMwMA_d42c72dc-d9a3-453c-a3e7-66403d56a6fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItNy0xLTEtNDMwMA_b3d97c68-38ef-4aa6-b5a7-5adc981cef06">878,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItOS0xLTEtNDMwMA_522ee2fa-dcec-4583-b302-d09b4f9ab3ca">140,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMTEtMS0xLTQzMDA_e3bc0abc-df49-4aa0-901d-35cbe9a28d94">634,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMTMtMS0xLTQzMDA_26dda997-985e-40d7-8530-4c9047d4591b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMTUtMS0xLTQzMDA_5184b603-d22c-4344-9a18-acd95322d1d8">775,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMS0xLTEtNDMwMA_f5b55168-39d8-419d-a255-a6ff153ebd39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMy0xLTEtNDMwMA_31350c3b-edcc-45ec-ab46-3902b824c8b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtNS0xLTEtNDMwMA_cf17dc32-46e6-47db-8a96-c455043ffdb4">184,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtNy0xLTEtNDMwMA_1a1c62f2-a258-4b37-886a-2679717f4d54">184,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtOS0xLTEtNDMwMA_a01d2afd-92e3-4118-86ae-122f3e014f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMTEtMS0xLTQzMDA_f0f8a67d-dfed-40b3-9538-d8244abac040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMTMtMS0xLTQzMDA_7a100df7-000f-4ada-b90c-b41deb93c3df">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMTUtMS0xLTQzMDA_6885b67e-608c-4e44-bea4-83a24da8b167">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMS0xLTEtNDMwMA_55ce118b-f84c-4dd9-85a9-0ee6bdf86ab3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMy0xLTEtNDMwMA_3cc8dbf5-f8fd-4058-a7b9-78dfbaac81df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtNS0xLTEtNDMwMA_e0dda820-b6ae-4221-84d0-c83bd0937153">184,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtNy0xLTEtNDMwMA_448a4a32-eff5-4047-8231-8ab6986440f2">184,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtOS0xLTEtNDMwMA_c2c44da8-d5fc-4750-baa1-5fc1d2a6c8d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMTEtMS0xLTQzMDA_4191045b-d0a2-45d1-9945-e2f65b6538ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMTMtMS0xLTQzMDA_f59d8159-ca23-4539-bc0a-b2b3e686a0ac">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMTUtMS0xLTQzMDA_88a437d4-0c12-4036-b823-433f780c54ad">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration, which was incurred in connection with the acquisition of Omniome, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability by discounting the probability-weighted outcomes to present value using an estimate of our borrowing rate and the risk-free rate. The potential outcomes of milestone achievement dates are within the period from June&#160;30, 2023 to June&#160;30, 2025. A decrease in the probability of an earlier scenario within this range would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- and B credit rating, which ranges from <ix:nonFraction unitRef="number" contextRef="iab42dea2b5104f92933733e4ae8b828c_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTQ5NzU1ODE5MjYz_21d7efe8-ce7e-44be-9b73-2e6c7ad8b45b">9.3</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id826230d5e794444a1100227d2df4064_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTQ5NzU1ODE5MjY3_c3c0413f-ba12-4983-b5b7-1792c96617cb">10.2</ix:nonFraction>%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="i7807b89920e845e1be6bc603bec712e3" continuedAt="id171be75263a44a0ab6d4b39363f3bea"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTEyMQ_00d158f1-8463-43f9-9942-3817efdba4f5" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOmQxN2Q4MTRmZTUyOTRkNzFiMDFkYmMwMzhmOGEyYzUzL3RhYmxlcmFuZ2U6ZDE3ZDgxNGZlNTI5NGQ3MWIwMWRiYzAzOGY4YTJjNTNfMS0xLTEtMS00MzAw_3c24fcb0-04dd-4cf5-93a1-c847c2c67a22">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOmQxN2Q4MTRmZTUyOTRkNzFiMDFkYmMwMzhmOGEyYzUzL3RhYmxlcmFuZ2U6ZDE3ZDgxNGZlNTI5NGQ3MWIwMWRiYzAzOGY4YTJjNTNfMi0xLTEtMS00MzAw_10cd08f5-6aa2-4241-a7ef-9c54fb3b5f96">12,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOmQxN2Q4MTRmZTUyOTRkNzFiMDFkYmMwMzhmOGEyYzUzL3RhYmxlcmFuZ2U6ZDE3ZDgxNGZlNTI5NGQ3MWIwMWRiYzAzOGY4YTJjNTNfMy0xLTEtMS00MzAw_9602d317-8a4b-47ad-b5fd-d66f2ed82308">184,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as change in fair value of contingent consideration in the Condensed Consolidated Statement of Operations and Comprehensive Loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="id171be75263a44a0ab6d4b39363f3bea"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNDM5ODA0NjUyMTQyOA_ce58661a-df33-4ad8-b192-58c6ad906ef6" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents and investments (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f54406977384ecdbd22b1c966005bd1_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMy0xLTEtMS03MTM4_3a03aad5-de6b-4b7c-bb05-97c3f2b5a7f2">353,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f54406977384ecdbd22b1c966005bd1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMy0zLTEtMS03MTM4_3b31d76e-041f-405d-8344-fc271f68b96e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3f54406977384ecdbd22b1c966005bd1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMy01LTEtMS03MTM4_527ee8e0-04af-423e-b379-6d558e65cbda">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f54406977384ecdbd22b1c966005bd1_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMy03LTEtMS03MTM4_02dcd670-ee7b-4053-96b1-15a84cbeb775">353,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i447b3166a1894e65ad053b4aca1c8396_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNS0xLTEtMS03MTM4_f2cba353-cf19-445d-b658-e81fe9c8b1f2">110,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i447b3166a1894e65ad053b4aca1c8396_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNS0zLTEtMS03MTM4_514aef82-d60e-4cc7-be73-99ae0941b51c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i447b3166a1894e65ad053b4aca1c8396_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNS01LTEtMS03MTM4_8f1af1b9-d4e4-450f-bdf9-40b170fc40f2">153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i447b3166a1894e65ad053b4aca1c8396_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNS03LTEtMS03MTM4_5eac8a01-e377-4cb1-abbe-1a0925c9c75b">109,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2809d3f2dac4155af95932f49d85131_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNi0xLTEtMS03MTM4_602ad263-0383-4dbe-89d9-1d346c8915ff">87,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2809d3f2dac4155af95932f49d85131_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNi0zLTEtMS03MTM4_892e195d-cdeb-4e7a-86cb-8da6e13ce360">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if2809d3f2dac4155af95932f49d85131_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNi01LTEtMS03MTM4_6f024b80-6602-4b15-a4f4-621990e6cb23">344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2809d3f2dac4155af95932f49d85131_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNi03LTEtMS03MTM4_3a9ad227-3f76-4a52-82e2-afc771e344df">87,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaf35d3b973c84f74991c106cc5541b89_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNy0xLTEtMS03MTM4_4794fb58-a139-4976-b053-f77ea7775c7b">325,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaf35d3b973c84f74991c106cc5541b89_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNy0zLTEtMS03MTM4_88f94ff1-c855-49e4-a0b2-5e7b842c9f18">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iaf35d3b973c84f74991c106cc5541b89_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNy01LTEtMS03MTM4_03d9adb3-1622-477f-a736-7ef08ff96e4b">2,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaf35d3b973c84f74991c106cc5541b89_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNy03LTEtMS03MTM4_7b449acc-e5da-41a1-a8f3-9cd131be83d0">323,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3b785e7e49a249b7975eb905979aa957_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOC0xLTEtMS03MTM4_80928ca6-d7c1-412f-81c8-ae645bccc2d5">522,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3b785e7e49a249b7975eb905979aa957_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOC0zLTEtMS03MTM4_d79f1d21-393a-4e7f-a060-c5134da2c1ac">892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3b785e7e49a249b7975eb905979aa957_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOC01LTEtMS03MTM4_5ab3a38d-dabd-4908-928b-09918cb6f9d3">2,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3b785e7e49a249b7975eb905979aa957_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOC03LTEtMS03MTM4_dbc58289-eb79-4c1a-a069-1879ad923ec1">521,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOS0xLTEtMS03MTM4_a2770f20-b64f-4365-b517-9058eb47083e">876,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOS0zLTEtMS03MTM4_6b0f95f6-7cfa-4e16-ac9e-661277a70da6">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOS01LTEtMS03MTM4_e7300343-4be4-4cf1-840b-48fe63159f97">2,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOS03LTEtMS03MTM4_762d6421-2102-4ccd-8b33-ca352cc82e07">874,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTEtMS0xLTEtNzEzOA_56d236a3-23e5-499e-96d6-9ab1e8edb63e">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTEtNy0xLTEtNzEzOA_5ad2443a-c4e8-4504-8f57-be5f105fbdfd">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTItMS0xLTEtNzEzOA_c4f5d857-848f-43c5-a986-a26f84c272c5">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTItNy0xLTEtNzEzOA_fdb29764-2835-4ed1-aea9-f58f9011748e">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if53a52cbc7e348799f5eb8078ff67bb2_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTgtMS0xLTEtNzEzOA_9078c4ad-7ab8-4abe-80a4-ea3b44fba141">325,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if53a52cbc7e348799f5eb8078ff67bb2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTgtMy0xLTEtNzEzOA_931a0c34-2528-46e0-a713-4ec4ac1a14f6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if53a52cbc7e348799f5eb8078ff67bb2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTgtNS0xLTEtNzEzOA_a9c63193-1593-409a-ab76-7f802e42ad33">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if53a52cbc7e348799f5eb8078ff67bb2_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTgtNy0xLTEtNzEzOA_d6ab364e-9683-42d2-a3e3-ac80480cdaea">325,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i642d2faa764c497fb709bd8f7cf545ad_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjAtMS0xLTEtNzEzOA_400d3cab-5e31-434a-b586-a2b03c065cbf">127,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i642d2faa764c497fb709bd8f7cf545ad_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjAtMy0xLTEtNzEzOA_00303518-c3ea-4fa7-af0b-cc593f3e9f61">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i642d2faa764c497fb709bd8f7cf545ad_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjAtNS0xLTEtNzEzOA_945f621d-a395-4b94-bac4-1e372a92666a">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i642d2faa764c497fb709bd8f7cf545ad_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjAtNy0xLTEtNzEzOA_64ea8864-5b81-466c-9b0a-c9f7f5576fec">127,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjEtMS0xLTEtNzEzOA_2eb007bc-f825-4b5a-a9cc-2d6defac4cbb">49,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjEtMy0xLTEtNzEzOA_b00376d8-a7e7-4e23-a04f-7e63eabeb618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjEtNS0xLTEtNzEzOA_5507f721-9cfa-47fe-8a23-65e51251095a">507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjEtNy0xLTEtNzEzOA_21acc481-8f15-40f7-b4fb-a9c6d9962c93">49,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f0aa7e818a540b4b3800563f1640bb5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjItMS0xLTEtNzEzOA_12cfabc3-916c-416b-8a45-82139c99a826">274,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f0aa7e818a540b4b3800563f1640bb5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjItMy0xLTEtNzEzOA_cf0171ad-ea15-4cb4-95de-ef574f03e469">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f0aa7e818a540b4b3800563f1640bb5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjItNS0xLTEtNzEzOA_3c3fd9e4-9334-4234-bec3-64380d3a5a4c">3,880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f0aa7e818a540b4b3800563f1640bb5_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjItNy0xLTEtNzEzOA_efbb8970-218b-453f-aa64-d855ef151ee8">270,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjMtMS0xLTEtNzEzOA_270a938b-f458-4cbc-8032-68da39a508c9">451,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjMtMy0xLTEtNzEzOA_dbec8d04-5546-4184-ac2a-c1448023964a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjMtNS0xLTEtNzEzOA_c0447548-a2ec-423d-9119-3d6e74e919f6">4,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjMtNy0xLTEtNzEzOA_9d0506f3-a119-4f6b-a970-791396dc2abf">447,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjQtMS0xLTEtNzEzOA_903b61d2-852f-48d2-bde9-3e4a7e05d779">777,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjQtMy0xLTEtNzEzOA_6d61209c-d6cc-4176-9eae-c4c6875c5dc3">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjQtNS0xLTEtNzEzOA_4c43532c-057b-4656-8fcc-1c32fe02d516">4,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjQtNy0xLTEtNzEzOA_9899fe18-6193-44f9-9ff0-e9f820561366">772,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjYtMS0xLTEtNzEzOA_be4ef5c8-68d6-4de9-9abc-eb0942d44c88">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjYtNy0xLTEtNzEzOA_f9f05628-386b-4088-860b-b97289b2e2e6">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjctMS0xLTEtNzEzOA_71b92477-8424-4e9d-93fa-da922f026462">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjctNy0xLTEtNzEzOA_6b938c39-dacb-4a60-8da9-846e1f1d810f">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjJjNjY1MzFkMTczNTQwOTI5YWI0NTQ5NzkwOTBkMDk0L3RhYmxlcmFuZ2U6MmM2NjUzMWQxNzM1NDA5MjlhYjQ1NDk3OTA5MGQwOTRfMS0xLTEtMS00MzAw_d98ef60d-ff29-4865-a877-03f3a9924247">634,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjJjNjY1MzFkMTczNTQwOTI5YWI0NTQ5NzkwOTBkMDk0L3RhYmxlcmFuZ2U6MmM2NjUzMWQxNzM1NDA5MjlhYjQ1NDk3OTA5MGQwOTRfMi0xLTEtMS00MzAw_c70b9404-2154-4a70-8a54-828abdc9f65e">136,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjJjNjY1MzFkMTczNTQwOTI5YWI0NTQ5NzkwOTBkMDk0L3RhYmxlcmFuZ2U6MmM2NjUzMWQxNzM1NDA5MjlhYjQ1NDk3OTA5MGQwOTRfMy0xLTEtMS00MzAw_2681ed65-0bdd-4c46-8322-0e82f3f7f1d1">771,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM4OQ_7eb0fcbf-0fc1-4c82-8428-071178572618" continuedAt="ia5c0dc41fd5a4e5a8c8cb44ce2e95c84" escape="true">BALANCE SHEET COMPONENTS</ix:nonNumeric></span></div><ix:continuation id="ia5c0dc41fd5a4e5a8c8cb44ce2e95c84" continuedAt="i857ad5f8daa54af98bd836cd869e6c04"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory, net</span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5MA_5d50449f-4e01-4dfa-91b3-6fc41785f61a" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMS0xLTEtMS00MzAw_affc274d-d77d-42a2-aea5-0be762de9e79">25,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMS0zLTEtMS00MzAw_304a41d9-6c62-49fc-bcc7-e1fdf88c744d">24,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMi0xLTEtMS00MzAw_d69ea7b5-de37-4de8-9c7d-bee3a4090ff9">21,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMi0zLTEtMS00MzAw_ad42539b-94df-417a-9910-9f0e7602d51f">14,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMy0xLTEtMS00MzAw_1821144f-98b3-4144-9520-65ed2ea45fe2">14,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMy0zLTEtMS00MzAw_99970a5d-1ce7-455b-a2ce-2ca8e50e64cf">12,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfNC0xLTEtMS00MzAw_3eb7e261-b00b-4ce5-808b-36f09a24c02b">61,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfNC0zLTEtMS00MzAw_9027736c-b7f9-4ff0-af99-c267c9f295fc">50,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include acquired in-process research and development ("IPR&amp;D") of $<ix:nonFraction unitRef="usd" contextRef="i4c2165a552b2406aad1c18da3e5bcba1_I20210930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfMTQ5NA_9f960b06-44dc-455e-82e1-db9e1c059a3e">400</ix:nonFraction> million as a result of the Omniome acquisition in September 2021. The IPR&amp;D will remain on our Consolidated Balance Sheet as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development activities. During the development period following the acquisition, IPR&amp;D will not be amortized, but instead will be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. Upon completion of the development, we will begin to amortize the asset over the life of the product, or record an impairment charge if the asset is determined to be impaired.</span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5MQ_eac39a1f-7f74-4057-be80-2ef4acff48c9" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, definite-lived intangible assets included the following (in thousands, except years): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7f0c2ed914b74450b0a466f80963c39e_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi0xLTEtMS00MzAw_8338f8dc-f90d-428d-99f0-0491e4c14c16">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4bed7d66a5a240dd880c5f2e196b2fb4_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi0zLTEtMS00MzAw_4a205d7d-d0e8-478d-b4e6-849c864ac43f">11,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4bed7d66a5a240dd880c5f2e196b2fb4_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi01LTEtMS00MzAw_beaa7b5f-2fe2-4d6b-8d1d-c1f0a461ffe8">1,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4bed7d66a5a240dd880c5f2e196b2fb4_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi03LTEtMS00MzAw_6725a6b8-772c-4c47-8d21-bf5510936b8d">9,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6cf974ed2ad44f0b3a0fa6beaa4d15a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi05LTEtMS00MzAw_7a1d1b51-5472-4a6f-8990-c28f13c2774c">11,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6cf974ed2ad44f0b3a0fa6beaa4d15a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi0xMS0xLTEtNDMwMA_61a6d471-be0d-4636-8b83-f41082e57786">1,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6cf974ed2ad44f0b3a0fa6beaa4d15a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi0xMy0xLTEtNDMwMA_572726a8-33ab-4386-aca8-f204a80646c1">10,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i70ceb8bb0a3b41be9d4cc3b73a38fb83_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy0xLTEtMS00MzAw_81b1e520-5dba-42b9-aa7d-beb988c9e7f4">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia15d8c644eec4080836b0b62648963ed_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy0zLTEtMS00MzAw_cf731d52-ea83-47c0-b196-874a6d8f958d">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia15d8c644eec4080836b0b62648963ed_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy01LTEtMS00MzAw_7a78fd51-4dea-4518-a3f3-aa09f04d1ad6">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia15d8c644eec4080836b0b62648963ed_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy03LTEtMS00MzAw_2fc3fef1-6a0a-4158-86e8-fea4e0d5c4f8">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b8fbcede4404a2e8b1019f78237b47e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy05LTEtMS00MzAw_55364284-cd5f-444e-9802-db7bef4ef752">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4b8fbcede4404a2e8b1019f78237b47e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy0xMS0xLTEtNDMwMA_5e519b5d-bc41-40d6-a6f9-8699718ecf4e">255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b8fbcede4404a2e8b1019f78237b47e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy0xMy0xLTEtNDMwMA_5ce003e2-cba6-4ac8-adba-1fe5aeea8aad">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC0zLTEtMS00MzAw_7dbd08b0-e48b-4432-9a3f-fca605f91142">11,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC01LTEtMS00MzAw_011b3587-2f92-4a46-8529-14fd8173f46d">1,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC03LTEtMS00MzAw_00221f47-55ed-42fb-a499-c3458636f232">10,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC05LTEtMS00MzAw_f88e9be5-fad1-406b-ad54-0ce34e5fd423">11,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC0xMS0xLTEtNDMwMA_d3474e28-8cca-49c8-a0eb-cabc3ec001fc">1,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC0xMy0xLTEtNDMwMA_cd055242-3e8b-4504-a158-dc48896f4241">10,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5Mg_452cb624-23cc-456a-a6d5-aea3cc265b99" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfMC0xLTEtMS00MzAw_8352bdad-3860-4098-9fa7-0d63796bdde1">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfMS0xLTEtMS00MzAw_4a093009-81af-48dc-91f1-35444cb510f0">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfMi0xLTEtMS00MzAw_0bc756e9-9dc0-4d7b-8641-ecd39226bf60">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfMy0xLTEtMS00MzAw_dd0e5af3-ee7a-4626-b476-2046137cfa9e">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfNC0xLTEtMS00MzAw_913e8ac2-42f0-45b7-b1ae-82598564a0a3">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfNS0xLTEtMS00MzAw_57ec7340-3488-4841-b93f-95066f267b6a">6,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfNi0xLTEtMS00MzAw_6a403dbe-aeac-403a-bfa1-a0d1eb18c78d">10,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review definite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2022, noting <ix:nonFraction unitRef="usd" contextRef="i36c2bb89833b4cfcb9dcbf700eebd5b0_D20220401-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfMjg4OA_4e3afcca-8192-478a-962d-a1e0e1d12d4e">no</ix:nonFraction> impairment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, we entered into an Amended and Restated Development and Commercialization Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Invitae Corporation (&#8220;Invitae&#8221;). During the three months ended March&#160;31, 2023, Invitae did not purchase any of the instruments or consumables under the terms of the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="i857ad5f8daa54af98bd836cd869e6c04"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated Agreement. As of March&#160;31, 2023 and December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i8d7ed9bee28b4168b9214818a5a04afc_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODMwOTI1_9ded0fd7-3d3d-4cbe-9523-884462230880"><ix:nonFraction unitRef="usd" contextRef="if2d5823f4ed048deabd8e0c7591c429c_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODMwOTI1_e46ac36c-59b7-421c-b446-15c26f5e921f">21.4</ix:nonFraction></ix:nonFraction> million of deferred revenue, current, is recorded on the Condensed Consolidated Balance Sheet relating to all future performance obligations under the Amended and Restated Agreement. Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3 &#8211; Invitae Collaboration</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had a total of $<ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODIxNzIy_4f3ce485-dbc0-4ada-ab5a-36dbc20ffc56">32.7</ix:nonFraction>&#160;million of deferred revenue, $<ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDk0NzgwMjM0MDIzMw_41cff15a-df52-4ca9-8368-8a2256800510">30.9</ix:nonFraction>&#160;million of which was recorded as deferred revenue, current, and primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae. The deferred revenue, non-current balance of $<ix:nonFraction unitRef="usd" contextRef="i16bd2f0eca824f1797f501f4e0391099_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODIyMDYy_16547383-7f95-46ab-b64f-3f4d7b4eeb12"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODIyMDYy_64d3b224-bc94-4b71-a93d-dad3eed5175b">1.8</ix:nonFraction></ix:nonFraction>&#160;million primarily relates to deferred service contract revenues and is scheduled to be recognized in the next <ix:nonNumeric contextRef="i16bd2f0eca824f1797f501f4e0391099_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfMzM5MA_ebb8b7cc-4bea-4afb-ae47-bf47be3cd1a6">5</ix:nonNumeric> years. Revenue recorded in the three months ended March&#160;31, 2023 includes $<ix:nonFraction unitRef="usd" contextRef="i3df88f6219dc43ce83dc501b125501a1_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODIyMDcw_9e63e505-d07b-4b18-902d-42ac39b5fa63">3.5</ix:nonFraction>&#160;million of previously deferred revenue that was included in deferred revenue as of December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. There were no material changes in estimates for the periods presented below. </span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5Mw_84ca569c-540a-4b59-b86a-6977a6c4bb28" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfMi0xLTEtMS00MzAw_f020ccb5-bb66-4708-9c96-71be6f5113b8">1,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib71260de6ee845f5827e04115b08241b_I20211231" decimals="-3" name="us-gaap:ProductWarrantyAccrual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfMi0zLTEtMS00MzAw_a48ada63-bb66-4804-9dcd-7cd11ec43187">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfMy0xLTEtMS00MzAw_17be0ecf-18d8-42fe-b88c-255f72fd89b9">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfMy0zLTEtMS00MzAw_f645aa00-298c-4736-87f4-8f58c481f8b6">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfNC0xLTEtMS00MzAw_abcf382f-a993-4353-af20-f6d3176b2445">631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfNC0zLTEtMS00MzAw_974aaeff-b0a9-4f6c-9f6b-bc39b0ca364a">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfNS0xLTEtMS00MzAw_3cbf431a-67ea-4f7d-85c7-9ec7056b797d">1,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfNS0zLTEtMS00MzAw_f121997e-a152-48b5-8e78-a5562a3dc6d1">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term loans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Omniome, we acquired $<ix:nonFraction unitRef="usd" contextRef="icea01b3eb40349d587b12f4dca39ef4e_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDY2NA_d58b4f81-01e8-4a7e-9e9f-08eb79f97689">1.3</ix:nonFraction> million in short-term debt and $<ix:nonFraction unitRef="usd" contextRef="icea01b3eb40349d587b12f4dca39ef4e_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDY5MA_6dd77d35-8290-43df-b617-ec821fbc6dd0">3.0</ix:nonFraction> million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#8217;s purchases of equipment, which serves as collateral. Each term loan has a term of <ix:nonNumeric contextRef="i8ff3053e324549d69983b4ab416817c9_D20210701-20210930" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDkyNw_06e55dd9-8427-4577-bdd5-06d57871b118">43</ix:nonNumeric> months and bears a fixed interest rate of approximately <ix:nonFraction unitRef="number" contextRef="id3a16d74a89a48b188694cf52ea1bf6d_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDk3OQ_d950eac6-b596-4199-92dd-260905372e26">17</ix:nonFraction>% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the <ix:nonNumeric contextRef="ic22b2f234d3f44dea2cb7006091d3cfa_D20210701-20210930" name="pacb:DebtInstrumentTermLoanElectiveOption" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDM5ODA0NjUyOTcwMg_b92c82ee-2825-436d-b894-5d9902a801a1">24</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month and before the <ix:nonNumeric contextRef="i8484a2b1bd284e689338fd42dc179878_D20210701-20210930" name="pacb:DebtInstrumentTermLoanElectiveOption" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDM5ODA0NjUyOTcwNg_0d229de3-5cc5-468d-ab9d-ce8a2b3ea7c0">43</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month after the commencement date, is <ix:nonFraction unitRef="number" contextRef="i8ff3053e324549d69983b4ab416817c9_D20210701-20210930" decimals="INF" name="pacb:PercentageOfFeeToPrepayDebt" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTE3Nw_a15a11b3-609f-49e5-b8dc-92daf71c8e27">4</ix:nonFraction>% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the carrying value of term loans outstanding was $<ix:nonFraction unitRef="usd" contextRef="id3026c43f5474b3aaf648b1b685a4b02_I20230331" decimals="-3" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDM5ODA0NjUyNjMzMA_28cac3d8-1f52-4ef1-bf34-b928335f7b8a">1.9</ix:nonFraction>&#160;million. The related long-term portion of $<ix:nonFraction unitRef="usd" contextRef="i8dd1b10964904b3baf45a616d35f8e4a_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODI5MDQ5_ab22a5a1-ecbc-4619-acc5-f343d77ac9ab">0.2</ix:nonFraction>&#160;million was recorded as part of other liabilities, non-current and the short-term portion of $<ix:nonFraction unitRef="usd" contextRef="ibe51e70a3fcd4e399fbfdbb8e358e931_I20230331" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODI5MDQ1_f83bc244-d3d8-49ba-bde7-8e0cebbc526f">1.7</ix:nonFraction>&#160;million was recorded as part of other liabilities, current on the Condensed Consolidated Balance Sheet. The interest expense was $<ix:nonFraction unitRef="usd" contextRef="i6066f8de0b274e42940b04267565bdf7_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODI5MTAz_f3764b9c-4bcd-4730-8474-2a73fddcd459">0.1</ix:nonFraction>&#160;million for the three months ended March 31, 2023, which was included as part of interest expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss.</span></div><div><span style="font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"></span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5NA_82359371-d1d5-43a0-8a17-8e2aeb04ef0c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future principal payments on the term loans (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3026c43f5474b3aaf648b1b685a4b02_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjIyNDZkMjliMDU4MjQwYzI4ZTFjMDJkNmEwNzJkZWJkL3RhYmxlcmFuZ2U6MjI0NmQyOWIwNTgyNDBjMjhlMWMwMmQ2YTA3MmRlYmRfMC0xLTEtMS00MzAw_913b3c38-ca05-4b2e-b1fb-644df1dbe671">1,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3026c43f5474b3aaf648b1b685a4b02_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjIyNDZkMjliMDU4MjQwYzI4ZTFjMDJkNmEwNzJkZWJkL3RhYmxlcmFuZ2U6MjI0NmQyOWIwNTgyNDBjMjhlMWMwMmQ2YTA3MmRlYmRfMS0xLTEtMS00MzAw_8149a690-709b-4f24-96b4-8b2251bda600">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3026c43f5474b3aaf648b1b685a4b02_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjIyNDZkMjliMDU4MjQwYzI4ZTFjMDJkNmEwNzJkZWJkL3RhYmxlcmFuZ2U6MjI0NmQyOWIwNTgyNDBjMjhlMWMwMmQ2YTA3MmRlYmRfMy0xLTEtMS00MzAw_a1e89c7d-122e-4c29-94df-39e735fbcabd">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="idd15d706814f4821992e3c53513cc1e0_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNjQzNQ_a8950d4e-0174-440d-81ed-e7cc564a9465" continuedAt="i36a3e5f42eff4bbf9b2de7858fe8acb6" escape="true">CONVERTIBLE SENIOR NOTES </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i36a3e5f42eff4bbf9b2de7858fe8acb6" continuedAt="id28f218f11c64b2dbf6244c6acc1ac46">On February&#160;9, 2021, we entered into an investment agreement (the &#8220;Investment Agreement&#8221;) with SB Northstar LP (the &#8220;Purchaser&#8221;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $<ix:nonFraction unitRef="usd" contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMjQ3_36eb7339-f1a7-42a8-bee2-eb07e9374565">900</ix:nonFraction> million in aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMjg3_0d524ada-6ab7-4254-bec0-044d80a443df">1.5</ix:nonFraction>% Convertible Senior Notes (the &#8220;Notes&#8221;). The Notes were issued on February&#160;16, 2021.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="id28f218f11c64b2dbf6244c6acc1ac46" continuedAt="i6c1cd61d65b44315b57d5218f9d9b369"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are governed by an indenture (the &#8220;Indenture&#8221;) between the Company and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNTIx_62557857-bebe-4826-b2c5-fd00db9935d4">1.5</ix:nonFraction>% per annum. Interest on the Notes is payable semi-annually in arrears on February 15 and August 15 and commenced on August 15, 2021. The Notes will mature on February&#160;15, 2028, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the Notes (which is equal to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTE0Mw_667dd665-4d80-4956-99b3-0713970bc1e3">43.50</ix:nonFraction> per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after February 20, 2026, the Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" decimals="INF" name="pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTU2Ng_6bfe6e0a-aabe-49c6-8b3a-e7b9e8062b48">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" name="pacb:DebtInstrumentRedemptionPriceTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTYyMQ_07ddbb65-7133-48fe-82db-b65a6c7042fd">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" name="pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTY3Nw_095fc2c9-2317-4c77-b8ec-be32b955de4a">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTg5OQ_0b7b0941-8d21-4dc6-9bc4-097fe1fa0212">100</ix:nonFraction>% of the principal amount of such Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges (a &#8220;Fundamental Change&#8221;), the holders of the Notes may require that we repurchase all or part of the principal amount of the Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk1Mw_20814e47-a2ac-4697-aa89-2d806269533d">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMjkzMQ_3d42305f-0abd-4c32-bd5b-903f00304216">0.25</ix:nonFraction>% per annum of the principal amount of the Notes outstanding for each day during the first <ix:nonNumeric contextRef="i8b06909acc8846a687b88fb4008d393a_D20210216-20210216" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk2Mw_6ada062b-c57e-4e92-a748-d6fa79cc787f">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk1OA_46c617c5-6e98-45c1-a485-2269cf65ba4d">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMzI0Nw_6d61c34a-767d-46d4-9372-4b4c79825802">0.50</ix:nonFraction>% per annum of the principal amount of the Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="i87dcdd78b25e4f46a8ae756042953485_D20210216-20210216" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk4Mw_cbfb0154-5a00-40d8-974e-cdef40930743">181</ix:nonNumeric>st calendar day to, and including, the <ix:nonNumeric contextRef="i82f01855a6084151a5dd9a070e4784b3_D20210216-20210216" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk3OA_716a4ef6-1322-4893-b1f6-f26effe7ea22">360</ix:nonNumeric>th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the Indenture). On the <ix:nonNumeric contextRef="i20a09135868a48e4afb9690de6dd439c_D20210216-20210216" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk3Mw_b208c9ad-370d-4a11-8c24-ed684e8f46bf">361</ix:nonNumeric>st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="i20a09135868a48e4afb9690de6dd439c_D20210216-20210216" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk2OA_55978d04-9014-4bb4-9b15-8e1632ed1372">361</ix:nonNumeric>st day), the Notes shall be subject to acceleration as provided for in the Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the Notes were not issued at a premium; therefore, the Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNTY1MA_98cb7a64-3de6-4720-9f66-9bb33ab8eae3">4.5</ix:nonFraction> million, which were recorded as debt issuance cost and are presented as a reduction to the Notes on our Consolidated Balance Sheets and are </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="i6c1cd61d65b44315b57d5218f9d9b369" continuedAt="i05bf5778a1fa4e63afb5612182474bdb"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortized to interest expense using the effective interest method over the term of the Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNTkyMg_610d7dca-d39b-4cdd-b2da-4c077daa11d2">1.6</ix:nonFraction>%. </span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNjQzNg_4d8d8674-2153-4b6c-9aaf-c2af00d1b43c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the Notes is recorded as convertible senior notes, net, non-current in the Condensed Consolidated Balance Sheets as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i742c54bedefe423c93b513816a6c3979_I20230331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMS0xLTEtMS00MzAw_48c1dcfe-45a6-4594-8dd5-d1008c433a43">900,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib40b2b69144d46d385bf12dbac4912ed_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMS0zLTEtMS00MzAw_349162f8-db85-492e-a2b8-76e7615d7ff0">900,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMi0xLTEtMS00MzAw_97b488b9-daa5-4c4f-9bde-b35fa23206f3">3,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMi0zLTEtMS00MzAw_1cacd164-f999-414f-8aa2-b4ffba639333">3,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMy0xLTEtMS00MzAw_ee3047ad-e7b4-4810-b0c6-cfc2a520a17d">896,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMy0zLTEtMS00MzAw_8fddfb31-fb56-49ff-b3b1-94f3937c14ab">896,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="pacb:ScheduleOfInterestExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNjQzNA_8f5cae5a-e231-4a81-839a-581ddfbe2dea" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, interest expense for the Notes was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:71.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.104%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i618edbbfddab4833a48509103c51d343_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfMi0xLTEtMS00MzAw_d81813f7-47fd-4d60-9a12-1b889f866080">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i98efc311e4834a52b95558f1635f4df5_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfMi0zLTEtMS00MzAw_da8ba35e-c6d0-4840-8011-470914481eba">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfMy0xLTEtMS00MzAw_a99a375e-fb73-4911-b45d-a42308947fd2">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfMy0zLTEtMS00MzAw_2c5e4106-382e-4c53-b12e-7b48c833554c">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfNC0xLTEtMS00MzAw_79bcd4ff-335a-4028-947e-8479f9ee4c1c">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfNC0zLTEtMS00MzAw_be82ff3c-fe47-4e40-8bfb-d46ab7a8f9c0">3,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i05bf5778a1fa4e63afb5612182474bdb">As of March&#160;31, 2023, the estimated fair value (Level 2) of the Notes was $<ix:nonFraction unitRef="usd" contextRef="i6f811a83540b4cdb8df5a2ca849b6ae0_I20230331" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNjI3Mw_238ab663-8bd1-4e67-93df-79a720da8f3c">693.0</ix:nonFraction> million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.</ix:continuation> </span></div><div id="idd15d706814f4821992e3c53513cc1e0_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:LossContingencyDisclosures" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81Mi9mcmFnOjBlOWJmNWRlMmZiNTQ0YjZhMTJlYzdhZWIzYmNkYTQxL3RleHRyZWdpb246MGU5YmY1ZGUyZmI1NDRiNmExMmVjN2FlYjNiY2RhNDFfNjUzOA_1b54d1d4-5055-4c43-b0e1-1fda73f97109" continuedAt="id9f88d3b46f84c3a8cb886309b9e453a" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="id9f88d3b46f84c3a8cb886309b9e453a" continuedAt="i505f7acb53b3414fac96a7b9e629d386"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements, primarily relating to our corporate offices. See </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8 &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Leases&#8221;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for information regarding the Company&#8217;s maturity of lease liabilities under its lease agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_91">Legal Proceedings, in  Part II, Item 1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i505f7acb53b3414fac96a7b9e629d386">expense amounts. No additional liability associated with such indemnification obligations has been recorded as of March&#160;31, 2023 and December&#160;31, 2022.</ix:continuation></span></div><div id="idd15d706814f4821992e3c53513cc1e0_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTE 6. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQ2OQ_a41db0fa-335d-4bad-a1e0-aed100eac3f6" continuedAt="i21c6b26d415049deaf35d00e44a34c93" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="i21c6b26d415049deaf35d00e44a34c93" continuedAt="i3da6455dd938482298ba6877a61feae0"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Underwritten Public Equity Offering</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into an underwriting agreement, relating to the public offering of <ix:nonFraction unitRef="shares" contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131" decimals="INF" name="pacb:PublicOfferingShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTM4Mw_f4399b0a-0517-4d3c-9d86-854beff15ed4">17.5</ix:nonFraction> million shares of our common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3539bf245d854192abfe418d43a09772_I20230131" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQ2Mg_b7b5e57c-0d1f-4149-bf35-9ea743a6fbe9">0.001</ix:nonFraction> par value per share, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3539bf245d854192abfe418d43a09772_I20230131" decimals="INF" name="pacb:OfferingShareAmountMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQwMg_a502455b-b063-4d0d-b177-da58ce87a670">10.00</ix:nonFraction> per share. Under the terms of the underwriting agreement, we also granted the underwriters a <ix:nonNumeric contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQxMA_6fafa168-3ff7-4781-bc42-14529c07b87d">30</ix:nonNumeric>-day option to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131" decimals="INF" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQ1MQ_01642c19-8361-41e9-a64d-9ba48028329b">2.6</ix:nonFraction> million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold <ix:nonFraction unitRef="shares" contextRef="if0172c443e454bb9826a003845a4aa13_D20230131-20230131" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDM5ODA0NjUyOTU1OQ_0d297a57-fea5-4c34-a628-85ae098d67d7">20.1</ix:nonFraction> million shares of our common stock. We paid a commission equal to <ix:nonFraction unitRef="number" contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131" decimals="INF" name="pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQxNA_89181e91-f590-4678-810c-da1888602dc4">5.75</ix:nonFraction>% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $<ix:nonFraction unitRef="usd" contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131" decimals="-5" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQyMQ_7f7d3c7a-dbdf-4782-856f-1e0e27356028">189.7</ix:nonFraction>&#160;million, excluding approximately $<ix:nonFraction unitRef="usd" contextRef="i756aff43669a4bee98c53b5da2ad6ad6_D20230101-20230131" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQzNw_8037f472-1081-4a5a-a56a-ad3c28528cbc">0.5</ix:nonFraction>&#160;million of offering expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information on the Company's underwritten public equity offerings and private placement of common stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had <ix:nonFraction unitRef="shares" contextRef="i6620f4b62a6245299f332889d2275280_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMjQ0OA_6fcd9158-c4f9-4cfd-ad9c-6f32a4fce5e2">12.8</ix:nonFraction>&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information on the Company's equity plans</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-based Stock Options</span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwOQ_bb48220e-a361-4cc8-b96a-401e75bf55af" continuedAt="ia9c598d785fd44d2a3e4c155caec01f7" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards (shares in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i638e0be2cf05429d9d48a17c3ad3afc4_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMS0xLTEtMS00MzAw_9e533998-700b-4ee2-beb2-42e1c2c5d24b">14,618</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i638e0be2cf05429d9d48a17c3ad3afc4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMS01LTEtMS00MzAw_9046031d-a0e5-44db-becf-a96e63bc82b0">10.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMi0xLTEtMS00MzAw_74e89dcf-85b2-48fb-8689-f6884e8501cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMi01LTEtMS00MzAw_2897967e-92f1-4dd7-aa30-0f5fb687499a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMy0xLTEtMS00MzAw_5c1397ae-de5b-4556-91d0-577765e3b5a7">250</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMy01LTEtMS00MzAw_616e2224-e5f3-42ef-ae87-fd557eb81dcc">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfNC0xLTEtMS00MzAw_61b31b8c-4bbf-4b9f-95c7-8db3ab29a64d">362</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfNC01LTEtMS00MzAw_db757128-dd83-4ce1-84ff-16cf179700f0">17.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia9475351ae4143b49d057e49d769bac5_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfNS0xLTEtMS00MzAw_27bbab0b-4046-4ac9-b327-56c0527a9a2c">14,006</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9475351ae4143b49d057e49d769bac5_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfNS01LTEtMS00MzAw_ba3138c3-3ace-4422-b83e-a7ee66db05ec">10.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="i3da6455dd938482298ba6877a61feae0" continuedAt="i601909df58e240ad90cdb10f1daa5142"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Stock Options</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:continuation id="ia9c598d785fd44d2a3e4c155caec01f7"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for performance-based awards (shares in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMS0xLTEtMS00MzAw_497b9ec6-3c68-4dcd-9442-764dc61c739d">258</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMS01LTEtMS00MzAw_7af5fe54-636b-47cc-90e0-10efaf167c22">4.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMi0xLTEtMS00MzAw_2f327b30-947b-45bd-9c05-a0b5b09b2f3e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMi01LTEtMS00MzAw_c488a93f-7049-4f1d-99ed-2faf57a0abd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMy0xLTEtMS00MzAw_1d12e70c-ec76-4b14-be34-b0816559ffb6">230</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMy01LTEtMS00MzAw_a5353ebe-e751-404d-a7ba-08f2d064d9c5">4.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfNC0xLTEtMS00MzAw_6a49b66c-f74e-4075-bac3-82f2ac1951d6">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfNC01LTEtMS00MzAw_e14092e6-de58-4103-9ff9-1763ec7e19ec">4.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifb8601e7bab34e959227a80dc0653b82_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfNS0xLTEtMS00MzAw_9f273bde-0841-4a80-828a-a63061d27120">24</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb8601e7bab34e959227a80dc0653b82_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfNS01LTEtMS00MzAw_c1e80011-5969-4814-bf52-a2a1255ddaf1">4.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (&#8220;RSU&#8221;) and Performance Stock Units ("PSU") </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We issue PSUs for which the number of shares issuable in the third year of the performance period based on performance relative to specified revenue targets and continued employment through the vesting period. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwNA_36a6a81d-ad54-4254-972b-6fe73e056951" continuedAt="ifbaf5f6352894e98a8dd3fb730c1fed5" escape="true">The following table summarizes the time-based RSUs and PSUs activity (shares in thousands): </ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="ifbaf5f6352894e98a8dd3fb730c1fed5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i557fdaad292c4b3fb9316667a1bba49e_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMS0xLTEtMS00MzAw_9ed01f4d-d54d-48c7-8bbd-824bfd0e3b84">8,535</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMS0zLTEtMS0xNDMwNg_35f705a7-f190-43c2-977a-76282eafe6c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i557fdaad292c4b3fb9316667a1bba49e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMS0zLTEtMS00MzAw_6de99fbd-1bef-4784-932f-94dfc3b58fe2">15.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMS03LTEtMS0xNDMxMA_417b6aa6-2669-4901-b822-8261b0c5df33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMi0xLTEtMS00MzAw_deee4680-f8ce-4deb-a4d6-cab469239cd9">6,341</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMi0zLTEtMS0xNDMwNg_2901f7a4-ee99-43cb-b560-b2f30a5edba0">564</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMi0zLTEtMS00MzAw_8a622dd0-bca6-49a7-8166-fe76ec6adbd9">9.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMi03LTEtMS0xNDMxMA_2e6e4029-cdd3-4c0a-a5d9-970902277a53">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMy0xLTEtMS00MzAw_39e44cab-d909-4b0e-91fe-f96e99c351d1">1,640</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMy0zLTEtMS0xNDMwNg_716a472f-556f-4bcc-bfa1-f06d1f8449a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMy0zLTEtMS00MzAw_d206cd40-a894-4852-9d48-9cdde4f2369d">16.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMy03LTEtMS0xNDMxMA_8b7c1696-3be5-4d0a-a038-ff966b167208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNC0xLTEtMS00MzAw_7661da59-3f50-4e83-b70a-4b37ac709322">465</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNC0zLTEtMS0xNDMwNg_9ee96ff3-4137-4b98-9800-9b2bd444d99c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNC0zLTEtMS00MzAw_bc23f895-2994-4332-89ab-c483825e1e43">17.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNC03LTEtMS0xNDMxMA_358a6be1-473c-4757-877f-6e24159996db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib5b211de82ab46bd9b8e7ecfb559c3d6_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNS0xLTEtMS00MzAw_f88918e7-aa90-4fe1-82d7-aebb13445c2f">12,771</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifb8601e7bab34e959227a80dc0653b82_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNS0zLTEtMS0xNDMwNg_2bba6925-4d01-47bf-9686-2ba384421564">564</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5b211de82ab46bd9b8e7ecfb559c3d6_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNS0zLTEtMS00MzAw_c20930ee-2728-4333-8b5b-eff2566857ce">12.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb8601e7bab34e959227a80dc0653b82_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNS03LTEtMS0xNDMxMA_25571dba-b3c9-4580-bcd6-e435f8dfd25c">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under our ESPP were <ix:nonFraction unitRef="shares" contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMzQwOQ_f78d87eb-ff80-44bb-88a4-25d5f145cb32">1,052,908</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMzQxNg_082bbb73-b54a-4008-91e4-6b6311d2a1a5">1,316,923</ix:nonFraction> during the three months ended March&#160;31, 2023 and 2022, respectively. In February 2023, an additional <ix:nonFraction unitRef="shares" contextRef="ife7d26135b95464faa9c223629b18165_D20220201-20220228" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMzQ5Mg_34d58d90-296c-4d2e-9e37-ea0682496204">4.0</ix:nonFraction>&#160;million shares were reserved under the ESPP. As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="id0a53ada800e4aa28d98cf54fcb50068_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMzU0Mg_c47224f9-6e00-4dfa-bc7a-3222189da045">12.9</ix:nonFraction>&#160;million shares of our common stock remain available for issuance under our ESPP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwNQ_352560de-3e72-48e3-873d-d9da1e0fe2b0" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife8c470b6b7746deb6ce4dee0f7e41f1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfMi0xLTEtMS00MzAw_7e8cf663-45c3-4fa3-b594-bb7e4b3f51cf">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i425ffb2f994b48168f939e71d5ba1ad5_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfMi0zLTEtMS00MzAw_d80efa3f-9402-4ff0-91b5-6a002ef71889">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibb3065503208462293114ba3cebc247b_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfMy0xLTEtMS00MzAw_0ff410a7-b8dc-49ec-ac50-82f4ccf06979">6,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab6e067725af44f990c3a8d3a8d5c108_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfMy0zLTEtMS00MzAw_4483cb7f-d486-4cee-8b1d-23a4315d5585">8,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if4665a48d6d14296985783f51f19db3f_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfNC0xLTEtMS00MzAw_00f309b1-50c1-4206-a260-c3fdb6d5fa40">9,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i197db529bcc44b64992d8392908d33c9_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfNC0zLTEtMS00MzAw_001993c3-0222-4149-b2f7-989fbcbfa8cf">11,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfOS0xLTEtMS00MzAw_d5b73f30-1316-49b0-b4c0-7e17ac490222">17,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfOS0zLTEtMS00MzAw_4242e586-3f69-4a2b-a777-f06ccd6c021e">22,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determining Fair Value</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="i601909df58e240ad90cdb10f1daa5142"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is <ix:nonFraction unitRef="number" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNTQ5NQ_c135bd2c-6bbc-4ef0-a470-d9069f1216a7">zero</ix:nonFraction> for all periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwNg_1d00935b-f990-49d5-849c-ce3737fd5922" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, there were no employee stock options granted. The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfMi0zLTEtMS0xNTUwMQ_3bf12d9b-8f04-4e2a-9838-b7685d6c146b">4.60</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfMy0zLTEtMS0xNTUwMQ_b2a4b612-bafe-433e-8ffd-006d127286f8">70</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfNC0zLTEtMS0xNTUwMQ_2f3307f6-7924-45fb-8f8c-a9e59b9a5b66">1.76</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfNS0zLTEtMS0xNTUwMQ_2a17db88-899f-49e7-b71b-cbb6200fc4fd">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfNi0zLTEtMS0xNTUwMQ_b29debb1-d6c5-4461-9109-91cb44e4fd70">6.66</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T<ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwNw_e378159b-0f7e-4cea-9784-75785c02bd20" continuedAt="i208cd0cbf5ed43d684db06e72b04e6e1" escape="true">he fair value of shares to be issued under the ESPP was estimated using the following assumptions:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i208cd0cbf5ed43d684db06e72b04e6e1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ceb564dadd349a3923864a97aebdd11_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMi0xLTEtMS00MzAwL3RleHRyZWdpb246NTE3NTgwMTJhNjAyNGMyN2I1NDhiMzdjMTY1NzBkNmVfNA_4f1d9836-0849-4d00-a6e3-d8dd858d3903">0.5</ix:nonNumeric> &#8212; <ix:nonNumeric contextRef="i978408a314554860834dc737c3b1419c_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMi0xLTEtMS00MzAwL3RleHRyZWdpb246NTE3NTgwMTJhNjAyNGMyN2I1NDhiMzdjMTY1NzBkNmVfOQ_80b1f725-ec81-4818-94a5-391481ed32a5">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31f9e8f8b14e405e9c92d12a3b2a9e3c_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMi0zLTEtMS00MzAwL3RleHRyZWdpb246N2UyZTJhZGNjNzVkNDQ2NDk1MjYyNWRmMjYzNDhiYTJfNA_b876815c-220c-41e1-ba2d-3a9ea6f882b3">0.5</ix:nonNumeric> &#8212; <ix:nonNumeric contextRef="i801b0f6773b4475bb9dd53e570abb778_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMi0zLTEtMS00MzAwL3RleHRyZWdpb246N2UyZTJhZGNjNzVkNDQ2NDk1MjYyNWRmMjYzNDhiYTJfOQ_4962eeeb-a3c7-409c-8f39-0e2f7ac94318">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMy0xLTEtMS00MzAw_8cbc5d63-c5ab-47d0-9dd9-7a4b3e778556">97</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMy0zLTEtMS00MzAw_7547a740-404b-4ee0-b0eb-1a45da5f301a">70</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNC0xLTEtMS00MzAwL3RleHRyZWdpb246ZTdhMjg5ZDQ3OWVkNDg1MGEzN2JkNjRkYTdlMTUxYjNfNA_1afc6d03-d71c-4b02-86d6-0bd33d6195e0">4.89</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNC0xLTEtMS00MzAwL3RleHRyZWdpb246ZTdhMjg5ZDQ3OWVkNDg1MGEzN2JkNjRkYTdlMTUxYjNfOQ_f46720d5-548b-463b-ab20-ace8006f6d38">5.20</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNC0zLTEtMS00MzAwL3RleHRyZWdpb246Nzg5M2ZlYTk5NjE1NDIwMDk1OGZmZjlhOTUwNTQzN2VfNA_a53f8558-9309-43b3-9ca9-40b18b1812b4">0.60</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNC0zLTEtMS00MzAwL3RleHRyZWdpb246Nzg5M2ZlYTk5NjE1NDIwMDk1OGZmZjlhOTUwNTQzN2VfOQ_e95669a7-933b-4be9-a840-b32c5872edec">1.31</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNS0xLTEtMS00MzAw_a35bf2f2-6f41-4b65-bb76-a23e301db336">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNS0zLTEtMS00MzAw_7440db0d-82d6-4c00-b255-649d82de9ba8">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNi0xLTEtMS00MzAw_80e8a01d-479a-4fe8-873e-2f2ca055fac3">5.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNi0zLTEtMS00MzAw_d9fe509c-9e77-455b-a191-6319c8f99d55">5.42</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="idd15d706814f4821992e3c53513cc1e0_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RleHRyZWdpb246N2IyY2JhZDcxMjgyNDE5Zjk4YjNkZDQ0ZTQzYzY4OTZfMTYyMg_2105ff8b-f714-4693-8b85-872d04ee5705" continuedAt="i41281aaad7a34d58a4a0a77d1fe4cc0f" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i41281aaad7a34d58a4a0a77d1fe4cc0f" continuedAt="ia37737bd042e430487f2894cc8103dcf">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the convertible senior notes, using the if-converted method, and outstanding equity awards using the treasury stock method.       </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><ix:continuation id="ia37737bd042e430487f2894cc8103dcf" continuedAt="id2f69542a44342509b4769d4c9a53883"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RleHRyZWdpb246N2IyY2JhZDcxMjgyNDE5Zjk4YjNkZDQ0ZTQzYzY4OTZfMTYyMw_f1a584ad-d893-47be-9005-fd3f6e44f339" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMy0xLTEtMS00MzAw_180ac82d-7879-45e7-b0ba-7e446f74f323">88,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMy0zLTEtMS00MzAw_1037df71-c58f-4685-b84c-026b0e4042c1">81,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing basic net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfNy0xLTEtMS00MzAw_90e6e9a6-cf74-43f8-ac8a-f9e0b1e72b64">242,032</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfNy0zLTEtMS00MzAw_f75848ca-c31c-4ff1-9997-9e11cb83d017">222,289</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfOC0xLTEtMS00MzAw_5b0f7cf3-5049-48cb-a87b-282b97dd3b2c">0.36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfOC0zLTEtMS00MzAw_788e6681-0099-4acd-a76c-9555ab11ac6f">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMTUtMS0xLTEtNDMwMA_67531178-09f0-440a-a020-eaceddafb1d9">242,032</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMTUtMy0xLTEtNDMwMA_8a559b42-d772-48fe-b8cc-2931e87fc2ad">222,289</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMTYtMS0xLTEtNDMwMA_a7c7ef44-2b58-4331-a668-0393eb792926">0.36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMTYtMy0xLTEtNDMwMA_5ae5f6d9-ddc4-4ca1-b717-e1b2414f6718">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RleHRyZWdpb246N2IyY2JhZDcxMjgyNDE5Zjk4YjNkZDQ0ZTQzYzY4OTZfMTYyNA_e13d8086-6dea-4cf4-9f38-0f13acc20ef6" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia7a1b740447c43f8a9ab44e87fa30129_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjA2YWEwMTc1ODNkMDRhMjBhNWQ5Nzg0N2FmMjZkZjRkL3RhYmxlcmFuZ2U6MDZhYTAxNzU4M2QwNGEyMGE1ZDk3ODQ3YWYyNmRmNGRfMi0xLTEtMS00MzAw_f95c3b46-a3d5-471c-b036-dd36e73d8178">20,690</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i04cac2e649ab434a97832d035f40bb55_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjA2YWEwMTc1ODNkMDRhMjBhNWQ5Nzg0N2FmMjZkZjRkL3RhYmxlcmFuZ2U6MDZhYTAxNzU4M2QwNGEyMGE1ZDk3ODQ3YWYyNmRmNGRfMi0zLTEtMS00MzAw_bc7b53e3-1f76-4ae9-9b84-ffb0e492a75a">20,690</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i14c86fb9249949768d1bdd6a89aac5c5_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjA2YWEwMTc1ODNkMDRhMjBhNWQ5Nzg0N2FmMjZkZjRkL3RhYmxlcmFuZ2U6MDZhYTAxNzU4M2QwNGEyMGE1ZDk3ODQ3YWYyNmRmNGRfNy0xLTEtMS0xNDQ3Nw_0989d2cf-356a-4c78-8c64-c41f97e51b56">30,366</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i22ec828e984b4ebc8d4bd50a11327be6_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjA2YWEwMTc1ODNkMDRhMjBhNWQ5Nzg0N2FmMjZkZjRkL3RhYmxlcmFuZ2U6MDZhYTAxNzU4M2QwNGEyMGE1ZDk3ODQ3YWYyNmRmNGRfNy0zLTEtMS0xNDQ3Nw_3cb4e55b-1e35-4ea3-b53e-33f63f58b34e">26,752</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><ix:continuation id="id2f69542a44342509b4769d4c9a53883" continuedAt="id428c319746d4f12b2cae6caf5769dd8"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Business Acquisitions </span></ix:continuation><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id428c319746d4f12b2cae6caf5769dd8">in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022, the contingently issuable shares would be due upon the achievement of a milestone.</ix:continuation> </span></div><div id="idd15d706814f4821992e3c53513cc1e0_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RleHRyZWdpb246NjMyNzU0NTJlNTVlNDc4MzgzOWJmZjcxMDlkNGM2YTBfMjQ3_921f247c-6b0d-4cf4-9564-7ad391166971" continuedAt="i273d6f6ce97949c18437980304a30833" escape="true">REVENUE</ix:nonNumeric></span></div><ix:continuation id="i273d6f6ce97949c18437980304a30833"><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RleHRyZWdpb246NjMyNzU0NTJlNTVlNDc4MzgzOWJmZjcxMDlkNGM2YTBfMjQ4_8cffd165-7288-4a96-be43-382bb9d291aa" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows (in thousands): </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:71.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.104%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icb8e95a9d8854d71946cebeffe0b0fb3_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfMi0xLTEtMS00MzAw_79753edd-d517-4eda-8217-a362dc851467">19,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib607a9972ac84fbcba2120fd9f7e766b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfMi0zLTEtMS00MzAw_fd3004e0-ac32-4d2b-a6b7-972deec0706a">19,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1641ad7927bc43fd949abadef487d0a9_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfMy0xLTEtMS00MzAw_00922382-7ea7-4b5f-993a-73b9bdaba8d6">7,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d1a78f0fe194bdfb72bae3a006f6e4b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfMy0zLTEtMS00MzAw_1463065f-88ee-4bb3-8194-44a17bb73965">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icd4c824aaa2f49fc9e518b8402729d62_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfNC0xLTEtMS00MzAw_411be84c-d92a-4e80-b6c4-70c029aaca7e">11,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1f27eacedc494a34b10e2794baf8cdf4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfNC0zLTEtMS00MzAw_1096c3b5-08e7-4de0-a25b-e539a8c1892b">8,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfNS0xLTEtMS00MzAw_4f0de8c1-126f-4659-a5c8-66f65817cb9b">38,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfNS0zLTEtMS00MzAw_1c5af888-5022-4921-a3b2-bd6310900903">33,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RleHRyZWdpb246NjMyNzU0NTJlNTVlNDc4MzgzOWJmZjcxMDlkNGM2YTBfMjQ5_ea2d2866-ab70-4ce9-9bfb-1aac254a9180" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows (in thousands): </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:71.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.104%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf52ec5feb514b609a102b910f6fa20e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfMi0xLTEtMS00MzAw_3bb73a0c-cca3-4650-b654-c9f052abdf61">20,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7da4fe9d8e6343d5a93b936c584e420e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfMi0zLTEtMS00MzAw_08b87121-9fd0-4097-9a67-9922a133dec2">15,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i978f0bc925a24496b995a232807ed9bb_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfMy0xLTEtMS00MzAw_2ec9aec0-7171-4106-a3b8-4865e916d0c3">13,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie2efc93840c24155946c8e1c76fe58de_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfMy0zLTEtMS00MzAw_95d3591b-d8d3-43e5-a8b5-c7fdd84b899b">12,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice0a062bee2249a4af687c1d872b4327_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNC0xLTEtMS00MzAw_c2c2db87-da3c-4185-b07e-06fe6c37a9da">34,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib1cbb2936bb243b9a6592d611b169c16_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNC0zLTEtMS00MzAw_964b21d8-3502-46f0-82a9-ac7148dcdd5d">28,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4b86da148fb47efb77eed316c399b1d_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNS0xLTEtMS00MzAw_d1d2e5a0-ff86-4192-a539-0ddefd792449">4,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5cf85b8a953e446a85fd97c4f01de732_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNS0zLTEtMS00MzAw_5d35f0e5-5a6f-4847-b925-4a829045d0ae">4,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNi0xLTEtMS00MzAw_8544ac08-73fa-4454-84d6-936855f488be">38,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNi0zLTEtMS00MzAw_bdf57662-46fd-482c-939d-34104590ddc9">33,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes that are included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 filed with the U.S. Securities and Exchange Commission, or the SEC, on February 28, 2023, or our Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current plans, expectations and beliefs that involve risks and uncertainties. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q, and you should not place undue reliance on our forward-looking statements. We do not assume any obligation to update any forward-looking statements. In preparing this MD&amp;A, we presume that readers have access to and have read the MD&amp;A in our Annual Report on Form 10-K, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management&#8217;s Discussion and Analysis (MD&amp;A) is organized into the following sections: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Overview and Outlook </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Results of Operations </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Off Balance Sheet Arrangements</span></div><div id="idd15d706814f4821992e3c53513cc1e0_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Outlook</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">About PacBio</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long-read sequencing technology and our emerging Sequencing by Binding ("SBB") short-read sequencing technology. Our products address solutions across a broad set of research applications including human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies and agricultural companies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our commercial team consisted of approximately 196 employees, including 59 quota-carrying representatives, many with advanced degrees in biology and significant experience in the genomics industry.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Objectives </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2023 strategic objectives are to: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.64pt">Drive rapid adoption of Revio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> by converting existing Sequel</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> II/IIe customers and attracting new PacBio customers </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.64pt">Demonstrate Onso&#8217;s extraordinary level of accuracy in the field and show how it can transform research in needle-in-haystack applications </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.64pt">Progress development of ultra-high-throughput and benchtop long-read sequencers and next generation SBB</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> short-read sequencer </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.64pt">Leverage current infrastructure to drive toward positive cash flow </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.64pt">Expand partnerships across ecosystem and workflow to drive customer adoption of SBB short-read sequencing and HiFi long-read sequencing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will continue to leverage our commercial organization and make significant improvements in the efficiency and usability of our products to seek to reach a broader customer base. We believe the commercial investments we have recently made will further help drive growth in our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To increase the adoption of HiFi sequencing, we have various development programs in progress to expand our product portfolio as well as increase the throughput and improve the usability of our existing sequencing technologies. We continue to focus on programs to accelerate new platform launches in the near to mid-term as well as increase applications for our technologies. In October 2022, we announced Revio, our new HiFi long-read sequencing system. We began taking orders in the fourth quarter of 2022 and commenced commercial Revio shipments in the first quarter of 2023. To address the oncology research markets with a highly differentiated alternative to existing third-party short-read sequencing products already on the market, we are also progressing development of Onso</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our SBB short-read platform. We began taking orders in the first quarter of 2023 and we believe we remain on track for commercial shipment in the second quarter of 2023.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to believe that with the capabilities of our HiFi chemistry and SMRT</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> technology, we can be a market leader in whole-genome clinical sequencing. Leading institutions have adopted our products to study rare and inherited disease. We believe the market opportunity for clinical sequencing is significant and could drive substantial revenue growth for the company. We plan to continue to pursue partner collaborations where the technologies being developed or applications being considered extend beyond whole-genome clinical sequencing. Collaborative arrangements add to the awareness of our products and service offerings and may drive new applications for use of our technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and efforts to control its spread have significantly curtailed the movement of people, goods, and services worldwide, including in the regions in which we sell our products and services and conduct our business operations. In the past, we were negatively impacted by the COVID-19 pandemic and we may be negatively impacted by any future resurgence of the COVID-19 pandemic.  Additionally, macroeconomic dynamics including rising inflation, global supply chain constraints, volatile capital markets, competition, exchange rates and lockdown restrictions associated with COVID-19 have adversely impacted our customers and lengthened customer sales cycles.  We expect these factors to continue to impact our revenues and results of operations throughout 2023, the size and duration of which is significantly uncertain, and as a result, we cannot reasonably estimate the future impact to our operations and financial results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See the </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_94">Risk Factors</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> section for further discussion of the possible impact of the COVID-19 pandemic on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key highlights of the three months ended March 31, 2023 consolidated financial results include the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.53pt">Revenue increased $5.7 million, or 17%, to $38.9 million for the three months ended March 31, 2023, as compared to $33.2 million for the three months ended March 31, 2022. The increase was primarily driven by the launch of Revio in the first quarter ended March&#160;31, 2023, which is sold at a higher average selling price than our previous Sequel II and IIe platform. We ended the quarter with an installed base of 32 Revio systems and we shipped 6 Sequel IIe systems in the quarter.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Gross profit as a percentage of revenue (gross margin) was 25% for the three months ended March 31, 2023, compared to 43% for the three months ended March 31, 2022. Gross margin declined due in part to instrument mix, as Revio instruments sold during the quarter had a lower margin primarily due to loyalty discounts provided and higher initial manufacturing costs, as well as adjustments of approximately $3.5 million primarily relating to excess consumables inventory resulting from a faster-than-expected decline in demand of Sequel II/IIe consumables due to the product transition to Revio. Our gross margin in future periods will depend on several factors, including new product transitions and offerings, strategic product pricing; product mix as a result of higher-margin consumables; supply chain constraints and inflation increasing costs of raw materials; manufacturing capacity and production volumes impacting the cost of inventory; freight costs; and excess or obsolete inventories.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.64pt">Loss from operations increased $13.7 million, or 18%, to $91.3 million for the three months ended March 31, 2023, as compared to $77.5 million for the three months ended March 31, 2022, driven primarily by an increase of $9.3 million of operating expenses, including a $4.0 million decrease in research and development expenses and a $13.3 million increase in the change in the fair value of the contingent consideration, and a decline in gross profit of $4.4 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.64pt">Cash, cash equivalents, and short-term investments were $874.9 million at March&#160;31, 2023, which represents a 13% increase compared to the balance at December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="idd15d706814f4821992e3c53513cc1e0_70"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three months ended March 31, 2023 and 2022 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(in thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of product revenue </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cost of revenue </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 68.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating Expense:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,063)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expense </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(91,252)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(77,523)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income (expense), net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(88,015)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(81,499)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,516)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $5.7 million, or 17%, to $38.9 million for the three months ended March 31, 2023, as compared to $33.2 million for the three months ended March 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Instrument revenue increased $5.2 million, or 33%, to $20.7 million for the three months ended March 31, 2023, as compared to $15.6 million for the three months ended March 31, 2022, primarily due to the sale of 32 newly launched Revio systems that have a higher average selling price. We expect sales volumes and the installed base of Revio instruments to grow, reflecting customer demand for the new product. As a result of this new product launch, we anticipate installed base and sales volumes of Sequel II/IIe to decline compared to recent quarters.   &#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Consumables revenue increased $1.3 million, or 10%, to $14.0 million for the three months ended March 31, 2023, as compared to $12.7 million for the three months ended March 31, 2022. The increase in consumable sales was primarily due to higher Revio and Sequel II/IIe consumables sales attributable to the growth in the instrument installed base as compared to the same period in the prior year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Service and other revenue decreased $0.7 million, or 14%, to $4.2 million for the three months ended March 31, 2023, as compared to $4.9 million for the three months ended March 31, 2022, primarily due to the change in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:107%">our terms of the warranty provided with the instrument during the first quarter of 2022 to remove the service component. As a result, the warranty is no longer a separate performance obligation and, accordingly, we accrue for the cost of the assurance warranty when revenue of the instrument is recognized, and no longer recognize a component of the instrument revenue in service and other revenue over the warranty period. We expect service revenue to continue to decline during the remainder of the year as we anticipate customers transitioning their service contracts to Revio following the standard warranty period, with fewer customers renewing Sequel service contracts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue, Gross Profit and Gross Margin</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product revenue increased $10.3 million, or 70%, for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The cost of product revenue increased primarily due to higher overall product costs, as well as adjustments of approximately $3.5 million primarily relating to excess consumables inventory resulting from a faster-than-expected decline in demand of Sequel II/IIe consumables due to the product transition to Revio.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Gross profit decreased $4.4 million, or 31%, to $9.8 million for the three months ended March 31, 2023, compared to $14.2 million for the three months ended March 31, 2022. Gross margin was 25% for the three months ended March 31, 2023, compared to gross margin of 43% for the three months ended March 31, 2022.  The decrease in gross margin was due in part to instrument mix, as Revio instruments sold during the quarter had a lower margin primarily due to loyalty discounts provided and higher initial manufacturing costs, as well as adjustments of approximately $3.5 million primarily relating to excess consumables inventory resulting from a faster-than-expected decline in demand of Sequel II/IIe consumables due to the product transition to Revio. While we expect gross margin to expand during the remainder of the year, gross margin could fluctuate depending on the pace at which Sequel II/IIe usage declines and Revio manufacturing is scaled. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by $4.0 million, or 8%, to $48.9 million for the three months ended March 31, 2023, compared to the $52.9 million for three months ended March 31, 2022. The decrease was primarily driven by the transition of Revio from development to commercialization. Research and development expense included share-based compensation expense of $6.7 million and $9.0 million during the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales, General and Administrative Expense</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative expense remained consistent at $39.8 million for each of the three months ended March 31, 2023 and 2022. Sales, general, and administrative expense included share-based compensation expense of $9.3 million and $12.0 million during the three months ended March 31, 2023 and 2022, respectively. The decrease in share-based compensation expense of $2.7 million was primarily offset by an increase in marketing expenses of $2.3 million during the three months ended March 31, 2023 as compared to the three months ended March 31, 2022.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration of $12.3 million during the three months ended March 31, 2023, represents the remeasurement impact of the contingent consideration liability of $200 million (composed of $100 million in cash and $100 million in shares of our common stock) that is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of both an instrument and related consumables, utilizing SBB technology. The increase in contingent consideration liability was primarily due to changes in the probabilities of milestone achievement, as well as the passage of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March 31, 2023, was $3.6 million compared to $3.7 million for the three months ended March 31, 2022 and was primarily comprised of interest on the Convertible Senior Notes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net for the three months ended March 31, 2023, was $6.9 million compared to $(0.3) million for the three months ended March 31, 2022. The $7.1 million increase was primarily due to investment income.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity, other than our holdings of cash, cash equivalents, and investments, has primarily been through the issuance of debt or equity securities, together with cash flow from operating activities. We have historically incurred, and expect to continue to incur, operating losses and generate negative cash flows from operations on an annual basis due to the investments we intend to make as described in Results of Operations above, and as a result, we may require additional capital resources to execute our strategic initiatives to grow our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">January 2023 Public Offering</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2023, we issued and sold an aggregate of 20,125,000 shares of our common stock at a purchase price of $10.00 per share pursuant to an automatic shelf registration statement filed on Form S-3 with the Securities and Exchange Commission, resulting in aggregate gross proceeds of approximately $201.3 million. After deducting underwriting discounts and commissions and offering costs paid or payable by us of approximately $12.1&#160;million, the net proceeds from the offering were approximately $189.2 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and investments of $874.9 million compared to $772.3 million as of December&#160;31, 2022. We believe that our existing cash, cash equivalents and investments will be sufficient to fund our projected operating requirements beyond the next 12 months from the date of filing of this Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may affect our capital needs include, but are not limited to, the pace of adoption of our products, which affects the sales of our products and services; our ability to obtain new collaboration and customer arrangements and maintain existing collaborations and arrangements; the progress of our research and development programs; initiation or expansion of research programs and collaborations; the purchase of patent licenses; manufacturing costs; service costs; the impact of product quality; litigation costs, including the costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; costs of developing new and enhanced products; acquisitions of complementary businesses, technologies or assets; and other factors. There can be no assurance that funds will be available on favorable terms, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Cash Flows</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(94,691)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(79,029)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(72,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">195,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31,761)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash in operating activities include the development of future products and product enhancements, manufacturing, and support functions related to our sales, general and administrative activities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the three months ended March 31, 2023, of $94.7 million was due primarily to a $88.0 million net loss that included non-cash items such as share-based compensation of $18.0&#160;million,  change in estimated fair value of contingent consideration of $12.3&#160;million, depreciation expense of $2.8&#160;million, amortization of right-of-use assets of $1.5&#160;million. This was offset by the accretion of discount and amortization of premium on marketable securities, net of $2.2&#160;million and $43.1&#160;million in net changes to operating assets and liabilities. Cash flow impact from changes in net operating assets and liabilities were primarily driven by increases in inventory, accounts receivable and prepaid and other assets, as well as decreases in accrued expenses, other liabilities and operating lease liabilities. These uses of cash were partially offset by an increase in accounts payable. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the three months ended March 31, 2022, of $79.0 million was due primarily to a $81.5 million net loss that included non-cash items such as share-based compensation of $22.7 million, depreciation expense of $2.3 million, amortization of right-of-use assets of $1.7 million, a $1.1 million decrease in liability due to the change in estimated fair value of contingent consideration, and a net cash outflow due to $24.4 million in net changes to operating assets and liabilities. Cash flow impact from changes in net operating assets and liabilities were primarily driven by decreases in accrued expenses, other liabilities and operating </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease liabilities, as well as increases in inventory, accounts receivable and prepaid and other assets. These uses of cash were partially offset by increases in accounts payable and deferred revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities consist primarily of capital expenditures and investment purchases, sales, and maturities. Cash used in investing activities for the three months ended March 31, 2023, was due to $164.5&#160;million of maturities and sales of investments offset by $233.3&#160;million in purchases of investments, and $3.7&#160;million in purchases of property and equipment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities consist primarily of capital expenditures and investment purchases, sales and maturities.  Cash provided by investing activities for the three months ended March 31, 2022, was due primarily to $122.1 million in maturities of investments offset by net purchases of investments of $76.4 million, and partially offset by purchases of property and equipment of $3.6 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the three months ended March 31, 2023 primarily resulted from  $189.2&#160;million in net proceeds related to the issuance of common stock from the underwritten public equity offering and $7.2&#160;million from the issuance of common stock through our equity compensation plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the three months ended March 31, 2022, resulted from proceeds of $5.6 million from the issuance of common stock through our equity compensation plans. </span></div><div><span><br/></span></div><div id="idd15d706814f4821992e3c53513cc1e0_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with the rules and regulations of the SEC. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in the Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_31">Note 1. Organization and Significant Accounting Policies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Recent Accounting Pronouncements&#8221;, in Part I, Item 1 of this Quarterly Report on Form 10-Q for information regarding applicable recent accounting pronouncements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we did not have any off-balance sheet arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we enter into standard indemnification arrangements. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology, or from claims relating to our performance or non-performance under a contract, any defective products supplied by us, or any acts or omissions, or willful misconduct, committed by us or any of our employees, agents or representatives. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in future periods but have not yet been made. To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between us and such third parties in connection with such fundraising efforts. To the extent that such indemnification obligations apply to the lawsuits described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_52">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_52">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_52">. Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification agreements has been recorded as of March 31, 2023.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry our convertible senior notes at the principal amount, less unamortized debt issuance costs, on our Condensed Consolidated Balance Sheets. Because the notes have a fixed annual interest rate of 1.50%, we do not have any economic interest rate exposure or financial statement risk associated with changes in interest rates. The fair value of the notes, however, may fluctuate when interest rates and the market price of our stock changes. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_49">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_49">4</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_49">. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we invested in cash equivalents, U.S. government and agency securities, U.S. Treasury securities, and corporate debt securities which were designated as cash equivalents and available-for-sale investments. Our cash equivalents and available-for-sale securities as of March&#160;31, 2023 was $875 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio comprising of marketable securities. We invest in a number of securities including U.S. government and agency securities, U.S. Treasury securities, and corporate debt securities and money market funds. We attempt to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in high grade investment securities. The fair market value of our fixed rate securities may be adversely impacted by increases in interest rates while income earned may decline as a result of decreases in interest rates. A hypothetical 100 basis-point (one percentage point) increase or decrease in interest rates compared to rates at March&#160;31, 2023 would have affected the fair value of our investment portfolio by approximately $3.5 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes in market risk from the information provided in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer, our Chief Financial Officer and our Chief Accounting Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer to determine whether any change in our internal control over financial reporting occurred during the fiscal quarter ended March 31, 2023 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There were no material changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2023, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_88"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="idd15d706814f4821992e3c53513cc1e0_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Legal Proceedings </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. District Court Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 26, 2019, Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the &#8220;PGI District Court matter&#8221;). The matter from this complaint is based on PGI&#8217;s U.S. Patent No. 7,767,441 (the &#8220;&#8216;441 Patent&#8221;). We plan to vigorously defend in this matter. On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking a declaratory judgement of invalidity of the &#8216;441 Patent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 22, 2020, we filed a petition requesting institution of an inter-partes review ("IPR") to the Patent Trial and Appeals Board (the &#8220;Board&#8221;) at the United States Patent Office requesting the Board to find a set of claims in the &#8216;441 Patent invalid. On June 27, 2020, we filed a second petition requesting institution of an IPR requesting the Board to find another set of claims in the &#8216;441 Patent invalid. The two petitions (the &#8220;PacBio IPR Petitions&#8221;) requesting IPRs assert that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions be instituted on all grounds presented. On January 18, 2022, the Board issued decisions on the two IPRs. In one IPR, all challenged claims were found unpatentable, including PGI&#8217;s core device claims. In the second IPR, the Board did not find the disputed claims unpatentable. We are appealing the decision in the second IPR to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 19, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties pending a final written decision on the IPRs. Following the final decision on the IPRs described above, on February 2, 2022, the judge ordered that the PGI District Court matter be reopened. However, in a subsequent order dated September 15, 2022, the judge stayed the PGI District Court matter pending a final decision by the U.S. Court of Appeals for the Federal Circuit regarding the appeal described above. We plan to vigorously defend against the remaining claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, Take2 Technologies, Ltd. and the Chinese University of Hong Kong filed a complaint in the U.S. District Court for Delaware against us alleging infringement of U.S. Patent No. 11,091,794 (the &#8220;&#8217;794 Patent&#8221;) (C.A. No. 22- cv-01595). The complaint alleges that our Sequel&#8482; II systems, Sequel IIe Systems, and Revio&#8482; Systems that operate version 11.0 or later of the SMRT&#8482; Link software, infringe the &#8216;794 Patent. The complaint seeks unspecified monetary damages and an order enjoining us from infringing the &#8217;794 Patent. We filed a motion to dismiss on February 14, 2023. We also filed a motion to transfer the case to the Northern District of California on March 2, 2023. We believe the infringement allegations in the complaint lack merit and we intend to vigorously defend in this matter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Proceedings in China</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 12, 2020, PGI filed a complaint in the Wuhan Intermediate People&#8217;s Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the &#8220;CN321 Patent&#8221;), which is related to the &#8216;441 Patent. On November 23, 2020 we filed an Invalidation Petition at the China National Intellectual Property Administration (CNIPA) demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid. On December 1, 2021, PGI filed an appeal with the Beijing IP Court, contesting the CNIPA decision. We filed a petition with the Wuhan Intermediate People&#8217;s court requesting dismissal of the infringement action </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">based on the CNIPA invalidation decision, and PGI filed a petition to withdraw its complaint. The Wuhan Intermediate People&#8217;s court granted PGI&#8217;s petition and dismissed the infringement action in May 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may also be involved in a variety of other claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment, and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">You should carefully consider the risks and uncertainties described below, together with all of the other information in our public filings with the SEC, which could materially affect our business, financial condition, results of operations and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition, results of operations and prospects. In addition, any worsening of the economic environment and the ongoing COVID-19 pandemic may exacerbate the risks described below, any of which could have a material impact on us. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Summary Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a summary of the principal risks that could adversely affect our business, operations, and financial results. Such risks are discussed more fully below and include, but are not limited to, risks related to:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to successfully market, commercialize, and sell current and future products and related maintenance services;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to achieve profitability for our business;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to successfully leverage and integrate our acquisitions and future acquisitions;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to successfully research, develop and timely manufacture our current and future products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">management of new product introductions and transitions, resultant costs, and ability of new products to generate promised performance;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">recent significant changes to our leadership team and resultant disruptions to our business;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">retention, recruitment, and training of senior management, key personnel, scientists and engineers;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to further penetrate nucleic acid sequencing applications, as well as grow product demand;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our reliance on outsourcing to other companies for manufacturing certain components and sub-assemblies, some of which are sole-sourced;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to consistently manufacture our instruments and consumables to meet customers&#8217; specifications, quantity, cost, or performance requirements;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the high amount of competition we face in our industry;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to attract customers and increase sales of current and future products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reliance on a limited number of customers for a significant portion of our revenues, including academic, research and government institutions;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the complexity of our products giving rise to defects or errors;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our unpredictable and lengthy sales cycles;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our business, financial condition and results of operations could be adversely affected by political and economic tensions between the United States and other countries, including China and Russia;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">securing and maintaining patent or other intellectual property protection for our products and related improvements;</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">current and future legal proceedings filed against us claiming intellectual property infringement;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the potential adverse impact of health epidemics, including the ongoing COVID-19 pandemic;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">governmental regulations that burden operations or narrow the market for our products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">evolving ethical, legal, privacy, social, and regulatory concerns regarding genetic testing;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">volatility of the price of our common stock; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our stock price falling as a result of future offerings or sales of securities.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our risk factors are not guarantees that no such conditions exist as of the date hereof and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expand into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have made and expect to continue making substantial investments to develop new products and enhance our existing products through our acquisitions and research and development efforts. For example, we recently announced our new Revio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> long-read sequencing system in the fourth quarter of 2022, and commenced commercial Revio shipments in the first quarter of 2023, and we are also progressing development of Onso</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, our SBB short-read platform, and we believe we remain on track for commercial shipment in the second quarter of 2023. Our future success is substantially dependent on our ability to successfully develop and commercialize our products, including Revio and Onso, which are anticipated to be used in demanding scientific research that requires substantial levels of accuracy and precision. In addition, we may not be successful in transitioning our Revio and Onso products from our prior generation products, and could incur related obsolete inventory charges. Customers may also be slower that we anticipate in making new capital equipment acquisitions, especially in the current economic environment. However, due to challenges we may experience in developing and marketing our existing products and launching new products, we may not be able to effectively:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">manage the timeliness of our new product introductions and the rate at which sales of our new products may cannibalize sales of our older products or manage sales and marketing of multiple sequencing platforms;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">drive adoption of our current and future products, including the Sequel II/IIe Systems, the Revio system and products under development related to our emerging SBB technology, including the Onso system;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">maintain our competitive position by continuing to attract and retain customers for our products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">provide appropriate levels of customer training and support for our products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">implement an effective marketing strategy to promote awareness of our products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">develop and implement an effective sales and distribution strategy for our current and future products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">develop, manufacture and commercialize new products or achieve an acceptable return on our manufacturing or research and development efforts and expenses;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">comply with regulatory requirements applicable to our products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">anticipate and adapt to changes in our market;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">accommodate customer expectations and demands with respect to our products, increase product adoption by our existing customers or develop new customer relationships;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">deliver our beta systems to our external beta testing sites or complete our external beta testing program on our currently expected timelines;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">overcome unexpected challenges discovered during beta testing;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">complete the scientific and technical validation of new products, such as Onso, on our currently expected timeline or at all;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">deliver our future products in a timely manner to our customers;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">grow our share by marketing and selling our products for new and additional applications;</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">manage the significant burdens that expanding our existing or future products into current and new markets may impose on marketing, compliance, and other administrative and managerial resources;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">maintain and develop strategic relationships with vendors, manufacturers, and other industry partners to acquire necessary materials for the production of, and to develop, manufacture and commercialize, our existing or future products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adapt or scale our manufacturing activities to meet performance specifications and potential demand at a reasonable cost;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">avoid infringement and misappropriation of third-party intellectual property;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obtain and maintain any necessary licenses to third-party intellectual property on commercially reasonable terms;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obtain valid and enforceable patents that give us a competitive advantage or enforce existing patents;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">protect our proprietary technology; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">attract, retain, and motivate qualified personnel.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The risks noted above, especially with respect to the marketing, sales, and commercialization of our products, may be heightened by the impact of current uncertain market and other conditions. In addition, a high percentage of our expenses is and will continue to be fixed. Accordingly, if we do not generate revenue as and when anticipated, we could suffer a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have incurred losses to date, and we expect to continue to incur significant losses as we develop our business and may never achieve profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have generally incurred net losses each quarter since inception, and we cannot be certain if or when we will produce sufficient revenue from our operations to support our costs. Even if profitability is achieved in the future, we may not be able to sustain profitability on a consistent basis. We expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our net losses since inception and our expectation of incurring substantial losses and negative cash flow for the foreseeable future could:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">make it more difficult for us to satisfy our obligations;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">increase our vulnerability to general adverse economic and industry conditions;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">limit our ability to fund future working capital, capital expenditures, research and development and other business opportunities;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">increase the volatility of the price of our common stock;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">limit our flexibility to react to changes in our business and the industry in which we operate;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">place us at a disadvantage to other companies that offer nucleic acid sequencing equipment or consumables; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">limit our ability to borrow additional funds.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, inflationary pressure, including as a result of supply shortages, has adversely impacted and could continue to adversely impact our financial results, and our operating costs may increase. We may not fully offset these cost increases by raising prices for our products and services, which could result in downward pressure on our margins. Further, our customers may choose to reduce their business with us if we increase our pricing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any or all of the foregoing may have a material adverse effect on our business, operations, financial condition, and prospects. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are not cash flow positive and may not have sufficient cash to make required payments under the terms of our debt or fund our long-term planned operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Additional funds may not be available on terms acceptable to us or at all. We have incurred and may further incur additional debt, including the debt incurred through issuance of $900.0 million in aggregate principal amount of 1.50% </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Convertible Senior Notes due 2028. We may not have sufficient cash to make required payments under the terms of this debt, and should this occur, debt holders have rights senior to common stockholders to make claims on our assets. We may not be able to issue equity securities due to unacceptable terms and conditions to us in the capital markets. To the extent that we intend to raise additional funds through the sale of our common stock, downward fluctuations in our stock price could adversely affect such fundraising efforts. Furthermore, equity financings normally involve shares sold at a discount to the current market price and fundraising through sales of additional shares of common stock or other equity securities will have a dilutive effect on our existing investors. The shares may also be sold at a time when the market price for our common stock is low because we are in need of the funds, which will further dilute existing holders more than if the market price for our common stock was higher.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that our growth will depend, in part, on our ability to fund our commercialization efforts and our efforts to develop new products, including any improvements to our existing products and the continued development and anticipated launch of the Onso SBB short-read system. To the extent our existing resources are not sufficient, it may require us to delay, or even not allow us to conduct any or all of these activities that we believe would be beneficial for our future growth. We may need to raise additional funds through public or private debt or equity financing or alternative financing arrangements, which may include collaborations or licensing arrangements. If we are unable to raise funds on favorable terms, or at all, we may have to reduce our cash burn rate and may not be able to support our commercialization efforts, launching of new products, or operations, or to increase or maintain the level of our research and development activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to generate sufficient cash flows or to raise adequate funds to finance our forecasted expenditures, we may have to make significant changes to our operations, including delaying or reducing the scope of, or eliminating some or all of, our development programs. We also may have to reduce sales, marketing, engineering, customer support or other resources devoted to our existing or new products, or we may need to cease operations. Any of these actions could materially impede our ability to achieve our business objectives and could materially harm our operating results. If our cash, cash equivalents and investments are insufficient to fund our projected operating requirements and we are unable to raise capital, it could have a material adverse effect on our business, financial condition and results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have made acquisitions and, in the future, may continue to acquire businesses, technologies or assets, form joint ventures or make other strategic investments with companies that could adversely affect our operating results, dilute our stockholders&#8217; ownership, or cause us to incur debt or significant expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our business strategy, we have acquired and expect to continue to pursue acquisitions of complementary businesses, technologies, or assets. We may also pursue technology license arrangements, strategic alliances or investments that complement our business. In July 2021, we acquired Circulomics, and in September 2021, we acquired Omniome. As of March&#160;31, 2023, we recorded goodwill of $410.0&#160;million and intangible assets of $410.0&#160;million. See </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 2. Business Acquisitions </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Acquisitions and strategic transactions involve numerous risks, any of which could harm our business and negatively affect our financial condition and results of operations, including:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">intense competition for suitable acquisition targets, which could increase prices and adversely affect our ability to consummate deals on favorable or acceptable terms;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failure or material delay in closing a transaction;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">transaction-related lawsuits or claims;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulties in integrating the technologies, operations, existing contracts, and personnel of an acquired company;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulties in retaining key employees or business partners of an acquired company;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulties in retaining suppliers, partners, or customers of an acquired company;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">challenges with integrating the brand identity of an acquired company with our own;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">diversion of financial and management resources from existing operations or alternative acquisition opportunities;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failure to realize the anticipated benefits or synergies of a transaction;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulties in developing technology post-acquisition;</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failure to identify the problems, liabilities, or other shortcomings or challenges of an acquired company or technology, including issues related to intellectual property, regulatory compliance practices, litigation, revenue recognition or other accounting practices, or employee or user issues;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">risks that regulatory bodies may enact new laws or promulgate new regulations that are adverse to an acquired company or business;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">risks that regulatory bodies do not approve our acquisitions or business combinations or delay such approvals;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">theft of our trade secrets or confidential information that we share with potential acquisition candidates or other potential strategic partners;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">risk that an acquired company or investment in new services cannibalizes a portion of our existing business; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adverse market reaction to an acquisition or other strategic transaction.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To finance any acquisitions or other strategic investments, we may raise additional funds, which could adversely affect our existing stockholders and our business. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. In addition, our stockholders may experience substantial dilution as a result of additional securities we may issue for acquisitions. Open market sales of substantial amounts of our common stock issued to stockholders of companies we acquire could also depress our stock price. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we fail to address the foregoing risks or other problems encountered in connection with past or future acquisitions of businesses, new technologies, services, and other assets and strategic investments, or if we fail to successfully integrate such acquisitions or investments, our business, financial condition, and results of operations could be adversely affected, including potential impairments of goodwill and intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to successfully develop and timely manufacture our current and future products, including with respect to SMRT Cells, Sequel II/IIe Systems, Revio, Onso, and other SMRT Cell, HiFi, and SBB products under development, and related products, our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In light of the highly complex technologies involved in our products, there can be no assurance that we will be able to manufacture and commercialize our current and future products on a timely basis or continue providing adequate support for our existing products. The commercial success of our products, including the Sequel, Sequel II/IIe and Revio Systems, and the Onso product under development, depends on a number of factors, including performance and reliability of the systems, our anticipating and effectively addressing customer preferences and demands, the success of our sales and marketing efforts, effective forecasting and management of product demand, purchase commitments and inventory levels, effective management of manufacturing and supply costs, and the quality of our products, including consumables such as SMRT Cells and reagents. Should we face delays in or discover unexpected defects during the further development or manufacturing process of instruments or consumables related to our products, including with respect to SMRT Cells, reagents, Sequel II/IIe Systems, Revio, Onso, and other SMRT Cell, HiFi, and SBB products under development, and including any delays or defects in software development or product functionality, the timing and success of the continued rollout and scaling of our products may be significantly impacted, which may materially and negatively impact our revenue and gross margin. The ability of our customers to successfully utilize our products will also depend on our ability to deliver high quality SMRT Cells and reagents. We have designed SMRT Cells and other consumables specifically for the Sequel, Sequel II/IIe, and Revio Systems, and may need to develop in the future, other customized SMRT Cells and consumables for our future products. Our production of the SMRT Cells for the Sequel and Sequel II/IIe Systems has been and may in the future, including with respect to the Revio system, be below desired levels and yields, and we have experienced and may experience in the future manufacturing delays, product or quality defects, SMRT Cell variability, and other issues. For example, the COVID&#8211;19 pandemic outbreak has impacted and could result in more pronounced impacts to our manufacturing and our ability to supply products. The performance of our consumables is critical to our customers&#8217; successful utilization of our products, and any defects or performance issues with our consumables would adversely affect our business. All of the foregoing could materially negatively impact our ability to sell our products or result in other material adverse effects on our business, operations, financial condition, operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The development of our products is complex and costly. Problems in the design or quality of our products may have a material and adverse effect on our brand, business, financial condition, and operating results, and could result in us losing our certifications from the International Organization for Standardization (&#8220;ISO&#8221;). If we were to lose ISO certification, then our customers might choose not to purchase products from us and this could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adversely impact our ability to develop products approved for clinical uses. Unanticipated problems with our products could divert substantial resources, which may impair our ability to support our new and existing products and could substantially increase our costs. If we encounter development challenges or discover errors in our products late in our development cycle, including during external beta testing, we may be forced to undertake design and/or production changes, delay product shipments or the scaling of manufacturing or supply. The completion of the production and external testing of our beta systems may also take longer than currently planned, cost more than currently expected and the scientific and technical validation may not be completed on our currently expected timelines or at all. Such testing may also expose fundamental flaws in our products that may cause us to abandon the further development of such products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the continued rollout of our current and future products, including with respect to the SMRT Cell, the Sequel II/IIe, Revio, and Onso Systems, is delayed or is not successful or less successful than anticipated, then we may not be able to achieve an acceptable return, if any, on our substantial research and development efforts, and our business may be materially and adversely affected. The expenses or losses associated with delayed or unsuccessful product development or lack of market acceptance of our existing and new products, including the SMRT Cell, Sequel II/IIe Systems, Revio, and Onso, could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our research and development efforts may not result in the benefits that we anticipate, and our failure to successfully market, sell, and commercialize our current and future products could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have dedicated significant resources to developing our current products, including sequencing systems and consumables based on our proprietary SMRT sequencing technology and our Sequel and Sequel II/IIe Systems. We are also engaged in substantial and complex research and development efforts, which, if successful, may result in the introduction of new products in the future, including in connection with the SMRT Cell, the Sequel II/IIe Systems and Revio, in addition to Onso and other SBB products currently under development. Our research and development efforts are complex and require us to incur substantial expenses. We may not be able to develop, manufacture and commercialize new products, obtain regulatory approval if necessary, or achieve an acceptable return, if any, on our research and development efforts and expenses or joint research and development efforts with partners. Our joint research and development efforts with partners require significant management attention and operational resources. If we are unable to successfully manage such joint research and development efforts, our future results may be adversely impacted. For example, in January 2021, we entered into a development agreement with Invitae, which was amended and restated on June 24, 2022 (the &#8220;Invitae Development Agreement&#8221;), regarding a multi-year collaboration for the development of a production-scale high-throughput sequencing platform. While we anticipate that in connection with the Invitae Development Agreement, we will continue to receive feedback, input and insight from Invitae in connection with our intended development of new high-throughput sequencing systems, such feedback is not contractually required and Invitae has no contractual right to participate in decisions regarding the development program for such new sequencing systems. Invitae is not contractually obligated to reimburse us for development costs under the Invitae Development Agreement. We do not expect to receive any additional revenue under the Invitae Development Agreement apart from potential purchases by Invitae of our instruments and consumables. In consideration of non-refundable Development Costs (as defined in the Invitae Development Agreement) paid by Invitae to us pursuant to the Invitae Development Agreement, we have provided Invitae with credits in connection with Invitae&#8217;s anticipated purchase of currently available and in-development sequencing systems (instruments and consumables). In addition, subject to certain conditions, Invitae will be entitled to most favored pricing for our Sequel IIe systems and certain in-development systems, including the Revio system and we may be required to sell instruments to Invitae at below-market prices. Furthermore, we will need to continue to expand our internal capabilities or seek new partnerships or collaborations, or both, in order to successfully develop, market, sell and commercialize our products for and in the markets we seek to reach. If we are unable to do so or are delayed, then this could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We must successfully manage new product introductions and transitions, including with respect to the SMRT Cell, the Sequel II/IIe and Revio Systems, and the development of the Onso SBB short-read sequencing system, and we may incur significant costs during these transitions and development, and these efforts may not result in the benefits we anticipate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our products and services fail to deliver the performance, scalability or results expected by our current and future customers, or are not delivered on a timely basis, our reputation and credibility may suffer, our current and future sales and revenue may be materially harmed and our business may not succeed. For instance, if we are not able to realize the benefits we anticipate from the development and commercialization of the SMRT Cell, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sequel II/IIe Systems, the Revio HiFi long-read sequencing system, and the Onso SBB short-read sequencing system, and any future products that may be developed for research, medical and clinical uses, it could have a material adverse effect on our business, financial condition and results of operations. In addition, the introduction of future products, including with respect to future long-read and short-read products, and related consumables, has and may in the future lead to our limiting or ceasing development of further enhancements to our existing products as we focus our resources on new products, and has resulted and could in the future result in reduced marketplace acceptance and loss of sales of our existing products, materially adversely affecting our revenue and operating results. The introduction of new products, including the recent announcement of our Revio system, has had and may in the future also have a negative impact on our revenue in the near-term as our current and future customers have delayed or cancelled and may in the future delay or cancel orders of existing products in anticipation of new products and we may also be pressured to decrease prices for our existing products. Our experience in managing product transitions is limited, and we have experienced, and may in the future experience, difficulty in managing or forecasting customer reactions, purchasing decisions or transition requirements with respect to newly launched products. We have incurred and may continue to incur significant costs in completing these transitions, including costs of write-downs of our products, as current or future customers transition to new products. If we do not successfully manage these product transitions, including with respect to the SMRT Cell, Sequel II/IIe Systems, the Revio and Onso Systems, and any future long-read and short-read products, our business, operations, financial condition, and prospects may be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business may be adversely affected by health epidemics, including the ongoing COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business has been and could be further adversely impacted by the effects of COVID-19 or other epidemics or pandemics. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although it is not possible at this time to estimate the impact that health epidemics, including the ongoing COVID-19 pandemic, could have on our business, the continued spread of pandemics and the measures taken by the governments of countries affected could disrupt the supply chain and the manufacture of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our manufacturing partners and suppliers have been and could continue to be disrupted by conditions related to COVID-19 or other epidemics or pandemics, possibly resulting in disruption to the production of our products. If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. There is significant uncertainty relating to the long-term effect of COVID-19 on our business. Infections may resurge or become more widespread and any ensuing disruptions to business activities or supply chains could have a negative impact on our business, financial condition, and operating results. Because our semiconductor manufacturers are located in a region where immunization rates in certain communities may be low, new and emerging variants of COVID-19 could impact workforce availability at those locations and disrupt supply. For example, the Chinese government may re-impose lockdowns or similar measures to combat the spread of COVID-19 and such measures have had, and may continue to have in the future, a negative impact on manufacturing and/or supply chains, as well as customer demand for our products and demand through certain distributors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic has caused us to modify our business practices, including limiting certain of our commercial operations and limiting certain employees from working in the office. We have offered, and may plan to continue to offer, a significant percentage of our employees flexibility in the amount of time they work in an office, which could adversely impact the productivity of certain employees and harm our business, including our future operating results. This may also present risks for our strategy and may present operational, cybersecurity, and workplace culture challenges that may adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even after the COVID-19 pandemic has subsided, we may continue to experience an adverse impact to our business as a result of its global economic impact, including recessionary effects and inflationary pressures. Specifically, difficult macroeconomic conditions, such as decreases in discretionary capital expenditure spending, changes to the government funding environment, a reduction in or the lapsing of COVID-19-related governmental stimulus measures, increased and prolonged unemployment or a decline in consumer confidence as a result of the COVID-19 pandemic, as well as limited or significantly reduced points of access of our products, could have a continuing adverse effect on the demand for some of our products and, consequently, related maintenance and support services. The degree of impact of COVID-19 on our business will depend on several factors, such as the duration and the extent of the pandemic, the risk of waning immunity among persons already vaccinated and an increase in fatigue or skepticism with respect to initial or booster vaccinations, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Significant changes to our leadership team and the resulting management transitions might harm our future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have experienced significant changes to our leadership team. Our President and Chief Executive Officer Christian O. Henry was appointed effective September 14, 2020, succeeding Dr. Michael Hunkapiller who retired on December 31, 2020. Our Chief Financial Officer Susan G. Kim was appointed effective September 28, 2020, succeeding Susan K. Barnes who retired on August 7, 2020. Our Chief Operating Officer Mark Van Oene was appointed effective January 8, 2021. Jeff Eidel was appointed Chief Commercial Officer effective August 16, 2022, succeeding Peter Fromen who resigned effective May 20, 2022. Also, our Vice President and Chief Accounting Officer Michele Farmer was appointed effective May 17, 2021, and our Chair of the Board Dr. John F. Milligan was appointed effective September 14, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we believe these leadership transitions are in the best interest of our stakeholders, these transitions may result in the loss of personnel with deep institutional or technical knowledge. Further, the transition could potentially disrupt our operations and relationships with employees, suppliers, partners, and customers due to added costs, operational inefficiencies, decreased employee morale and productivity and increased turnover. We must successfully recruit and integrate our new leadership team members within our organization to achieve our operating objectives; as such, the leadership </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">transition</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> may temporarily affect our business performance and results of operations while the new members of our leadership team become familiar with our business. In addition, our competitors may seek to use this transition and the related potential disruptions to gain a competitive advantage over us. Furthermore, these changes increase our dependency on the other members of our leadership team that remain with us, who are not contractually obligated to remain employed with us and may leave at any time. Any such departure could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional management turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. Our future operating results depend substantially upon the continued service of our key personnel and in significant part upon our ability to attract and retain qualified management personnel. If we are unable to mitigate these or other similar risks, our business, results of operations and financial condition may be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified scientists, engineers, sales personnel and other employees, our ability to maintain, develop and commercialize our products could be harmed and we may be unable to achieve our goals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our success depends upon the continuing services of members of our senior management team and scientific and engineering personnel. In particular, our scientists and engineers are critical to our technological and product innovations, and we will need to hire additional qualified personnel. Our industry, particularly in the San Francisco Bay Area, is characterized by high demand and intense competition for talent, and the turnover rate has been and may continue to be high. We compete for qualified management and scientific personnel with other life science companies, academic institutions and research institutions, particularly those focusing on genomics. This competition has been exacerbated by the increase in employee resignations in 2021 and 2022, as well as continued employee turnover, that have been experienced by us and reported by employers nationwide. In addition, we have experienced significant turnover in our senior management team in recent periods. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued stock options and restricted stock units that vest over time. The value to employees of stock options and restricted stock units that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. We may face challenges in retaining and recruiting such individuals due to sustained declines in our stock price that could reduce the retention value of equity awards. The loss of qualified employees, or an inability to attract, retain, and motivate employees, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and launches, business growth prospects, results of operations and financial condition. In addition, we will need to continue to recruit, hire and retain sales personnel to support the commercialization of our existing and new products. Our employees could leave our company with little or no prior notice and would be free to work for a competitor. In addition, changes to U.S. immigration policies, particularly to H-1B and other visa programs, could restrain the flow of technical and professional talent into the U.S. and may inhibit our ability to hire qualified personnel. If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we may not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have &#8220;key person&#8221; life insurance policies covering any member of our management team or other key personnel. Further, our vaccination and return to office protocols related to COVID-19 may also impact the recruitment and retention of key employees. The loss of any of these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">individuals or any inability to attract or retain qualified personnel, including scientists, engineers, sales personnel and others, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and introductions, business growth prospects, results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our success is highly dependent on our ability to further penetrate nucleic acid sequencing applications as well as on the growth and expansion of the demand for our products. If our products fail to achieve and sustain sufficient market acceptance, we will not generate expected revenue and our business may not succeed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although nucleic acid sequencing technology is well-established, our SMRT Sequencing technology is relatively new and evolving. We cannot be sure that our current or future products will gain acceptance in the marketplace at levels sufficient to support our costs. Our success depends, in part, on our ability to expand overall demand for nucleic acid sequencing to include new applications that are not practicable with other current technologies and to introduce new products that capture a larger share of growing overall demand for sequencing. To accomplish this, we must successfully commercialize, and continue development of, our proprietary SMRT Sequencing technology for use in a variety of life science and other research applications, including uses by academic, government and clinical laboratories, as well as pharmaceutical, diagnostic, biotechnology, and agriculture companies, among others. However, we may be unsuccessful in these efforts and the sale and commercialization of the SMRT Cell, Sequel II/IIe and Revio Systems, and anticipated sale and commercialization of Onso, and related products may not grow sufficiently to cover our costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There can be no assurance that we will be successful in adding new products or securing additional customers for our current and future products, including with respect to the SMRT Cell, Sequel II/IIe Systems, Revio and Onso. If we are unable to successfully develop SBB technology and sell acquired technology products, we may fail to achieve our strategic commercial initiatives in connection with the planned release of new products and anticipated entry into new markets. Our ability to further penetrate existing applications and any new applications depends on a number of factors, including the cost, performance and perceived value associated with our products, as well as customers&#8217; willingness to adopt a different approach to nucleic acid sequencing. Potential customers may have already made significant investments in other sequencing technologies and may be unwilling to invest in new technologies. We are experiencing pricing pressures caused by industry competition and increased demand for lower-priced instruments and lower operational costs. We have limited experience commercializing and selling products outside of the academic and research settings, and we cannot guarantee success in acquiring additional customers. Furthermore, we cannot guarantee that our products will be satisfactory to potential customers or that our products will perform in accordance with customer expectations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nucleic acid sequencing applications are new and dynamic, and there can be no assurance that they will develop as quickly as we anticipate, that they will reach their full potential or that our products will be appropriate or competitive for these applications. As a result, we may be required to refocus our marketing efforts, and we may have to make changes to the specifications of our products to enhance our ability to enter particular applications more quickly. We may also need to delay full-scale commercial deployment of new products as we develop them in order to perform quality control and early access user testing. We also need to maintain reliable supply chains for the various components in our new products and consumables to support large-scale commercial production. Even if we are able to implement our technology successfully, we and/or our sales and distribution partners may fail to achieve or sustain market acceptance of our current or future products across the full range of our intended life science and other applications. We need to continue to expand and update our internal capabilities or to collaborate with other partners, or both, in order to successfully expand sales of our products in the applications that we seek to reach, which we may be unable to do at the scale required to support our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the demand for our products grows more slowly than anticipated, if we are unable to successfully scale or otherwise ensure sufficient manufacturing capacity for new products to meet demand, if we are not able to successfully market and sell our products, if competitors develop better or more cost-effective products, if our product launches and commercialization are not successful, or if we are unable to further grow our customer base or do not realize the growth with existing customers that we are expecting, our current and future sales and revenue may be materially and adversely harmed, or we may recognize an impairment loss, and our business may not succeed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We rely on other companies for the manufacture of certain components and sub-assemblies and intend to outsource additional sub-assemblies in the future, some of which are sole sources. We may not be able to successfully scale the manufacturing process necessary to build and test multiple products on a full commercial basis, which could materially harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our products are complex and involve a large number of unique components, many of which require precise manufacturing. The nature of our products requires customized components that are currently available only from a limited number of sources, and in some cases, single sources. We have chosen to source certain critical components from a single source, including suppliers for our SMRT Cells, reagents, and instruments. We cannot assure you that product supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply collaborators, or that product supplies will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. We may be unable to negotiate binding agreements with our current and future sole source third-party manufacturing and supply collaborators or, in the event that such collaborators&#8217; services become interrupted for any reason, find replacement manufacturers to support our development and commercial activities at commercially reasonable terms. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or fail to provide sufficient quantities in a timely manner. If we are required to purchase these components from alternative sources, it could take several months or longer to qualify the alternative sources. If we are unable to source these product components from sole-source third-party manufacturing and supply collaborators for any reason, including in connection with acts of terrorism, hostilities, military conflict and acts of war, including between China and Taiwan, or secure a sufficient supply of these product components on a timely basis, or if these components do not meet our expectations or specifications for quality and functionality, our operations and manufacturing would be materially and adversely affected, we could be unable to meet customer demand and our business and results of operations may be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The operations of our third-party manufacturing partners and suppliers have been and could continue to be disrupted by conditions unrelated to our business or operations or that are beyond our control, including but not limited to international trade restrictions, inflation, supply chain disruptions, and conditions related to COVID-19 or other epidemics. If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. For example, the global shortage of semiconductors, which has been reported since early 2021, has caused challenges for us in our supply chain and resulted in some cost increases that have and may continue to adversely impact margins. During these periods of shortages or delays, the price of components may increase, or the components may not be available at all. Our suppliers have raised their prices and may continue to raise prices that we may not be able to pass on to our customers, which could adversely affect our business, including our competitive position, market share, revenues, and profit margins in material ways. We may not be able to secure enough components at reasonable prices or of acceptable quality to build new products in a timely manner in the quantities or configurations needed. For example, the Chinese government may re-impose lockdowns or similar measures to combat the spread of COVID-19 and these measures have had, and may continue to have in the future, a negative impact on manufacturing and/or supply chains, in addition to customer demand for our products and demand through certain distributors. If as a result of global economic or political instability, such as the political uncertainty associated with an escalation of the war in Ukraine, potential uncertainty related to Taiwan and its relationship with China, other disease outbreaks, or supply issues, we or our contractors could experience shortages, business disruptions or delays for materials sourced or manufactured in the affected countries, and their ability to supply us with instruments or product components may be affected. From time to time, certain components of our systems and reagents may reach the end of their life cycles or become obsoleted by our suppliers, and we would have to procure alternative sources for these end-of-life products. If we encounter delays or difficulties in securing the quality and quantity of materials we require for our products, our supply chain would be interrupted, which would adversely affect sales. If any of these events occur, our business and operating results could be harmed. Accordingly, if any of the foregoing occurs, our ability to commercialize our products, revenue and gross margins could suffer until lockdowns from COVID-19 infections are reduced, supply issues or business disruptions are resolved and/or other sources can be developed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, because our semiconductor suppliers are in regions that may have communities with low vaccination rates, the Omicron variant of COVID-19, or any variants that evolve in the future, could lead to increased infections among workers that could further disrupt the supply chain. Our current manufacturing process is characterized by long lead times between the placement of orders for and delivery of our products. If we do not accurately anticipate our needs or if we receive insufficient components to manufacture our products </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on a timely basis to meet customer demand, our sales and our gross margin may be adversely affected, and our business could be materially harmed. If we are unable to reduce our manufacturing costs and establish and maintain reliable, high-volume manufacturing suppliers as we scale our operations and expand our product offerings, our business, operations, financial condition, and prospects could be materially and adversely harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be unable to consistently manufacture our instruments and consumables, including SMRT Cells and reagents, to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to successfully generate revenue from our products, we need to supply our customers with products that meet their expectations for quality and functionality in accordance with established specifications. Our customers have experienced variability in the performance of our products. We have experienced and may continue to experience delays, quality issues or other difficulties leading to customer dissatisfaction with our products. Our production of SMRT Cells, flow cells, and of reagents for both our long- and short-read technologies, involve a long and complex manufacturing process and has been and may in the future be below desired yields and resulting output levels. We have experienced and may experience in the future manufacturing delays, product defects, variability in the performance of SMRT Cells, flow cells and other products, inadequate reserves for inventory, or other issues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is no assurance that we will be able to manufacture our products so that they consistently achieve the product specifications and quality that our customers expect, including any products developed for clinical uses. Problems in the design or quality of our products, including low manufacturing yields of SMRT Cells, flow cells, or sub-performing reagent lots, may have a material adverse </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">effect</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> on our brand, business, financial condition, and operating results, and could result in us losing our ISO certifications. If we were to lose our ISO certifications, then our customers might choose not to purchase products from us. There is also no assurance that we will be able to increase manufacturing yields and decrease costs, particularly if high rates of inflation continue, or that we will be successful in forecasting customer demand or manufacturing and supply costs, or that product supplies, including reagents or integrated chips, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices. Furthermore, while we are undertaking efforts to increase our manufacturing scale and capability, we may not be able to increase manufacturing to meet anticipated demand or may experience downtime in our manufacturing facilities, including, for example, if we experience increased cases of COVID-19 among our employees, or if our suppliers are unable to meet our increased demand at a time when the supply chain is under duress due to potential dislocations and disruptions in product and employee availability due to COVID-19. An inability to manufacture products and components that consistently meet specifications, in necessary quantities and at commercially acceptable costs, will have a negative impact, and may have a material adverse effect on our business, product development timelines, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Rapidly changing technology in life sciences and research diagnostics could make our products obsolete unless we continue to develop, manufacture and commercialize new and improved products and pursue new opportunities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry standards. Our future success depends on our ability to continually improve our products, to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis and to pursue new opportunities. These new opportunities may be outside the scope of our proven expertise or in areas where demand is unproven, and new products and services developed by us may not gain market acceptance or may not adequately perform in order to capture market share. Our inability to develop and introduce new products and to gain market acceptance of our existing and new products could harm our future operating results. Unanticipated difficulties or delays in replacing existing products with new products or in commercializing our existing or new products in sufficient quantities and of acceptable quality to meet customer demand, including with respect to the SMRT Cell, Sequel II/IIe Systems, Revio and Onso, could diminish future demand for our products and may materially and adversely harm our future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The size of the markets for our products, including our Revio and Onso instruments, may be smaller than estimated, and new market opportunities may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The market for sequencing systems and consumables products is evolving, making it difficult to accurately predict the size of the markets for our current and future products, including our Revio and Onso instruments. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our estimates of the total addressable market for our current and future products are based on a number of internal and third-party estimates and assumptions that may be incorrect, including the assumptions that academic, governmental, corporate, or other sources of funding will continue to be available to life sciences researchers at times and in amounts necessary to allow them to purchase our products. In addition, sales of new products may take time to develop and mature and we cannot be certain that these market opportunities will develop as we expect. While we believe our assumptions and the data underlying our estimates of the total addressable market for our products are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates, or those underlying the third-party data we have used, may change at any time, thereby reducing the accuracy of our estimates. As a result, our estimates of the total addressable market and growth opportunities for our products may be incorrect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The future growth of the market for our current and future products depends on many factors beyond our control, including recognition and acceptance of our products by the research and scientific communities, the growth, prevalence and costs of competing products and solutions and the development of robust ecosystems supporting our products and their methodologies. For example, our long-read sequencers, such as Revio, require tools for effective, high quality sample collection and preparation as well as advanced bioinformatic tools to process results; if these tools are unavailable to our customers, whether at a reasonable cost or at all, the market acceptance and growth of our long-read sequencers, like Revio, may be negatively impaired. There can be no assurance that our current or future products will gain traction in the market. If the markets for our current and future products are smaller than estimated or do not develop as we expect, our growth may be limited, and it could materially and adversely affect our business, operations, financial condition and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Increased market adoption of our products by customers may depend on the availability of sample preparation and informatics tools, some of which may be developed by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our commercial success may depend in part upon the development of sample preparation and software and informatics tools by third parties for use with our products. We cannot guarantee that product supplies, including reagents, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices, or that third parties will develop tools that our current and future customers will find useful with our products, or that customers will adopt such third-party tools on a timely basis or at all. A lack of complementary sample preparation and informatics tools, or delayed updates of such tools, may impede the adoption of our products and may materially and adversely impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are a significant number of companies offering nucleic acid sequencing products and/or services, including Illumina, BGI Genomics (also known as MGI or Complete Genomics), Thermo, ONT Ltd., Roche, Bionano, and Qiagen. Other companies recently entering the market include Ultima Genomics, Element Biosciences and Singular Genomics. Many of these companies currently have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater financial, technical, research and/or other resources, more experience in new product development, larger and more established manufacturing capabilities and marketing, sales, and support functions, and/or more established distribution channels to deliver products to customers than we do. These companies may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are also several companies that are in the process of developing or have already developed and commercialized new, competing or potentially competing technologies, products and/or services, including ONT Ltd. and its subsidiaries, against whom we have filed complaints for patent infringement in the U.S. District Court for the District of Delaware and, previously, with the U.S. International Trade Commission, in the High Court of England and Wales and in the District Court of Mannheim, Germany. ONT Ltd. previously filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany, also for patent infringement, and its subsidiary, Oxford Nanopore Technologies, Inc. (&#8220;ONT Inc.&#8221;), filed counterclaims against us in the U.S. District Court for the District of Delaware seeking declaratory judgements of non-infringement, invalidity and unenforceability of the asserted patents, as well as antitrust, false advertising and unfair competition counterclaims that were subsequently dismissed by that court. Roche is developing potentially competing sequencing products. Increased competition may result in pricing pressures, which could harm our sales, profitability or market share. Our failure to further enhance our existing products and to introduce new products to compete effectively could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may be unable to successfully increase sales of our current products or market and sell our future products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to achieve profitability depends, in part, on our ability to attract customers for our current and future products including Revio and Onso, and we may be unable to effectively market or sell our products or find appropriate partners to do so. To perform sales, marketing, distribution, and customer support functions successfully, we face a number of risks, including:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to attract, retain and manage qualified sales, marketing, and service personnel necessary to expand market acceptance for our technologies;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the performance and commercial availability expectations of our existing and potential customers with respect to new and existing products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">availability of potential sales and distribution partners to sell our technologies, and our ability to attract and retain such sales and distribution partners;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the time and cost of maintaining and growing a specialized sales, marketing and service force for a particular application, which may be difficult to justify in light of the revenue generated; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our sales, marketing and service force may be unable to execute successful commercial activities.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have enlisted and may continue to enlist third parties to assist with sales, distribution and customer support. There is no guarantee that we will be successful in attracting desirable sales and distribution partners, that we will be able to enter into arrangements with such partners on terms favorable to us or that we will be able to retain such partners on a going-forward basis. If our sales and marketing efforts, or those of any of our third-party sales and distribution partners, are not successful, or our products do not perform in accordance with customer expectations, our technologies and products may not gain market acceptance, which could materially and adversely impact our business, operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Large purchases by a limited number of customers represent a significant portion of our revenue, and any loss or delay of expected purchases has resulted, and in the future could result, in material quarter-to-quarter fluctuations of our revenue or otherwise adversely affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We receive a significant portion of our revenue from a limited number of customers. For example, for the years ended December 31, 2022, 2021, and 2020, one of our customers, who is our primary distributor in China, accounted for approximately 12%, 13%, and 14% of our total revenue, respectively. Many of these customers make large purchases on a purchase-order basis rather than pursuant to long-term contracts. As a consequence of the concentrated nature of our customer base and their purchasing behavior, our quarterly revenue and results of operations have fluctuated, and may fluctuate in the future, from quarter to quarter and are difficult to forecast. For example, the cancellation of orders or acceleration or delay in anticipated product purchases or the acceptance of shipped products by our larger customers has materially affected, and in the future could materially affect, our revenue and results of operations in any quarterly period. We have been, and may in the future be, unable to sustain or increase our revenue from our larger customers, or offset any discontinuation or decrease of purchases by our larger customers with purchases by new or other existing customers. To the extent one or more of our larger customers experience significant financial difficulty, bankruptcy or insolvency, this could have a material adverse effect on our sales and our ability to collect on receivables, which could materially and adversely harm our financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, many of our customers, including some of our larger customers, have negotiated, or may in the future negotiate, volume-based discounts or other more favorable terms from us or our sales and distribution partners, which can and have had a negative effect on our gross margins or revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect that such concentrated purchases will continue to contribute materially to our revenue for the foreseeable future and that our results of operations may fluctuate materially as a result of such larger customers&#8217; buying patterns. In addition, we may see consolidation of our customer base. The loss of one of our larger customers, a significant delay or reduction in its purchases, or any volume-based discount or other more favorable terms that we or our sales and distribution partner(s) may agree to provide, in light of the aggregated purchase volume or buying power resulting from such consolidation, has harmed, and in the future could harm, our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our products are highly complex, have recurring support requirements and could have unknown defects or errors, which may give rise to claims against us or divert application of our resources from other purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Products using our SMRT sequencing and SBB technology are highly complex and may develop or contain undetected defects or errors. Our customers have previously experienced reliability issues with our existing products, including the Sequel System and the Sequel II/IIe Systems. In addition, it is possible our customers </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">could experience reliability issues with current or future products, including the Sequel II/IIe, Onso, and Revio Systems. Despite internal and external testing, defects, or errors may arise in our products, which could result in a failure to obtain, maintain, or increase market acceptance of our products, diversion of development resources, injury to our reputation and increased warranty, service, and maintenance costs. New products, including Revio and Onso, or enhancements to our existing products, including the SMRT Cell and Sequel II/IIe Systems, in particular may contain undetected errors or performance problems that are discovered only after delivery to customers. If our products have reliability or other quality issues or require unexpected levels of support in the future, the market acceptance and utilization of our products may not grow to levels sufficient to support our costs and our reputation and business could be harmed. Low utilization rates of our products could cause our revenue and gross margins to be adversely affected. We provide a warranty for our sequencing instruments and consumables, which is generally limited to replacing, repairing, or at our option, giving credit for any sequencing instrument or consumable with defects in material or workmanship. Service contracts for our sequencing instruments may be separately purchased. Defects or errors in our products may also discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may be substantial and could materially and adversely affect our operating margins. If our service and support costs increase, our business and operations may be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, such defects or errors could lead to the filing of product liability claims against us or against third parties whom we may have an obligation to indemnify against such claims, which could be costly and time-consuming to defend and result in substantial damages. Although we have product liability insurance, any product liability insurance that we have or procure in the future may not protect our business from the financial impact of a product liability claim. Moreover, we may not be able to obtain adequate insurance coverage on acceptable terms. Any insurance that we have or obtain will be subject to deductibles and coverage limits. A product liability claim could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A significant portion of our sales depends on customers&#8217; spending budgets that may be subject to significant and unexpected variation which could have a negative effect on the demand for our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our instruments represent significant capital expenditures for our customers in research applications. Current and potential customers for our current or future products include academic and government institutions, genome centers, medical research institutions, clinical laboratories, pharmaceutical, agricultural, biotechnology, diagnostic and chemical companies. Their spending budgets can have a significant effect on the demand for our products. Spending budgets are based on a wide variety of factors, including the allocation of available resources to make purchases, funding from government sources which is highly uncertain and subject to change, the spending priorities among various types of research equipment, policies regarding capital expenditures during economically uncertain periods and the impact of COVID-19. Any decrease in capital spending or change in spending priorities of our current and potential customers could significantly reduce the demand for our products. Any delay or reduction in purchases by current or potential customers or our inability to forecast fluctuations in demand could materially and adversely harm our future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not be able to convert our orders in backlog into revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our backlog represents product orders from our customers that we have confirmed but have not been able to fulfill, and, accordingly, for which we have not yet recognized revenue. We may not receive revenue from these orders, and any order backlog we report may not be indicative of our future revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Many events can cause an order to be delayed or not completed at all, some of which may be out of our control, including the potential impacts from COVID-19 and our suppliers, especially our sole source suppliers, not being able to provide us with products or components. If we delay fulfilling customer orders or if customers reconsider their orders, those customers may seek to cancel or modify their orders with us. Customers may otherwise seek to cancel or delay their orders even if we are prepared to fulfill them. If our orders in backlog do not result in sales, our operating results may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our sales cycles are unpredictable and lengthy, which makes it difficult to forecast revenue and may increase the magnitude of quarterly or annual fluctuations in our operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The sales cycles for our sequencing instruments are lengthy because they represent a major capital expenditure and generally require the approval of our customers&#8217; senior management. This may contribute to substantial fluctuations in our quarterly or annual operating results, particularly during periods in which our sales volume is low. Because of these fluctuations, it is likely that in some future quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our stock would likely </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decrease. Past fluctuations in our quarterly and annual operating results have resulted in decreases in our stock price. Such fluctuations also mean that investors may not be able to rely on our operating results in any particular period as an indication of future performance. Sales to existing customers and the establishment of a business relationship with other potential customers is a lengthy process, generally taking several months and sometimes longer. Following the establishment of the relationship, the negotiation of purchase terms can be time-consuming, including as a result of seasonal factors, as discussed below, and a potential customer may require an extended evaluation and testing period. Our sales cycles may also lengthen as we introduce our Revio and Onso instruments and their associated consumables to the market, as our customers may have additional administrative, technical or other requirements associated with transitioning to new products and technologies. In anticipation of product orders, we may incur substantial costs before the sales cycle is complete and before we receive any customer payments. As a result, if a sale is not completed or is canceled or delayed, we may have incurred substantial expenses, making it more difficult for us to become profitable or otherwise negatively impacting our financial results. Even if our selling efforts are successful, the realization of revenue may be substantially delayed, our ability to forecast our future revenue may be more limited and our revenue may fluctuate significantly from quarter to quarter and year over year. For more information on the impact of these fluctuations on our results and stock price, see &#8220;</span><span style="color:#3051f2;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline" href="#i2c4f1d7e68d3489cba35abba53da6f70_893691">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i2c4f1d7e68d3489cba35abba53da6f70_893691">,&#8221; below</a></span><span style="color:#3051f2;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Because some of our customers and suppliers are based in China, our business, financial condition and results of operations could be adversely affected by the political and economic tensions between the United States and China.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to risks associated with political conflicts between the U.S. and China. A significant portion of our revenue is generated from China. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, for the years ended </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 31, 2022, 2021, and 2020, one of our customers, who is our primary distributor in China, accounted for approximately 12%, 13%, and 14%</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of our total revenue, respectively. In addition, certain c</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">omponents, some of which are critical components, of our products are manufactured in China. These components are either sourced directly from companies in China or indirectly from third parties that source from companies in China.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consequently, we are subject to significant risks associated with the trading relationship between the U.S. and China, which is currently characterized by significant uncertainty. Tariffs imposed by the U.S. and China have increased, and may continue to increase, our costs. Additionally, export restrictions imposed by the U.S. may impact our ability to export certain products to customers or distributors in China and restrict our ability to use certain integrated circuits in our products, and it is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. Moreover, the Chinese government may retaliate against U.S. trade restrictions in ways that could impact our business. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional import, export, tax, or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations. For more information, see &#8220;&#8212;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline" href="#i2c4f1d7e68d3489cba35abba53da6f70_893894">Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline" href="#i2c4f1d7e68d3489cba35abba53da6f70_893894">,</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i2c4f1d7e68d3489cba35abba53da6f70_893894">&#8221;</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i2c4f1d7e68d3489cba35abba53da6f70_893894"> below</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other risks could include:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">interruptions to operations in China as a result of the COVID-19 pandemic or other disease outbreaks and natural catastrophic events, which have in the past and can result in the future in business closures, transportation restrictions, import and export complications and cause shortages in the supply of raw materials or disruptions in manufacturing;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">product supply disruptions and increased costs as a result of heightened exposure to changes in the policies of the Chinese government, political unrest or unstable economic conditions in China; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the nationalization or other expropriation of private enterprises or intellectual property by the Chinese government.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Difficulties in this relationship may require us to take actions adverse to our business to comply with governmental restrictions on business and trade with China.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We face significant risks associated with doing business with Taiwanese suppliers and manufacturers due to the tense relationship between Taiwan and mainland China.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Substantially all of our consumable chips are partly manufactured by a company based in Taiwan. Our supply of consumables chips and other critical components may be materially and adversely affected by diplomatic, geopolitical, military and other developments affecting the relationship between China and Taiwan. Recent military exercises in the Taiwan Strait have contributed to geopolitical uncertainty regarding the future of the relationship between China and Taiwan. Current or future diplomatic, geopolitical, military or other tensions between China and Taiwan may lead to circumstances that negatively affect the availability of such consumable chips and other critical components to us, which could limit or prohibit our ability to manufacture consumable chips and other critical components or lead to an increase in our supply costs if we cannot find a similar cost alternative supplier, which could materially and adversely impact our business, operations, prospects, financial condition and results, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span id="i2c4f1d7e68d3489cba35abba53da6f70_893691"></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We operate on a December 31st year-end and believe that there are significant seasonal factors which may cause sales of our products, and particularly our sequencing instruments, to vary on a quarterly or yearly basis, contribute to lengthy sales cycles for our sequencing instruments, and increase the magnitude of quarterly or annual fluctuations in our operating results. We believe that this seasonality results from a number of factors, including the procurement and budgeting cycles of many of our customers, especially government-funded customers, which often coincide with government fiscal year ends. For example, the U.S. government&#8217;s fiscal year-end occurs in our third quarter and may result in increased sales of our products during this quarter if government-funded customers have unused funds that may be forfeited, or future budgets that may be reduced if funds remain unspent at fiscal year-end. Furthermore, Lunar New Year celebrations, which occur during our first quarter, and may last for a week or longer, resulting in closure of many of our customers&#8217; offices in China and across the Asia-Pacific region have caused, and may in the future cause, decreased sales of our consumables during our first quarter. These factors have contributed, and in the future may contribute, to substantial fluctuations in our quarterly operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operating results during any given period can also be impacted by numerous other factors, including the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">market acceptance for our products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to attract new customers;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the length of our sales cycles, as discussed above;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to achieve economies of scale and other manufacturing efficiencies at the rate we anticipate;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">publications of studies by us, our competitors or third parties;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the timing and success of new product introductions by us or our competitors or other changes in the competitive dynamics of our industry, such as consolidation;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the amount and timing of our costs and expenses;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes in our pricing policies or those of our competitors;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">general economic, industry and market conditions;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the regulatory environment in which we operate;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expenses associated with warranty obligations or unforeseen product quality issues;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the hiring, training, and retention of key employees, including our ability to grow our sales organization;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">litigation or other claims against us for intellectual property infringement or otherwise;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to obtain additional financing as necessary; </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes or trends in new technologies and industry standards; and the impact of COVID--19.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consequently, it is possible that in some quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our common stock would likely decrease. These fluctuations, among other factors, also mean that our operating results in any particular period may not be relied upon as an indication of future performance. Seasonal or cyclical variations in our sales have in the past, and may in the future, become more or less pronounced over time, and have in the past materially </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">affected, and may in the future materially affect, our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to use net operating losses to offset future taxable income may be subject to substantial limitations, and changes to U.S. tax laws may cause us to make adjustments to our financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under Section 382 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (&#8220;NOLs&#8221;) to offset future taxable income. We believe that we have had one or more ownership changes, and as a result, our existing NOLs are currently subject to limitation. Future changes in our stock ownership could result in additional ownership changes, including potentially material changes, under Section 382. Consequently, we may not be able to utilize some or all of our NOLs even if we attain profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our facilities in California are located near earthquake faults, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our facilities in California are located near earthquake fault zones and are vulnerable to damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired. In addition, the nature of our activities could cause significant delays in our research programs and commercial activities and make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to secure patent or other intellectual property protection for our products and improvements to our products may reduce our ability to maintain any technological or competitive advantage over our current and potential competitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to protect and enforce our intellectual property rights is uncertain and depends on complex legal and factual questions. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties. For example:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications or issued patents;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we or our licensors might not have been the first to file patent applications for these inventions;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">it is possible that neither our pending patent applications nor the pending patent applications of our licensors will result in issued patents;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the scope of the patent protection we or our licensors obtain may not be sufficiently broad to prevent others from practicing our technologies, developing competing products, designing around our patented technologies or independently developing similar or alternative technologies;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our and our licensors&#8217; patent applications or patents have been, are and may in the future be, subject to interference, opposition or similar administrative proceedings, which could result in those patent applications failing to issue as patents, those patents being held invalid or the scope of those patents being substantially reduced;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our enforcement of patents and proprietary rights in other countries may be problematic or unpredictable;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we or our partners may not adequately protect our trade secrets;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may not develop additional proprietary technologies that are patentable; or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the patents of others may limit our freedom to operate and prevent us from commercializing our technology in accordance with our plans.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The occurrence of any of these events could impair our ability to operate without infringing upon the proprietary rights of others or prevent us from establishing or maintaining a competitive advantage over our competitors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Variability in intellectual property laws may adversely affect our intellectual property position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Intellectual property laws, and patent laws and regulations in particular, have been subject to significant variability either through administrative or legislative changes to such laws or regulations or changes or differences in judicial interpretation, and it is expected that such variability will continue to occur. Additionally, intellectual property laws and regulations differ by country. Variations in the patent laws and regulations or in interpretations of patent laws and regulations in the United States and other countries may diminish the value of our intellectual property and may change the impact of third-party intellectual property on us. Accordingly, we cannot predict the scope of the patents that may be granted to us with certainty, the extent to which we will be able to enforce our patents against third parties or the extent to which third parties may be able to enforce their patents against us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Some of the intellectual property that is important to our business is owned by other companies or institutions and licensed to us, and changes to the rights we have licensed may adversely impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We license from third parties some of the intellectual property that is important to our business. If the third parties who license intellectual property to us fail to maintain the intellectual property that we have licensed, or lose rights to that intellectual property, the rights we have licensed may be reduced or eliminated, which would eliminate barriers against our competition. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, or could subject us to claims of intellectual property infringement or contract breach in litigation or other administrative proceedings that could result in damage awards against us and injunctions that could prohibit us from selling our products. In addition, some of our licenses from third parties limit the field in which we can use the licensed technology. Therefore, in order for us to use such licensed technology in potential future applications that are outside the licensed field of use, we may be required to negotiate new licenses with our licensors or expand our rights under our existing licenses. We cannot be certain that we will be able to obtain such licenses or expanded rights on reasonable terms or at all. In the event a dispute with our licensors were to occur, our licensors may seek to renegotiate the terms of our licenses, increase the royalty rates that we pay to obtain and maintain those licenses, limit the field or scope of the licenses, or terminate the license agreements. In addition, we have limited rights to participate in the prosecution and enforcement of the patents and patent applications that we have licensed. If we fail to meet our obligations under these licenses, or if we have a dispute regarding the terms of the licenses, these third parties could terminate the licenses, which could subject us to claims of intellectual property infringement. As a result, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. Further, because of the rapid pace of technological change in our industry, we may need to rely on key technologies developed or licensed by third parties, and we may not be able to obtain licenses and technologies from these third parties at all or on reasonable terms. The occurrence of these events may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The measures that we use to protect the security of and enforce our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to patents, we also rely upon trademarks, trade secrets, copyrights, and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented, or misappropriated. In addition, we attempt to protect our intellectual property and proprietary information by requiring our employees and consultants to enter into confidentiality and assignment of inventions agreements, and by entering into confidentiality agreements with our third-party development, manufacturing, sales, and distribution partners, who may also acquire, develop and/or commercialize alternative or competing products or provide services to our competitors. For example, Roche had certain access to our trade secrets and other proprietary information pursuant to an agreement we had entered into with Roche, subject to the confidentiality provisions thereof (certain of which provisions survive the termination of the agreement); however, Roche is developing potentially competing sequencing products. There can be no assurance that our measures have provided or will provide adequate protection for our intellectual property and proprietary information. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets and other proprietary information may be disclosed to others, or others may gain access to or disclose our trade secrets and other proprietary information. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. Additionally, others may independently develop proprietary information and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">techniques that are substantially equivalent to ours. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our intellectual property may be subject to challenges in the United States or foreign jurisdictions that could adversely affect our intellectual property position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our pending, issued and granted U.S. and foreign patents and patent applications have been, are and may in the future be, subject to challenges by ONT Ltd., ONT Inc. and Metrichor, Ltd. (&#8220;Metrichor&#8221; and, together with ONT Ltd. and ONT Inc., &#8220;ONT&#8221;) in addition to other parties asserting prior invention by others or invalidity on various grounds, through proceedings, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">interferences</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, reexaminations, or opposition proceedings. Addressing these challenges to our intellectual property has been, and any future challenges can be, costly and distract management&#8217;s attention and resources. For example, we previously incurred significant legal expenses to litigate and settle a complaint seeking review of a patent interference decision of the U.S. Patent and Trademark Office. Additionally, ONT previously requested that the U.S. Patent and Trademark Office institute </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> reviews of certain patents that we have asserted against ONT Inc. and ONT Ltd. in litigation proceedings for patent infringement. While none of the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> reviews requested by ONT were instituted by the U.S. Patent and Trademark Office, challenges of this nature before the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) in the future could result in determinations that our patents or pending patent applications are unpatentable to us, or are invalidated or unenforceable in whole or in part and could require us to expend significant time, funds, and other resources in litigating such challenges. Accordingly, adverse rulings in such proceedings could negatively impact the scope of our intellectual property protection for our products and technology and could materially and adversely affect our business. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation, cancellation, or amendment of any foreign patents we hold now or in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such products. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Some of our technology is subject to &#8220;march-in&#8221; rights by the U.S. government.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Some of our patented technology was developed with U.S. federal government funding. When new technologies are </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">developed</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that such action is necessary to (i) achieve practical application of the U.S. government-funded technology, (ii) alleviate health or safety needs, (iii) meet requirements of federal regulations, or (iv) give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government and such government funding must be disclosed in any resulting patent applications. Furthermore, our rights in such inventions are subject to government license rights and foreign manufacturing restrictions. The U.S. government has generally denied requests to exercise its march-in rights, even to provide access to potentially life-saving medications; however, if the U.S. government were to exercise its march-in rights to our patent technologies funded by the U.S. government, particularly for the benefit of one of more of our competitors, that may have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are involved in legal proceedings to enforce our intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our intellectual property rights involve complex factual, scientific, and legal questions. We operate in an industry characterized by significant intellectual property litigation. Even though we may believe that we have a valid patent on a particular technology, other companies have from time to time taken, and may in the future take, actions that we believe violate our patent rights. For example, we were previously involved in legal proceedings with ONT and Harvard University in several United States and European jurisdictions. We have in the past received adverse rulings against us with respect to our complaint with the United States International Trade Commission for one of these proceedings. Legal actions to enforce our patent rights have been, and will continue to be, expensive, and may divert significant management time and resources. Adverse parties from previous legal actions have brought, and they and others may in the future bring, claims against us and/or our intellectual property. Litigation is a significant ongoing expense, recognized in sales, general and administrative expense, with an uncertain outcome, and has been, and may in the future be, a material expense for us. Our enforcement actions may not be successful, have given rise to legal claims against us and could result in some of our intellectual property rights being determined to be invalid or not enforceable. Furthermore, an adverse determination or judgement could lead to an award of damages against us, or the issuance of an injunction </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">against us or our products that could prevent us from selling any products found to be infringing the intellectual property rights of another party.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have been, are currently, and could in the future be, subject to legal proceedings with third parties who may claim that our products infringe or misappropriate their intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our products are based on complex, rapidly developing technologies. We may not be aware of issued or previously filed patent applications that belong to third parties that mature into issued patents that cover some aspect of our products or their use. In addition, because patent litigation is complex and the outcome inherently uncertain, our belief that our products do not </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">infringe</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> third-party patents of which we are aware or that such third-party patents are invalid and unenforceable may be determined to be incorrect. As a result, third parties have claimed, and may in the future claim, that we infringe their patent rights and have filed, and may in the future file lawsuits or engage in other proceedings against us to enforce their patent rights. For example, we are involved in legal proceedings for alleged patent infringement and related matters in the United States with Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;), Take2 Technologies, Ltd., and the Chinese University of Hong Kong. In addition, ONT Ltd. and Harvard University have, in the past, filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany for patent infringement, and PGI has filed claims against us in the U.S. District Court for the District of Delaware and in the Wuhan People&#8217;s Court in China. We are aware of other issued patents and patent applications owned by third parties that could be construed to read on our products, and related maintenance and support services. Although we do not believe that our products or services infringe any valid issued patents, the third-party owners of these patents and applications may in the future claim that we infringe their patent rights and file lawsuits against us. In addition, as we enter new markets, our competitors and other third parties may claim that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to further develop or commercialize products or services and could result in the award of substantial damages against us. Patent litigation between competitors in our industry is common. Additionally, we have certain obligations to many of our customers and suppliers to indemnify and defend them against claims by third parties that our products or their use infringe any intellectual property of these third parties. In defending ourselves against any of these claims, we have in the past incurred, and could in the future incur, to defend ourselves or our customers, substantial costs, and the attention of our management and technical personnel could be diverted. For example, we previously incurred significant legal expenses to litigate and settle a complaint alleging patent infringement. Even if we have an agreement that indemnifies us against such costs, the indemnifying party may be unable to uphold its contractual obligations. To avoid or settle legal claims, it may be necessary or desirable in the future to obtain licenses relating to one or more products or relating to current or future technologies, which could negatively affect our gross margins. We may not be able to obtain these licenses on commercially reasonable terms, or at all. We may be unable to modify our products so that they do not infringe the intellectual property rights of third parties. In some situations, the results of litigation or settlement of claims may require us to cease allegedly infringing activities which could prevent us from selling some or all of our products. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in the course of our business, we may from time to time have access or be alleged to have access to confidential or proprietary information of others, which, though not patented, may be protected as trade secrets. Others could bring claims against us asserting that we improperly used their confidential or proprietary information, or that we misappropriated their technologies and incorporated those technologies into our products. A determination that we illegally used the confidential or proprietary information or misappropriated technologies of others in our products could result in us paying substantial damage awards or being prevented from further developing or selling some or all of our products, which could materially and adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Some of our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our use of &#8220;open source&#8221; software could adversely affect our ability to sell our products and subject us to possible litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A portion of the products or technologies developed and/or distributed by us incorporate &#8220;open source&#8221; software, and we may incorporate open source software into other products or technologies in the future. Some open source software licenses require that we disclose the source code for any modifications to such open source software that we make and distribute to one or more third parties, and that we license the source code for such modifications to third parties, including our competitors, at no cost. We monitor the use of open source software in our products to avoid uses in a manner that would require us to disclose or grant licenses under our source code that we wish to maintain as proprietary; however, there can be no assurance that such efforts have been or will be successful. In some circumstances, distribution of our software that includes or is linked with open source software could require that we disclose and license some or all of our proprietary source code in that software, which could include permitting the use of such software and source code at no cost to the user. Open source license terms are often ambiguous and there is little legal precedent governing the interpretation of these licenses. Successful claims made by the licensors of open source software that we have violated the terms of these licenses could result in unanticipated obligations, including being subject to significant damages, being enjoined from distributing products that incorporate open source software and being required to make available our proprietary source code pursuant to an open source license, which could substantially help our competitors develop products that are similar to or better than ours or otherwise materially and adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are, and may become, subject to governmental regulations that may impose burdens on our operations, and the markets for our products may be narrowed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject, both directly and indirectly, to the adverse impact of government regulation of our operations and markets. For example, export of our instruments may be subject to strict regulatory control in a number of jurisdictions. Following Russia&#8217;s invasion of Ukraine in February 2022, the United States and other countries imposed certain economic sanctions and severe export control restrictions against Russia and Belarus as well as certain Russian nationals and individuals and entities with ties to Russia, Belarus, and this conflict. These sanctions and restrictions have continued to increase as the conflict has further escalated and now cover the export of our products to Russia, and the United States and other countries could impose even wider sanctions and export restrictions and take other actions in the future that could further limit our ability to provide products in certain locations. Additionally, new restrictions on the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing to China without an export license discussed above impact our ability to provide products to customers or distributors in China. We have expanded and are continuing to expand the international jurisdictions into which we supply products, which increases the risks surrounding governmental regulations relating to our business. The need to or failure to satisfy export control criteria or to obtain necessary clearances could delay or prevent shipment of products, which could materially and adversely affect our revenue and profitability. Moreover, the life sciences industry, which is expected to continue to be one of the primary markets for our technology, has historically been heavily regulated. There are, for example, laws in several jurisdictions restricting research in genetic engineering, which may narrow our markets. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulations that may adversely affect our market opportunities. Additionally, if ethical and other concerns surrounding the use of genetic information, diagnostics or therapies become widespread, there may be less demand for our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life science industry in particular. Failure to comply with government regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenue and the cost of operating our business. In addition, changes to laws and government regulations could cause a material adverse effect on our business as we will need to adapt our business to comply with such changes. For example, a governmental prohibition on the use of human </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> diagnostics or other regulations that negatively impact the research and development activities of our customers would adversely impact our commercialization of products on which we have expended significant research and development resources, which would in turn have a material adverse impact on our business and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our products could become subject to government regulation as medical devices by the U.S. Food and Drug Administration or other domestic and international regulatory agencies even if we do not elect to seek regulatory clearance or approval to market our products for diagnostic purposes, which could increase our costs and impede or delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our products are currently labeled and promoted as research use only (&#8220;RUO&#8221;) products, and are not currently designed, or intended to be used, for clinical diagnostic tests or as medical devices. However, in the future, certain of our products or related applications, such as those that may be developed for clinical uses, could be subject to regulation by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), or the FDA&#8217;s regulatory jurisdiction could be expanded to include our products. Also, even if our products are labeled, promoted, and intended as RUO, the FDA or comparable agencies of other countries could disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with the FDA&#8217;s guidance on RUO products. For example, our customers may independently elect to use our RUO labeled products in their own laboratory developed tests (&#8220;LDTs&#8221;) for clinical diagnostic use, which could subject our products to government regulation, and the regulatory clearance or approval and maintenance process for such products may be uncertain, expensive, and time-consuming. Regulatory requirements related to marketing, selling, and distribution of RUO products could change or be uncertain, even if clinical uses of our RUO products by our customers were done without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected. In the event that we fail to obtain and maintain necessary regulatory clearances or approvals for products that we develop for clinical uses, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations may be materially harmed. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. We do not have experience in obtaining FDA approvals and no assurance can be given that we will be able to obtain or to maintain such approvals. Furthermore, any approvals that we may obtain can be revoked if safety or efficacy problems develop.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against laboratories developing and offering LDTs. However, in 2014, the FDA issued two draft guidance documents that set forth the FDA&#8217;s proposed risk-based framework for regulating LDTs, which are designed, manufactured, and used within a single laboratory. The draft guidance documents provide the anticipated details through which the FDA would propose to establish an LDT oversight framework, including pre-market review for higher-risk LDTs, such as those that have the same intended use as FDA-approved or cleared companion diagnostic tests currently on the market. In 2017, the FDA announced that it would not issue final guidance on the oversight of LDTs, and manufacturers of products used for LDTs, but would seek further public discussion on an appropriate oversight approach, and give Congress an opportunity to develop a legislative solution. More recently, the FDA has issued warning letters to certain genomics labs for illegally marketing genetic tests that claim to predict patients&#8217; responses to specific medications, noting that the FDA has not created a legal &#8220;carve-out&#8221; for LDTs and retains discretion to take action when appropriate, such as when certain genomic tests raise significant public health concerns.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As manufacturers develop more complex diagnostic tests and diagnostic software, the FDA may increase its regulation of LDTs. Any future legislative or administrative rule making or oversight of LDTs, if and when finalized, may impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with these laws. We cannot predict how these various efforts will be resolved, how Congress or the FDA will regulate LDTs in the future, or how that regulatory system will impact our business. Changes to the current regulatory framework, including the imposition of additional or new regulations, including regulation of our products, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation and enforcement by the applicable government agencies. Such laws include, without limitation, state and federal anti-kickback or anti-referral laws, healthcare fraud and abuse laws, false claims laws, privacy and security laws, Physician Payments Sunshine Act and related transparency and manufacturer reporting laws, and other laws and regulations applicable to medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, in 2013, the FDA issued Final Guidance &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only.&#8221; The guidance emphasizes that the FDA will review the totality of the circumstances when it comes to evaluating whether equipment and testing components are properly labeled as RUO. The final guidance states that merely including a labeling statement that the product is for research purposes only will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">not necessarily render the device exempt from the FDA&#8217;s clearance, approval, and other regulatory requirements if the circumstances surrounding the distribution, marketing and promotional practices indicate that the manufacturer knows its products are, or intends for its products to be, used for clinical diagnostic purposes. These circumstances may include written or verbal sales and marketing claims or links to articles regarding a product&#8217;s performance in clinical applications and a manufacturer&#8217;s provision of technical support for clinical applications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2020, the Department of Health and Human Services ("HHS") announced rescission of guidance and other informal issuances of FDA regarding pre-market review of LDT absent notice-and-comment rulemaking, stating that, absent notice-and-comment rulemaking LDTs are not required to obtain FDA pre-market authorization. In November 2021, HHS under the Biden administration issued a statement that withdrew the August 2020 policy announcement stating that HHS does not have a policy on LDTs that is separate from FDA&#8217;s longstanding approach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Legislative and administrative proposals to amend the FDA's oversight of LDTs have been introduced in recent years, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (the "VALID Act"), which aims to create a new category of medical products separate from medical devices called &#8220;in vitro clinical tests,&#8221; or IVCTs, and bring all such products within the scope of the FDA&#8217;s oversight. To date, Congress has not passed the VALID Act, but may revisit the VALID Act or similar policy riders and enact other FDA programmatic reforms in the future. It is unclear how future legislation by federal and state governments and FDA regulation will impact the industry, including our business and that of our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the FDA determines our products or related applications should be subject to additional regulation as in vitro diagnostic devices based upon customers&#8217; use of our products for clinical diagnostic or therapeutic decision-making purposes, our ability to market and sell our products could be impeded and our business, prospects, results of operations and financial condition may be adversely affected. In addition, the FDA could consider our products to be misbranded or adulterated under the Federal Food, Drug, and Cosmetic Act and subject to recall and/or other enforcement action.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">To the extent we elect to label and promote any of our products as medical devices, we would be required to obtain prior approval or clearance by the FDA or comparable foreign regulatory authority, which could take significant time and expense and could fail to result in a marketing authorization for the intended uses we believe are commercially attractive. Obtaining marketing authorization in one jurisdiction does not mean that we will be successful in obtaining marketing authorization in other jurisdictions where we conduct business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we elect to label and market our products for use as, or in the performance of, clinical diagnostics in the United States, thereby subjecting them to FDA regulation as medical devices, we would be required to obtain pre-market 510(k) clearance or pre-market approval from the FDA, unless an exception applies. It is possible, in the event we elect to submit 510(k) applications for certain of our products, that the FDA would take the position that a more burdensome pre-market application, such as a PMA or a </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">de novo</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> application is required for some of our products. If such applications were required, greater time and investment would be required to obtain FDA approval. Even if the FDA agreed that a 510(k) was appropriate, FDA clearance can be expensive and time consuming. It generally takes a significant amount of time to prepare a 510(k), including conducting appropriate testing on our products, and several months to years for the FDA to review a submission. Notwithstanding the effort and expense, FDA clearance or approval could be denied for some or all of our products for which we choose to market as a medical device or a clinical diagnostic device. Even if we were to seek and obtain regulatory approval or clearance, it may not be for the intended uses we request or that we believe are important or commercially attractive. There can be no assurance that future products for which we may seek pre-market clearance or approval will be approved or cleared by FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of such products. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our products. The lengthy and unpredictable pre-market clearance or approval process, as well as the unpredictability of the results of any required clinical studies, may result in our failing to obtain regulatory clearance or approval to market such products, which would significantly harm our business, results of operations, reputation, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we sought and received regulatory clearance or approval for certain of our products, we would be subject to ongoing FDA obligations and continued regulatory oversight and review, including the general controls listed above and the FDA&#8217;s QSRs for our development and manufacturing operations. In addition, we would be required to obtain a new 510(k) clearance before we could introduce subsequent material modifications or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">improvements to such products. We could also be subject to additional FDA post-marketing obligations for such products, any or all of which would increase our costs and divert resources away from other projects. If we sought and received regulatory clearance or approval and are not able to maintain regulatory compliance with applicable laws, we could be prohibited from marketing our products for use as, or in the performance of, clinical diagnostics and/or could be subject to enforcement actions, including warning letters and adverse publicity, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, if we decide to seek regulatory clearance or approval for certain of our products in countries outside of the United States or if a foreign regulatory authority determines that our products are regulated as medical devices, we would be subject to extensive medical device laws and regulations outside of the United States. Sales of such products outside the United States will likely be subject to foreign regulatory requirements, which can vary greatly from country to country. As a result, the time required to obtain clearances or approvals outside the United States may differ from that required to obtain FDA clearance or approval and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. In Europe, we would need to comply with the Medical Device Regulation 2017/745 and In Vitro Diagnostic Regulation 2017/746, which became effective May 26, 2017, with application dates of May 26, 2021 (postponed from 2020) and May 26, 2022, respectively. This will increase the difficulty of regulatory approvals in Europe in the future. In addition, the FDA regulates exports of medical devices. The number and scope of these requirements are increasing. Unlike many of the other companies offering nucleic acid sequencing equipment or consumables, this is an area where we do not have expertise. We, or our other third-party sales and distribution partners, may not be able to obtain regulatory approvals in such countries or may incur significant costs in obtaining or maintaining our foreign regulatory approvals. In addition, the export by us of certain of our products, which have not yet been cleared for domestic commercial distribution, may be subject to FDA or other export restrictions. Failure to comply with these regulatory requirements or obtain and maintain required approvals, clearances and certifications could impair our ability to commercialize our products for diagnostic use outside of the United States. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span id="i2c4f1d7e68d3489cba35abba53da6f70_893894"></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations, or other trade barriers may materially harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are continuing to expand our international operations as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the United States, especially the Asia-Pacific region, as discussed above. There is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, government regulations and tariffs. Starting in September 2018, the U.S. Trade Representative (the &#8220;USTR&#8221;) enacted various tariffs of 7.5%, 10%, 15%, and 25% on the import of Chinese products, including non-U.S. components and materials that may be used in our products. Additionally, China also has imposed tariffs on imports into China from the United States. These tariffs have and could continue to raise our costs. Furthermore, tariffs, trade restrictions, or trade barriers that have been, and may in the future be, placed on products such as ours by foreign governments, especially China, have raised, and could further raise, amounts paid for some or all of our products, which may result in the loss of customers and our business, and our financial condition and results of operations may be harmed. Further tariffs may be imposed that could cover imports of components and materials used in our products, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to components or materials used in our products or increased amounts that must be paid for our products, which could materially harm our business, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the U.S. government recently announced new controls restricting the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing to China without an export license. These new controls also apply to certain hardware containing these specified integrated circuits. In many cases, these licenses are subject to a policy of denial and will not be issued. These controls may impact our ability to export certain products to customers or distributors in China and restrict our ability to use certain integrated circuits in our products. The U.S. government also recently added additional entities in China to restricted party lists impacting the ability of U.S. companies to provide items to these entities. Moreover, in November 2018, the U.S. Commerce Department&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) released an advance notice of proposed rulemaking to control the export of emerging technologies. This notice included &#8220;[b]iotechnology, including nanobiology; synthetic biology; genomic and genetic engineering; or neurotech&#8221; as possible areas of increased export controls. The Biden Administration has continued to provide updated lists of emerging technologies subject to national security consents, and it continues to include biotechnologies including &#8220;[g]enome and protein engineering including design tools&#8221; and &#8220;[b]iomanufacturing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and bioprocessing technologies.&#8221; Therefore, it is possible that our ability to export our products to customers or distributors in China may be further restricted in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is possible that the Chinese government will retaliate in response to existing or future U.S. export controls or trade restrictions in ways that could impact our business. It also is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. The continued threats of tariffs, trade restrictions and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively impact our sales. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional tax or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our international business could expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Engaging in international business inherently involves a number of difficulties and risks, including:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">required compliance with existing and changing foreign regulatory requirements and laws that are or may be applicable to our business in the future, such as the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;) and other data privacy requirements, labor and employment regulations, anti-competition regulations, the U.K. Bribery Act of 2010 and other anti-corruption laws, regulations relating to the use of certain hazardous substances or chemicals in commercial products, and require the collection, reuse, and recycling of waste from products we manufacture;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">required compliance with U.S. laws such as the Foreign Corrupt Practices Act, and other U.S. federal laws and trade and economic sanctions and other regulations established by the Office of Foreign Asset Control;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">export requirements and import or trade restrictions;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">laws and business practices favoring local companies;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">restrictions on both inbound and outbound cross-border investment;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">foreign currency exchange, longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes in social, economic, and political conditions or in laws, regulations and policies governing foreign trade, manufacturing, research and development, and investment both domestically as well as in the other countries and jurisdictions in which we operate and into which we may sell our products including as a result of the separation of the United Kingdom from the European Union (&#8220;Brexit&#8221;) and ongoing geopolitical tensions related to the political uncertainty and military actions associated with the war in Ukraine, resulting sanctions imposed by the U.S. and other countries, and retaliatory actions taken by Russia in response to such sanctions;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements, and other trade barriers;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulties and costs of staffing and managing foreign operations; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulties protecting, maintaining, enforcing, or procuring intellectual property rights and defending against intellectual property claims under the law and judicial systems of other countries.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If one or more of these risks occurs, it could require us to dedicate significant resources to remedy such occurrence, and if we are unsuccessful in finding a solution, our financial results will suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our operations involve the use of hazardous materials, and we must comply with environmental, health and safety laws, which can be expensive and may adversely affect our business, operating results and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development and manufacturing activities involve the use of hazardous materials, including chemicals and biological materials, and some of our products include hazardous materials. Accordingly, we are subject to federal, state, local and foreign laws, regulations, and permits relating to environmental, health and safety matters, including, among others, those governing the use, storage, handling, exposure to and disposal of hazardous materials and wastes, the health and safety of our employees, and the shipment, labeling, collection, recycling, treatment, and disposal of products containing hazardous materials. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. For example, under certain circumstances and under certain environmental laws, we could be held liable for costs relating to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contamination at our or our predecessors&#8217; past or present facilities and at third-party waste disposal sites. We could also be held liable for damages arising out of human exposure to hazardous materials. There can be no assurance that violations of environmental, health and safety laws will not occur as a result of human error, accident, equipment failure or other causes. The failure to comply with past, present or future laws could result in the imposition of substantial fines and penalties, remediation costs, property damage and personal injury claims, investigations, the suspension of production or product sales, loss of permits or a cessation of operations. Any of these events could harm our business, operating results, and financial condition. We also expect that our operations will be affected by new environmental, health and safety laws and regulations on an ongoing basis, or more stringent enforcement of existing laws and regulations. New laws or changes to existing laws may result in additional costs and may increase penalties associated with violations or require us to change the content of our products or how we manufacture them, which could have a material adverse effect on our business, operating results, and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Ethical, legal, privacy, data protection and social concerns or governmental restrictions surrounding the use of genetic information could reduce demand for our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our products may be used to provide genetic information about humans, agricultural crops and other living organisms. The information obtained from our products could be used in a variety of applications which may have underlying ethical, legal, privacy, data protection and social concerns, including the genetic engineering or modification of agricultural products or testing for genetic predisposition for certain medical conditions. Governmental authorities could, for safety, social or other purposes, call for limits on or regulation of the use of genetic testing, and may consider or adopt such regulations or other restrictions. Such concerns or governmental restrictions could limit the use of our products or be costly and burdensome to comply with, and actual or perceived violations of any such restrictions may lead to the imposition of substantial fines and penalties, remediation costs, claims and litigation, regulatory investigations and proceedings, and other liability, any of which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Regulations related to conflict minerals has caused us to incur, and will continue to cause us to incur, additional expenses and could limit the supply and increase the costs of certain materials used in the manufacture of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 that require us to conduct diligence and report on whether or not our products contain conflict minerals. The implementation of these requirements could adversely affect the sourcing, availability and pricing of the materials used in the manufacture of components used in our products. Furthermore, the complex nature of our products requires components and materials that may be available only from a limited number of sources and, in some cases, from only a single source. We have incurred, and will continue to incur, additional costs to comply with the disclosure requirements, including costs related to conducting diligence procedures to determine the sources of conflict minerals that may be used or necessary to the production of our products and, if applicable, potential changes to components, processes, or sources of supply as a consequence of such verification activities. We may face reputational harm if we determine that certain of our products contain minerals that are not determined to be conflict free or if we are unable to alter our processes or sources of supply to avoid using such materials. In such circumstances, the reputational harm could materially and adversely affect our business, financial condition, or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">R</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">isks Related to Owning Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The price of our common stock has been, is, and may continue to be, highly volatile, and you may be unable to sell your shares at or above the price you paid to acquire them.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The market price of our common stock is highly volatile, and we expect it to continue to be volatile for the foreseeable future in response to many risk factors listed in this section, and others beyond our control, including:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">actual or anticipated fluctuations in our financial condition and operating results;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">announcements of new products, technological innovations or strategic partnerships by us or our competitors;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">announcements by us, our customers, partners, or suppliers relating directly or indirectly to our products, services or technologies;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">overall conditions in our industry and market;</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">addition or loss of significant customers;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes in laws or regulations applicable to our products;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">actual or anticipated changes in our growth rate relative to our competitors;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or achievement of significant milestones;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">additions or departures of key personnel;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">competition from existing products or new products that may emerge;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">issuance of new or updated research or reports by securities analysts;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">announcement or expectation of additional financing efforts;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sales of our common stock by us or our stockholders;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reports, guidance and ratings issued by securities or industry analysts;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">operating results below the expectations of securities analysts or investors; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">general economic and market conditions, which could be impacted by various events including COVID-19 or interest rate fluctuations, increases in fuel prices, foreign currency fluctuations, international tariffs, acts of terrorism, hostilities or the perception that hostilities may be imminent, military conflict and acts of war, including further political uncertainty and military actions associated with the war in Ukraine and the related response, including sanctions or other restrictive actions, by the United States and/or other countries.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any of the forgoing occurs, it would cause our stock price or trading volume to decline. Stock markets in general and the market for companies in our industry in particular have experienced price and volume fluctuations, which have been exacerbated by the COVID-19 pandemic, and current macroeconomic trends and geopolitical events, and have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, companies that </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been a party to this type of litigation in the past and may be the target of this type of litigation again in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could reduce the market price that our common stock might otherwise attain and may dilute your voting power and your ownership interest in us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could adversely affect the market price of our common stock and may make it more difficult for existing stockholders to sell their common stock at a time and price that they deem appropriate and may dilute their voting power and ownership interest in us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, if our existing stockholders sell, or indicate an intent to sell, a large number of shares of our common stock in the public market, it could cause our stock price to fall. We may also issue shares of common stock or securities convertible into our common stock in connection with a financing, acquisition, our equity incentive plans, or otherwise. Any such issuances would result in dilution to our existing stockholders and the market price of our common stock may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, in connection with the closing of the Omniome Merger, we completed a private placement of an aggregate of 11,214,953 shares of our common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300 million (the &#8220;Private Placement&#8221;) and registered the Private Placement shares for resale on a registration statement on Form S-3. The Private Placement Investors may sell any or all of their shares pursuant to the registration statement from time to time.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 27, 2023, we issued and sold an aggregate of 20,125,000 shares of our common stock at a purchase price of $10.00 per share pursuant to an automatic shelf registration statement filed on Form S-3 (File No. 333-249999) with the Securities and Exchange Commission, resulting in aggregate gross proceeds of approximately $201.3 million. The investors may sell any or all of their shares from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of ownership by our principal stockholders may result in control by such stockholders of the composition of our board of directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our existing principal stockholders, executive officers, directors, and their affiliates beneficially own a significant number of our outstanding shares of common stock. In addition, such parties may acquire additional control by purchasing stock that we issue in connection with our future fundraising efforts. These parties may now and in the future be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors. This control could have the effect of delaying or preventing a change of control of our company or changes in management and will make the approval of certain transactions difficult or impossible without the support of these stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">authorize our board of directors to issue, without further action by the stockholders, up to 50,000,000 shares of undesignated preferred stock and up to approximately 1,000,000,000 shares of authorized but unissued shares of common stock;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">specify that special meetings of our stockholders can be called only by our board of directors, the Chair of the Board, the Chief Executive Officer or the President;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">establish advance notice procedures for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">provide that our directors may be removed only for cause; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for certain stockholder litigation matters, and also provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, each of which could limit our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, stockholders, or employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf&#894; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, stockholders, officers, or other employees to us or our stockholders&#894; (iii) any action arising pursuant to any provision of the Delaware General Corporation Law; (iv) any action to interpret, apply, enforce or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws&#894; or (v) any action asserting a claim governed by the internal affairs doctrine, except as to each of (i) through (v) above, for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws also provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any person or entity purchasing, holding or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to the foregoing bylaw provisions. Although we believe these exclusive forum provisions benefit us by providing increased consistency in the application of Delaware law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or any of our directors, stockholders, officers or other employees, which may discourage lawsuits with respect to such claims against us and our current and former directors, stockholders, officers or other employees. In addition, a stockholder that is unable to bring a claim in the judicial forum of its choosing may be required to incur additional costs in the pursuit of actions which are subject to the exclusive forum provisions described above. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder as a result of our exclusive forum provisions. Further, in the event a court finds either exclusive forum provision contained in our bylaws to be unenforceable or inapplicable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our large number of authorized but unissued shares of common stock may potentially dilute existing stockholders&#8217; stockholdings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have a significant number of authorized but unissued shares of common stock. Our board of directors may issue shares of common stock from this authorized but unissued pool from time to time without stockholder approval, resulting in the dilution of our existing stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We do not intend to pay dividends for the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash or to repurchase the Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, we issued $900.0 million in aggregate principal amount of 1.50% Convertible Senior Notes due 2028, which we refer to as the Notes. The Notes will mature on February 15, 2028, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. Holders of the Notes will have the right to require us to repurchase all or a portion of their Notes upon the occurrence of a fundamental change before the maturity date at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus unpaid interest to, but excluding, the maturity date. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to settle a portion or all of our conversion obligation in cash in respect of the Notes being converted. Moreover, we will be required to repay the Notes in cash at their maturity unless earlier converted, redeemed, or repurchased. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or pay cash with respect to Notes being converted or at their maturity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our ability to repurchase Notes or to pay cash upon conversions of Notes or at their maturity may be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase Notes at a time when the repurchase is required by the indenture or to pay cash upon conversions of Notes or at their maturity as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. Moreover, the occurrence of a fundamental change under the indenture could constitute an event of default under any such agreement. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness or to pay cash amounts due upon conversion, upon required repurchase or at maturity of the Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If the Notes are converted, it may adversely affect our financial condition and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Holders of the Notes are entitled to convert their Notes at any time at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">General Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General conditions in the global economy and in the global financial markets could adversely affect our results of operations, including the potential effects from the ongoing COVID-19 pandemic as discussed above, and the overall demand for nucleic acid sequencing products may be particularly vulnerable to unfavorable economic conditions. A global financial crisis, inflation or a global or regional political disruption, as well as acts of terrorism, hostilities, military conflict and acts of war, including any further political uncertainty and military actions associated with the war in Ukraine and the related response, could cause extreme volatility in the capital and credit markets. A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our product and services. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on third-party carriers for the timely delivery of our products. As a result, we are subject to carrier disruptions and increased costs that are beyond our control. Any failure to deliver products to our customers in a safe and timely manner may damage our reputation and brand and could cause us to lose customers. If our relationship with any of these third-party carriers is terminated or impaired or if any of these carriers are unable to deliver our products, the delivery of our products by our customers may be delayed, which could harm our business and financial results. The failure to deliver our products in a safe and timely manner may harm our relationship with our customers, increase our costs and otherwise disrupt our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Doing business internationally creates operational and financial risks for our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently conduct operations in various countries and jurisdictions, and continue to expand to new international jurisdictions as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the U.S. We sell directly and through distribution partners throughout Europe, the Asia-Pacific region, Mexico, Brazil, and South Africa and have a significant portion of our sales and customer support personnel in Europe and the Asia-Pacific region. As a result, we or our distribution partners may be subject to additional regulations and increased diversion of management time and efforts. Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources. If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be materially and adversely affected and failure to comply with laws and regulations applicable to business operations in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">foreign jurisdictions may also subject us to significant liabilities and other penalties. International operations entail a variety of other risks, including, without limitation:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.628%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">limits to travel as a result of the COVID-19 pandemic or other epidemics;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">challenges in staffing and managing foreign operations;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">potentially longer sales cycles and more time required to engage and educate customers on the benefits of our platform outside of the United States;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the potential need for localized software and documentation;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reduced protection for intellectual property rights in some countries and practical difficulties of enforcing intellectual property and contract rights abroad;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">defending against intellectual property claims in other countries;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">restrictions on both inbound and outbound cross-border investment, including enhanced oversight by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) and substantial restrictions on investment from China;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. and foreign government trade restrictions, including those which may impose restrictions on the importation, exportation, re-exportation, sale, shipment or other transfer of programming, technology, components, and/or services to foreign persons;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes, sanctions, and other trade barriers;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs by the U.S. government on various imports from China, Canada, Mexico, and the European Union (&#8220;E.U.&#8221;) and by the governments of these jurisdictions on certain U.S. goods, and any other possible tariffs that may be imposed on products such as ours, the scope and duration of which, if implemented, remains uncertain;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">deterioration of political relations between the U.S. and Russia, China, Japan, Korea, Canada, the United Kingdom (&#8220;U.K.&#8221;), and the E.U., which could have a material adverse effect on our sales and operations in these countries;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes in social, political, and economic conditions or in laws, regulations and policies governing foreign trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions into which we sell our products, including as a result of the withdrawal of the U.K. from the E.U.;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulties in obtaining export licenses or in overcoming other trade barriers and restrictions resulting in delivery delays;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">fluctuations in currency exchange rates and the related effect on our results of operations;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">increased financial accounting and reporting burdens and complexities;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">disruptions to global trade due to disease outbreaks or conflicts;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">potential increases on tariffs or restrictions on trade generally; and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">significant taxes or other burdens of complying with a variety of foreign laws and regulations, including laws and regulations relating to privacy and data protection such as the E.U. General Data Protection Regulation which took effect in the E.U. in 2018.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In conducting our international operations, we are subject to U.S. laws relating to our international activities, such as the Foreign Corrupt Practices Act of 1977, as well as foreign laws relating to our activities in other countries, such as the United Kingdom Bribery Act of 2010. Additionally, the inclusion of one of our foreign customers on any U.S. Government sanctioned persons list, including but not limited to the U.S. Department of Commerce&#8217;s List of Denied Persons and the U.S. Department of Treasury&#8217;s List of Specially Designated Nationals and Blocked Persons List, could be material to our earnings. Failure to comply with these laws may subject us to claims or financial and/or other penalties in the United States and/or foreign countries that could materially and adversely impact our operations or financial condition. These risks have become increasingly prevalent as we have expanded our sales into countries that are generally recognized as having a higher risk of corruption.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face risks related to the current global economic environment, which could delay or prevent our customers from purchasing our products, which could in turn harm our business, financial condition, and results of operations. The state of the global economy continues to be uncertain. The current global economic conditions and uncertain credit markets and concerns regarding the availability of credit pose a risk that could impact </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers, and creditors, including financial institutions. If the current global economic environment deteriorates, our business could be negatively affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able to sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers&#8217; local currencies could make our products more expensive, impacting our ability to compete or as a result of financial or other instability in such locations which could result in decreased sales of our products. Our costs of materials from international suppliers may also increase as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Such actions may materially and adversely impact our financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Violations of complex foreign and U.S. laws and regulations could result in fines and penalties, criminal sanctions against us, our officers, or our employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially affect our brand, our international growth efforts, our ability to attract and retain employees, our business, and our operating results. Even if we implement policies or procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our distribution partners, our employees, contractors, or agents will not violate our policies and subject us to potential claims or penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business and our stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. We may in the future discover areas of our internal financial and accounting controls and procedures that need improvement. Operating as a public company requires sufficient resources within the accounting and finance functions in order to produce timely financial information, ensure the level of segregation of duties, and maintain adequate internal control over financial reporting customary for a U.S. public company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company will have been detected. Pursuant to Section 404 of the Sarbanes-Oxley Act, we perform periodic evaluations of our internal control over financial reporting. While we have in the past performed this evaluation and concluded that our internal control over financial reporting was operating effectively, there can be no assurance that in the future material weaknesses or significant deficiencies will not exist or otherwise be discovered. In addition, if we are unable to produce accurate financial statements on a timely basis, investors could lose confidence in the reliability of our financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our business could be negatively impacted by changes in the United States political environment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is significant ongoing uncertainty with respect to potential legislation, regulation and government policy at the federal level, as well as the state and local levels. Any such changes could significantly impact our business as well as the markets in which we compete. Specific legislative and regulatory proposals discussed during election campaigns and more recently that might materially impact us include, but are not limited to, changes to spending priorities and potential reductions in research funding. Uncertainty about U.S. government funding has posed, and may continue to pose, a risk as customers may choose to postpone or reduce spending in response to actual or anticipated restraints on funding. To the extent changes in the political environment have a negative impact on us or on our markets, our business, results of operation and financial condition could be materially and adversely impacted in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Disruption of critical information technology systems or material breaches in the security of our systems could harm our business, customer relations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information technology (&#8220;IT&#8221;) helps us to operate efficiently, interface with customers, maintain financial accuracy and efficiently and accurately produce our financial statements. IT systems are used extensively in virtually all aspects of our business, including sales forecast, order fulfillment and billing, customer service, logistics, and management of data from running samples on our products. Our success depends, in part, on the continued and uninterrupted performance of our IT systems. Our IT systems may be vulnerable to damage from a variety of sources, including telecommunications or network failures, power loss, natural disasters, human acts, computer viruses, ransomware, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Furthermore, there may be a heightened risk of potential cybersecurity incidents and security breaches to which we could be vulnerable by state-sponsored or affiliated actors or others in connection with the political uncertainty and military actions associated with the war in Ukraine. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, disruption of our operations, which could harm our reputation and financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we do not allocate and effectively manage the resources necessary to build and sustain the proper IT infrastructure, we could be subject to transaction errors, processing inefficiencies, loss of customers, business disruptions or loss of or damage to intellectual property. If our data management systems do not effectively collect, store, process and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies or human error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our reputation, financial condition, results of operations, cash flows and the timeliness with which we report our internal and external operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our IT infrastructure may be vulnerable to attacks by hackers, computer viruses, malicious codes, ransomware, unauthorized access attempts, and cyber- or phishing-attacks, or breached or otherwise disrupted due to employee error, malfeasance, faulty password management or other disruptions. Third parties may attempt to fraudulently induce employees or other persons into disclosing usernames, passwords or other sensitive information, which may in turn be used to access our IT systems, commit identity theft or carry out other unauthorized or illegal activities. Any such breach or incident could compromise our systems and networks and the information stored or otherwise processed there could be accessed, publicly disclosed, lost, stolen or otherwise processed in an unauthorized manner. We engage third-party vendors and service providers to store and otherwise process some of our data, including sensitive and personal information. Our vendors and service providers may also be the targets of the risks described above, including cyberattacks, malicious software, ransomware, phishing schemes, and fraud. Our ability to monitor our vendors and service providers&#8217; data security is limited, and, in any event, third parties may be able to circumvent those security measures, resulting in the unauthorized access to, misuse, disclosure, loss or destruction of our data, including sensitive and personal information, and disruption of our or third-party service providers&#8217; systems. We and our third-party service providers may face difficulties in identifying, or promptly responding to, potential security breaches and other instances of unauthorized access to, or disclosure or other loss or unavailability of, information. Any hacking or other attack on our or our third-party service providers&#8217; or vendors&#8217; systems, and any unauthorized access to, or disclosure or other loss of, information suffered by us or our third-party service providers or vendors, or the perception that any of these have occurred, could result in legal claims or proceedings, loss of intellectual property, liability under laws that protect the privacy of personal information, negative publicity, disruption of our operations and damage to our reputation, and data integrity issues, which could divert our management&#8217;s attention from the operation of our business and materially and adversely affect our business, revenues and competitive position. Moreover, we may need to increase our efforts to train our personnel to detect and defend against cyber- or phishing-attacks, which are becoming more sophisticated and frequent, and we may need to implement additional protective measures to reduce the risk of potential security breaches and security incidents, which could cause us to incur significant additional expenses. Retaliatory acts by Russia in response to Western sanctions or otherwise in connection with the war in Ukraine could include cyber attacks </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that could disrupt the economy generally or that may either directly or indirectly impact our operations specifically.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our insurance may be insufficient to cover our losses resulting from cyber-attacks, breaches, or other interruptions, and any incidents may result in loss of, or increased costs of, such insurance. The successful assertion of one or more large claims against us that exceed available insurance coverage, the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, or denials of coverage, could have a material adverse effect on our business, including our financial condition, results of operations and reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations imposing obligations on how we collect, store and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our future customer base, and thereby decrease our revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of our business, we currently, and in the future will, collect, store, transfer, use or process sensitive data, including personally identifiable information of employees, and intellectual property and proprietary business information owned or controlled by ourselves and other parties. The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy. We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, various federal and state regulators, including governmental agencies like the Consumer Financial Protection Bureau and the Federal Trade Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which increases privacy rights for California residents and imposes obligations on companies that process their personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In November 2020, California also passed the California Privacy Rights Act, or (&#8220;CPRA&#8221;), which significantly expanded the CCPA as of January 1, 2023, including by introducing additional obligations such as data minimization and storage limitations and granting additional rights to consumers, among others. The enactment of the CCPA has prompted similar legislative developments in other states, such as Virginia, which in March 2021 enacted a Consumer Data Protection Act that is effective as of January 1, 2023, Colorado, which in June 2021 enacted a Colorado Privacy Act that is effective as of July 1, 2023, Utah, which in March 2022 enacted a Utah Consumer Privacy Act that is effective as of July 1, 2023, Connecticut, which in May 2022 enacted a similar law, an Act Concerning Personal Data Privacy and Online Monitoring, that is effective as of July 1, 2023, and Iowa, which in March 2023 enacted an Act Relating to Consumer Data Protection, that is effective as of January 1, 2025. Similar laws are being considered by other state legislatures. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personal information has been disclosed as a result of a data breach. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law. These and future laws and regulations may increase our compliance costs and potential liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), establish privacy and security standards that limit the use and disclosure of individually identifiable health information (known as &#8220;protected health information&#8221;) and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses and may be subject to changing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">interpretation. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as the HIPAA, the Health Information Technology for Economic and Clinical Health Act, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and for extensive breaches, notice may need to be made to the media or State Attorneys General. Such a notice could harm our reputation and our ability to compete.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we have in place formal policies and procedures related to the storage, collection, and processing of information, and have conducted data privacy audits, we continue to evaluate our compliance needs, including the need to conduct additional internal and external data privacy audits or adopt additional policies and procedures, to ensure our compliance with all applicable data protection laws and regulations. Additionally, we do not currently have policies and procedures in place for assessing our third-party vendors&#8217; compliance with applicable data protection laws and regulations. All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any failure or perceived failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any applicable federal, state or similar foreign laws and regulations relating to data privacy and security, could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Increased scrutiny of our environmental, social or governance responsibilities may result in additional costs and risks, and may adversely impact our reputation, employee retention, and willingness of customers and suppliers to do business with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investor advocacy groups, institutional investors, investment funds, proxy advisory services, stockholders, and customers are increasingly focused on environmental, social, and governance (&#8220;ESG&#8221;) practices of companies. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continues to grow. If our ESG practices fail to meet regulatory requirements or investor or other industry stakeholders' evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted and customers and suppliers may be unwilling to do business with us. In addition, as we work to align our ESG practices with industry standards, we will likely continue to expand our disclosures in these areas and doing so may result in additional costs and require additional resources to monitor, report, and comply with our various ESG practices. If we fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy the expectations of stakeholders, our reputation, business, financial performance, and growth may be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Default Upon Senior Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_106"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="idd15d706814f4821992e3c53513cc1e0_109"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Incorporated by reference herein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filing Date</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-20230331x10qxexx311.htm">31</a>.1</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-20230331x10qxexx311.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-20230331x10qxexx312.htm">31</a>.2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-20230331x10qxexx312.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-20230331x10qxexx321.htm">32.1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-20230331x10qxexx321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furnished herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-20230331x10qxexx322.htm">32.2</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-20230331x10qxexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furnished herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">______________________________________________________________________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.7pt">The certification</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s att</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><div id="idd15d706814f4821992e3c53513cc1e0_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd15d706814f4821992e3c53513cc1e0_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;4, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;&#160;&#160;Christian O. Henry </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;4, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;&#160;&#160;Susan G. Kim</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Susan G. Kim</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;4, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;&#160;&#160;Michele Farmer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michele Farmer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President and Chief Accounting Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>pacb-20230331x10qxexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib76d4a42535f45aba2373ee4fd97bcec_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christian Henry, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">I have reviewed this quarterly report on Form 10-Q of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:20pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:44.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry<br>&#160;President and Chief Executive Officer <br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>pacb-20230331x10qxexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i120bfad9f05546fc88c280ca1d891816_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Susan Kim, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">I have reviewed this quarterly report on Form 10-Q of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt;text-indent:40.5pt"><font><br></font></div><div style="margin-top:6pt;text-indent:40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:43.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Susan G. Kim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Susan G. Kim<br>Chief Financial Officer <br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:9pt;padding-left:72pt;text-indent:24.5pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>pacb-20230331x10qxexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia81154a9218445ffbb865ec8df3c6274_1"></div><div style="min-height:45pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Christian Henry, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Quarterly Report of the Company on Form 10-Q for the period ended March&#160;31, 2023 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:42.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry<br>&#160;President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>pacb-20230331x10qxexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i30e7a52b52534c4eb05679dbba3340c8_1"></div><div style="min-height:45pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Susan Kim, Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Quarterly Report of the Company on Form 10-Q for the period ended March&#160;31, 2023 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Susan G. Kim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Susan G. Kim </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pacb-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1a1845fe-2bc6-4ddb-97ba-df0aaca6d029,g:3aa17778-fe5e-42a5-997b-9f59380cc331-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pacb="http://www.pacificbiosciences.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacificbiosciences.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pacificbiosciences.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://www.pacificbiosciences.com/role/CondensedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000007 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS">
        <link:definition>0000008 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTS" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS">
        <link:definition>0000009 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTES" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES">
        <link:definition>0000010 - Disclosure - CONVERTIBLE SENIOR NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000012 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE">
        <link:definition>0000013 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUE" roleURI="http://www.pacificbiosciences.com/role/REVENUE">
        <link:definition>0000014 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000015 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>0000016 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSTables" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables">
        <link:definition>0000017 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESTables" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables">
        <link:definition>0000018 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>0000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables">
        <link:definition>0000020 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUETables" roleURI="http://www.pacificbiosciences.com/role/REVENUETables">
        <link:definition>0000021 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>0000022 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000023 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>0000024 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails">
        <link:definition>0000025 - Disclosure - FINANCIAL INSTRUMENTS - Changes in estimated fair value of contingent consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails">
        <link:definition>0000026 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails">
        <link:definition>0000027 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails">
        <link:definition>0000028 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails_1" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1">
        <link:definition>0000028 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSComponentsofInventoryDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails">
        <link:definition>0000029 - Disclosure - BALANCE SHEET COMPONENTS - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails">
        <link:definition>0000030 - Disclosure - BALANCE SHEET COMPONENTS - Definite-lived Intangible Assets from Business Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails">
        <link:definition>0000031 - Disclosure - BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails">
        <link:definition>0000032 - Disclosure - BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails">
        <link:definition>0000033 - Disclosure - BALANCE SHEET COMPONENTS - Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails">
        <link:definition>0000034 - Disclosure - CONVERTIBLE SENIOR NOTES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails">
        <link:definition>0000035 - Disclosure - CONVERTIBLE SENIOR NOTES (Schedule of Net Carrying Amount) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails">
        <link:definition>0000036 - Disclosure - CONVERTIBLE SENIOR NOTES (Schedule of Interest Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>0000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails">
        <link:definition>0000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Summary of Time Based Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails">
        <link:definition>0000039 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails">
        <link:definition>0000040 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Summary of RSUs and PSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>0000041 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails">
        <link:definition>0000042 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails">
        <link:definition>0000043 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails">
        <link:definition>0000044 - Disclosure - NET LOSS PER SHARE - Computation of Basic and Diluted Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails">
        <link:definition>0000045 - Disclosure - NET LOSS PER SHARE - Antidilutive Shares Excluded from Computation of Diluted Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEScheduleofRevenuebyGeographicLocationDetails" roleURI="http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails">
        <link:definition>0000046 - Disclosure - REVENUE - Schedule of Revenue by Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESummaryofRevenuebyCategoryDetails" roleURI="http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails">
        <link:definition>0000047 - Disclosure - REVENUE - Summary of Revenue by Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pacb_DomesticCustomersMember" abstract="false" name="DomesticCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_TimeBasedStockOptionMember" abstract="false" name="TimeBasedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ConvertibleSeniorNotesMember" abstract="false" name="ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_StandardProductWarrantyPeriod" abstract="false" name="StandardProductWarrantyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_EmployeeStockPurchasePlanMember" abstract="false" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionAxis" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_IncomeLossPerShareAbstract" abstract="true" name="IncomeLossPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ConsumableMember" abstract="false" name="ConsumableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ScheduleOfBalanceSheetComponentsTable" abstract="true" name="ScheduleOfBalanceSheetComponentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" abstract="false" name="PublicOfferingOptionToPurchaseAdditionalSharesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_PublicOfferingShares" abstract="false" name="PublicOfferingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_TermLoansMember" abstract="true" name="TermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_InstrumentMember" abstract="false" name="InstrumentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_FinancialInstrumentsLineItems" abstract="true" name="FinancialInstrumentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_FinancialInstrumentsTable" abstract="true" name="FinancialInstrumentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsRsusMember" abstract="false" name="TimeBasedRestrictedStockUnitsRsusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentTermLoanElectiveOption" abstract="false" name="DebtInstrumentTermLoanElectiveOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ShelfOfferingMember" abstract="true" name="ShelfOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_PercentageOfFeeToPrepayDebt" abstract="false" name="PercentageOfFeeToPrepayDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_DebtConversionTermsOneMember" abstract="true" name="DebtConversionTermsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_InvitaeCorporationMember" abstract="false" name="InvitaeCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_BalanceSheetComponentsLineItems" abstract="true" name="BalanceSheetComponentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ScheduleOfInterestExpenseTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionDomain" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_CustomerOneMember" abstract="false" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtConversionTermsTwoMember" abstract="true" name="DebtConversionTermsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" abstract="false" name="DebtInstrumentRedemptionPricePercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_DebtInstrumentAdditionalInterestInEventOfDefault" abstract="false" name="DebtInstrumentAdditionalInterestInEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" abstract="false" name="PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_OfferingShareAmountMaximum" abstract="false" name="OfferingShareAmountMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pacb_DebtInstrumentDebtDefaultCalendarDays" abstract="false" name="DebtInstrumentDebtDefaultCalendarDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_OmniomeIncMember" abstract="false" name="OmniomeIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" abstract="false" name="PublicOfferingOptionToPurchaseAdditionalSharesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_OptionsToPurchaseCommonStockMember" abstract="false" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" abstract="true" name="SupplementalBalanceSheetComponentsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_EquityIncentivePlan2020Member" abstract="false" name="EquityIncentivePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentInterestInTheEventOfDefault" abstract="false" name="DebtInstrumentInterestInTheEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_ServiceAndOtherMember" abstract="false" name="ServiceAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pacb-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1a1845fe-2bc6-4ddb-97ba-df0aaca6d029,g:3aa17778-fe5e-42a5-997b-9f59380cc331-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_380cfd3c-8994-4499-8c17-804c730333e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5d093d44-ab1e-4de0-8582-a459a6930aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_380cfd3c-8994-4499-8c17-804c730333e6" xlink:to="loc_us-gaap_AssetsCurrent_5d093d44-ab1e-4de0-8582-a459a6930aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_40ed51de-6b57-4dac-94e4-98af147dc35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_380cfd3c-8994-4499-8c17-804c730333e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_40ed51de-6b57-4dac-94e4-98af147dc35d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1f00a2f8-96d7-4858-8187-1595043e9ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_380cfd3c-8994-4499-8c17-804c730333e6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1f00a2f8-96d7-4858-8187-1595043e9ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_095e58e0-c91b-4217-9df0-aa860b2b3ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_380cfd3c-8994-4499-8c17-804c730333e6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_095e58e0-c91b-4217-9df0-aa860b2b3ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0ab33e5e-a484-4b4c-93f5-91a56a7f3e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_380cfd3c-8994-4499-8c17-804c730333e6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0ab33e5e-a484-4b4c-93f5-91a56a7f3e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0daff16d-2d4a-4fd9-a9d5-add9b66d2563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_380cfd3c-8994-4499-8c17-804c730333e6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0daff16d-2d4a-4fd9-a9d5-add9b66d2563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_27b7dd88-3bbb-48e1-a6ab-e5132673d999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_380cfd3c-8994-4499-8c17-804c730333e6" xlink:to="loc_us-gaap_Goodwill_27b7dd88-3bbb-48e1-a6ab-e5132673d999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b7b0c12b-2020-4ba8-bbcd-71363fa082f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6173a718-4bf8-45c5-80d1-1e4b734d6011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b7b0c12b-2020-4ba8-bbcd-71363fa082f0" xlink:to="loc_us-gaap_Liabilities_6173a718-4bf8-45c5-80d1-1e4b734d6011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8c9701ad-1f67-4fd6-badc-e689dc0d981c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b7b0c12b-2020-4ba8-bbcd-71363fa082f0" xlink:to="loc_us-gaap_StockholdersEquity_8c9701ad-1f67-4fd6-badc-e689dc0d981c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8ef3c256-0573-4101-959a-2ae4bc1df553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b7b0c12b-2020-4ba8-bbcd-71363fa082f0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8ef3c256-0573-4101-959a-2ae4bc1df553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_479021a1-8476-4abe-bbce-651965d2b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8a7fc3e1-d7bd-4c28-ba0b-0f569ce5622c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_479021a1-8476-4abe-bbce-651965d2b5ea" xlink:to="loc_us-gaap_AccountsPayableCurrent_8a7fc3e1-d7bd-4c28-ba0b-0f569ce5622c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_935f568f-db60-40c8-af49-5b2c37ffa3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_479021a1-8476-4abe-bbce-651965d2b5ea" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_935f568f-db60-40c8-af49-5b2c37ffa3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d390b898-d4a4-4332-87fd-15eb83ba4224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_479021a1-8476-4abe-bbce-651965d2b5ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d390b898-d4a4-4332-87fd-15eb83ba4224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1eca12cd-d19c-41ed-be16-b662d4bb95c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_479021a1-8476-4abe-bbce-651965d2b5ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1eca12cd-d19c-41ed-be16-b662d4bb95c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4264d06c-db4d-4955-8e03-71aa03f65cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_479021a1-8476-4abe-bbce-651965d2b5ea" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4264d06c-db4d-4955-8e03-71aa03f65cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4adcc6ce-b411-4988-9aa1-30f0d0beee1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_479021a1-8476-4abe-bbce-651965d2b5ea" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4adcc6ce-b411-4988-9aa1-30f0d0beee1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_af7f17a7-a682-48e0-aea7-f4b7a3fd42a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b9c971e2-6d9f-4caf-a552-7ce14f76fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7f17a7-a682-48e0-aea7-f4b7a3fd42a4" xlink:to="loc_us-gaap_PreferredStockValue_b9c971e2-6d9f-4caf-a552-7ce14f76fc7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_adee4479-e9b4-4271-ac52-eaaa3df652d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7f17a7-a682-48e0-aea7-f4b7a3fd42a4" xlink:to="loc_us-gaap_CommonStockValue_adee4479-e9b4-4271-ac52-eaaa3df652d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_51bc0457-b793-4c66-a20d-6981386be58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7f17a7-a682-48e0-aea7-f4b7a3fd42a4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_51bc0457-b793-4c66-a20d-6981386be58d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e9340d2-9dd7-4109-8b4b-2d4dae1e0325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7f17a7-a682-48e0-aea7-f4b7a3fd42a4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e9340d2-9dd7-4109-8b4b-2d4dae1e0325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b17d8706-5677-4a9f-9c8d-068a1e4f613b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_af7f17a7-a682-48e0-aea7-f4b7a3fd42a4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b17d8706-5677-4a9f-9c8d-068a1e4f613b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_aaadf906-fb17-4a4a-8781-238d0394a9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d7c42010-4ddb-4922-b383-6e421fc6f788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aaadf906-fb17-4a4a-8781-238d0394a9fe" xlink:to="loc_us-gaap_LiabilitiesCurrent_d7c42010-4ddb-4922-b383-6e421fc6f788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b261a706-5bcf-498a-83f7-3d721022b450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aaadf906-fb17-4a4a-8781-238d0394a9fe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b261a706-5bcf-498a-83f7-3d721022b450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b2957ede-4b67-4d95-a526-6a856c081640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aaadf906-fb17-4a4a-8781-238d0394a9fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b2957ede-4b67-4d95-a526-6a856c081640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_040bde7b-958a-4681-862e-fe1ce317a829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aaadf906-fb17-4a4a-8781-238d0394a9fe" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_040bde7b-958a-4681-862e-fe1ce317a829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e206c39e-31ed-468e-a9b1-1457799793ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_aaadf906-fb17-4a4a-8781-238d0394a9fe" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e206c39e-31ed-468e-a9b1-1457799793ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_938e9028-4869-4583-8dcd-16e33c3f2725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2aeec808-b7fc-4b0c-aab6-d85c4b0fa1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_938e9028-4869-4583-8dcd-16e33c3f2725" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2aeec808-b7fc-4b0c-aab6-d85c4b0fa1d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_54493a06-3deb-4d0c-94dd-5db9a52aae00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_938e9028-4869-4583-8dcd-16e33c3f2725" xlink:to="loc_us-gaap_ShortTermInvestments_54493a06-3deb-4d0c-94dd-5db9a52aae00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e2379ede-be97-4435-b619-277ea1483e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_938e9028-4869-4583-8dcd-16e33c3f2725" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e2379ede-be97-4435-b619-277ea1483e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c58007b1-96c2-4d2d-833a-049f0f436712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_938e9028-4869-4583-8dcd-16e33c3f2725" xlink:to="loc_us-gaap_InventoryNet_c58007b1-96c2-4d2d-833a-049f0f436712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2858ba58-48a0-4a92-80f8-d09ef6b96f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_938e9028-4869-4583-8dcd-16e33c3f2725" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2858ba58-48a0-4a92-80f8-d09ef6b96f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f9f289eb-a279-4c28-a155-e51f61f5ba3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_938e9028-4869-4583-8dcd-16e33c3f2725" xlink:to="loc_us-gaap_RestrictedCashCurrent_f9f289eb-a279-4c28-a155-e51f61f5ba3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1cbba5fa-cbc2-41e8-9749-9aecb79f3770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_302b2d25-d801-4f8b-beea-0ef5d2c26f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_1cbba5fa-cbc2-41e8-9749-9aecb79f3770" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_302b2d25-d801-4f8b-beea-0ef5d2c26f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f25b786b-7661-4579-a3b0-309b6d00f7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_1cbba5fa-cbc2-41e8-9749-9aecb79f3770" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f25b786b-7661-4579-a3b0-309b6d00f7e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_115f2bae-6785-4a1f-8d3e-453f6c24e83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f37ac200-aaf3-4b29-9735-0c4d6250e980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_115f2bae-6785-4a1f-8d3e-453f6c24e83b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f37ac200-aaf3-4b29-9735-0c4d6250e980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4568541b-7d75-4d0c-99d2-0f5358780455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_115f2bae-6785-4a1f-8d3e-453f6c24e83b" xlink:to="loc_us-gaap_CostOfRevenue_4568541b-7d75-4d0c-99d2-0f5358780455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c01c542e-d9eb-4878-b096-e4ebb8fb2138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_760ffab3-649a-4663-a941-d74aca73d751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c01c542e-d9eb-4878-b096-e4ebb8fb2138" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_760ffab3-649a-4663-a941-d74aca73d751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9285158-b53e-4155-82ad-770cfb33404d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c01c542e-d9eb-4878-b096-e4ebb8fb2138" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9285158-b53e-4155-82ad-770cfb33404d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5d044a07-f4fd-4f49-b396-5a48af333072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0e00838a-943b-44ee-94c4-82a74ac89a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5d044a07-f4fd-4f49-b396-5a48af333072" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0e00838a-943b-44ee-94c4-82a74ac89a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dc67d3e2-8b46-4a15-88c2-d469e6c23152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5d044a07-f4fd-4f49-b396-5a48af333072" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dc67d3e2-8b46-4a15-88c2-d469e6c23152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_020b38ab-452d-4022-b499-adc68dade207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5d044a07-f4fd-4f49-b396-5a48af333072" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_020b38ab-452d-4022-b499-adc68dade207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_363efdad-cbba-4466-8e1a-7f9664839594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5cc055a4-48b7-4c56-a796-ea64ab8fabe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_363efdad-cbba-4466-8e1a-7f9664839594" xlink:to="loc_us-gaap_GrossProfit_5cc055a4-48b7-4c56-a796-ea64ab8fabe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_65e6e9df-b344-4341-a5c4-267cb28c8e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_363efdad-cbba-4466-8e1a-7f9664839594" xlink:to="loc_us-gaap_OperatingExpenses_65e6e9df-b344-4341-a5c4-267cb28c8e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4b3ec723-c1e0-4185-ab5c-faaa52dd20c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ac288ba-27c0-49c3-bc59-1a8407dbe502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4b3ec723-c1e0-4185-ab5c-faaa52dd20c4" xlink:to="loc_us-gaap_NetIncomeLoss_8ac288ba-27c0-49c3-bc59-1a8407dbe502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_14e97d9e-a083-49ab-a6f6-7032a2ba9645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4b3ec723-c1e0-4185-ab5c-faaa52dd20c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_14e97d9e-a083-49ab-a6f6-7032a2ba9645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c49ea324-6fab-490c-8f0b-faf5ffd4a692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4d4fe1c8-9073-4c95-aa75-fafefe4f2555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c49ea324-6fab-490c-8f0b-faf5ffd4a692" xlink:to="loc_us-gaap_OperatingIncomeLoss_4d4fe1c8-9073-4c95-aa75-fafefe4f2555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ec101dd0-7cf2-4bd5-a6de-98236420e22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c49ea324-6fab-490c-8f0b-faf5ffd4a692" xlink:to="loc_us-gaap_InterestExpense_ec101dd0-7cf2-4bd5-a6de-98236420e22f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_92a7a1ca-23a8-4b26-898a-bb1c508b13c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c49ea324-6fab-490c-8f0b-faf5ffd4a692" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_92a7a1ca-23a8-4b26-898a-bb1c508b13c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dbc9628b-9fa7-473c-abad-30e7960f878f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a242a110-72d7-4535-b934-1c3b3a699082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dbc9628b-9fa7-473c-abad-30e7960f878f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a242a110-72d7-4535-b934-1c3b3a699082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5bbc1e99-e820-48c6-8fd1-f01a3f60574c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dbc9628b-9fa7-473c-abad-30e7960f878f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5bbc1e99-e820-48c6-8fd1-f01a3f60574c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_44bb24ff-1fdb-44b4-bb2a-5a1346472ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dbc9628b-9fa7-473c-abad-30e7960f878f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_44bb24ff-1fdb-44b4-bb2a-5a1346472ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7bd6f043-0c73-4e3d-803e-6589b4339acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dbc9628b-9fa7-473c-abad-30e7960f878f" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7bd6f043-0c73-4e3d-803e-6589b4339acd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfb2a312-d3f2-4a35-a536-2afa8a38cff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6548ce7c-9ba3-4f35-8bfb-1347129626ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfb2a312-d3f2-4a35-a536-2afa8a38cff5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6548ce7c-9ba3-4f35-8bfb-1347129626ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_18299ad5-1d94-4ffd-834c-384b6b4802ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfb2a312-d3f2-4a35-a536-2afa8a38cff5" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_18299ad5-1d94-4ffd-834c-384b6b4802ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8eecc36d-6544-4ed2-bbc0-76b965e6db8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfb2a312-d3f2-4a35-a536-2afa8a38cff5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8eecc36d-6544-4ed2-bbc0-76b965e6db8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98c81eb5-9a0e-4983-8150-168972c038ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_600b21ab-6699-4275-b0d0-ca44992f2596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98c81eb5-9a0e-4983-8150-168972c038ff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_600b21ab-6699-4275-b0d0-ca44992f2596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_996252e8-c07c-4ba8-a90d-0731a533d941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98c81eb5-9a0e-4983-8150-168972c038ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_996252e8-c07c-4ba8-a90d-0731a533d941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fdc52ba-a631-4528-aa42-3af719c91880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6af2ad5-ca22-4a50-9693-b0b3e248863c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fdc52ba-a631-4528-aa42-3af719c91880" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6af2ad5-ca22-4a50-9693-b0b3e248863c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e245c4cc-94ca-40b1-96b1-faa7bba6154d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fdc52ba-a631-4528-aa42-3af719c91880" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e245c4cc-94ca-40b1-96b1-faa7bba6154d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7da2331-10d0-44cf-af81-467fb68d4e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fdc52ba-a631-4528-aa42-3af719c91880" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7da2331-10d0-44cf-af81-467fb68d4e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3ba00d1d-1caa-4e17-acc8-5b383f940ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_Depreciation_3ba00d1d-1caa-4e17-acc8-5b383f940ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_7027f08d-9ecf-41b0-a972-a9a14f667b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_7027f08d-9ecf-41b0-a972-a9a14f667b5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f5345c03-e0b4-494e-a1be-9fb249913411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f5345c03-e0b4-494e-a1be-9fb249913411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2b661291-aad1-41af-b823-297d21404a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2b661291-aad1-41af-b823-297d21404a96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_82ca380e-717f-40c9-b200-15eb6fb73688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_82ca380e-717f-40c9-b200-15eb6fb73688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_45f6fcf6-ee04-4e65-a2b7-530a0f5f4b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_45f6fcf6-ee04-4e65-a2b7-530a0f5f4b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_07d346b2-2c4e-4d92-9b51-6562f89dec2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_07d346b2-2c4e-4d92-9b51-6562f89dec2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dbdeee1f-5dc6-4b19-a2a0-c797ca8a30dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dbdeee1f-5dc6-4b19-a2a0-c797ca8a30dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f1fd34f-cd93-4e92-aa7d-ca221d428bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_NetIncomeLoss_2f1fd34f-cd93-4e92-aa7d-ca221d428bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_65af033a-58b6-4f8d-90b6-f69ee891a172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_65af033a-58b6-4f8d-90b6-f69ee891a172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_227ef74a-a77c-4a9e-915c-db6f9a7d28fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_227ef74a-a77c-4a9e-915c-db6f9a7d28fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d76a3f08-5ac1-411a-a1c7-f7cdb89bd251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_InventoryWriteDown_d76a3f08-5ac1-411a-a1c7-f7cdb89bd251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0fa8a62b-2d00-4493-9177-7ae1ba70ffb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0fa8a62b-2d00-4493-9177-7ae1ba70ffb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ac3078fd-4aba-4da5-a245-6ef717f2e1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_ShareBasedCompensation_ac3078fd-4aba-4da5-a245-6ef717f2e1f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8ab32b6d-6009-4cf2-b6cc-61574d7ee0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8ab32b6d-6009-4cf2-b6cc-61574d7ee0c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eb05e1a3-75ec-4597-9dfe-9aaa17055662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eb05e1a3-75ec-4597-9dfe-9aaa17055662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b07373a7-7239-4011-a667-8f6e877e9bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b07373a7-7239-4011-a667-8f6e877e9bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f8992fbd-e766-4fcb-a70d-976ad015bbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f59e94eb-3fb3-4b83-917b-10633a82cd31" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f8992fbd-e766-4fcb-a70d-976ad015bbd0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ea5c419b-d744-4afb-8fe7-1b0d3284b778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f3cada54-a327-4efa-b1c1-aa54bce56128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ea5c419b-d744-4afb-8fe7-1b0d3284b778" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f3cada54-a327-4efa-b1c1-aa54bce56128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_c7eb898a-edd1-400a-9112-329e514b03d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ea5c419b-d744-4afb-8fe7-1b0d3284b778" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_c7eb898a-edd1-400a-9112-329e514b03d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_556bfb93-31dc-40bb-937f-55c4376b5537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ea5c419b-d744-4afb-8fe7-1b0d3284b778" xlink:to="loc_us-gaap_RestrictedCashCurrent_556bfb93-31dc-40bb-937f-55c4376b5537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7659e3f5-97d7-498a-a84f-c5e3ffb86c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ea5c419b-d744-4afb-8fe7-1b0d3284b778" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7659e3f5-97d7-498a-a84f-c5e3ffb86c92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_feaedb1b-e232-4909-83d2-5dddc8eab95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ea3c503e-ae17-4ff6-ad4d-26d4e80becde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_feaedb1b-e232-4909-83d2-5dddc8eab95d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ea3c503e-ae17-4ff6-ad4d-26d4e80becde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_44f0b846-597a-42d6-a330-099be8bf12f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_feaedb1b-e232-4909-83d2-5dddc8eab95d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_44f0b846-597a-42d6-a330-099be8bf12f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_b196dc3b-b523-4e27-b91c-8d0240800f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_feaedb1b-e232-4909-83d2-5dddc8eab95d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_b196dc3b-b523-4e27-b91c-8d0240800f5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c2076953-3b54-4258-beec-6002e6e7f553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_7020d048-1c08-42f8-9ed5-70fe1a267f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c2076953-3b54-4258-beec-6002e6e7f553" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_7020d048-1c08-42f8-9ed5-70fe1a267f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_2ae27fd6-16b2-45d0-8645-e9e9de844e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c2076953-3b54-4258-beec-6002e6e7f553" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_2ae27fd6-16b2-45d0-8645-e9e9de844e11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_159823b0-75d8-472f-8181-913c35adb4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_53232920-0601-4961-8e00-fa7f708cd1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_159823b0-75d8-472f-8181-913c35adb4ef" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_53232920-0601-4961-8e00-fa7f708cd1c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c93b03e1-1605-4c6b-8d72-d9c448e53010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_159823b0-75d8-472f-8181-913c35adb4ef" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c93b03e1-1605-4c6b-8d72-d9c448e53010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_98c3b5e1-cc84-4f3c-bb83-62913263fc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_159823b0-75d8-472f-8181-913c35adb4ef" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_98c3b5e1-cc84-4f3c-bb83-62913263fc47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8c9c0e9-bb74-47db-bc2c-d2cae66e47ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3ca18558-7348-4135-b672-aefc0b738636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8c9c0e9-bb74-47db-bc2c-d2cae66e47ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3ca18558-7348-4135-b672-aefc0b738636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ac18589b-87a3-4cba-823c-86cb1b6828b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8c9c0e9-bb74-47db-bc2c-d2cae66e47ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ac18589b-87a3-4cba-823c-86cb1b6828b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c45b5f4f-abe3-4b58-a2af-f83b3012e503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c2447bb2-19cb-4209-a59f-fb885ef6811f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c45b5f4f-abe3-4b58-a2af-f83b3012e503" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c2447bb2-19cb-4209-a59f-fb885ef6811f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5af5323c-b8c4-4fac-ba37-fae608f45c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c45b5f4f-abe3-4b58-a2af-f83b3012e503" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5af5323c-b8c4-4fac-ba37-fae608f45c5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c8de610b-8a58-4db1-938a-909ec0859cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c45b5f4f-abe3-4b58-a2af-f83b3012e503" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c8de610b-8a58-4db1-938a-909ec0859cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_933e9fc8-b9ac-4400-9637-3541a67e42a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c45b5f4f-abe3-4b58-a2af-f83b3012e503" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_933e9fc8-b9ac-4400-9637-3541a67e42a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3ac70257-1d06-4ec4-8507-646a894ccf32" xlink:href="pacb-20230331.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c45b5f4f-abe3-4b58-a2af-f83b3012e503" xlink:to="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3ac70257-1d06-4ec4-8507-646a894ccf32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1a960ab2-477c-4a65-a79a-bcbc0cf6fd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c45b5f4f-abe3-4b58-a2af-f83b3012e503" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1a960ab2-477c-4a65-a79a-bcbc0cf6fd50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6a20b1f6-665f-4ba2-bc5c-bd4ebb2b2367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_10930612-9897-418c-bb3e-573aa60dff8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6a20b1f6-665f-4ba2-bc5c-bd4ebb2b2367" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_10930612-9897-418c-bb3e-573aa60dff8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0eb5f186-a8dc-4b94-b3f6-9e938a275b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6a20b1f6-665f-4ba2-bc5c-bd4ebb2b2367" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0eb5f186-a8dc-4b94-b3f6-9e938a275b81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8a3dbfbc-232e-435b-bf4e-2bdf8e3dea0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4222e14f-6d18-45b4-9b96-f54a2af65911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8a3dbfbc-232e-435b-bf4e-2bdf8e3dea0e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4222e14f-6d18-45b4-9b96-f54a2af65911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4458be50-f98b-446d-aa19-9fd88b2cb9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8a3dbfbc-232e-435b-bf4e-2bdf8e3dea0e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4458be50-f98b-446d-aa19-9fd88b2cb9de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f717d6f5-c1a9-4905-870a-07717c56fd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_947c1d72-1508-45cb-bd3d-62ce1de9e687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_f717d6f5-c1a9-4905-870a-07717c56fd0c" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_947c1d72-1508-45cb-bd3d-62ce1de9e687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_871c2468-be04-4980-a993-9bf676f0d1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_f717d6f5-c1a9-4905-870a-07717c56fd0c" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_871c2468-be04-4980-a993-9bf676f0d1b0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pacb-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1a1845fe-2bc6-4ddb-97ba-df0aaca6d029,g:3aa17778-fe5e-42a5-997b-9f59380cc331-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i3e93629acab74770bc929dee96f72f8a_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3e240636-042f-4497-aee2-d6177d006645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_RevenuesAbstract_3e240636-042f-4497-aee2-d6177d006645" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dd7594ed-cb02-4c28-b891-953cd2bb65c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_3e240636-042f-4497-aee2-d6177d006645" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dd7594ed-cb02-4c28-b891-953cd2bb65c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_50501ec3-22da-45da-8b84-ecd115e928bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_50501ec3-22da-45da-8b84-ecd115e928bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_f4d92040-f15b-4437-a6c4-83a440aaf741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_f4d92040-f15b-4437-a6c4-83a440aaf741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_50c656c1-d4fc-469f-8b02-0c8869713283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:to="loc_us-gaap_CostOfRevenue_50c656c1-d4fc-469f-8b02-0c8869713283" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_84aafc32-3be0-4313-b473-885562b5b330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_GrossProfit_84aafc32-3be0-4313-b473-885562b5b330" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2c1b6de-74bd-4525-9e37-b2c0b3eae051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2c1b6de-74bd-4525-9e37-b2c0b3eae051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca12dcee-680a-4105-b070-0e4d439191dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca12dcee-680a-4105-b070-0e4d439191dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_03016c8e-899b-41e3-9aa6-a3f6a8c0d502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_03016c8e-899b-41e3-9aa6-a3f6a8c0d502" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_55594e15-acca-4259-8bac-f9beedf842ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:to="loc_us-gaap_OperatingExpenses_55594e15-acca-4259-8bac-f9beedf842ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cd7ca7ae-fff8-4dba-b2fe-c8b54c5c2953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_OperatingIncomeLoss_cd7ca7ae-fff8-4dba-b2fe-c8b54c5c2953" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7cc452de-65e1-484d-9067-9293db2442eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_InterestExpense_7cc452de-65e1-484d-9067-9293db2442eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4c18a82c-c5bd-4ebc-af34-93b50462c853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4c18a82c-c5bd-4ebc-af34-93b50462c853" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ebe19e0-f11d-449c-934f-597c3cc6dfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ebe19e0-f11d-449c-934f-597c3cc6dfb8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9944c571-4a43-4870-8b05-242a5ef5a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9944c571-4a43-4870-8b05-242a5ef5a2c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f84e201a-f73f-4d7f-b915-25bc2528c07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_NetIncomeLoss_f84e201a-f73f-4d7f-b915-25bc2528c07c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9dab6cad-c4db-4676-9737-aede07c571fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9dab6cad-c4db-4676-9737-aede07c571fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1d093071-2d09-4e69-b9ea-e8b751de95bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9dab6cad-c4db-4676-9737-aede07c571fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1d093071-2d09-4e69-b9ea-e8b751de95bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba2b09b1-1dbb-4ae1-8826-4f14ebcdabdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba2b09b1-1dbb-4ae1-8826-4f14ebcdabdf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_1dd3f976-5c03-4bcc-880d-cbdfe180ec08" xlink:href="pacb-20230331.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_pacb_IncomeLossPerShareAbstract_1dd3f976-5c03-4bcc-880d-cbdfe180ec08" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e1f10f9e-6b6a-4c69-b5d0-6a09a8c9815a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_1dd3f976-5c03-4bcc-880d-cbdfe180ec08" xlink:to="loc_us-gaap_EarningsPerShareBasic_e1f10f9e-6b6a-4c69-b5d0-6a09a8c9815a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_24d4ef98-3bb2-4e69-9963-98610eca208d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_1dd3f976-5c03-4bcc-880d-cbdfe180ec08" xlink:to="loc_us-gaap_EarningsPerShareDiluted_24d4ef98-3bb2-4e69-9963-98610eca208d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_3e3b784f-b58c-4757-b772-75f7150ec00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_3e3b784f-b58c-4757-b772-75f7150ec00b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f02caa08-a8ab-4228-bd03-e90f12808dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_3e3b784f-b58c-4757-b772-75f7150ec00b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f02caa08-a8ab-4228-bd03-e90f12808dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fde647b-635c-4f7c-ad6e-1fbde2a14ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_3e3b784f-b58c-4757-b772-75f7150ec00b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fde647b-635c-4f7c-ad6e-1fbde2a14ef2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eea1997d-4adc-475a-b4fe-f9940aa1b47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_StatementTable_eea1997d-4adc-475a-b4fe-f9940aa1b47a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cdd67cfd-221a-41c4-9f9c-94e876b120bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_eea1997d-4adc-475a-b4fe-f9940aa1b47a" xlink:to="loc_srt_ProductOrServiceAxis_cdd67cfd-221a-41c4-9f9c-94e876b120bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cdd67cfd-221a-41c4-9f9c-94e876b120bd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cdd67cfd-221a-41c4-9f9c-94e876b120bd" xlink:to="loc_srt_ProductsAndServicesDomain_cdd67cfd-221a-41c4-9f9c-94e876b120bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf5d56a6-efb0-4cc7-9d3b-365776b5ea0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cdd67cfd-221a-41c4-9f9c-94e876b120bd" xlink:to="loc_srt_ProductsAndServicesDomain_bf5d56a6-efb0-4cc7-9d3b-365776b5ea0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5df1d4f3-d858-4870-816e-b727e9605560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bf5d56a6-efb0-4cc7-9d3b-365776b5ea0d" xlink:to="loc_us-gaap_ProductMember_5df1d4f3-d858-4870-816e-b727e9605560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_6ae09d27-5888-4470-9d80-7fa852a0af98" xlink:href="pacb-20230331.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bf5d56a6-efb0-4cc7-9d3b-365776b5ea0d" xlink:to="loc_pacb_ServiceAndOtherMember_6ae09d27-5888-4470-9d80-7fa852a0af98" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i7106060c5fb344de864902c98cd9df33_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c1a3c97d-2a6e-4912-9614-51ebbedb9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c1a3c97d-2a6e-4912-9614-51ebbedb9c68" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2fc7c106-7c4e-44a7-bd84-4d063ba90762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2fc7c106-7c4e-44a7-bd84-4d063ba90762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6011166e-774b-4431-b009-0adf73408c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockholdersEquity_6011166e-774b-4431-b009-0adf73408c42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f38a7cdf-c924-41a0-a0f4-50db31b98b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_NetIncomeLoss_f38a7cdf-c924-41a0-a0f4-50db31b98b1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed5b973e-e29f-4258-98f1-e71f5e433e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed5b973e-e29f-4258-98f1-e71f5e433e72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86e7a2fd-0106-4255-846b-15ee4b72d116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86e7a2fd-0106-4255-846b-15ee4b72d116" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e903f19-fe61-43c4-bf8d-2191f176e8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e903f19-fe61-43c4-bf8d-2191f176e8e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f589d202-39c1-4557-a6af-5ce4a93a0294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f589d202-39c1-4557-a6af-5ce4a93a0294" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_14209c6f-4bcb-48c1-89dd-e263802a6be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_14209c6f-4bcb-48c1-89dd-e263802a6be4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ea489edb-84bf-4252-87db-7d28b3874770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ea489edb-84bf-4252-87db-7d28b3874770" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e14e0f82-e6ae-4e26-8a4b-77b0df642982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_674728b6-9781-4f22-9f19-c5abb63c51cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3c7afd5f-786d-4dca-b674-be4ba9c670c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c1a3c97d-2a6e-4912-9614-51ebbedb9c68" xlink:to="loc_us-gaap_StatementTable_3c7afd5f-786d-4dca-b674-be4ba9c670c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8d9a772d-a1aa-4ffd-8a08-449eba35c932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3c7afd5f-786d-4dca-b674-be4ba9c670c5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8d9a772d-a1aa-4ffd-8a08-449eba35c932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8d9a772d-a1aa-4ffd-8a08-449eba35c932_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d9a772d-a1aa-4ffd-8a08-449eba35c932" xlink:to="loc_us-gaap_EquityComponentDomain_8d9a772d-a1aa-4ffd-8a08-449eba35c932_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d9a772d-a1aa-4ffd-8a08-449eba35c932" xlink:to="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b391753d-3d19-4649-860c-3adb69be7021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:to="loc_us-gaap_CommonStockMember_b391753d-3d19-4649-860c-3adb69be7021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4fa2ae02-63a6-4676-8a59-ff520ee471a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4fa2ae02-63a6-4676-8a59-ff520ee471a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3d34b310-1d98-434c-8a7a-c9f6dc2de024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3d34b310-1d98-434c-8a7a-c9f6dc2de024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a27e4c07-a919-47e4-8827-ddb1ae23ead7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:to="loc_us-gaap_RetainedEarningsMember_a27e4c07-a919-47e4-8827-ddb1ae23ead7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="id14060d16ea9436a94b966d0d89d1218_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_423652b8-1333-4a02-9c69-571e56a1241c" xlink:href="pacb-20230331.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a8bc4e00-1e3a-4e84-9cb7-e29ac6a94cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_423652b8-1333-4a02-9c69-571e56a1241c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a8bc4e00-1e3a-4e84-9cb7-e29ac6a94cfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:href="pacb-20230331.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_423652b8-1333-4a02-9c69-571e56a1241c" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ddf5f5a-0682-485a-8017-d2ce44a770e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ddf5f5a-0682-485a-8017-d2ce44a770e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ddf5f5a-0682-485a-8017-d2ce44a770e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ddf5f5a-0682-485a-8017-d2ce44a770e8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ddf5f5a-0682-485a-8017-d2ce44a770e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba7c127-9de0-4f07-8152-703be99cbdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ddf5f5a-0682-485a-8017-d2ce44a770e8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba7c127-9de0-4f07-8152-703be99cbdec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7227c0e1-55ac-4d17-b495-c3ce05b52e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba7c127-9de0-4f07-8152-703be99cbdec" xlink:to="loc_us-gaap_SalesRevenueNetMember_7227c0e1-55ac-4d17-b495-c3ce05b52e6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5f9b612e-d6fc-47e6-82c9-39544d86e770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba7c127-9de0-4f07-8152-703be99cbdec" xlink:to="loc_us-gaap_AccountsReceivableMember_5f9b612e-d6fc-47e6-82c9-39544d86e770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b552aea0-45cc-4d27-bcb1-7701490648c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:to="loc_srt_MajorCustomersAxis_b552aea0-45cc-4d27-bcb1-7701490648c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b552aea0-45cc-4d27-bcb1-7701490648c2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b552aea0-45cc-4d27-bcb1-7701490648c2" xlink:to="loc_srt_NameOfMajorCustomerDomain_b552aea0-45cc-4d27-bcb1-7701490648c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b552aea0-45cc-4d27-bcb1-7701490648c2" xlink:to="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember_b0c28432-16c0-4184-93a2-71e387e60e81" xlink:href="pacb-20230331.xsd#pacb_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:to="loc_pacb_CustomerOneMember_b0c28432-16c0-4184-93a2-71e387e60e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerTwoMember_d535208c-6e0c-4e82-8799-efa36c0aac38" xlink:href="pacb-20230331.xsd#pacb_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:to="loc_pacb_CustomerTwoMember_d535208c-6e0c-4e82-8799-efa36c0aac38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember_78437d93-8eb6-465b-9196-cc7962e262ff" xlink:href="pacb-20230331.xsd#pacb_DomesticCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:to="loc_pacb_DomesticCustomersMember_78437d93-8eb6-465b-9196-cc7962e262ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a3c92a56-8b05-489d-93d9-2f8b369d69ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a3c92a56-8b05-489d-93d9-2f8b369d69ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_dd2e5f4f-3fe1-406c-8e2c-d1ceea6bce37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a3c92a56-8b05-489d-93d9-2f8b369d69ce" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_dd2e5f4f-3fe1-406c-8e2c-d1ceea6bce37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i2700d6b4d9b84b37be5d8037acb8dc2e_FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_deb48b40-5251-459c-b547-0dfa4309fea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_deb48b40-5251-459c-b547-0dfa4309fea9" xlink:to="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4195d2c0-daa7-4714-bf72-03abd70d59d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4195d2c0-daa7-4714-bf72-03abd70d59d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_12c9c75b-ef5c-4b13-8a37-ba25150d5ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_12c9c75b-ef5c-4b13-8a37-ba25150d5ec1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_9d16876b-8659-42da-b8d8-c49ef2954362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_RestrictedCashCurrent_9d16876b-8659-42da-b8d8-c49ef2954362" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_900d50b5-e347-4f92-aa30-3faf4aafd011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_900d50b5-e347-4f92-aa30-3faf4aafd011" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a83b87a8-87b7-4cf6-9205-4eacbf18aa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a83b87a8-87b7-4cf6-9205-4eacbf18aa4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_524df401-5c39-4323-b123-a66a7a16c739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_deb48b40-5251-459c-b547-0dfa4309fea9" xlink:to="loc_us-gaap_LiabilitiesAbstract_524df401-5c39-4323-b123-a66a7a16c739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4471c5e-600a-4af1-bb9c-209a22f7b168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_524df401-5c39-4323-b123-a66a7a16c739" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4471c5e-600a-4af1-bb9c-209a22f7b168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_beeed1e7-4b61-4a4a-9d42-030614aeedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_524df401-5c39-4323-b123-a66a7a16c739" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_beeed1e7-4b61-4a4a-9d42-030614aeedbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_deb48b40-5251-459c-b547-0dfa4309fea9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61be8a76-86a6-4bc7-b830-458cd35f2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61be8a76-86a6-4bc7-b830-458cd35f2d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61be8a76-86a6-4bc7-b830-458cd35f2d18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61be8a76-86a6-4bc7-b830-458cd35f2d18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61be8a76-86a6-4bc7-b830-458cd35f2d18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61be8a76-86a6-4bc7-b830-458cd35f2d18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_192e1ad5-ef80-4292-a973-6219f625bfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_192e1ad5-ef80-4292-a973-6219f625bfd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e4d37704-d2fc-4d44-b973-425cb1d6d434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e4d37704-d2fc-4d44-b973-425cb1d6d434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b7913792-f5f4-40f4-813f-4ef69de70a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b7913792-f5f4-40f4-813f-4ef69de70a6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a8e1bb23-d5bd-4285-8697-d597f5d39690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a8e1bb23-d5bd-4285-8697-d597f5d39690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8e1bb23-d5bd-4285-8697-d597f5d39690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a8e1bb23-d5bd-4285-8697-d597f5d39690" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a8e1bb23-d5bd-4285-8697-d597f5d39690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fe573868-e428-4d83-b549-d0de6135b2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a8e1bb23-d5bd-4285-8697-d597f5d39690" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fe573868-e428-4d83-b549-d0de6135b2de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fe573868-e428-4d83-b549-d0de6135b2de" xlink:to="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_db4338f8-836e-45e2-adf5-57ebc4211373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_db4338f8-836e-45e2-adf5-57ebc4211373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4256ca4c-7c28-487b-be81-d05c59cfd6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4256ca4c-7c28-487b-be81-d05c59cfd6b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_89e5d1a5-1086-4883-aee7-be834a5f935e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_89e5d1a5-1086-4883-aee7-be834a5f935e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="i0719a4f4c724447ea6c3e242597d0194_FINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems_4a2574fe-2d27-4495-8b5f-2688ceb65756" xlink:href="pacb-20230331.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0a3e283b-42c5-47bd-8aae-166d7b074b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_4a2574fe-2d27-4495-8b5f-2688ceb65756" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0a3e283b-42c5-47bd-8aae-166d7b074b0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:href="pacb-20230331.xsd#pacb_FinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_FinancialInstrumentsLineItems_4a2574fe-2d27-4495-8b5f-2688ceb65756" xlink:to="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4d1b2dc2-986d-4960-9316-b9e66ca46c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4d1b2dc2-986d-4960-9316-b9e66ca46c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4d1b2dc2-986d-4960-9316-b9e66ca46c3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4d1b2dc2-986d-4960-9316-b9e66ca46c3e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4d1b2dc2-986d-4960-9316-b9e66ca46c3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bdb11768-ad38-4e28-b638-641d54b09a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4d1b2dc2-986d-4960-9316-b9e66ca46c3e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bdb11768-ad38-4e28-b638-641d54b09a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_eea889d4-1f83-444f-91bb-1cfd5fae0642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_bdb11768-ad38-4e28-b638-641d54b09a09" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_eea889d4-1f83-444f-91bb-1cfd5fae0642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de849abf-b0be-4c0c-9cbd-060c082b5238" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:to="loc_srt_RangeAxis_de849abf-b0be-4c0c-9cbd-060c082b5238" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de849abf-b0be-4c0c-9cbd-060c082b5238_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_de849abf-b0be-4c0c-9cbd-060c082b5238" xlink:to="loc_srt_RangeMember_de849abf-b0be-4c0c-9cbd-060c082b5238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e306fc0-6703-4967-b91c-1ed3bb4c6214" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_de849abf-b0be-4c0c-9cbd-060c082b5238" xlink:to="loc_srt_RangeMember_6e306fc0-6703-4967-b91c-1ed3bb4c6214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2ab8fdec-e1f2-408c-89aa-f68ee953e6c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e306fc0-6703-4967-b91c-1ed3bb4c6214" xlink:to="loc_srt_MinimumMember_2ab8fdec-e1f2-408c-89aa-f68ee953e6c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f11351a0-e431-459f-b2d6-5d838bb9581a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e306fc0-6703-4967-b91c-1ed3bb4c6214" xlink:to="loc_srt_MaximumMember_f11351a0-e431-459f-b2d6-5d838bb9581a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended" id="i12eb78361cca4a12872e44885d16ceac_FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6177136a-9541-4a21-bb1a-0366a757448c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6177136a-9541-4a21-bb1a-0366a757448c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31751f07-ef0c-477a-a426-16095e7781f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31751f07-ef0c-477a-a426-16095e7781f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b17e286f-c7bf-4744-87bf-c037fc6f1d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b17e286f-c7bf-4744-87bf-c037fc6f1d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9256bc99-6f67-4a49-a247-94e668b38b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9256bc99-6f67-4a49-a247-94e668b38b06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_bc4ee689-d1db-4c69-b7a2-39f49d8a2454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_RestrictedCashCurrent_bc4ee689-d1db-4c69-b7a2-39f49d8a2454" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3f662dec-8452-45ba-ad79-a35f82c32371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3f662dec-8452-45ba-ad79-a35f82c32371" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2333eb7a-88e6-4c8f-b39b-dbced63ec930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2333eb7a-88e6-4c8f-b39b-dbced63ec930" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_00d1d218-3711-424d-9fd1-8d8a760bc541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2333eb7a-88e6-4c8f-b39b-dbced63ec930" xlink:to="loc_us-gaap_FinancialInstrumentAxis_00d1d218-3711-424d-9fd1-8d8a760bc541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00d1d218-3711-424d-9fd1-8d8a760bc541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00d1d218-3711-424d-9fd1-8d8a760bc541" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00d1d218-3711-424d-9fd1-8d8a760bc541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81798c06-59ab-4c1a-9952-e5e33113647b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00d1d218-3711-424d-9fd1-8d8a760bc541" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81798c06-59ab-4c1a-9952-e5e33113647b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_c2b12887-b525-4dcb-aab6-bbbc8b1ed173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81798c06-59ab-4c1a-9952-e5e33113647b" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_c2b12887-b525-4dcb-aab6-bbbc8b1ed173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81798c06-59ab-4c1a-9952-e5e33113647b" xlink:to="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_0f701f69-8b4d-4677-9f87-7741c61f88f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_0f701f69-8b4d-4677-9f87-7741c61f88f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_457e0ebf-9b5c-4a74-802b-e1aa823ccf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_457e0ebf-9b5c-4a74-802b-e1aa823ccf1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e8c5ede9-0fc5-44a1-af47-8b0cd39b7141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e8c5ede9-0fc5-44a1-af47-8b0cd39b7141" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended" id="i76cfa494a7814c13a82eb6c52d706189_BALANCESHEETCOMPONENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:href="pacb-20230331.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49783a7e-a5ab-44e6-83e3-176d95ae14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49783a7e-a5ab-44e6-83e3-176d95ae14f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_60337129-d3cd-4293-ac60-9e373d87c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_60337129-d3cd-4293-ac60-9e373d87c8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63eac09c-65ec-479e-aabe-91442ff7afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63eac09c-65ec-479e-aabe-91442ff7afc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eec2cda6-9ebf-4550-9c6a-a8ef3a891509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eec2cda6-9ebf-4550-9c6a-a8ef3a891509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e62bb77c-0e22-4aad-a1d1-0dfd5b6c4895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e62bb77c-0e22-4aad-a1d1-0dfd5b6c4895" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5dbaca48-6c0c-4084-904c-9262225729c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5dbaca48-6c0c-4084-904c-9262225729c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_247f570d-5f2d-4ee7-b811-961a268a7f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_247f570d-5f2d-4ee7-b811-961a268a7f31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b0c80291-60fe-441d-a6c3-d9bf58d270fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b0c80291-60fe-441d-a6c3-d9bf58d270fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_d92eff0a-adc0-4c9a-8479-96063db6e327" xlink:href="pacb-20230331.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_StandardProductWarrantyPeriod_d92eff0a-adc0-4c9a-8479-96063db6e327" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c606f2b3-6cda-494d-8cc1-a6f5c323c214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c606f2b3-6cda-494d-8cc1-a6f5c323c214" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2528f19-3b40-457f-b320-1c680b5ee828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2528f19-3b40-457f-b320-1c680b5ee828" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c12f5b5c-1cb2-4c78-b672-d91081f0a7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtInstrumentTerm_c12f5b5c-1cb2-4c78-b672-d91081f0a7a5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df4637e9-9c16-435d-958d-be0d64d5f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df4637e9-9c16-435d-958d-be0d64d5f0f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentTermLoanElectiveOption_7bb6cdba-8b11-46ee-a24f-aad6e327532e" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentTermLoanElectiveOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_DebtInstrumentTermLoanElectiveOption_7bb6cdba-8b11-46ee-a24f-aad6e327532e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFeeToPrepayDebt_133e4e20-b310-4d68-9113-5f517ee21406" xlink:href="pacb-20230331.xsd#pacb_PercentageOfFeeToPrepayDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_PercentageOfFeeToPrepayDebt_133e4e20-b310-4d68-9113-5f517ee21406" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_10b1ad73-17f8-4294-a980-8e58eb0478de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_10b1ad73-17f8-4294-a980-8e58eb0478de" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c634da7a-fb9c-455c-aeff-2a12d0eef076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c634da7a-fb9c-455c-aeff-2a12d0eef076" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_262709ed-ecb2-4d55-89dc-04f2be353fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ShortTermBorrowings_262709ed-ecb2-4d55-89dc-04f2be353fc9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a0fd923b-e18d-4821-a31c-852afc9746b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_InterestExpenseDebt_a0fd923b-e18d-4821-a31c-852afc9746b3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:href="pacb-20230331.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3e8d08f2-ca23-49f3-be09-ee46c418bc28_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:to="loc_srt_NameOfMajorCustomerDomain_3e8d08f2-ca23-49f3-be09-ee46c418bc28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:to="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCorporationMember_1fac43a9-47e1-492e-becf-5693bb402767" xlink:href="pacb-20230331.xsd#pacb_InvitaeCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:to="loc_pacb_InvitaeCorporationMember_1fac43a9-47e1-492e-becf-5693bb402767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7771062-b049-4677-af73-2d7ff3ba2c35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7771062-b049-4677-af73-2d7ff3ba2c35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_aab2b505-0837-494f-8e49-2acc3c349bdd" xlink:href="pacb-20230331.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:to="loc_pacb_OmniomeIncMember_aab2b505-0837-494f-8e49-2acc3c349bdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6033a423-7358-461d-a50f-61f3fabd5f97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6033a423-7358-461d-a50f-61f3fabd5f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bff7cd81-6415-447c-bba6-d168899c5d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bff7cd81-6415-447c-bba6-d168899c5d05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2958537f-bd54-4e32-b270-a5ce4b393544_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2958537f-bd54-4e32-b270-a5ce4b393544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TermLoansMember_76926325-6b78-4894-839c-d091d1663c82" xlink:href="pacb-20230331.xsd#pacb_TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:to="loc_pacb_TermLoansMember_76926325-6b78-4894-839c-d091d1663c82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a3278e2-3ec6-4395-bd0c-a692a43a4038_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a3278e2-3ec6-4395-bd0c-a692a43a4038_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_048e89b2-5bfa-4cc1-80c6-81f96000dca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:to="loc_us-gaap_SecuredDebtMember_048e89b2-5bfa-4cc1-80c6-81f96000dca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2f1d0e08-ec6d-4926-ba50-c0305c427201_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2f1d0e08-ec6d-4926-ba50-c0305c427201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_067a255b-cf4d-4e0c-ab0e-88231a8141c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:to="loc_us-gaap_SecuredDebtMember_067a255b-cf4d-4e0c-ab0e-88231a8141c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b7a95751-e6c0-488c-878a-ea750ff713fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b7a95751-e6c0-488c-878a-ea750ff713fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f58d2063-40fb-4e7f-92d0-5de895a2a6ae_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:to="loc_srt_RangeMember_f58d2063-40fb-4e7f-92d0-5de895a2a6ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:to="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ee22c6e1-fc0d-4d59-86db-8db21737ddd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:to="loc_srt_MinimumMember_ee22c6e1-fc0d-4d59-86db-8db21737ddd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1aacaf60-8a58-4985-8f81-daa36b844a27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:to="loc_srt_MaximumMember_1aacaf60-8a58-4985-8f81-daa36b844a27" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="extended" id="i1dce4b377536472db8a7f861ae6086d4_BALANCESHEETCOMPONENTSNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:href="pacb-20230331.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49783a7e-a5ab-44e6-83e3-176d95ae14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49783a7e-a5ab-44e6-83e3-176d95ae14f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_60337129-d3cd-4293-ac60-9e373d87c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_60337129-d3cd-4293-ac60-9e373d87c8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63eac09c-65ec-479e-aabe-91442ff7afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63eac09c-65ec-479e-aabe-91442ff7afc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eec2cda6-9ebf-4550-9c6a-a8ef3a891509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eec2cda6-9ebf-4550-9c6a-a8ef3a891509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e62bb77c-0e22-4aad-a1d1-0dfd5b6c4895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e62bb77c-0e22-4aad-a1d1-0dfd5b6c4895" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5dbaca48-6c0c-4084-904c-9262225729c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5dbaca48-6c0c-4084-904c-9262225729c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_247f570d-5f2d-4ee7-b811-961a268a7f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_247f570d-5f2d-4ee7-b811-961a268a7f31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b0c80291-60fe-441d-a6c3-d9bf58d270fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b0c80291-60fe-441d-a6c3-d9bf58d270fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_d92eff0a-adc0-4c9a-8479-96063db6e327" xlink:href="pacb-20230331.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_StandardProductWarrantyPeriod_d92eff0a-adc0-4c9a-8479-96063db6e327" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c606f2b3-6cda-494d-8cc1-a6f5c323c214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c606f2b3-6cda-494d-8cc1-a6f5c323c214" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2528f19-3b40-457f-b320-1c680b5ee828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2528f19-3b40-457f-b320-1c680b5ee828" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c12f5b5c-1cb2-4c78-b672-d91081f0a7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtInstrumentTerm_c12f5b5c-1cb2-4c78-b672-d91081f0a7a5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df4637e9-9c16-435d-958d-be0d64d5f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df4637e9-9c16-435d-958d-be0d64d5f0f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentTermLoanElectiveOption_7bb6cdba-8b11-46ee-a24f-aad6e327532e" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentTermLoanElectiveOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_DebtInstrumentTermLoanElectiveOption_7bb6cdba-8b11-46ee-a24f-aad6e327532e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFeeToPrepayDebt_133e4e20-b310-4d68-9113-5f517ee21406" xlink:href="pacb-20230331.xsd#pacb_PercentageOfFeeToPrepayDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_PercentageOfFeeToPrepayDebt_133e4e20-b310-4d68-9113-5f517ee21406" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_10b1ad73-17f8-4294-a980-8e58eb0478de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_10b1ad73-17f8-4294-a980-8e58eb0478de" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c634da7a-fb9c-455c-aeff-2a12d0eef076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c634da7a-fb9c-455c-aeff-2a12d0eef076" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_262709ed-ecb2-4d55-89dc-04f2be353fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ShortTermBorrowings_262709ed-ecb2-4d55-89dc-04f2be353fc9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a0fd923b-e18d-4821-a31c-852afc9746b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_InterestExpenseDebt_a0fd923b-e18d-4821-a31c-852afc9746b3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:href="pacb-20230331.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3e8d08f2-ca23-49f3-be09-ee46c418bc28_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:to="loc_srt_NameOfMajorCustomerDomain_3e8d08f2-ca23-49f3-be09-ee46c418bc28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:to="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCorporationMember_1fac43a9-47e1-492e-becf-5693bb402767" xlink:href="pacb-20230331.xsd#pacb_InvitaeCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:to="loc_pacb_InvitaeCorporationMember_1fac43a9-47e1-492e-becf-5693bb402767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7771062-b049-4677-af73-2d7ff3ba2c35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7771062-b049-4677-af73-2d7ff3ba2c35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_aab2b505-0837-494f-8e49-2acc3c349bdd" xlink:href="pacb-20230331.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:to="loc_pacb_OmniomeIncMember_aab2b505-0837-494f-8e49-2acc3c349bdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6033a423-7358-461d-a50f-61f3fabd5f97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6033a423-7358-461d-a50f-61f3fabd5f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bff7cd81-6415-447c-bba6-d168899c5d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bff7cd81-6415-447c-bba6-d168899c5d05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2958537f-bd54-4e32-b270-a5ce4b393544_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2958537f-bd54-4e32-b270-a5ce4b393544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TermLoansMember_76926325-6b78-4894-839c-d091d1663c82" xlink:href="pacb-20230331.xsd#pacb_TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:to="loc_pacb_TermLoansMember_76926325-6b78-4894-839c-d091d1663c82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a3278e2-3ec6-4395-bd0c-a692a43a4038_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a3278e2-3ec6-4395-bd0c-a692a43a4038_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_048e89b2-5bfa-4cc1-80c6-81f96000dca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:to="loc_us-gaap_SecuredDebtMember_048e89b2-5bfa-4cc1-80c6-81f96000dca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2f1d0e08-ec6d-4926-ba50-c0305c427201_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2f1d0e08-ec6d-4926-ba50-c0305c427201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_067a255b-cf4d-4e0c-ab0e-88231a8141c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:to="loc_us-gaap_SecuredDebtMember_067a255b-cf4d-4e0c-ab0e-88231a8141c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f58d2063-40fb-4e7f-92d0-5de895a2a6ae_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:to="loc_srt_RangeMember_f58d2063-40fb-4e7f-92d0-5de895a2a6ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:to="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ee22c6e1-fc0d-4d59-86db-8db21737ddd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:to="loc_srt_MinimumMember_ee22c6e1-fc0d-4d59-86db-8db21737ddd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1aacaf60-8a58-4985-8f81-daa36b844a27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:to="loc_srt_MaximumMember_1aacaf60-8a58-4985-8f81-daa36b844a27" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="extended" id="ic56e4fe033cc4337bec8bd0e0ae37cb6_BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a2ea28a-5767-4b6e-b06f-f884379bd5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a2ea28a-5767-4b6e-b06f-f884379bd5f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_95a0387d-e84a-4bf5-b1f1-7adf869a2207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_95a0387d-e84a-4bf5-b1f1-7adf869a2207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ea1dfdbc-af37-46e1-a209-42cd02e9d41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ea1dfdbc-af37-46e1-a209-42cd02e9d41b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ea2ba130-4ac7-4c64-8561-912d17d3a44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ea2ba130-4ac7-4c64-8561-912d17d3a44d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82d829aa-60cc-4389-9d77-db3057964561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82d829aa-60cc-4389-9d77-db3057964561" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eea87425-2f84-4144-9c5b-a487c75991a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82d829aa-60cc-4389-9d77-db3057964561" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eea87425-2f84-4144-9c5b-a487c75991a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eea87425-2f84-4144-9c5b-a487c75991a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eea87425-2f84-4144-9c5b-a487c75991a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eea87425-2f84-4144-9c5b-a487c75991a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8527761d-7662-4a74-84ef-486b2a19aa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eea87425-2f84-4144-9c5b-a487c75991a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8527761d-7662-4a74-84ef-486b2a19aa9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_91cdfebe-4db4-497f-a4f5-17b756a235a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8527761d-7662-4a74-84ef-486b2a19aa9a" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_91cdfebe-4db4-497f-a4f5-17b756a235a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_7a9bbc66-f605-4f8b-aead-885205e61ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8527761d-7662-4a74-84ef-486b2a19aa9a" xlink:to="loc_us-gaap_CustomerRelationshipsMember_7a9bbc66-f605-4f8b-aead-885205e61ed3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails" xlink:type="extended" id="i6863f0fd71d04a8cb0a31b9f1f602bb5_BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_be2e4d2a-0297-4d92-9e2e-7ab73571f64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be2e4d2a-0297-4d92-9e2e-7ab73571f64e" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d4237607-f500-4d52-aa1c-f87c8d210635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d4237607-f500-4d52-aa1c-f87c8d210635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9a7874ec-e6b4-4872-a302-0c6a114c4f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9a7874ec-e6b4-4872-a302-0c6a114c4f27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a1621712-d8e4-42ad-9273-6473304df6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:to="loc_us-gaap_LongTermDebt_a1621712-d8e4-42ad-9273-6473304df6d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11142108-def6-4bb2-9050-e64ac23a8823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be2e4d2a-0297-4d92-9e2e-7ab73571f64e" xlink:to="loc_us-gaap_DebtInstrumentTable_11142108-def6-4bb2-9050-e64ac23a8823" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d5bbcf6-dec2-417a-a9fa-7693366e18b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11142108-def6-4bb2-9050-e64ac23a8823" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d5bbcf6-dec2-417a-a9fa-7693366e18b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3d5bbcf6-dec2-417a-a9fa-7693366e18b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d5bbcf6-dec2-417a-a9fa-7693366e18b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3d5bbcf6-dec2-417a-a9fa-7693366e18b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b043edbd-c5b6-4247-9b54-da0db65d17f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d5bbcf6-dec2-417a-a9fa-7693366e18b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b043edbd-c5b6-4247-9b54-da0db65d17f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TermLoansMember_d81ff23d-43e2-453d-9650-a23800965b11" xlink:href="pacb-20230331.xsd#pacb_TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b043edbd-c5b6-4247-9b54-da0db65d17f4" xlink:to="loc_pacb_TermLoansMember_d81ff23d-43e2-453d-9650-a23800965b11" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended" id="ibb36141bf6ac4aa989f9641a64f5407c_CONVERTIBLESENIORNOTESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c2ce29d7-b804-4cc3-b1b0-78f44c01a684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c2ce29d7-b804-4cc3-b1b0-78f44c01a684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11b2e0b9-7464-47fb-911e-891cc3d06908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11b2e0b9-7464-47fb-911e-891cc3d06908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_7f0ae6a3-0e22-4b7c-b61a-a2561ffaf0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_7f0ae6a3-0e22-4b7c-b61a-a2561ffaf0ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3b99beeb-6ffa-4670-ba1e-b1be4e393a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3b99beeb-6ffa-4670-ba1e-b1be4e393a25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_5243b008-28f8-4de7-b63e-701de2b29ba9" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_5243b008-28f8-4de7-b63e-701de2b29ba9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_8b97fe8d-ccbe-4f2f-acf3-702fc63e71e0" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_8b97fe8d-ccbe-4f2f-acf3-702fc63e71e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_615d37c5-a7fb-4982-8e62-92ce12368eef" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_615d37c5-a7fb-4982-8e62-92ce12368eef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5868e62f-6d98-44dc-b0e7-b37784e6989e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5868e62f-6d98-44dc-b0e7-b37784e6989e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_557f5cab-9542-4c7d-84d5-614088d642d1" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_557f5cab-9542-4c7d-84d5-614088d642d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_771622e0-de37-4c9f-ad9a-bbb69a53bfa9" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_771622e0-de37-4c9f-ad9a-bbb69a53bfa9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_8ee0c149-d0bf-4e11-8eea-dc1c63d3e135" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_8ee0c149-d0bf-4e11-8eea-dc1c63d3e135" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_c77cb6a2-436b-4999-99ad-2b6f71040d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_c77cb6a2-436b-4999-99ad-2b6f71040d91" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_afad200b-8bc0-41b5-8cce-b2082152d5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_afad200b-8bc0-41b5-8cce-b2082152d5a3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_6c3d25da-9186-46af-9a51-3a58137a6593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_6c3d25da-9186-46af-9a51-3a58137a6593" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5c9f217-6178-4c5a-932c-c4362c9d4763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5c9f217-6178-4c5a-932c-c4362c9d4763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b5c9f217-6178-4c5a-932c-c4362c9d4763_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5c9f217-6178-4c5a-932c-c4362c9d4763" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b5c9f217-6178-4c5a-932c-c4362c9d4763_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_41ecff23-d0cc-4da4-9666-284be42582b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5c9f217-6178-4c5a-932c-c4362c9d4763" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_41ecff23-d0cc-4da4-9666-284be42582b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_e7d8ca6b-ea83-461e-a4e5-fb6d816265cb" xlink:href="pacb-20230331.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41ecff23-d0cc-4da4-9666-284be42582b4" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_e7d8ca6b-ea83-461e-a4e5-fb6d816265cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_77b75d0c-5b08-4e05-aa18-adde7492599f" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_77b75d0c-5b08-4e05-aa18-adde7492599f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_77b75d0c-5b08-4e05-aa18-adde7492599f_default" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_77b75d0c-5b08-4e05-aa18-adde7492599f" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_77b75d0c-5b08-4e05-aa18-adde7492599f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_0762c28c-67e0-4395-b389-546efb679a30" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_77b75d0c-5b08-4e05-aa18-adde7492599f" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_0762c28c-67e0-4395-b389-546efb679a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_25c485be-717b-4fdd-9415-204df69ca742" xlink:href="pacb-20230331.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_0762c28c-67e0-4395-b389-546efb679a30" xlink:to="loc_pacb_DebtConversionTermsOneMember_25c485be-717b-4fdd-9415-204df69ca742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_c5e073d0-552c-4649-af4a-eead596bdd32" xlink:href="pacb-20230331.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_0762c28c-67e0-4395-b389-546efb679a30" xlink:to="loc_pacb_DebtConversionTermsTwoMember_c5e073d0-552c-4649-af4a-eead596bdd32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c5d863d0-bc68-4aeb-aa73-1132116bc6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c5d863d0-bc68-4aeb-aa73-1132116bc6ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c5d863d0-bc68-4aeb-aa73-1132116bc6ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5d863d0-bc68-4aeb-aa73-1132116bc6ed" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c5d863d0-bc68-4aeb-aa73-1132116bc6ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_560443db-454e-488c-bba1-23f8d72425cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5d863d0-bc68-4aeb-aa73-1132116bc6ed" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_560443db-454e-488c-bba1-23f8d72425cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_df10cf01-97df-49d8-9cc3-d55ee9abdd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_560443db-454e-488c-bba1-23f8d72425cb" xlink:to="loc_us-gaap_ConvertibleDebtMember_df10cf01-97df-49d8-9cc3-d55ee9abdd86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed75d4a2-c342-4d4b-aeac-426895635257" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_srt_RangeAxis_ed75d4a2-c342-4d4b-aeac-426895635257" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed75d4a2-c342-4d4b-aeac-426895635257_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed75d4a2-c342-4d4b-aeac-426895635257" xlink:to="loc_srt_RangeMember_ed75d4a2-c342-4d4b-aeac-426895635257_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b95ad07f-495c-46a7-ac35-207fb91b3a1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed75d4a2-c342-4d4b-aeac-426895635257" xlink:to="loc_srt_RangeMember_b95ad07f-495c-46a7-ac35-207fb91b3a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6228248a-94bf-4633-95ab-520ca9b29521" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b95ad07f-495c-46a7-ac35-207fb91b3a1a" xlink:to="loc_srt_MaximumMember_6228248a-94bf-4633-95ab-520ca9b29521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8065894f-c386-4c7b-b854-1a7d093f9676" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b95ad07f-495c-46a7-ac35-207fb91b3a1a" xlink:to="loc_srt_MinimumMember_8065894f-c386-4c7b-b854-1a7d093f9676" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended" id="i3de1e518cbf94c71a8a0a5ff0d2e99bb_CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a76fc755-2f3b-4b49-8264-343367646a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a76fc755-2f3b-4b49-8264-343367646a84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5a8cde00-900e-4bba-bf17-aae1be81f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5a8cde00-900e-4bba-bf17-aae1be81f1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3d138f83-320a-4c1c-8cb7-678c855ea074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:to="loc_us-gaap_LongTermDebt_3d138f83-320a-4c1c-8cb7-678c855ea074" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b6cb5da4-ed50-4507-9188-8f3ad2cca4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:to="loc_us-gaap_DebtInstrumentTable_b6cb5da4-ed50-4507-9188-8f3ad2cca4f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6113efbe-f371-4232-8987-70d115d4543d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b6cb5da4-ed50-4507-9188-8f3ad2cca4f5" xlink:to="loc_us-gaap_DebtInstrumentAxis_6113efbe-f371-4232-8987-70d115d4543d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6113efbe-f371-4232-8987-70d115d4543d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6113efbe-f371-4232-8987-70d115d4543d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6113efbe-f371-4232-8987-70d115d4543d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a5141def-68b7-4c4b-8928-26777f98c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6113efbe-f371-4232-8987-70d115d4543d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a5141def-68b7-4c4b-8928-26777f98c0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_3303d15a-76a4-4001-b5c3-f5f67cdd3fff" xlink:href="pacb-20230331.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a5141def-68b7-4c4b-8928-26777f98c0a5" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_3303d15a-76a4-4001-b5c3-f5f67cdd3fff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended" id="i4aa3fe94768b4fdaa204011d2bdb79f1_CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_2e650731-1a4d-4789-b3f4-7371eae04b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_2e650731-1a4d-4789-b3f4-7371eae04b2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_31a911d8-3d83-4bf1-a3e5-277afc825690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_31a911d8-3d83-4bf1-a3e5-277afc825690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_da224ac7-6bca-4d2a-a6af-593c28b79c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:to="loc_us-gaap_InterestExpenseDebt_da224ac7-6bca-4d2a-a6af-593c28b79c3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55591a31-94d9-4cf4-94fa-f8efe368fa50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:to="loc_us-gaap_DebtInstrumentTable_55591a31-94d9-4cf4-94fa-f8efe368fa50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c388a253-2d54-4e1b-a3f1-07fa538e2694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55591a31-94d9-4cf4-94fa-f8efe368fa50" xlink:to="loc_us-gaap_DebtInstrumentAxis_c388a253-2d54-4e1b-a3f1-07fa538e2694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c388a253-2d54-4e1b-a3f1-07fa538e2694_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c388a253-2d54-4e1b-a3f1-07fa538e2694" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c388a253-2d54-4e1b-a3f1-07fa538e2694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_881f824e-aa08-47d5-835f-eed5f9521695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c388a253-2d54-4e1b-a3f1-07fa538e2694" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_881f824e-aa08-47d5-835f-eed5f9521695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_6bbb2c76-eabf-4f71-8ed1-e9375d413030" xlink:href="pacb-20230331.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_881f824e-aa08-47d5-835f-eed5f9521695" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_6bbb2c76-eabf-4f71-8ed1-e9375d413030" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended" id="i4bcfb210f1f84d5d8f2b47850e3e500d_STOCKHOLDERSEQUITYNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares_9eae216b-9aec-44d3-943e-9b582b9f32db" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_PublicOfferingShares_9eae216b-9aec-44d3-943e-9b582b9f32db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_33ba1c5f-a081-4e9b-9f68-6d8036224fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_33ba1c5f-a081-4e9b-9f68-6d8036224fe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum_e13fa700-0011-4d9c-bb58-95c4f5a44442" xlink:href="pacb-20230331.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_OfferingShareAmountMaximum_e13fa700-0011-4d9c-bb58-95c4f5a44442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_934a5e24-665b-4673-8921-9a4a42a2e900" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_934a5e24-665b-4673-8921-9a4a42a2e900" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_2fa8178e-08f1-4681-993b-7e1d62080cce" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_2fa8178e-08f1-4681-993b-7e1d62080cce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eee46471-ebe8-4fa0-be12-e675033381ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eee46471-ebe8-4fa0-be12-e675033381ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_7469342f-57c1-4502-9ab2-c94dcf5d3d32" xlink:href="pacb-20230331.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_7469342f-57c1-4502-9ab2-c94dcf5d3d32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_ddf4e3bc-930d-4bb2-a134-44c5cf4d105f" xlink:href="pacb-20230331.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_ddf4e3bc-930d-4bb2-a134-44c5cf4d105f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_eb509944-4f4b-49c2-bb42-1803f95dcb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_eb509944-4f4b-49c2-bb42-1803f95dcb27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f91f8306-0be1-4308-85fc-b3689d7539a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f91f8306-0be1-4308-85fc-b3689d7539a6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_012ab02b-7641-41a6-9680-a03ec058b0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_012ab02b-7641-41a6-9680-a03ec058b0d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d1347611-6d1a-4119-abb4-c82164591888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d1347611-6d1a-4119-abb4-c82164591888" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_95c88b3a-5353-458d-b69e-1e1acb497ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_95c88b3a-5353-458d-b69e-1e1acb497ae4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_ba7eefa7-576f-4d96-a94e-c71f993d2807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_ba7eefa7-576f-4d96-a94e-c71f993d2807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ba7eefa7-576f-4d96-a94e-c71f993d2807_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_ba7eefa7-576f-4d96-a94e-c71f993d2807" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_ba7eefa7-576f-4d96-a94e-c71f993d2807_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c95ecb9a-eb27-4fac-856b-9c46ecf71815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_ba7eefa7-576f-4d96-a94e-c71f993d2807" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c95ecb9a-eb27-4fac-856b-9c46ecf71815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member_d14483c4-6025-47f1-a691-8aa74b9ecca6" xlink:href="pacb-20230331.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c95ecb9a-eb27-4fac-856b-9c46ecf71815" xlink:to="loc_pacb_EquityIncentivePlan2020Member_d14483c4-6025-47f1-a691-8aa74b9ecca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_aff4b342-623d-4a0a-a994-0cdb5ffd9b6e" xlink:href="pacb-20230331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c95ecb9a-eb27-4fac-856b-9c46ecf71815" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_aff4b342-623d-4a0a-a994-0cdb5ffd9b6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fc0c7142-b915-47bb-b41e-ce164455c22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fc0c7142-b915-47bb-b41e-ce164455c22f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc0c7142-b915-47bb-b41e-ce164455c22f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc0c7142-b915-47bb-b41e-ce164455c22f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc0c7142-b915-47bb-b41e-ce164455c22f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdb40a4b-a6c2-4613-8c26-086ecf836a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc0c7142-b915-47bb-b41e-ce164455c22f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdb40a4b-a6c2-4613-8c26-086ecf836a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember_a1be7ae5-b7e1-416c-9c02-0387d8c689b0" xlink:href="pacb-20230331.xsd#pacb_ShelfOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdb40a4b-a6c2-4613-8c26-086ecf836a73" xlink:to="loc_pacb_ShelfOfferingMember_a1be7ae5-b7e1-416c-9c02-0387d8c689b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails" xlink:type="extended" id="ia87e8ae0e6a14f1d87c600fc9fae0c37_STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_871eea9b-331f-4484-aa46-abe283072a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_871eea9b-331f-4484-aa46-abe283072a08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75add0df-a9f1-4ebd-823e-110c8fd8d812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75add0df-a9f1-4ebd-823e-110c8fd8d812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0d0a88b0-6fe7-4723-9900-bc7e79d6a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0d0a88b0-6fe7-4723-9900-bc7e79d6a03c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77d97da8-4f66-41cc-b6f3-73d590cfe6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77d97da8-4f66-41cc-b6f3-73d590cfe6bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_145529a1-e491-4203-b55d-3f4c8d0d5616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_145529a1-e491-4203-b55d-3f4c8d0d5616" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d3c66f0-94db-4f62-9f3e-08b5c09d0f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_871eea9b-331f-4484-aa46-abe283072a08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7739bade-f32c-4f99-919f-410ec6334a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7739bade-f32c-4f99-919f-410ec6334a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bdf1fdc3-039d-4372-9b5b-b3605c59eeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bdf1fdc3-039d-4372-9b5b-b3605c59eeae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e3a2224-dcec-42e8-90ce-c43c3c872b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e3a2224-dcec-42e8-90ce-c43c3c872b52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72425018-ae85-4d0c-85db-f76e8f399d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72425018-ae85-4d0c-85db-f76e8f399d59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e5d24203-2f62-4830-bfb3-20bfc78cd871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74104d4f-ae8b-4520-81ec-00302aae1a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_871eea9b-331f-4484-aa46-abe283072a08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74104d4f-ae8b-4520-81ec-00302aae1a59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73f6b9b8-e464-4783-b307-5071ee69e691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74104d4f-ae8b-4520-81ec-00302aae1a59" xlink:to="loc_us-gaap_AwardTypeAxis_73f6b9b8-e464-4783-b307-5071ee69e691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73f6b9b8-e464-4783-b307-5071ee69e691_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_73f6b9b8-e464-4783-b307-5071ee69e691" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73f6b9b8-e464-4783-b307-5071ee69e691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00c82c47-bf14-495b-bd48-afebf5f75bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_73f6b9b8-e464-4783-b307-5071ee69e691" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00c82c47-bf14-495b-bd48-afebf5f75bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_44f6f963-d014-4e13-9a99-5e7b9fa1267e" xlink:href="pacb-20230331.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00c82c47-bf14-495b-bd48-afebf5f75bfa" xlink:to="loc_pacb_TimeBasedStockOptionMember_44f6f963-d014-4e13-9a99-5e7b9fa1267e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" xlink:type="extended" id="i9c5d614cb9314e1c9d9e715cb6a0862c_STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d48378a0-3a5f-479e-bd91-250da3615820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d48378a0-3a5f-479e-bd91-250da3615820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d568af0d-a230-475a-8685-3332bd8b5817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d568af0d-a230-475a-8685-3332bd8b5817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_806dbe2a-a6f0-4f82-87d9-d0391d185572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_806dbe2a-a6f0-4f82-87d9-d0391d185572" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d13279e0-8807-4683-84fb-db668ca08104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d13279e0-8807-4683-84fb-db668ca08104" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_23b96ac6-7e9d-4780-8f91-ad089c66c4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_23b96ac6-7e9d-4780-8f91-ad089c66c4e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_47ff3e71-8a03-4500-8692-d1e9b70b10ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d48378a0-3a5f-479e-bd91-250da3615820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1701daa2-878c-43a3-8eb2-a84153d7765e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1701daa2-878c-43a3-8eb2-a84153d7765e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40203ce5-6e1d-44b1-8ea3-60b81e5bfde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40203ce5-6e1d-44b1-8ea3-60b81e5bfde8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1456e649-965d-4f4c-801b-6fe4db5cfa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1456e649-965d-4f4c-801b-6fe4db5cfa5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_eafe7f3a-b220-49a5-bd72-d0d9e3403ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_eafe7f3a-b220-49a5-bd72-d0d9e3403ba3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_828fc4ed-42dd-452d-8172-15d7f7ef505a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_f145c762-9357-40f4-babf-5c53da9485f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d48378a0-3a5f-479e-bd91-250da3615820" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_f145c762-9357-40f4-babf-5c53da9485f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e139c2ae-096e-4b41-a3c7-85799eaaea0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_f145c762-9357-40f4-babf-5c53da9485f0" xlink:to="loc_us-gaap_AwardTypeAxis_e139c2ae-096e-4b41-a3c7-85799eaaea0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e139c2ae-096e-4b41-a3c7-85799eaaea0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e139c2ae-096e-4b41-a3c7-85799eaaea0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e139c2ae-096e-4b41-a3c7-85799eaaea0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b813978-8c72-4b00-8cad-7523ac1d2b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e139c2ae-096e-4b41-a3c7-85799eaaea0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b813978-8c72-4b00-8cad-7523ac1d2b8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_75ed6de9-4537-42a2-930d-fef672ab727a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b813978-8c72-4b00-8cad-7523ac1d2b8d" xlink:to="loc_us-gaap_PerformanceSharesMember_75ed6de9-4537-42a2-930d-fef672ab727a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" xlink:type="extended" id="ib06a48be6f5f497787bfa4aafe64dfa1_STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7867f43-5264-4c05-861d-579171e2b6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7867f43-5264-4c05-861d-579171e2b6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_376c906f-3df9-4b34-b64b-2c6e82579fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_376c906f-3df9-4b34-b64b-2c6e82579fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bdf8bd8-cf08-4a8d-a033-45aef6c63209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bdf8bd8-cf08-4a8d-a033-45aef6c63209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_968ecdaa-2222-43b3-989f-cf164b7adc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_968ecdaa-2222-43b3-989f-cf164b7adc64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_56e6e884-2662-4618-8bbf-27497a5d2224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_56e6e884-2662-4618-8bbf-27497a5d2224" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ecaac716-a4d7-49b4-84e7-94fdbe3744db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7867f43-5264-4c05-861d-579171e2b6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb0a36e9-2e1c-464a-957f-61d5c5354bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb0a36e9-2e1c-464a-957f-61d5c5354bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a50aba96-bafd-408c-8480-167d6c879ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a50aba96-bafd-408c-8480-167d6c879ddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0d9dd993-0194-4914-b9ca-7c045d4244b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0d9dd993-0194-4914-b9ca-7c045d4244b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2794b2b5-a526-4f62-8341-0d59c598cee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2794b2b5-a526-4f62-8341-0d59c598cee4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ea3f9321-4141-474d-9f2a-1f4d7763f8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_316d6be6-960d-42d4-8e9a-02844f50a3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7867f43-5264-4c05-861d-579171e2b6ff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_316d6be6-960d-42d4-8e9a-02844f50a3b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5fe1969f-267a-4a43-91c5-7fdf2b3409ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_316d6be6-960d-42d4-8e9a-02844f50a3b4" xlink:to="loc_us-gaap_AwardTypeAxis_5fe1969f-267a-4a43-91c5-7fdf2b3409ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5fe1969f-267a-4a43-91c5-7fdf2b3409ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5fe1969f-267a-4a43-91c5-7fdf2b3409ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5fe1969f-267a-4a43-91c5-7fdf2b3409ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0cc365-d8b2-4993-a332-72dfc7ff78fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5fe1969f-267a-4a43-91c5-7fdf2b3409ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0cc365-d8b2-4993-a332-72dfc7ff78fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_c37077d0-003d-40cd-a4ac-008084271395" xlink:href="pacb-20230331.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0cc365-d8b2-4993-a332-72dfc7ff78fd" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_c37077d0-003d-40cd-a4ac-008084271395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_815e56cd-fb9e-4089-aa16-4bfb325fe790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0cc365-d8b2-4993-a332-72dfc7ff78fd" xlink:to="loc_us-gaap_PerformanceSharesMember_815e56cd-fb9e-4089-aa16-4bfb325fe790" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended" id="if96f5bb2083c4f1591482287178a1fad_STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d67598d7-9b3c-4d28-af42-d1e1e7f507c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e64f4fc-0c1e-478b-b99d-7386eb195e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d67598d7-9b3c-4d28-af42-d1e1e7f507c4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e64f4fc-0c1e-478b-b99d-7386eb195e57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91539f19-e40e-4daa-b252-efc34e53c74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d67598d7-9b3c-4d28-af42-d1e1e7f507c4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91539f19-e40e-4daa-b252-efc34e53c74b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_994954b4-cec6-416d-86b9-62acab968578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91539f19-e40e-4daa-b252-efc34e53c74b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_994954b4-cec6-416d-86b9-62acab968578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_994954b4-cec6-416d-86b9-62acab968578_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_994954b4-cec6-416d-86b9-62acab968578" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_994954b4-cec6-416d-86b9-62acab968578_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_994954b4-cec6-416d-86b9-62acab968578" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_1d77b10a-f1eb-4747-95e1-916e68d53218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:to="loc_us-gaap_CostOfSalesMember_1d77b10a-f1eb-4747-95e1-916e68d53218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29d2ae17-e3b2-44b1-bc16-f098b8bdcfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29d2ae17-e3b2-44b1-bc16-f098b8bdcfb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ad5b7b4-940c-4cbf-9f65-5478030e306b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ad5b7b4-940c-4cbf-9f65-5478030e306b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended" id="i20784915e435400db8c2de6909746540_STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11537133-6c41-40ff-9794-9ffe62d5ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11537133-6c41-40ff-9794-9ffe62d5ae5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_567c8b6d-300c-4137-84e9-3a72c41da464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_567c8b6d-300c-4137-84e9-3a72c41da464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_877dd10a-b594-43b6-9f2d-13b7911be462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_877dd10a-b594-43b6-9f2d-13b7911be462" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dfda2e45-c729-4ca2-8725-bb3d081c5b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dfda2e45-c729-4ca2-8725-bb3d081c5b86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2deec0b3-f8c7-4d32-b824-25807583bb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2deec0b3-f8c7-4d32-b824-25807583bb25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ec28bf0f-afda-4c76-8e5b-152b0a80e812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:to="loc_us-gaap_AwardTypeAxis_ec28bf0f-afda-4c76-8e5b-152b0a80e812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec28bf0f-afda-4c76-8e5b-152b0a80e812_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ec28bf0f-afda-4c76-8e5b-152b0a80e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec28bf0f-afda-4c76-8e5b-152b0a80e812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47bc572e-093d-43dc-abeb-699445bb0191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ec28bf0f-afda-4c76-8e5b-152b0a80e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47bc572e-093d-43dc-abeb-699445bb0191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_ae8a2a79-37cd-4c17-960f-2b6098aa5295" xlink:href="pacb-20230331.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47bc572e-093d-43dc-abeb-699445bb0191" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_ae8a2a79-37cd-4c17-960f-2b6098aa5295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e2d14e1c-e6a9-410b-9441-24d5c8d21db7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:to="loc_srt_RangeAxis_e2d14e1c-e6a9-410b-9441-24d5c8d21db7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e2d14e1c-e6a9-410b-9441-24d5c8d21db7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e2d14e1c-e6a9-410b-9441-24d5c8d21db7" xlink:to="loc_srt_RangeMember_e2d14e1c-e6a9-410b-9441-24d5c8d21db7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6230a23b-c1ba-4fc4-86eb-954fc31ee136" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e2d14e1c-e6a9-410b-9441-24d5c8d21db7" xlink:to="loc_srt_RangeMember_6230a23b-c1ba-4fc4-86eb-954fc31ee136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_455c46cd-48c4-4c50-8fad-122c2daa559d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6230a23b-c1ba-4fc4-86eb-954fc31ee136" xlink:to="loc_srt_MinimumMember_455c46cd-48c4-4c50-8fad-122c2daa559d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c749948a-efb0-4ed2-ac21-94dbe85bb54b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6230a23b-c1ba-4fc4-86eb-954fc31ee136" xlink:to="loc_srt_MaximumMember_c749948a-efb0-4ed2-ac21-94dbe85bb54b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended" id="ib520a860c1d444c6a7e64a7f5005a5d6_STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f43b2412-c0d7-4d1f-842b-2e174e9c191b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f43b2412-c0d7-4d1f-842b-2e174e9c191b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4bcb6272-8dba-455c-a1d9-8668dda95f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4bcb6272-8dba-455c-a1d9-8668dda95f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_76cdb5dd-4a56-4d18-97b6-516265ccbe72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_76cdb5dd-4a56-4d18-97b6-516265ccbe72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a213179b-f311-4f68-ace2-df6a60d9eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a213179b-f311-4f68-ace2-df6a60d9eb3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6d364e46-78a7-458d-ab2c-bd38234c8cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6d364e46-78a7-458d-ab2c-bd38234c8cc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9dc5487f-610e-4341-93b1-f43674aecb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9dc5487f-610e-4341-93b1-f43674aecb8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ae3facf-f283-4700-bfb1-ad5212083a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ae3facf-f283-4700-bfb1-ad5212083a3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f06e5207-3475-4e64-a8f0-22d8c0b34115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f06e5207-3475-4e64-a8f0-22d8c0b34115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_f06e5207-3475-4e64-a8f0-22d8c0b34115_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f06e5207-3475-4e64-a8f0-22d8c0b34115" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_f06e5207-3475-4e64-a8f0-22d8c0b34115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_db4af526-031a-4d95-b47a-806991aac9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f06e5207-3475-4e64-a8f0-22d8c0b34115" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_db4af526-031a-4d95-b47a-806991aac9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_0caa4d33-101b-4989-8167-b6f96d8a3a71" xlink:href="pacb-20230331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_db4af526-031a-4d95-b47a-806991aac9d3" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_0caa4d33-101b-4989-8167-b6f96d8a3a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b917b168-64f8-4a09-b6f0-0c65e403a247" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:to="loc_srt_RangeAxis_b917b168-64f8-4a09-b6f0-0c65e403a247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b917b168-64f8-4a09-b6f0-0c65e403a247_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b917b168-64f8-4a09-b6f0-0c65e403a247" xlink:to="loc_srt_RangeMember_b917b168-64f8-4a09-b6f0-0c65e403a247_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e498ec85-a7e3-4817-992e-ba515032416d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b917b168-64f8-4a09-b6f0-0c65e403a247" xlink:to="loc_srt_RangeMember_e498ec85-a7e3-4817-992e-ba515032416d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f2921ba9-eec5-4448-8914-a141d0bc04dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e498ec85-a7e3-4817-992e-ba515032416d" xlink:to="loc_srt_MinimumMember_f2921ba9-eec5-4448-8914-a141d0bc04dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a8158e1c-4ad5-49ed-8130-b48da42b024e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e498ec85-a7e3-4817-992e-ba515032416d" xlink:to="loc_srt_MaximumMember_a8158e1c-4ad5-49ed-8130-b48da42b024e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails" xlink:type="extended" id="i35c6dc673b4041479baed8aa1ef397dc_NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0b12b7d-4012-448a-8605-f2aebf61a9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f2585a6-d741-4a67-b487-f51669522188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0b12b7d-4012-448a-8605-f2aebf61a9b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f2585a6-d741-4a67-b487-f51669522188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ef4b39b0-2821-4a91-ab4e-7cdc61610258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0b12b7d-4012-448a-8605-f2aebf61a9b5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ef4b39b0-2821-4a91-ab4e-7cdc61610258" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2eb8df3b-f103-4992-854a-3792ff497e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ef4b39b0-2821-4a91-ab4e-7cdc61610258" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2eb8df3b-f103-4992-854a-3792ff497e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2eb8df3b-f103-4992-854a-3792ff497e0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2eb8df3b-f103-4992-854a-3792ff497e0b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2eb8df3b-f103-4992-854a-3792ff497e0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a8a6d5d-8073-43fe-869e-36a15498f206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2eb8df3b-f103-4992-854a-3792ff497e0b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a8a6d5d-8073-43fe-869e-36a15498f206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_8f1fce8f-0155-4562-85ff-7337c405f361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a8a6d5d-8073-43fe-869e-36a15498f206" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_8f1fce8f-0155-4562-85ff-7337c405f361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_0783a799-54de-421f-9491-c31131eb46eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a8a6d5d-8073-43fe-869e-36a15498f206" xlink:to="loc_us-gaap_StockCompensationPlanMember_0783a799-54de-421f-9491-c31131eb46eb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#REVENUEScheduleofRevenuebyGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended" id="i47c0c6f067724769a914716ea8f056d7_REVENUEScheduleofRevenuebyGeographicLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_868bf935-6486-44b5-ab21-7094225d58c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20c60b2a-79e2-4d85-9892-4d8f800a3d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_868bf935-6486-44b5-ab21-7094225d58c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20c60b2a-79e2-4d85-9892-4d8f800a3d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f664b19c-d259-40d9-9343-02dd80204b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_868bf935-6486-44b5-ab21-7094225d58c4" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f664b19c-d259-40d9-9343-02dd80204b3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4fbd1aef-5baf-4172-9bdf-ad14924bdc45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f664b19c-d259-40d9-9343-02dd80204b3f" xlink:to="loc_srt_StatementGeographicalAxis_4fbd1aef-5baf-4172-9bdf-ad14924bdc45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4fbd1aef-5baf-4172-9bdf-ad14924bdc45_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4fbd1aef-5baf-4172-9bdf-ad14924bdc45" xlink:to="loc_srt_SegmentGeographicalDomain_4fbd1aef-5baf-4172-9bdf-ad14924bdc45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4fbd1aef-5baf-4172-9bdf-ad14924bdc45" xlink:to="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_a4e5df67-4236-4cf1-be02-462175d675d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:to="loc_srt_AmericasMember_a4e5df67-4236-4cf1-be02-462175d675d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_a3f4726a-37a8-4b55-a2a5-99d5adfe41a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:to="loc_us-gaap_EMEAMember_a3f4726a-37a8-4b55-a2a5-99d5adfe41a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_94e4dc6f-2436-4983-be05-451fdf4ee522" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:to="loc_srt_AsiaPacificMember_94e4dc6f-2436-4983-be05-451fdf4ee522" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#REVENUESummaryofRevenuebyCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails" xlink:type="extended" id="i484db9cb37dd4afca368970f3769bc28_REVENUESummaryofRevenuebyCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_30194ced-4c6d-4b9b-b301-2c4975b4e5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_efe3fd14-ffcf-4b0b-80b9-eaf5aa7f5f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_30194ced-4c6d-4b9b-b301-2c4975b4e5cd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_efe3fd14-ffcf-4b0b-80b9-eaf5aa7f5f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e51abd54-d416-46a0-b975-df15f5831900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_30194ced-4c6d-4b9b-b301-2c4975b4e5cd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e51abd54-d416-46a0-b975-df15f5831900" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_01ff6037-fd71-4c9b-a85f-f9fe3fda7660" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e51abd54-d416-46a0-b975-df15f5831900" xlink:to="loc_srt_ProductOrServiceAxis_01ff6037-fd71-4c9b-a85f-f9fe3fda7660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01ff6037-fd71-4c9b-a85f-f9fe3fda7660_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_01ff6037-fd71-4c9b-a85f-f9fe3fda7660" xlink:to="loc_srt_ProductsAndServicesDomain_01ff6037-fd71-4c9b-a85f-f9fe3fda7660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_01ff6037-fd71-4c9b-a85f-f9fe3fda7660" xlink:to="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_1a12a57d-9a0b-4296-8bbc-40d46062badc" xlink:href="pacb-20230331.xsd#pacb_InstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:to="loc_pacb_InstrumentMember_1a12a57d-9a0b-4296-8bbc-40d46062badc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_44e3ab99-bad4-4965-8a42-26bc09a11fbb" xlink:href="pacb-20230331.xsd#pacb_ConsumableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:to="loc_pacb_ConsumableMember_44e3ab99-bad4-4965-8a42-26bc09a11fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0e1cc631-0650-45a1-ab85-de9ecb84e68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:to="loc_us-gaap_ProductMember_0e1cc631-0650-45a1-ab85-de9ecb84e68a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_83bb8e96-4842-41e4-9b45-a004912d5cbe" xlink:href="pacb-20230331.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:to="loc_pacb_ServiceAndOtherMember_83bb8e96-4842-41e4-9b45-a004912d5cbe" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pacb-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1a1845fe-2bc6-4ddb-97ba-df0aaca6d029,g:3aa17778-fe5e-42a5-997b-9f59380cc331-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a956fcfb-1e35-4d94-b005-ea9afeaf2583_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_fae3d2a0-ebae-439b-86e4-e58052857108_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs with time-based vesting</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Restricted Stock Units Rsus [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:href="pacb-20230331.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a55fc4a0-a377-4c84-a6c9-38b8efe4e7b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_77721e6d-04de-44f2-839c-43deb768aab9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bf13334a-53d6-4881-9f4e-27ccc3db1e2b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_655432b1-30f8-4a9b-bddc-2fe6342684f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_96181eab-ed07-4765-97ba-8e8861428343_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d2e75898-b010-47db-94c2-8ea456594bce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_4b8c9690-d300-4f80-95f9-3d2d3c4ab63f_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, debt default, calendar days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:to="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_1fab51ef-88a2-4197-9962-12a1b5a524c0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OmniomeIncMember_f05e5f54-b87b-4167-8a4a-87bc3fcc4d94_terseLabel_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome, Inc</link:label>
    <link:label id="lab_pacb_OmniomeIncMember_label_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome Inc [Member]</link:label>
    <link:label id="lab_pacb_OmniomeIncMember_documentation_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome, Inc. (&#8220;Omniome&#8221;), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember" xlink:href="pacb-20230331.xsd#pacb_OmniomeIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OmniomeIncMember" xlink:to="lab_pacb_OmniomeIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_11e8a42f-e21f-4132-b8e0-df8ae763e7a2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_01d7f40a-fd12-4efe-ae55-ff128dad5790_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_857c5207-0a66-41ab-a625-2cabefdf399c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Rate of Time Deposits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:to="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_ebf7244d-6cee-4efb-ac1f-91a61b56a524_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e0034c92-f0a2-4dc6-8a5e-e4f49ec140f1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_14e64f18-dc2d-41de-82aa-d16baa363efd_terseLabel_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_label_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_documentation_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Components Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b41afd9b-8c28-45fc-a61e-d38ff7963e37_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Eligible Item or Group [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_04695997-1dc8-45f9-9537-6eedcefa1771_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_label_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:href="pacb-20230331.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:to="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d84c0397-e6f6-434b-ba4d-e2a9be0fd6c2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_69cd2c32-074c-479a-9239-fe7b98ea2fab_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b3d76e68-3531-48f4-90c3-542e2c561fb3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10bb5e86-260c-4c04-aba6-dc00612841a0_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_c1a1ff5f-21e0-411b-81fb-5f4d543630dc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_1cd2dfae-edf4-4cc9-ba56-2a9ba661f753_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a4a0c4d-b0c1-4fa8-8091-e7d10f35f83a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_917cb9a2-7ded-49c0-a7ae-fa1ab0ae2371_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_c380fe7e-9e9e-4329-8e07-d186713379ca_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_22c5e2bf-7861-45cc-8512-691b3abde568_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_03f9a326-8ec1-4f0e-97c9-79ae8828ba4d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_210c124b-bf35-4617-be00-128928c2f3f5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_036257fa-2be5-4043-b75a-f8aa3775390d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f4edbc22-b498-4f21-be41-6a26abc7875f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_f2e0b8cb-e643-4c7c-8611-2672a9f9efb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_d1273fba-0947-451a-ab55-c76d3ce568a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fb59c694-2356-4927-bbcf-1329d7a12dbf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7ed020c8-8372-48ce-94b9-d4020285b865_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_01307634-822f-41c7-978a-c81125c1d8c5_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_e5033fee-7a8d-4aff-95ac-cb0b8b9b4381_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_cf2a6f67-2b85-4259-a999-1077ac3dfeea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_724ecc84-3c5a-4abd-8fec-3f537334206a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8cb3ef1d-e607-4700-bbb9-c765a5955613_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_d18b673d-40d4-41b2-8875-573f59d7e399_terseLabel_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard product warranty, period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_label_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_documentation_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod" xlink:href="pacb-20230331.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StandardProductWarrantyPeriod" xlink:to="lab_pacb_StandardProductWarrantyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_88d28e13-9059-4c60-a4d2-0afaf8c1a5e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_62ecebff-34c2-4481-a04f-82603233a3ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_21157019-94d0-46b7-9de3-fdccac739b8b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_59eb6663-231a-4431-b167-1bb196947de3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_24ba8d0e-467a-4eaa-a610-712a8d49632a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cc94068a-4d21-4dc6-9fe5-50072573f096_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57b250f5-1f18-4d38-8b93-5fbea73ac45c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_daba888c-c9a0-43ba-b059-7a1e5020680c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_e9e4f831-5d2e-4058-833f-8e77baee8e86_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_8a76c906-1289-4d42-9374-b8d0f8849bbf_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redemption, consecutive trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f0ed5684-85e6-4c2f-946a-c0ec634a0332_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_b331962e-93aa-411d-943d-3fe30cb30e62_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2b8f3509-7d52-42b7-9237-3fbd795bc220_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2c73a4c7-cf29-48a5-a933-906586ad3670_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8e72dc69-4ffa-4fcb-94f1-b0626267eddc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt, excluding current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8ae340ee-0546-41a6-9101-fbbbc5cac915_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_5661c036-61ba-42e7-abd3-9aff6695e3ef_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ebae53e-f42c-4c37-95d3-a87c785d7d86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TermLoansMember_5496d603-de20-44c8-b6c0-f4a7509f95cc_terseLabel_en-US" xlink:label="lab_pacb_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
    <link:label id="lab_pacb_TermLoansMember_label_en-US" xlink:label="lab_pacb_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans [Member]</link:label>
    <link:label id="lab_pacb_TermLoansMember_documentation_en-US" xlink:label="lab_pacb_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TermLoansMember" xlink:href="pacb-20230331.xsd#pacb_TermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TermLoansMember" xlink:to="lab_pacb_TermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dbdeca10-a3cd-4311-9e45-c91efe837174_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_7abc36f8-eebe-495e-b8a7-be1593c72372_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discount and amortization of premium on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f15d326d-067f-4f0d-a3b5-f7c06523167c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_17f21541-1048-4c4f-9da2-12994f1745de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repairs and replacements</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_078b3fad-c597-4f4d-9a9c-43f72001a63a_terseLabel_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_label_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_documentation_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems" xlink:href="pacb-20230331.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FinancialInstrumentsLineItems" xlink:to="lab_pacb_FinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1858571c-c4c2-4da0-8000-43495a9a216b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e68ea5db-db30-4a4e-8cc0-92fc9d08549a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1bbaab5d-fd45-4bd1-bd51-385571de5d00_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_35d65dc9-e925-473f-a3f0-e71fc8f2c796_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d33b9bf6-7060-4c51-8de7-0a8ea62e6f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_021eb7f1-6296-4434-8d0b-8271b9b25afe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1cdc41c-a046-448f-be59-8f517c07ed34_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_426a2ed5-4c37-4656-9bd6-bf09fd0e8e6b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4909d1a5-abf7-45e9-b9bb-14b05125c426_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONVERTIBLE SENIOR NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_c6d56a8a-4762-4c13-9892-6fc61e3e1016_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_f91ac48e-2637-43e5-a112-d6097fa8b413_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bf1c527d-6f68-46d0-87ab-7c8203c6791e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2b2d77d7-2110-478f-92e3-7779ebc8abee_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_4df6cd28-178a-4d55-b841-5ce73c9d00c1_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f20ceb5a-48ad-4896-81ce-14ebf10f840a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_e6559333-89ad-464a-aced-813b4aed8a55_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_935c01b0-2765-4e5f-a1fc-a2ecc78d172a_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cc4c84ab-5c82-465b-b860-aa56366e84ce_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_2c4bb29a-2708-4523-8517-1c6991278971_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_d39e0672-fdaa-4a88-a855-aa7a89f86835_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering, option to purchase additional shares, period</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_label_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Period</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_documentation_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:to="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_923ddbb6-f83e-4a2f-bcd6-162c1e463a64_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3bff0992-023d-46aa-98c1-8b6f7a5bb1ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_39193544-1e2f-4775-b7f8-1dfdba1e827b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6c3269f9-b12d-4978-87d1-796fe1fe6ff5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b21c06fc-6814-473b-9056-2c71285e56a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ServiceAndOtherMember_a819bee2-88dd-435d-8614-c7a9238c3a38_terseLabel_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_label_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service And Other [Member]</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_documentation_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember" xlink:href="pacb-20230331.xsd#pacb_ServiceAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ServiceAndOtherMember" xlink:to="lab_pacb_ServiceAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56763e76-9268-454f-8e38-79ec8dcd8909_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_d41622a3-f01f-4c07-b265-209fdd407900_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f40e43d2-0db4-490b-b54b-7698ffdaac6a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d6ee7a70-8f68-4b70-a5f5-0b2bf7fb9ef3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_926e2bb4-0a95-4924-8642-2664d9ac7eaf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_2f8346af-2292-4899-b316-33b120995cff_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_d4484afe-0dfa-47be-9a62-0ceb45417c19_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3386dd45-d6d4-4647-9bd9-bf8b5a21b0f7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before expense (benefit) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b09a13e3-0a46-404b-9d03-cde7f36f3851_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3690dcad-d840-4dbe-acb2-f67a1affc303_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d1277b8e-92c8-4fd6-bcff-616edbe9e4ec_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8491c02d-2892-44a0-9520-58a7fcb2aa6b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ce1f86c5-8da1-41d8-830e-314e910abf91_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0362d5ad-363b-440e-b332-cd937c8e852f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_46ce2ac9-185b-43e9-85e7-58411f3098cb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BALANCE SHEET COMPONENTS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5f8ccce6-8b7c-49fa-b5d4-8a44d6fa3c28_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3e7d04f-74b4-4651-922f-175037fd1f83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FinancialInstrumentsTable_796aad19-9868-4ed5-abe2-2f48c19fd6b2_terseLabel_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsTable_label_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsTable_documentation_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable" xlink:href="pacb-20230331.xsd#pacb_FinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FinancialInstrumentsTable" xlink:to="lab_pacb_FinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_24816d96-b750-4fe1-a50d-9c8314c02ad5_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9cb146cd-5efc-4a37-9e55-382c88ee3389_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f45f392d-1b29-47c3-8d0a-3f20318517de_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10ba68b9-1469-4639-a73a-3e6f219143b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_b1fbb31a-028e-47b0-8743-a4eac1784b3b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_48210642-6b83-4c5a-a40b-906fdc4ae443_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_61b65aa7-e2b7-4b55-9854-0087fd62fa55_terseLabel_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_label_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_3ff2ca49-969e-480b-b0a8-9e34f8b217b6_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_82dd8401-e41d-4376-bf52-476690cd64fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6edcbacd-c72a-464e-a727-283dbba201e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3121585f-4e8a-4123-bcab-4a396367e86e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_3c3c48a3-4029-43ca-864b-3ddf47e4c1df_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest in the event of default</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:to="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_7e84fe8d-9721-4b61-97e5-781451eae11c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_5283d20e-be56-45da-b6c7-3aa31ad4e679_terseLabel_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_label_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_documentation_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems" xlink:href="pacb-20230331.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BalanceSheetComponentsLineItems" xlink:to="lab_pacb_BalanceSheetComponentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8c8e75fe-8b18-4ffe-aa0d-71a71cea28f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7de3a695-31e8-45e9-8ec2-19d743083cda_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_705fac22-2196-4b73-8473-b273545fa42f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_83de4cc0-86c4-4515-8653-e8f21c896aa6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_0e9aaa03-be14-4513-89e6-b2547decf559_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory provision</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_d61aca3d-1e06-4071-9b5f-4a5c99b9632d_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember" xlink:href="pacb-20230331.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsTwoMember" xlink:to="lab_pacb_DebtConversionTermsTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07790d46-3e13-4300-8da5-36f54cdf9bf9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_794ae71a-5460-4534-b8d4-6d0dbd9d05fd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_35b96058-7694-41c4-bf70-7d4737fa5949_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_2a46533b-b3a4-4690-96ba-b5f76abda4b8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable upon conversion of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a8d23303-579f-4dcd-acab-5f017a4262cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_6d114f7b-9119-41e3-a0ca-12343b2a0a7f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f40fa6bd-5cae-45ed-a68e-ad1fe9723751_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_b45b2690-1143-4383-bf20-e3a50882383c_terseLabel_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="pacb-20230331.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_8f1628a8-265a-466f-8b21-8370e40ede6b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a64ba9e-f35f-4d08-b640-7511262f3b78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6940f8ca-2b31-4f18-806f-de08e811fa1c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_72fe62cb-a46f-41bb-a065-9543c67b5825_terseLabel_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_label_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan2020 [Member]</link:label>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_documentation_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member" xlink:href="pacb-20230331.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EquityIncentivePlan2020Member" xlink:to="lab_pacb_EquityIncentivePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageOfFeeToPrepayDebt_79007f5b-8f61-4fd2-9893-c7b60a23c97c_terseLabel_en-US" xlink:label="lab_pacb_PercentageOfFeeToPrepayDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fee to prepay debt</link:label>
    <link:label id="lab_pacb_PercentageOfFeeToPrepayDebt_label_en-US" xlink:label="lab_pacb_PercentageOfFeeToPrepayDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Fee to Prepay Debt</link:label>
    <link:label id="lab_pacb_PercentageOfFeeToPrepayDebt_documentation_en-US" xlink:label="lab_pacb_PercentageOfFeeToPrepayDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fee of the outstanding debt to prepay the debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFeeToPrepayDebt" xlink:href="pacb-20230331.xsd#pacb_PercentageOfFeeToPrepayDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageOfFeeToPrepayDebt" xlink:to="lab_pacb_PercentageOfFeeToPrepayDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_43aa2b07-0834-4493-8f88-8d459f20644c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_933bcc04-63b7-49e6-8872-0af45b747555_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fd19cc6d-dffc-4ab7-ad5d-0bd1fb100cf7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6851414d-6d0d-4c03-b357-d642085b4a01_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fd2f5d4d-bbee-411e-82b8-626aaa58d85e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7478c2bb-9228-4a48-81f9-77473819bf92_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_67c3e7af-9e23-430e-a40f-b7efdbad8849_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d597ecb0-9f33-4cf1-bf8a-17df07868ca3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_80b8e405-0a6a-47ca-b7f4-2611ab4aded5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_3af215e5-7339-4f99-a1c0-3354bedafd01_periodEndLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrual" xlink:to="lab_us-gaap_ProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_783756b0-8ccc-49c8-b299-fd0df65ebfac_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_087cb44c-5e51-45d3-bd43-c5fc27fd8c25_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_d026275a-2799-4cff-ac42-08c6856b278e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0a1be05c-d096-4799-acfa-943b9c35032e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2579afc1-1bb3-4936-b8f8-ade6f95d4e10_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net (loss) income per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_0495a63c-5f52-4809-95f2-4163b6b2f50d_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_f0b9cab3-90e9-4780-a273-608631dbd380_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short- and long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_80516b39-d807-4b26-a9c7-df9f806cfa74_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b52f49b7-d4a6-4df7-acf7-eda82e0f9a84_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0705f7e6-7bad-4e32-8692-8758bf205b35_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ad496f07-5138-4fa5-9ef4-70b7cf05853c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_15720a7d-a7a7-48e9-af57-257b8e837818_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ebac77ad-7491-47c1-b715-44689e7f8de7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_890d0e9e-6f38-4113-898c-b9c3b678e276_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_c4c6c9dc-35d2-4240-bf29-1adbc65c0082_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_01667220-d860-42ba-92ae-ad8a8ed3d9b3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_942b5d5c-b54b-4ecc-bed6-31df0d353fcd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9173a0cd-a1f8-467f-a424-503f1f4e1ecd_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ea2ddd07-4610-4085-8eae-067db687558c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_6d50b151-6013-4486-b336-47e863ab5367_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3e02da2b-56d3-40a8-9da4-e4eed5180cfa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_984d7eb5-0251-408d-a5ce-473f1654588b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the Estimated Fair Value of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f207ef85-128b-4c66-82a9-067a3c4042b8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_36aaf494-ceab-4f71-8e1e-5812cec68424_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e6ba02b6-e385-4bf7-9b8f-aeb805e75451_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e2803d0e-faf4-4bb8-96d4-08e69b7c2373_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7138db79-8de2-4096-af70-90888f4de463_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in conjunction with equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a72f27cb-3d1a-4d1f-b3ad-15e8b5f22283_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock remain available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_0e13e48f-122b-4bdf-b081-9a25a4a7af86_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redemption, trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_cc874ae7-6d6b-4e28-849d-aa866fe0511b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_c9651ee1-1ee1-4d1b-af6b-419e068bdbce_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cda999e6-0f21-477d-8411-d7f8bdbe9821_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_68b4856c-4e04-40b7-a37c-66d431d9fe52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d438a460-ccdd-4255-aaa8-7b05653bb207_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_89dbd4d8-1ed2-4ae3-9d55-2c69c20c6718_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_46e7811b-ce75-4c41-8444-5ca31096a9aa_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DomesticCustomersMember_4707c435-d8fa-493e-8df8-e35c75f8d4ea_terseLabel_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Customers</link:label>
    <link:label id="lab_pacb_DomesticCustomersMember_label_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Customers [Member]</link:label>
    <link:label id="lab_pacb_DomesticCustomersMember_documentation_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember" xlink:href="pacb-20230331.xsd#pacb_DomesticCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DomesticCustomersMember" xlink:to="lab_pacb_DomesticCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bbbf1e1c-19ae-40d9-a7d2-a5591d9f710f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4238724c-b26d-46db-be96-32d224f9461a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_584d07ca-c833-4e88-a6f1-bef929441f2d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_98272031-1bcc-44b4-9489-8d52f8d4e76c_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_22caca91-36b1-4158-9058-21a02ba7ab61_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographic Location</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_285a1e86-8b38-4e37-a4b0-b6eb6f546454_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5be13f0d-da0d-41b3-b6e9-dd08c4af1411_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_5a3f039b-529f-4621-be74-736a4b458c70_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d2ffd3c8-e9cc-4cfd-a46c-3326a1de86b8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_541b3950-8dd8-414d-8fc8-185c6315311b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_b20b46b0-d5ee-4385-b5ec-d5de83553280_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e062fdc-8d2f-49a6-ac8f-40da3a4aab42_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4f96220d-59af-4774-af38-ec2de08efc3c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80eac6c9-502a-4aee-a89b-758cc1e7dd5c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e67e89f8-0614-493a-8711-eb73609c4024_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e2dd8d86-a87e-4d2a-8aee-905a3c1cfe16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3866cbb0-3481-48a0-90a4-3f3243a0e3e3_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_e20d168e-bda6-44dd-abbd-9b6c1c368c87_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d85a14a4-b4c6-4b3c-9d86-389e95e48347_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_52c70531-f0e5-4aa5-be22-1f8799a64b0c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7d53f5e4-7ae4-4efc-84c3-0bd8d86db5af_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b34a6e22-c1bd-4557-9eb4-376c0aafcba7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the estimated fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61b7a5db-9809-4523-b343-96e14a44c8c5_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_28f8951e-d0fd-48e2-87e9-0aa083f055d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_22efdda9-82be-44c7-9ed1-a6198669fe11_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a6e2ab5f-b926-4369-9dd8-c641b1c05365_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_bff7441d-7c8d-4436-a346-3138e76235fc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_da8cdebd-e055-4939-9534-c2f16947917e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_f549275c-168b-41ae-b7fa-0c1787c0a952_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based stock option</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_label_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Stock Option [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based stock option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember" xlink:href="pacb-20230331.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedStockOptionMember" xlink:to="lab_pacb_TimeBasedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_52ce54b4-6a85-4b3d-a8fd-3e2a9f5fa6af_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f2b61b3d-d6c2-4089-aa8d-38d2e31f1467_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_00a6d1e0-bdbc-4202-9bfb-6723351ac163_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_65fa1f66-f2d6-4378-80b1-fd50676b1a22_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8f435768-844a-4d5f-b871-becb6b183e48_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86d4eb6f-65fb-40dd-bdc2-896706486a54_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d4d76289-52be-4c61-86fe-8788f7196afe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7a8f277e-4ae6-4703-92df-1187fcfec58f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d724bac0-e029-4249-9cf8-b71223fd170d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c6d37716-28d0-4e67-a507-c245ec47c7d3_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_93ae49b2-2d61-45b2-bb89-29123d02174d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_daa15d61-a4e3-4c3d-9949-fbeb95f6f00d_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_label_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_documentation_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:href="pacb-20230331.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32231e54-4805-4bbc-b742-859580d39144_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cfb08d02-ab34-4fa3-9902-d459573cb94f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense (benefit) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d0e61ad1-8a2a-42ed-8ed8-e355c0609609_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_c6dacf03-f735-4beb-9a34-bd3f00134188_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Reserve for Product Warranties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_04e2b883-7fc2-4ae2-b77e-b7d35d9afccc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_86eb48e1-1b8f-4e91-b3fa-a4e46d1ceb09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dce2af8e-6fa6-4f1a-9a5b-2950a5a7559a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c636df39-0f51-409a-9dff-eb2ce8cd2a8c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c23af91b-e3bb-4a7c-a92d-5a35b37a2f1c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_475f64c7-2ead-4306-95b6-68bef12047bd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_47f72bd6-45af-4a9d-9200-cb61452d5308_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_2aacd43d-10eb-4b8b-8b92-93a9ef3267a2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25d6ef63-f655-4764-87b5-5d0fa42ba7b1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d7ea1371-7501-4ea3-8973-f6d66faedb49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_c2fa83b0-9846-4d70-8c4f-61235109a3d3_terseLabel_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage commission of gross proceeds on sale of common stock under at-the-market offering</link:label>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_label_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</link:label>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_documentation_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:href="pacb-20230331.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:to="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b986b2e1-1cd4-4af3-ac01-602fd6014732_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_06aef860-eff2-4d13-b5f8-33e52d5c30b1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term debt acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2f002af6-24d2-4e3e-9243-7a1f6ac8b522_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1ff581b1-2d8c-49ec-af6b-735e6bd3fda9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_abbf931e-7a2e-458a-832e-73b82d8c316a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_70d9ac3b-6101-4aac-b7bf-992c3ea070a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized 1,000,000 shares; issued and outstanding 249,803 and 226,505 shares at March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b7f5382d-5e8b-411e-ad73-826dc639aae6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_dcd8af24-7897-45c5-8d46-b8601d24e692_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_f33020a3-a8ad-4ac9-b189-7096fe8eb33c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions charged to cost of product revenue</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e14d5399-04a5-4b7e-bf7d-4c0c613f9d94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_0df887ac-6244-49f4-a2cb-b5facd8e69b1_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_83ae78cb-f9e3-41a1-a221-78d69982c0db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3c93545b-0a48-4660-994e-c4a47c6ff0a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_a86492a3-2fbe-4091-81f9-6ccc18c405b6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_a2fa7a55-d1cc-4f65-b0cb-d4d29d5c2b80_terseLabel_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember" xlink:href="pacb-20230331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EmployeeStockPurchasePlanMember" xlink:to="lab_pacb_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_38253a04-4743-4d11-938b-0dd07289ff81_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b7088c1-fd5e-4f1f-85aa-dbcba91b2792_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc637f83-c457-4fd7-9d80-d88eaf08efcb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_57534721-6601-42b2-9bd1-9275722d2185_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c4eaaab7-1e83-4d07-bcf1-e0bce2041134_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_54eb6ffe-eda3-4331-a512-efb4ec738117_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8122650b-2580-4038-826a-06de9fc2f1d2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cbb71873-ac7b-40ad-af24-c489432c87cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_97e41daa-44a3-4c6e-b00b-5d905286c39c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_847be0b9-1cd6-424a-bf0e-0844a890a7d8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net, non-current</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4e0c33a8-774f-4597-93aa-5790c92c7403_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aac759df-18d9-42f1-8129-e84c9f06d9d9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee2237ee-69f7-4d20-9b2c-60e7ea2fab89_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_95dde5c9-d79d-4b95-9a05-bce7718d321c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_bddf49f9-74b3-458a-bd89-cc86167af0cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_16b0442e-49bf-410d-8982-7f0ca2066e3c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_52d55d34-16ac-4362-aaa1-804a1641a5ba_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock from equity plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_647a1a19-1d19-4ca5-b258-a2b65e9f85a8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d0c36083-9acf-4d1a-b04c-bd91bdf8ed05_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_dfc614be-d4e0-4896-9ff4-b90387e01cd2_terseLabel_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net of Issuance Costs</link:label>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity, net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:href="pacb-20230331.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_6acb6d03-1a6f-423e-a633-67971f3476c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6eebd5b3-b858-4425-8d88-36de4897c423_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_7e41e7ae-b9e5-4520-8bfe-c6e92f9e5acd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_8b396dc3-8348-4c40-be0d-6ec1501343f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_da5af37e-d5b6-4def-aabf-935d187545d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_b3bb3b52-18e9-40a8-8133-d0ab4439893a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable principal payoff</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_9c9fb1b6-4c50-484e-a228-679d3a7b40a8_terseLabel_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:href="pacb-20230331.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_08c856b8-f565-492b-ada4-b510a078f9d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e10d7212-be66-4b8a-bb6a-d95fbd4e4cab_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f56f156d-9b6f-4538-9cd2-35eafab6cd18_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a4eab57a-f8ef-4eca-a198-a78b3b79cc85_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_d9151169-bc30-4aab-ad31-9991d3d3f8c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_38a3ca76-8d35-4a31-bb00-983c8d8813b0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_2c8e7154-9914-49b6-8ed7-7e7893869b82_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8bbf5393-2cea-48dc-a436-f0a98fe3a3ee_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_961dd59b-a5eb-42d1-86a8-9f848ac119da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1c2ca5ed-0937-482d-a8c1-76796fdc8429_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Amortization Expense of Acquisition-Related Intangible Assets With Definite Lives</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5c4c170b-817b-4d14-bd93-1021ea2731f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2e293af2-f2d3-4029-98ee-844520243f09_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_95f3e85c-cf79-4374-9e38-21243122f04b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_137779da-d998-4316-b951-af46676b9a2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_860aa57b-9c9a-4461-a9f6-e8c02c40fcda_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_6e4c64fd-01f4-49ff-94b5-15083f9cf6fd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7e90db89-be49-4c4f-af20-9f11dfb97be2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_10e39185-e832-4171-b8fb-c1fc2e765518_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f7aaf054-eb75-41b9-9408-00ac6b772904_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_dec208f5-268f-47e0-92f5-068df4beeb55_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_a3462f05-8da9-4ec1-bffa-350446fa5d54_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b7f51bee-975e-4549-97cd-73dbe1c77f31_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a332c323-5fba-4ab0-a023-df1d7f0b53d5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_be28873e-b17f-4a88-af86-0e956be1e490_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_9a77a0c2-02ac-406f-a0ab-04cbbd93fa6f_terseLabel_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="pacb-20230331.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4abda094-40eb-43eb-b27d-a48405404f09_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e0a4748d-fd8d-4381-91f8-a9d1888362ee_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_00fa63e7-7ec0-4026-9f8e-5dd6ac73568c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5256d6d2-38ac-429f-997c-953861e27226_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c507b6b6-a060-4e5d-a5d6-b149c5ee06e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_1e12f31c-9823-4f11-8fb3-b46d9fd5217a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_769bfa83-ebee-4cca-a475-ad075884d97a_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_755fe047-800a-43a4-87f8-c2c92d9d9746_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_7c85a171-1f87-4784-bce6-b801f0eb696d_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Principal Payments, Fiscal Year Maturity</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_64e9d1d1-53d8-4f30-9019-1feeb31e9e71_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering, option to purchase additional shares (in shares)</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_label_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Shares</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_documentation_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:to="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_27c5ab00-af77-4a20-97b7-9e73f154686f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0cdd7bcf-2885-42e1-8d9c-0bffcdd47fdb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fc99e9d6-425f-4add-afc2-a75ed6868770_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d6c4b682-3fc1-4ddd-8879-7a550a0f226e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ConvertibleSeniorNotesMember_c658eeee-121c-409b-97e7-ce7896062e04_terseLabel_en-US" xlink:label="lab_pacb_ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember" xlink:href="pacb-20230331.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ConvertibleSeniorNotesMember" xlink:to="lab_pacb_ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_b0424286-291e-4be3-9a7b-4674808e4a43_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1f573752-c605-47d2-b398-4420b85fd263_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShelfOfferingMember_f732f605-f7f7-45fd-9b77-d50ca866c63b_terseLabel_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Offering</link:label>
    <link:label id="lab_pacb_ShelfOfferingMember_label_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Offering [Member]</link:label>
    <link:label id="lab_pacb_ShelfOfferingMember_documentation_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember" xlink:href="pacb-20230331.xsd#pacb_ShelfOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShelfOfferingMember" xlink:to="lab_pacb_ShelfOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_a302a72e-9606-43a5-b338-bafc3e0f3321_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_28ab7ee9-a996-42a8-8fd2-13e1a5283842_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in conjunction with equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_1491a7df-be60-418a-b4e6-af5344fa6518_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember" xlink:href="pacb-20230331.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsOneMember" xlink:to="lab_pacb_DebtConversionTermsOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentTermLoanElectiveOption_0b20bc2f-4bff-4ab1-b480-fd6508dd7fcf_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentTermLoanElectiveOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term loan, elective option</link:label>
    <link:label id="lab_pacb_DebtInstrumentTermLoanElectiveOption_label_en-US" xlink:label="lab_pacb_DebtInstrumentTermLoanElectiveOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term Loan, Elective Option</link:label>
    <link:label id="lab_pacb_DebtInstrumentTermLoanElectiveOption_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentTermLoanElectiveOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term Loan, Elective Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentTermLoanElectiveOption" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentTermLoanElectiveOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentTermLoanElectiveOption" xlink:to="lab_pacb_DebtInstrumentTermLoanElectiveOption" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingShares_0fab2ac0-c0ad-4b65-bba1-ba85318ef6d0_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering (in shares)</link:label>
    <link:label id="lab_pacb_PublicOfferingShares_label_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Shares</link:label>
    <link:label id="lab_pacb_PublicOfferingShares_documentation_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingShares" xlink:to="lab_pacb_PublicOfferingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7980aa10-23c6-4427-a0cd-30304ff8f1e6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_9c9f4280-38d0-487f-95be-e2861f3060ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite-lived Intangible Assets from Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_b83e099f-35ab-47d5-a35d-f890446a0ff7_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest in the event of default</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:to="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cd57c620-da88-493a-8371-eee9fa4fb9b1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb26916b-2aaf-4d02-83e2-335438e93394_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c84124d2-83bf-474c-a538-788447669342_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67653362-0d56-4bbf-b296-d85e300edc3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_bdb1cb48-651d-498b-bf8b-18b9e0166444_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_70806811-2213-4055-8502-6a6f5afeda4e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_a9181b8d-bdec-4acf-a551-052fa6bf5cd4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_03982b95-7d19-4aad-a13f-9ab34cc73690_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CustomerOneMember_8251ecd5-5f7c-41e7-987b-5c4ad4699625_terseLabel_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer</link:label>
    <link:label id="lab_pacb_CustomerOneMember_label_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_pacb_CustomerOneMember_documentation_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember" xlink:href="pacb-20230331.xsd#pacb_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CustomerOneMember" xlink:to="lab_pacb_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_94632b05-f8df-4c19-a318-726b9cc40cb8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_fa12bccb-7d7e-4b81-8c4f-bda0fe32286c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity offerings, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf288893-7352-45df-8ad8-7afe5b578415_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4009366a-1cd4-45ba-9aaf-ff5204b3a2f0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ea31ba64-5e5c-4680-9ab2-b292dd454df6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f14bebba-569c-41da-984e-9ce03a1c36c3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7ded25ae-38c7-4b1b-811d-b0a523db173d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_07c3552f-8aaa-42fe-abb3-ee56a221bf1b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_66eb6e47-8f6f-4289-ae00-80ee1053eae4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized 50,000 shares; No shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_3a106fc3-da0b-4b25-995d-32c4ffdc6ebd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CustomerTwoMember_f9705c6f-8330-4a99-b232-4b3d43afde82_terseLabel_en-US" xlink:label="lab_pacb_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Customers</link:label>
    <link:label id="lab_pacb_CustomerTwoMember_label_en-US" xlink:label="lab_pacb_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_pacb_CustomerTwoMember_documentation_en-US" xlink:label="lab_pacb_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerTwoMember" xlink:href="pacb-20230331.xsd#pacb_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CustomerTwoMember" xlink:to="lab_pacb_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_d82f0e54-0043-4a51-a8ea-72c58384b9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da170c53-3b5a-4d90-b11f-0664abeec8ca_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_4d06bce6-8b5a-431a-a253-d209191227e7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bb05047c-f38b-4151-aac8-6699744d5d2c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_19cfbf7a-27e8-43c8-980e-53b2288ec280_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2810ce32-677a-4716-802b-43126dcec09f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ConsumableMember_adaf7d78-de8b-4978-a7ea-3d488dc05529_terseLabel_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable revenue</link:label>
    <link:label id="lab_pacb_ConsumableMember_label_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable [Member]</link:label>
    <link:label id="lab_pacb_ConsumableMember_documentation_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember" xlink:href="pacb-20230331.xsd#pacb_ConsumableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ConsumableMember" xlink:to="lab_pacb_ConsumableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_bd64dc13-64b5-4d72-a584-de5e8ff90a37_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d98ff264-c323-4432-8a16-5dccc0d37963_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_d86d7af0-0b57-4491-b320-122c94062f35_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_2f85236e-d46b-4ce5-bb89-5d82ccd9f3db_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_51566e29-8e26-425e-b563-4982b8754286_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4e70f598-c51d-411b-968c-372fcb50543b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_aa2e36d0-207a-4112-917e-15abd50dc22a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_089c84a2-afad-443b-ac2c-3b43055769ef_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fcc77d34-a6d1-46b5-87a2-5a423c364f53_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_670e7679-1a3e-499d-8590-09cd2d0973be_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_5d1c5472-4a4a-4d4b-8ab4-7f070dc57e86_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0979ac65-ef12-42f9-8af4-7236cecbebea_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d3e9ac46-1bb6-460b-8fe2-2afdfbdbb4eb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7cb15bce-89b6-41fa-8b49-1fe62f69a58e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InvitaeCorporationMember_3199948f-ad10-486c-af96-b3ed86d03de5_terseLabel_en-US" xlink:label="lab_pacb_InvitaeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Corporation</link:label>
    <link:label id="lab_pacb_InvitaeCorporationMember_label_en-US" xlink:label="lab_pacb_InvitaeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Corporation [Member]</link:label>
    <link:label id="lab_pacb_InvitaeCorporationMember_documentation_en-US" xlink:label="lab_pacb_InvitaeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCorporationMember" xlink:href="pacb-20230331.xsd#pacb_InvitaeCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InvitaeCorporationMember" xlink:to="lab_pacb_InvitaeCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_ef166428-ad22-4384-9665-4e2cfddbb17b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f02f8eb4-87f6-487a-b180-bea118a0ccce_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_70d24e9f-d240-4880-af11-f2f50836cae5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_21003c52-8206-4047-ae17-e5f0a1d629e2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_60ff5f4b-f78b-44e1-bfa5-8a2771330553_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net (loss) income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b2b0cd42-3ff7-4b71-a504-f1ab1e7b652e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c4cb4267-6b32-4c6c-a818-3e9380f7fba3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_98adbeec-5cb1-4987-abd5-b89f566f2d89_terseLabel_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_label_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss per Share Abstrct</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_documentation_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss per Share Abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract" xlink:href="pacb-20230331.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeLossPerShareAbstract" xlink:to="lab_pacb_IncomeLossPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_761445ce-4c82-4c8e-afec-33fe77204e9b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_703cf63f-11a5-4135-be55-4bc6f7b2bc71_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposition of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7c3d7b98-523a-4e3e-95c0-8d28e7e3571c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b5a0db3f-0229-4363-acf2-10a178abb956_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_74b0cbe7-ed80-450a-94bb-4d72c0d6afde_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_337b49ec-f357-46d9-8e45-414fce6bb8ca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a79c186e-edf1-4b0e-bbb1-0e5ca3c41e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_3e21539d-b6f8-4b6f-a935-a4c45fcba20d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_c3cec129-26a6-4269-bd6c-40e8d45f14b2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_19f83941-f807-46a0-a2b5-34d8e8712c70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_deb0f4a3-9a05-4d2e-84e9-d0b3ac2366ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Time-Based RSUs Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_e9dbd7ff-125e-4d86-b6ed-833f2dd05650_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_34f2cc05-3a31-45e4-92fb-cc8f183af7cc_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_562d9a58-1c62-41a5-946b-10b39c8b8f59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AmericasMember_ef08476f-bbf6-457d-aa4c-c85842938c63_terseLabel_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_AmericasMember_label_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Americas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AmericasMember" xlink:to="lab_srt_AmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b040e2bb-3c3d-497b-b3b7-12800d8b7c2c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in calculating net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_6daf1492-c223-461f-85a3-ee5e108b6496_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7ab0d421-7b97-43a6-a3d3-15fb10241ffe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_397c48c1-20cb-4fff-b9b0-58ff5f587ff9_totalLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d31829c9-7601-4fa3-bc37-bfd604062249_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_43236d6b-5886-4bc0-a4dd-67d05fd998da_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_34088879-5be1-407e-a7f5-496f397a9327_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6a0a1d51-3bc5-4d4e-b2cc-09e73443bdc9_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_ef402d44-99f8-4889-b859-58b4c4b1fcc7_terseLabel_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_label_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options To Purchase Common Stock [Member]</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_documentation_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:href="pacb-20230331.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:to="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d52274ce-2d5a-40f7-8621-2a231be1b438_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government &amp; agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b1877f6f-3df1-46b9-af02-1cff0aa131ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9a0ca62d-71bc-4d8c-8638-ed00456ef85d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6c516de7-582e-43e3-b61f-4d975776b8f1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_171710aa-be89-4308-a8a7-35f4f42223b9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenue by Category</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_e6605df3-1223-4e45-9faa-93a32a94fe06_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_caaead67-edd0-4b09-8860-9799a0d3abdc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_c49e35e7-bcdd-409d-b381-ae6ba86979b1_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:to="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InstrumentMember_e35d7e78-765a-457f-9226-85313a2be420_terseLabel_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument revenue</link:label>
    <link:label id="lab_pacb_InstrumentMember_label_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument [Member]</link:label>
    <link:label id="lab_pacb_InstrumentMember_documentation_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember" xlink:href="pacb-20230331.xsd#pacb_InstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InstrumentMember" xlink:to="lab_pacb_InstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6b3cf47-4473-4324-9ec8-367ab45bf8c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_633dd58f-3841-48f7-8ec3-c3b9ce9fa5bc_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_8a6f00fe-7497-4045-a3d9-7692f0cb8758_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redemption, percentage of conversion price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:to="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a6c85958-35d7-4ea1-a988-67fe47137deb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e9d56b50-f4c1-4be3-a11a-b40125f5dc8c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3d4f77b5-8e69-4aca-9c19-cfd2282597d9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f1a9c605-da63-4955-b177-83027aa77212_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b9886d9e-ba42-4179-a4b2-c4cc560b4cc8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e26f2cb6-0672-446e-b909-386a01dd3aa3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c8d725a1-7e24-4b6c-ade4-2de7d727e896_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d06459e3-2cec-4748-a7f8-a60458337e90_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d44087f2-0a78-4149-be99-1d88ade96bd3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_09ee1a7c-7a36-4bf1-bd2a-6bad8b73ebfa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_649c0f61-8657-4ac0-862f-3b48233e1066_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e4f8519f-ed89-4c37-837b-5258b157850e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_fcff88a4-8cab-46c8-9dcf-a7127d9d85e5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_cbe722ab-6ca3-48c2-a177-43ab8c1c62d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_480fb3a6-36b4-41fe-a7ad-96b28586486b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_d122891e-4cb1-447f-95e7-f359584b4da7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e5e78cce-6c16-4acb-b9e4-62e27a8439cb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_20eae262-06d2-48a5-a95e-79ed440f014d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4628c6cd-a5ae-4ac6-b291-1e68e9a708b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_795692be-42b9-47e0-8c36-9a679f15bc00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_f2ee68cd-036f-4f5e-8e1b-3ee3dc720643_terseLabel_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering share amount maximum (in dollars per share)</link:label>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_label_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Share Amount Maximum</link:label>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_documentation_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Share Amount Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum" xlink:href="pacb-20230331.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OfferingShareAmountMaximum" xlink:to="lab_pacb_OfferingShareAmountMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_88777f59-97e4-4535-a2e9-1292cff56255_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_44f94699-346c-493f-898c-dd324317d158_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c77f69cc-3b00-4433-852c-280a57cee9e9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_242a6445-d2fd-4b9e-8254-9a602ca277a4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e5e3c247-5dc5-40bd-861c-85c747aac114_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_77bfd781-44be-427d-a6a4-ee5ed7d6217b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_f2ef9353-73d1-40c3-bc7f-f975c9612609_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_3acd6400-167a-4e0a-880a-f8c17488cafe_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pacb-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1a1845fe-2bc6-4ddb-97ba-df0aaca6d029,g:3aa17778-fe5e-42a5-997b-9f59380cc331-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/Cover" xlink:type="simple" xlink:href="pacb-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4e9b84b8-65c9-4a42-b7aa-a3dce660aef5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_DocumentType_4e9b84b8-65c9-4a42-b7aa-a3dce660aef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9a772811-0533-4510-aaac-5cc9b474f9fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_DocumentQuarterlyReport_9a772811-0533-4510-aaac-5cc9b474f9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_27612286-5fe5-44c6-a33f-7acf78c7235b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_DocumentPeriodEndDate_27612286-5fe5-44c6-a33f-7acf78c7235b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_96abde04-c353-47b7-b790-e93d115993c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_DocumentTransitionReport_96abde04-c353-47b7-b790-e93d115993c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9f678c97-8f2c-4d1f-9750-bae8d476f8dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityFileNumber_9f678c97-8f2c-4d1f-9750-bae8d476f8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e423946c-762a-4ad3-b4d1-5c611b869a6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityRegistrantName_e423946c-762a-4ad3-b4d1-5c611b869a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6679742b-b4af-421c-86aa-551104abcc84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6679742b-b4af-421c-86aa-551104abcc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f6c407a8-b05e-48d6-a4c0-bdbd7528e37e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityTaxIdentificationNumber_f6c407a8-b05e-48d6-a4c0-bdbd7528e37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c6564ba0-1937-4999-b55b-1860e77dea12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityAddressAddressLine1_c6564ba0-1937-4999-b55b-1860e77dea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fa17cdbf-1bd2-486d-ab5f-31cb937519cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityAddressCityOrTown_fa17cdbf-1bd2-486d-ab5f-31cb937519cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f213e2af-6b27-4fab-9a0a-b294cdabb903" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityAddressStateOrProvince_f213e2af-6b27-4fab-9a0a-b294cdabb903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9dfeb9ea-dbce-4092-a796-ee6652c9763a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityAddressPostalZipCode_9dfeb9ea-dbce-4092-a796-ee6652c9763a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_98b5cb8d-ea5d-4f52-917a-60dc2e811438" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_CityAreaCode_98b5cb8d-ea5d-4f52-917a-60dc2e811438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c4a13938-5545-4b81-9c28-92c3edf3ab0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_LocalPhoneNumber_c4a13938-5545-4b81-9c28-92c3edf3ab0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d5107e31-dacf-492c-a19c-18c93c97c1a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_Security12bTitle_d5107e31-dacf-492c-a19c-18c93c97c1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e88f23a6-720e-4940-8de6-62d062aea9ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_TradingSymbol_e88f23a6-720e-4940-8de6-62d062aea9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_894581ca-a9e1-4170-a0e8-70b57f905723" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_SecurityExchangeName_894581ca-a9e1-4170-a0e8-70b57f905723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e35f4e81-35f9-4f2a-89e2-041dd14f4ecb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityCurrentReportingStatus_e35f4e81-35f9-4f2a-89e2-041dd14f4ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b2011f07-d19a-496c-8c2b-f48cb45f427a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityInteractiveDataCurrent_b2011f07-d19a-496c-8c2b-f48cb45f427a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7edb6102-cde9-415d-854e-f36cdc6b8196" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityFilerCategory_7edb6102-cde9-415d-854e-f36cdc6b8196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5d2200b8-a1c0-4d3a-a642-2d8077d01636" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntitySmallBusiness_5d2200b8-a1c0-4d3a-a642-2d8077d01636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3bd0036c-0a07-4ce8-9405-11bdadc5a239" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityEmergingGrowthCompany_3bd0036c-0a07-4ce8-9405-11bdadc5a239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a6b3d013-7c1c-463a-9462-a65a599ecbdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityShellCompany_a6b3d013-7c1c-463a-9462-a65a599ecbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fd1a82b7-28b7-4910-931a-4346ad57d5e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fd1a82b7-28b7-4910-931a-4346ad57d5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f434211c-3c23-4368-b8fa-4f0ec483a811" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_EntityCentralIndexKey_f434211c-3c23-4368-b8fa-4f0ec483a811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_165edd30-3da3-4fef-8866-e5eeeb32c0a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_CurrentFiscalYearEndDate_165edd30-3da3-4fef-8866-e5eeeb32c0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2ad5637e-1109-474d-94ef-74d406f89ee1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_DocumentFiscalYearFocus_2ad5637e-1109-474d-94ef-74d406f89ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_91e4f561-f160-431d-8ac6-48f79ee104e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_DocumentFiscalPeriodFocus_91e4f561-f160-431d-8ac6-48f79ee104e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_aac87683-3689-4ef4-a43f-278f06d523fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0456d019-edfc-410f-8776-f57327c85f17" xlink:to="loc_dei_AmendmentFlag_aac87683-3689-4ef4-a43f-278f06d523fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_11d47ec0-d531-40c0-8aa6-56888e75449a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_11d47ec0-d531-40c0-8aa6-56888e75449a" xlink:to="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a770fc8-2443-4bb1-bcef-146c5a464fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a770fc8-2443-4bb1-bcef-146c5a464fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_9a17c6f1-aeb9-4a2b-9c80-27b42a1c3fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:to="loc_us-gaap_ShortTermInvestments_9a17c6f1-aeb9-4a2b-9c80-27b42a1c3fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cb981c2d-a6d2-4502-b3bd-b138e0d37d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cb981c2d-a6d2-4502-b3bd-b138e0d37d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_444a359d-48df-4c06-b46a-57d3cbe51708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:to="loc_us-gaap_InventoryNet_444a359d-48df-4c06-b46a-57d3cbe51708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4085e1e4-3df0-4d5f-ace0-2cbdf48aeb41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4085e1e4-3df0-4d5f-ace0-2cbdf48aeb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_aee648f6-6387-448d-9877-909e5f3822c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:to="loc_us-gaap_RestrictedCashCurrent_aee648f6-6387-448d-9877-909e5f3822c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6f8f56af-3967-40cd-a27d-8b3768e2c8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2545bc83-5b0c-4ca6-acf7-4d614a23cbd2" xlink:to="loc_us-gaap_AssetsCurrent_6f8f56af-3967-40cd-a27d-8b3768e2c8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a8af4d9-c76a-40c0-a443-18a4e5c66723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a8af4d9-c76a-40c0-a443-18a4e5c66723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e78a979d-2569-4f66-a895-7982fcb553d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e78a979d-2569-4f66-a895-7982fcb553d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_315ece97-dd87-442c-92ad-dcc938eb6732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_315ece97-dd87-442c-92ad-dcc938eb6732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e9be6a3c-76a9-4d48-a419-4b7194c60a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e9be6a3c-76a9-4d48-a419-4b7194c60a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_89588e2a-84a4-4aec-aad5-fbd356e2710b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:to="loc_us-gaap_Goodwill_89588e2a-84a4-4aec-aad5-fbd356e2710b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ace75e-f4bf-43d1-89ab-c55a6b1a3785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ace75e-f4bf-43d1-89ab-c55a6b1a3785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1bf75042-6895-4fea-98cb-d287a90acf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a526de98-e46e-4c0c-99ca-7fc1f9a197a3" xlink:to="loc_us-gaap_Assets_1bf75042-6895-4fea-98cb-d287a90acf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_11d47ec0-d531-40c0-8aa6-56888e75449a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e195207a-8869-4c8a-b18f-1734ee23ca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:to="loc_us-gaap_AccountsPayableCurrent_e195207a-8869-4c8a-b18f-1734ee23ca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f47c2725-bfc7-4150-a475-f02787c7d093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f47c2725-bfc7-4150-a475-f02787c7d093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e763001f-939f-431f-8161-6f003e4047d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e763001f-939f-431f-8161-6f003e4047d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_214b05dc-5085-4446-96ec-0154af221171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_214b05dc-5085-4446-96ec-0154af221171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_48d23476-a0bf-42ba-a0a7-a84d8e560628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_48d23476-a0bf-42ba-a0a7-a84d8e560628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1dcebe24-784f-4e3b-b44a-e0b95141238b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1dcebe24-784f-4e3b-b44a-e0b95141238b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2a1c6ea8-d8a9-4fb5-abd6-cd6b587654a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_01218f78-759a-4cf8-9978-a92dc105a45e" xlink:to="loc_us-gaap_LiabilitiesCurrent_2a1c6ea8-d8a9-4fb5-abd6-cd6b587654a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2f645d36-d2fc-472f-8c45-cbbad755fc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2f645d36-d2fc-472f-8c45-cbbad755fc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2464bb3-5f32-44f4-baed-405394c5af49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2464bb3-5f32-44f4-baed-405394c5af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_c1da5e6c-2a11-493b-b317-dd450a935e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_c1da5e6c-2a11-493b-b317-dd450a935e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5bf6f5ac-004f-4095-a7da-ff03a12fc379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5bf6f5ac-004f-4095-a7da-ff03a12fc379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2ea499ac-9a88-41b2-973b-4ed448c8b292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_Liabilities_2ea499ac-9a88-41b2-973b-4ed448c8b292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_47a21b75-1e8b-428d-a3cf-b2b5fcc2b2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_47a21b75-1e8b-428d-a3cf-b2b5fcc2b2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c270cec4-0927-465c-9756-2fba81a25a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c270cec4-0927-465c-9756-2fba81a25a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3e64aab8-6c20-4819-9cd7-cb6a143b2271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c270cec4-0927-465c-9756-2fba81a25a60" xlink:to="loc_us-gaap_PreferredStockValue_3e64aab8-6c20-4819-9cd7-cb6a143b2271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3fa6652a-bb6c-4c49-8e3f-28edffae1114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c270cec4-0927-465c-9756-2fba81a25a60" xlink:to="loc_us-gaap_CommonStockValue_3fa6652a-bb6c-4c49-8e3f-28edffae1114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_451de96e-9f63-4fde-9a1c-4c8b4f760744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c270cec4-0927-465c-9756-2fba81a25a60" xlink:to="loc_us-gaap_AdditionalPaidInCapital_451de96e-9f63-4fde-9a1c-4c8b4f760744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_650d96a1-b8ed-4436-831a-eba3e8c75479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c270cec4-0927-465c-9756-2fba81a25a60" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_650d96a1-b8ed-4436-831a-eba3e8c75479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df5b0996-0cad-40b5-8342-d71f2057f63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c270cec4-0927-465c-9756-2fba81a25a60" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df5b0996-0cad-40b5-8342-d71f2057f63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8f113998-0ed0-4118-b662-189afc00c3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c270cec4-0927-465c-9756-2fba81a25a60" xlink:to="loc_us-gaap_StockholdersEquity_8f113998-0ed0-4118-b662-189afc00c3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9a042c2c-44cc-4877-ac53-31731220a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c1b4a4-9bf2-429e-98a3-229284957d10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9a042c2c-44cc-4877-ac53-31731220a0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a6d1e9a4-9191-490d-9d9e-ad7be6296f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a6d1e9a4-9191-490d-9d9e-ad7be6296f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a8c36939-e509-4ff1-9695-b36e5ad5733c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a8c36939-e509-4ff1-9695-b36e5ad5733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_fb3cf2ed-8a7b-49da-a300-04ba81b7f37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:to="loc_us-gaap_PreferredStockSharesIssued_fb3cf2ed-8a7b-49da-a300-04ba81b7f37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4a19f81a-92cf-4d71-b50b-d588ae6cdc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4a19f81a-92cf-4d71-b50b-d588ae6cdc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6945b3ac-d251-425d-b1d3-5511dd684469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6945b3ac-d251-425d-b1d3-5511dd684469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e6ac8552-7d5b-4963-b0b4-59a10a15cf76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e6ac8552-7d5b-4963-b0b4-59a10a15cf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e11c83ce-c38c-4425-8552-2fdc38cfd68c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:to="loc_us-gaap_CommonStockSharesIssued_e11c83ce-c38c-4425-8552-2fdc38cfd68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26e37581-87c8-4b38-8f13-b2b50fc0bdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7cfb75b1-c29c-4c44-b3ab-51a1542ae688" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_26e37581-87c8-4b38-8f13-b2b50fc0bdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7815a909-fec9-4323-a647-d04a8c6582a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eea1997d-4adc-475a-b4fe-f9940aa1b47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7815a909-fec9-4323-a647-d04a8c6582a0" xlink:to="loc_us-gaap_StatementTable_eea1997d-4adc-475a-b4fe-f9940aa1b47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cdd67cfd-221a-41c4-9f9c-94e876b120bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eea1997d-4adc-475a-b4fe-f9940aa1b47a" xlink:to="loc_srt_ProductOrServiceAxis_cdd67cfd-221a-41c4-9f9c-94e876b120bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf5d56a6-efb0-4cc7-9d3b-365776b5ea0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cdd67cfd-221a-41c4-9f9c-94e876b120bd" xlink:to="loc_srt_ProductsAndServicesDomain_bf5d56a6-efb0-4cc7-9d3b-365776b5ea0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5df1d4f3-d858-4870-816e-b727e9605560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bf5d56a6-efb0-4cc7-9d3b-365776b5ea0d" xlink:to="loc_us-gaap_ProductMember_5df1d4f3-d858-4870-816e-b727e9605560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_6ae09d27-5888-4470-9d80-7fa852a0af98" xlink:href="pacb-20230331.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bf5d56a6-efb0-4cc7-9d3b-365776b5ea0d" xlink:to="loc_pacb_ServiceAndOtherMember_6ae09d27-5888-4470-9d80-7fa852a0af98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eea1997d-4adc-475a-b4fe-f9940aa1b47a" xlink:to="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3e240636-042f-4497-aee2-d6177d006645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_RevenuesAbstract_3e240636-042f-4497-aee2-d6177d006645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dd7594ed-cb02-4c28-b891-953cd2bb65c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3e240636-042f-4497-aee2-d6177d006645" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dd7594ed-cb02-4c28-b891-953cd2bb65c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_50501ec3-22da-45da-8b84-ecd115e928bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_50501ec3-22da-45da-8b84-ecd115e928bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_f4d92040-f15b-4437-a6c4-83a440aaf741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_f4d92040-f15b-4437-a6c4-83a440aaf741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_50c656c1-d4fc-469f-8b02-0c8869713283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_e80c1bf4-22c7-466f-b600-1c87e2048a49" xlink:to="loc_us-gaap_CostOfRevenue_50c656c1-d4fc-469f-8b02-0c8869713283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_84aafc32-3be0-4313-b473-885562b5b330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_GrossProfit_84aafc32-3be0-4313-b473-885562b5b330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2c1b6de-74bd-4525-9e37-b2c0b3eae051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2c1b6de-74bd-4525-9e37-b2c0b3eae051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca12dcee-680a-4105-b070-0e4d439191dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca12dcee-680a-4105-b070-0e4d439191dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_03016c8e-899b-41e3-9aa6-a3f6a8c0d502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_03016c8e-899b-41e3-9aa6-a3f6a8c0d502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_55594e15-acca-4259-8bac-f9beedf842ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6a3bf520-997e-432a-b859-54aae0529edf" xlink:to="loc_us-gaap_OperatingExpenses_55594e15-acca-4259-8bac-f9beedf842ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cd7ca7ae-fff8-4dba-b2fe-c8b54c5c2953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_OperatingIncomeLoss_cd7ca7ae-fff8-4dba-b2fe-c8b54c5c2953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7cc452de-65e1-484d-9067-9293db2442eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_InterestExpense_7cc452de-65e1-484d-9067-9293db2442eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4c18a82c-c5bd-4ebc-af34-93b50462c853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4c18a82c-c5bd-4ebc-af34-93b50462c853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ebe19e0-f11d-449c-934f-597c3cc6dfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ebe19e0-f11d-449c-934f-597c3cc6dfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9944c571-4a43-4870-8b05-242a5ef5a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9944c571-4a43-4870-8b05-242a5ef5a2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f84e201a-f73f-4d7f-b915-25bc2528c07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_NetIncomeLoss_f84e201a-f73f-4d7f-b915-25bc2528c07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9dab6cad-c4db-4676-9737-aede07c571fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9dab6cad-c4db-4676-9737-aede07c571fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1d093071-2d09-4e69-b9ea-e8b751de95bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9dab6cad-c4db-4676-9737-aede07c571fb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1d093071-2d09-4e69-b9ea-e8b751de95bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba2b09b1-1dbb-4ae1-8826-4f14ebcdabdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ba2b09b1-1dbb-4ae1-8826-4f14ebcdabdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_1dd3f976-5c03-4bcc-880d-cbdfe180ec08" xlink:href="pacb-20230331.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_pacb_IncomeLossPerShareAbstract_1dd3f976-5c03-4bcc-880d-cbdfe180ec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e1f10f9e-6b6a-4c69-b5d0-6a09a8c9815a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_1dd3f976-5c03-4bcc-880d-cbdfe180ec08" xlink:to="loc_us-gaap_EarningsPerShareBasic_e1f10f9e-6b6a-4c69-b5d0-6a09a8c9815a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_24d4ef98-3bb2-4e69-9963-98610eca208d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_1dd3f976-5c03-4bcc-880d-cbdfe180ec08" xlink:to="loc_us-gaap_EarningsPerShareDiluted_24d4ef98-3bb2-4e69-9963-98610eca208d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_3e3b784f-b58c-4757-b772-75f7150ec00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46e94a76-7a7e-4814-a55c-e1c9b5cd310c" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_3e3b784f-b58c-4757-b772-75f7150ec00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f02caa08-a8ab-4228-bd03-e90f12808dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_3e3b784f-b58c-4757-b772-75f7150ec00b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f02caa08-a8ab-4228-bd03-e90f12808dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fde647b-635c-4f7c-ad6e-1fbde2a14ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_3e3b784f-b58c-4757-b772-75f7150ec00b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5fde647b-635c-4f7c-ad6e-1fbde2a14ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_29d94df5-d98f-4d9a-a001-4af9eeb10db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3c7afd5f-786d-4dca-b674-be4ba9c670c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_29d94df5-d98f-4d9a-a001-4af9eeb10db3" xlink:to="loc_us-gaap_StatementTable_3c7afd5f-786d-4dca-b674-be4ba9c670c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8d9a772d-a1aa-4ffd-8a08-449eba35c932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3c7afd5f-786d-4dca-b674-be4ba9c670c5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8d9a772d-a1aa-4ffd-8a08-449eba35c932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d9a772d-a1aa-4ffd-8a08-449eba35c932" xlink:to="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b391753d-3d19-4649-860c-3adb69be7021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:to="loc_us-gaap_CommonStockMember_b391753d-3d19-4649-860c-3adb69be7021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4fa2ae02-63a6-4676-8a59-ff520ee471a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4fa2ae02-63a6-4676-8a59-ff520ee471a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3d34b310-1d98-434c-8a7a-c9f6dc2de024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3d34b310-1d98-434c-8a7a-c9f6dc2de024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a27e4c07-a919-47e4-8827-ddb1ae23ead7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b972b6c-3243-4947-a55a-e8305a23ba97" xlink:to="loc_us-gaap_RetainedEarningsMember_a27e4c07-a919-47e4-8827-ddb1ae23ead7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c1a3c97d-2a6e-4912-9614-51ebbedb9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3c7afd5f-786d-4dca-b674-be4ba9c670c5" xlink:to="loc_us-gaap_StatementLineItems_c1a3c97d-2a6e-4912-9614-51ebbedb9c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c1a3c97d-2a6e-4912-9614-51ebbedb9c68" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2fc7c106-7c4e-44a7-bd84-4d063ba90762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2fc7c106-7c4e-44a7-bd84-4d063ba90762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6011166e-774b-4431-b009-0adf73408c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockholdersEquity_6011166e-774b-4431-b009-0adf73408c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f38a7cdf-c924-41a0-a0f4-50db31b98b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_NetIncomeLoss_f38a7cdf-c924-41a0-a0f4-50db31b98b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed5b973e-e29f-4258-98f1-e71f5e433e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed5b973e-e29f-4258-98f1-e71f5e433e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86e7a2fd-0106-4255-846b-15ee4b72d116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86e7a2fd-0106-4255-846b-15ee4b72d116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e903f19-fe61-43c4-bf8d-2191f176e8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e903f19-fe61-43c4-bf8d-2191f176e8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f589d202-39c1-4557-a6af-5ce4a93a0294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f589d202-39c1-4557-a6af-5ce4a93a0294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_14209c6f-4bcb-48c1-89dd-e263802a6be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_14209c6f-4bcb-48c1-89dd-e263802a6be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ea489edb-84bf-4252-87db-7d28b3874770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ea489edb-84bf-4252-87db-7d28b3874770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e14e0f82-e6ae-4e26-8a4b-77b0df642982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e14e0f82-e6ae-4e26-8a4b-77b0df642982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_674728b6-9781-4f22-9f19-c5abb63c51cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0044d720-10ac-40a1-b133-034064f12536" xlink:to="loc_us-gaap_StockholdersEquity_674728b6-9781-4f22-9f19-c5abb63c51cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pacb-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55f54ca9-d64f-473f-8dca-1929b3d97f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55f54ca9-d64f-473f-8dca-1929b3d97f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aebddfe9-5caf-4275-8668-e65c205951ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55f54ca9-d64f-473f-8dca-1929b3d97f77" xlink:to="loc_us-gaap_NetIncomeLoss_aebddfe9-5caf-4275-8668-e65c205951ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55f54ca9-d64f-473f-8dca-1929b3d97f77" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_02d3c1d2-35a6-4816-88fd-060d9f825abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_Depreciation_02d3c1d2-35a6-4816-88fd-060d9f825abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b8adf09c-5ba2-407f-8dc9-2c6ebe22ae92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b8adf09c-5ba2-407f-8dc9-2c6ebe22ae92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a6172a61-4f92-45ec-9f80-19893e2878f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a6172a61-4f92-45ec-9f80-19893e2878f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e60fee95-6c99-4122-9f57-4cac945e7a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e60fee95-6c99-4122-9f57-4cac945e7a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cc3e5aa4-d454-41ee-84fc-558b2346114c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_ShareBasedCompensation_cc3e5aa4-d454-41ee-84fc-558b2346114c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_529f5f93-32b5-4d78-9f8c-a12ff32fb2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_529f5f93-32b5-4d78-9f8c-a12ff32fb2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c1d46ffb-80c1-4af4-a906-f1d1fb6a75d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c1d46ffb-80c1-4af4-a906-f1d1fb6a75d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_de141735-17bf-4717-8160-53bd827a8a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_InventoryWriteDown_de141735-17bf-4717-8160-53bd827a8a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_15cab63c-e62e-4b5f-8036-e2aea85cc4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e686b0a-d9a2-42dc-8639-29c7520d58dc" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_15cab63c-e62e-4b5f-8036-e2aea85cc4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55f54ca9-d64f-473f-8dca-1929b3d97f77" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_29a51b4c-7c20-43e8-b467-6c887a2b388d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_29a51b4c-7c20-43e8-b467-6c887a2b388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c8467fbe-b39b-4764-9a8a-26ccc87b23ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c8467fbe-b39b-4764-9a8a-26ccc87b23ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_435ea4a8-3f9c-45d2-8dbd-ab963cdd8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_435ea4a8-3f9c-45d2-8dbd-ab963cdd8a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d0be9347-cba4-40b2-8c1f-41286fa48dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d0be9347-cba4-40b2-8c1f-41286fa48dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5fa7e8e3-c783-40f9-9b1f-e04dba7b9ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5fa7e8e3-c783-40f9-9b1f-e04dba7b9ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e3017176-fa8e-4008-8506-3863d663bb93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e3017176-fa8e-4008-8506-3863d663bb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_aaa53d51-f076-4bfe-a1b6-e6a026d6650e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_aaa53d51-f076-4bfe-a1b6-e6a026d6650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0d814aab-dbd7-42b1-b390-dc285946a94e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9cb0fba7-d9fe-4275-b481-eb54c3da3d13" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0d814aab-dbd7-42b1-b390-dc285946a94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5368844a-a75f-457b-b5f9-fca79c7c8fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_55f54ca9-d64f-473f-8dca-1929b3d97f77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5368844a-a75f-457b-b5f9-fca79c7c8fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bc5b7ff4-9327-4b4d-915e-551e37a8f8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bc5b7ff4-9327-4b4d-915e-551e37a8f8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f2bcad80-aafd-4c42-bc93-0ea9748c9538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bc5b7ff4-9327-4b4d-915e-551e37a8f8d7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f2bcad80-aafd-4c42-bc93-0ea9748c9538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_22d80222-0cf6-444f-8fa1-335f5329365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bc5b7ff4-9327-4b4d-915e-551e37a8f8d7" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_22d80222-0cf6-444f-8fa1-335f5329365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3f1d1c90-e3a6-4285-ae82-e7bd8b57daeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bc5b7ff4-9327-4b4d-915e-551e37a8f8d7" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3f1d1c90-e3a6-4285-ae82-e7bd8b57daeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_50b7a4d3-737c-43af-9a81-c473ff0231b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bc5b7ff4-9327-4b4d-915e-551e37a8f8d7" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_50b7a4d3-737c-43af-9a81-c473ff0231b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f92e36cb-8829-4204-a637-d41e8733589d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bc5b7ff4-9327-4b4d-915e-551e37a8f8d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f92e36cb-8829-4204-a637-d41e8733589d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_701fc365-43cd-4d40-98d0-c3070448796f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_701fc365-43cd-4d40-98d0-c3070448796f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ea490a06-aecb-4b08-a1b9-a7c9a4c0f162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_701fc365-43cd-4d40-98d0-c3070448796f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ea490a06-aecb-4b08-a1b9-a7c9a4c0f162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4132f7e8-0a6e-4b25-b65b-a545273ba6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_701fc365-43cd-4d40-98d0-c3070448796f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4132f7e8-0a6e-4b25-b65b-a545273ba6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1b18d9b1-a4ad-4801-8324-30e4986a0812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_701fc365-43cd-4d40-98d0-c3070448796f" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1b18d9b1-a4ad-4801-8324-30e4986a0812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88838de8-ad60-4feb-80c1-2c01eb47f787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_701fc365-43cd-4d40-98d0-c3070448796f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88838de8-ad60-4feb-80c1-2c01eb47f787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2137ce4b-88f2-4dc6-a6c6-56be654ffcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2137ce4b-88f2-4dc6-a6c6-56be654ffcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00b71b27-6b8e-4b30-8498-cad6e68057f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00b71b27-6b8e-4b30-8498-cad6e68057f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b21a71b0-f093-4665-9bdf-b7653864deea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b21a71b0-f093-4665-9bdf-b7653864deea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_207e7a25-76c5-4e77-adc6-1a8068d2acd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_207e7a25-76c5-4e77-adc6-1a8068d2acd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ef1976cb-c153-4879-9d53-d284921fc10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ef1976cb-c153-4879-9d53-d284921fc10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cce825f7-4072-4b82-859d-f6a4738e51d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_308e4dcf-1612-4082-b951-b18a1ddc3158" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cce825f7-4072-4b82-859d-f6a4738e51d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="pacb-20230331.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21ff0d24-f2eb-4bd7-b9e0-2bef2ea92c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_eb384abf-dfd6-4156-abad-066c2b8ea1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21ff0d24-f2eb-4bd7-b9e0-2bef2ea92c4a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_eb384abf-dfd6-4156-abad-066c2b8ea1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9b66d4a3-731d-46e3-9252-c791884827d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_d50cc628-809d-4f65-b53e-85f5a48888db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9b66d4a3-731d-46e3-9252-c791884827d1" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_d50cc628-809d-4f65-b53e-85f5a48888db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_99f289e0-ad49-415b-a208-bd774d83bcc4" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_506528d1-089f-4054-908f-c4cacefbc13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_99f289e0-ad49-415b-a208-bd774d83bcc4" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_506528d1-089f-4054-908f-c4cacefbc13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_adb676a1-b491-4657-ac5b-f0d8a9d4a9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_99dbf0db-af2e-4e97-a2b2-15a9beb11079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_adb676a1-b491-4657-ac5b-f0d8a9d4a9e9" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_99dbf0db-af2e-4e97-a2b2-15a9beb11079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="pacb-20230331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a45aab17-c663-4e45-aee3-3a62dc7c87cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_a1cb9111-f22d-466d-9099-d5b676d3c537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a45aab17-c663-4e45-aee3-3a62dc7c87cd" xlink:to="loc_us-gaap_LossContingencyDisclosures_a1cb9111-f22d-466d-9099-d5b676d3c537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a85650f-6bde-4b0c-aa16-e43f67734f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_03b6ac47-09d8-482b-bb3e-37ebffc83919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a85650f-6bde-4b0c-aa16-e43f67734f71" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_03b6ac47-09d8-482b-bb3e-37ebffc83919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="pacb-20230331.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7a53274b-0110-45ad-9f09-01e0b55e05fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_fd798b32-327a-4df9-bc6e-02dbf477f772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7a53274b-0110-45ad-9f09-01e0b55e05fe" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_fd798b32-327a-4df9-bc6e-02dbf477f772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/REVENUE" xlink:type="simple" xlink:href="pacb-20230331.xsd#REVENUE"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/REVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef4d139e-423a-4a67-9881-028a888f272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_fb93828c-f2bf-4298-95d3-854ba5ade8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef4d139e-423a-4a67-9881-028a888f272b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_fb93828c-f2bf-4298-95d3-854ba5ade8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="pacb-20230331.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12242995-a398-44df-b63d-2e108827d01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87f06a7a-306d-44e7-ae92-34733ac79cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12242995-a398-44df-b63d-2e108827d01e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_87f06a7a-306d-44e7-ae92-34733ac79cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a2c4897e-2026-493d-9e5c-5cffcca549e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12242995-a398-44df-b63d-2e108827d01e" xlink:to="loc_us-gaap_UseOfEstimates_a2c4897e-2026-493d-9e5c-5cffcca549e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_50d26fe4-461d-4121-8d4d-8aba582645ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12242995-a398-44df-b63d-2e108827d01e" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_50d26fe4-461d-4121-8d4d-8aba582645ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_0e537d92-c393-4c3c-87a0-9d520e60ae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12242995-a398-44df-b63d-2e108827d01e" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_0e537d92-c393-4c3c-87a0-9d520e60ae4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_982b9066-7eff-4981-ab1a-4737b7c85efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12242995-a398-44df-b63d-2e108827d01e" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_982b9066-7eff-4981-ab1a-4737b7c85efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_09133c83-f664-40fe-9b46-e9c1f66c7b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12242995-a398-44df-b63d-2e108827d01e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_09133c83-f664-40fe-9b46-e9c1f66c7b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d7d50815-3fd3-4543-9a9a-c68e54adfa35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12242995-a398-44df-b63d-2e108827d01e" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d7d50815-3fd3-4543-9a9a-c68e54adfa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_729709bd-0750-4d7a-92ad-ab237e8fda7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c0044bfe-3c9e-4245-be44-3aefcb2a4b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_729709bd-0750-4d7a-92ad-ab237e8fda7e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c0044bfe-3c9e-4245-be44-3aefcb2a4b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15ba9e2a-5b7e-41d5-973d-858f31718bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_729709bd-0750-4d7a-92ad-ab237e8fda7e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_15ba9e2a-5b7e-41d5-973d-858f31718bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0132300b-6296-4187-8607-7e6966088641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_729709bd-0750-4d7a-92ad-ab237e8fda7e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0132300b-6296-4187-8607-7e6966088641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_6e27cb25-8bc9-4269-8320-3920f712a11a" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1f2d8103-ed90-473a-bd69-2abe11f4510c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_6e27cb25-8bc9-4269-8320-3920f712a11a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1f2d8103-ed90-473a-bd69-2abe11f4510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_765fecb4-7acc-4cff-9d78-8c7ff636f8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_6e27cb25-8bc9-4269-8320-3920f712a11a" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_765fecb4-7acc-4cff-9d78-8c7ff636f8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0489eee1-9e19-48f1-bda1-55845a2a214d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_6e27cb25-8bc9-4269-8320-3920f712a11a" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0489eee1-9e19-48f1-bda1-55845a2a214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_c05c45e5-ce51-497a-a57c-6f099c7aa42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_6e27cb25-8bc9-4269-8320-3920f712a11a" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_c05c45e5-ce51-497a-a57c-6f099c7aa42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_896ffc06-ed2d-4d9b-b1e2-978c6f99d223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_6e27cb25-8bc9-4269-8320-3920f712a11a" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_896ffc06-ed2d-4d9b-b1e2-978c6f99d223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d481c3c5-68d1-4499-bac9-78b4bf045cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_bdbfc0b8-b69a-48d3-af32-07ab867bea5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d481c3c5-68d1-4499-bac9-78b4bf045cc2" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_bdbfc0b8-b69a-48d3-af32-07ab867bea5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_873bec11-75ea-420a-9c0f-3a4482599809" xlink:href="pacb-20230331.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d481c3c5-68d1-4499-bac9-78b4bf045cc2" xlink:to="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_873bec11-75ea-420a-9c0f-3a4482599809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcdc841-976b-457b-8e7c-1464ef8bd03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_08322896-afef-4fef-9996-e8246f7393c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcdc841-976b-457b-8e7c-1464ef8bd03f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_08322896-afef-4fef-9996-e8246f7393c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ed1b9d9a-0d34-4b97-887c-cbddd9cfac9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcdc841-976b-457b-8e7c-1464ef8bd03f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ed1b9d9a-0d34-4b97-887c-cbddd9cfac9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_348ab098-a459-4e8f-a58e-9b672c5ea4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcdc841-976b-457b-8e7c-1464ef8bd03f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_348ab098-a459-4e8f-a58e-9b672c5ea4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_60701ee5-d7c2-467b-9b17-fc14c5c38187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcdc841-976b-457b-8e7c-1464ef8bd03f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_60701ee5-d7c2-467b-9b17-fc14c5c38187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_5b48c906-29ce-4246-8bfa-5efeff2578e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dcdc841-976b-457b-8e7c-1464ef8bd03f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_5b48c906-29ce-4246-8bfa-5efeff2578e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="pacb-20230331.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_512c322d-b7f2-4e56-b246-af14a001301d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_028a58d0-3bc6-4f79-bd98-938c7e5f29e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_512c322d-b7f2-4e56-b246-af14a001301d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_028a58d0-3bc6-4f79-bd98-938c7e5f29e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6c9a3865-7ae8-41d3-aeec-b1884cb6408e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_512c322d-b7f2-4e56-b246-af14a001301d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6c9a3865-7ae8-41d3-aeec-b1884cb6408e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/REVENUETables" xlink:type="simple" xlink:href="pacb-20230331.xsd#REVENUETables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/REVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e52aa233-ab69-4d09-84be-3393e274f0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_66ac1cdc-c2d2-4765-b24a-884791d4519c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e52aa233-ab69-4d09-84be-3393e274f0d2" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_66ac1cdc-c2d2-4765-b24a-884791d4519c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d899b6a8-0300-463c-b6b3-d08e2616ffda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e52aa233-ab69-4d09-84be-3393e274f0d2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d899b6a8-0300-463c-b6b3-d08e2616ffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db60271d-914f-4e5a-af9d-da2aaf93f33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:href="pacb-20230331.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db60271d-914f-4e5a-af9d-da2aaf93f33e" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ddf5f5a-0682-485a-8017-d2ce44a770e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ddf5f5a-0682-485a-8017-d2ce44a770e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba7c127-9de0-4f07-8152-703be99cbdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ddf5f5a-0682-485a-8017-d2ce44a770e8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba7c127-9de0-4f07-8152-703be99cbdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7227c0e1-55ac-4d17-b495-c3ce05b52e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba7c127-9de0-4f07-8152-703be99cbdec" xlink:to="loc_us-gaap_SalesRevenueNetMember_7227c0e1-55ac-4d17-b495-c3ce05b52e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5f9b612e-d6fc-47e6-82c9-39544d86e770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2ba7c127-9de0-4f07-8152-703be99cbdec" xlink:to="loc_us-gaap_AccountsReceivableMember_5f9b612e-d6fc-47e6-82c9-39544d86e770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b552aea0-45cc-4d27-bcb1-7701490648c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:to="loc_srt_MajorCustomersAxis_b552aea0-45cc-4d27-bcb1-7701490648c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b552aea0-45cc-4d27-bcb1-7701490648c2" xlink:to="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember_b0c28432-16c0-4184-93a2-71e387e60e81" xlink:href="pacb-20230331.xsd#pacb_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:to="loc_pacb_CustomerOneMember_b0c28432-16c0-4184-93a2-71e387e60e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerTwoMember_d535208c-6e0c-4e82-8799-efa36c0aac38" xlink:href="pacb-20230331.xsd#pacb_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:to="loc_pacb_CustomerTwoMember_d535208c-6e0c-4e82-8799-efa36c0aac38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember_78437d93-8eb6-465b-9196-cc7962e262ff" xlink:href="pacb-20230331.xsd#pacb_DomesticCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_438fc5a0-88fb-4fb9-8e1c-e04fc765c945" xlink:to="loc_pacb_DomesticCustomersMember_78437d93-8eb6-465b-9196-cc7962e262ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a3c92a56-8b05-489d-93d9-2f8b369d69ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6f36841b-84fb-4d42-9aa6-5b6bb5e1606d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a3c92a56-8b05-489d-93d9-2f8b369d69ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_dd2e5f4f-3fe1-406c-8e2c-d1ceea6bce37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a3c92a56-8b05-489d-93d9-2f8b369d69ce" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_dd2e5f4f-3fe1-406c-8e2c-d1ceea6bce37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_423652b8-1333-4a02-9c69-571e56a1241c" xlink:href="pacb-20230331.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_ea8cacd0-4746-413e-aee4-de0bef388615" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_423652b8-1333-4a02-9c69-571e56a1241c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a8bc4e00-1e3a-4e84-9cb7-e29ac6a94cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_423652b8-1333-4a02-9c69-571e56a1241c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a8bc4e00-1e3a-4e84-9cb7-e29ac6a94cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_fb80ba75-798d-40c6-89f3-8217f45d1d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_fb80ba75-798d-40c6-89f3-8217f45d1d14" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61be8a76-86a6-4bc7-b830-458cd35f2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61be8a76-86a6-4bc7-b830-458cd35f2d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61be8a76-86a6-4bc7-b830-458cd35f2d18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_192e1ad5-ef80-4292-a973-6219f625bfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_192e1ad5-ef80-4292-a973-6219f625bfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e4d37704-d2fc-4d44-b973-425cb1d6d434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e4d37704-d2fc-4d44-b973-425cb1d6d434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b7913792-f5f4-40f4-813f-4ef69de70a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60266c18-56c6-41a4-b811-a5df169796c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b7913792-f5f4-40f4-813f-4ef69de70a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a8e1bb23-d5bd-4285-8697-d597f5d39690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a8e1bb23-d5bd-4285-8697-d597f5d39690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fe573868-e428-4d83-b549-d0de6135b2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a8e1bb23-d5bd-4285-8697-d597f5d39690" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fe573868-e428-4d83-b549-d0de6135b2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fe573868-e428-4d83-b549-d0de6135b2de" xlink:to="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_db4338f8-836e-45e2-adf5-57ebc4211373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_db4338f8-836e-45e2-adf5-57ebc4211373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4256ca4c-7c28-487b-be81-d05c59cfd6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4256ca4c-7c28-487b-be81-d05c59cfd6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_89e5d1a5-1086-4883-aee7-be834a5f935e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_3781ba0a-350a-40ca-a38c-3962ece55cb9" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_89e5d1a5-1086-4883-aee7-be834a5f935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_deb48b40-5251-459c-b547-0dfa4309fea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cb964d3-f1f1-4a29-adfc-56dc2c217b48" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_deb48b40-5251-459c-b547-0dfa4309fea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_deb48b40-5251-459c-b547-0dfa4309fea9" xlink:to="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4195d2c0-daa7-4714-bf72-03abd70d59d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4195d2c0-daa7-4714-bf72-03abd70d59d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_12c9c75b-ef5c-4b13-8a37-ba25150d5ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_12c9c75b-ef5c-4b13-8a37-ba25150d5ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_9d16876b-8659-42da-b8d8-c49ef2954362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_RestrictedCashCurrent_9d16876b-8659-42da-b8d8-c49ef2954362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_900d50b5-e347-4f92-aa30-3faf4aafd011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_900d50b5-e347-4f92-aa30-3faf4aafd011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a83b87a8-87b7-4cf6-9205-4eacbf18aa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3974fe00-c42e-4356-b7c9-115b406ff49f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a83b87a8-87b7-4cf6-9205-4eacbf18aa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_524df401-5c39-4323-b123-a66a7a16c739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_deb48b40-5251-459c-b547-0dfa4309fea9" xlink:to="loc_us-gaap_LiabilitiesAbstract_524df401-5c39-4323-b123-a66a7a16c739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4471c5e-600a-4af1-bb9c-209a22f7b168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_524df401-5c39-4323-b123-a66a7a16c739" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4471c5e-600a-4af1-bb9c-209a22f7b168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_beeed1e7-4b61-4a4a-9d42-030614aeedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_524df401-5c39-4323-b123-a66a7a16c739" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_beeed1e7-4b61-4a4a-9d42-030614aeedbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5015f1e5-0331-41e6-a83d-5e8fa9f3504a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:href="pacb-20230331.xsd#pacb_FinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5015f1e5-0331-41e6-a83d-5e8fa9f3504a" xlink:to="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4d1b2dc2-986d-4960-9316-b9e66ca46c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4d1b2dc2-986d-4960-9316-b9e66ca46c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bdb11768-ad38-4e28-b638-641d54b09a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4d1b2dc2-986d-4960-9316-b9e66ca46c3e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bdb11768-ad38-4e28-b638-641d54b09a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_eea889d4-1f83-444f-91bb-1cfd5fae0642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_bdb11768-ad38-4e28-b638-641d54b09a09" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_eea889d4-1f83-444f-91bb-1cfd5fae0642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de849abf-b0be-4c0c-9cbd-060c082b5238" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:to="loc_srt_RangeAxis_de849abf-b0be-4c0c-9cbd-060c082b5238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e306fc0-6703-4967-b91c-1ed3bb4c6214" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_de849abf-b0be-4c0c-9cbd-060c082b5238" xlink:to="loc_srt_RangeMember_6e306fc0-6703-4967-b91c-1ed3bb4c6214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2ab8fdec-e1f2-408c-89aa-f68ee953e6c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e306fc0-6703-4967-b91c-1ed3bb4c6214" xlink:to="loc_srt_MinimumMember_2ab8fdec-e1f2-408c-89aa-f68ee953e6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f11351a0-e431-459f-b2d6-5d838bb9581a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e306fc0-6703-4967-b91c-1ed3bb4c6214" xlink:to="loc_srt_MaximumMember_f11351a0-e431-459f-b2d6-5d838bb9581a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems_4a2574fe-2d27-4495-8b5f-2688ceb65756" xlink:href="pacb-20230331.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_98effbd4-b616-40a1-8ad9-cf20b227806d" xlink:to="loc_pacb_FinancialInstrumentsLineItems_4a2574fe-2d27-4495-8b5f-2688ceb65756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0a3e283b-42c5-47bd-8aae-166d7b074b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_4a2574fe-2d27-4495-8b5f-2688ceb65756" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_0a3e283b-42c5-47bd-8aae-166d7b074b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_02b56878-7999-4a0a-b755-cfbe15706336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_676a217f-82d7-4fa2-adca-85acb32c57e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_02b56878-7999-4a0a-b755-cfbe15706336" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_676a217f-82d7-4fa2-adca-85acb32c57e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fbb146fc-2dfe-4d9a-b4e2-4d79e450821c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_676a217f-82d7-4fa2-adca-85acb32c57e7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fbb146fc-2dfe-4d9a-b4e2-4d79e450821c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4c75f325-3844-4cb4-a813-3e1f132d9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_676a217f-82d7-4fa2-adca-85acb32c57e7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4c75f325-3844-4cb4-a813-3e1f132d9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f2acf18-0b32-4b25-b3d4-f66505507726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_676a217f-82d7-4fa2-adca-85acb32c57e7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f2acf18-0b32-4b25-b3d4-f66505507726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_af61ec63-3f97-4dc9-82be-acf98e11463a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2333eb7a-88e6-4c8f-b39b-dbced63ec930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_af61ec63-3f97-4dc9-82be-acf98e11463a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2333eb7a-88e6-4c8f-b39b-dbced63ec930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_00d1d218-3711-424d-9fd1-8d8a760bc541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2333eb7a-88e6-4c8f-b39b-dbced63ec930" xlink:to="loc_us-gaap_FinancialInstrumentAxis_00d1d218-3711-424d-9fd1-8d8a760bc541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81798c06-59ab-4c1a-9952-e5e33113647b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00d1d218-3711-424d-9fd1-8d8a760bc541" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81798c06-59ab-4c1a-9952-e5e33113647b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_c2b12887-b525-4dcb-aab6-bbbc8b1ed173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81798c06-59ab-4c1a-9952-e5e33113647b" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_c2b12887-b525-4dcb-aab6-bbbc8b1ed173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81798c06-59ab-4c1a-9952-e5e33113647b" xlink:to="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_0f701f69-8b4d-4677-9f87-7741c61f88f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_0f701f69-8b4d-4677-9f87-7741c61f88f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_457e0ebf-9b5c-4a74-802b-e1aa823ccf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_457e0ebf-9b5c-4a74-802b-e1aa823ccf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e8c5ede9-0fc5-44a1-af47-8b0cd39b7141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_0f492e58-db42-4636-8c43-09c3ed991558" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e8c5ede9-0fc5-44a1-af47-8b0cd39b7141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2333eb7a-88e6-4c8f-b39b-dbced63ec930" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6177136a-9541-4a21-bb1a-0366a757448c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6177136a-9541-4a21-bb1a-0366a757448c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31751f07-ef0c-477a-a426-16095e7781f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31751f07-ef0c-477a-a426-16095e7781f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b17e286f-c7bf-4744-87bf-c037fc6f1d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b17e286f-c7bf-4744-87bf-c037fc6f1d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9256bc99-6f67-4a49-a247-94e668b38b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9256bc99-6f67-4a49-a247-94e668b38b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_bc4ee689-d1db-4c69-b7a2-39f49d8a2454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_RestrictedCashCurrent_bc4ee689-d1db-4c69-b7a2-39f49d8a2454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3f662dec-8452-45ba-ad79-a35f82c32371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_76bfeaaf-e829-439d-9976-d3645b3f68a3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3f662dec-8452-45ba-ad79-a35f82c32371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b8bbe64a-349c-4577-b309-2e25f8ab46b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_77fcfd75-db53-46ee-8b85-9fc58092f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b8bbe64a-349c-4577-b309-2e25f8ab46b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_77fcfd75-db53-46ee-8b85-9fc58092f14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_0ee57ddb-f69c-4469-b6d1-e16b14d9f830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b8bbe64a-349c-4577-b309-2e25f8ab46b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_0ee57ddb-f69c-4469-b6d1-e16b14d9f830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_d0f0bd9a-1070-4788-ab76-b548bd25a5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b8bbe64a-349c-4577-b309-2e25f8ab46b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_d0f0bd9a-1070-4788-ab76-b548bd25a5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_2c844911-793c-4e4d-97f0-fac114e04202" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:href="pacb-20230331.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_2c844911-793c-4e4d-97f0-fac114e04202" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3e8d08f2-ca23-49f3-be09-ee46c418bc28" xlink:to="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCorporationMember_1fac43a9-47e1-492e-becf-5693bb402767" xlink:href="pacb-20230331.xsd#pacb_InvitaeCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b46b4573-7bd1-40d7-8bfb-436f351d247a" xlink:to="loc_pacb_InvitaeCorporationMember_1fac43a9-47e1-492e-becf-5693bb402767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7771062-b049-4677-af73-2d7ff3ba2c35" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_aab2b505-0837-494f-8e49-2acc3c349bdd" xlink:href="pacb-20230331.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d03e36b6-db9e-4676-bf8b-627a7afb8434" xlink:to="loc_pacb_OmniomeIncMember_aab2b505-0837-494f-8e49-2acc3c349bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6033a423-7358-461d-a50f-61f3fabd5f97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bff7cd81-6415-447c-bba6-d168899c5d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60fc12af-9572-4e9c-9840-994e87bbfc9d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bff7cd81-6415-447c-bba6-d168899c5d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2958537f-bd54-4e32-b270-a5ce4b393544" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TermLoansMember_76926325-6b78-4894-839c-d091d1663c82" xlink:href="pacb-20230331.xsd#pacb_TermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d1392c8-25bc-4f1c-8398-db4bb77e9c51" xlink:to="loc_pacb_TermLoansMember_76926325-6b78-4894-839c-d091d1663c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a3278e2-3ec6-4395-bd0c-a692a43a4038" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_048e89b2-5bfa-4cc1-80c6-81f96000dca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8e92a88d-8450-40d3-b3d0-965f5e4aeafc" xlink:to="loc_us-gaap_SecuredDebtMember_048e89b2-5bfa-4cc1-80c6-81f96000dca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2f1d0e08-ec6d-4926-ba50-c0305c427201" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_067a255b-cf4d-4e0c-ab0e-88231a8141c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_67dd7fb8-cdfb-4b15-b682-92002e4f99d5" xlink:to="loc_us-gaap_SecuredDebtMember_067a255b-cf4d-4e0c-ab0e-88231a8141c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b7a95751-e6c0-488c-878a-ea750ff713fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b7a95751-e6c0-488c-878a-ea750ff713fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f58d2063-40fb-4e7f-92d0-5de895a2a6ae" xlink:to="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ee22c6e1-fc0d-4d59-86db-8db21737ddd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:to="loc_srt_MinimumMember_ee22c6e1-fc0d-4d59-86db-8db21737ddd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1aacaf60-8a58-4985-8f81-daa36b844a27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7ce64bd4-3c0e-470e-84b9-dfd1f335d06f" xlink:to="loc_srt_MaximumMember_1aacaf60-8a58-4985-8f81-daa36b844a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:href="pacb-20230331.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_57ea2e4a-1c96-41f8-8fae-9839c2e19ee6" xlink:to="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49783a7e-a5ab-44e6-83e3-176d95ae14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_49783a7e-a5ab-44e6-83e3-176d95ae14f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_60337129-d3cd-4293-ac60-9e373d87c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_60337129-d3cd-4293-ac60-9e373d87c8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63eac09c-65ec-479e-aabe-91442ff7afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63eac09c-65ec-479e-aabe-91442ff7afc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eec2cda6-9ebf-4550-9c6a-a8ef3a891509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eec2cda6-9ebf-4550-9c6a-a8ef3a891509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e62bb77c-0e22-4aad-a1d1-0dfd5b6c4895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e62bb77c-0e22-4aad-a1d1-0dfd5b6c4895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5dbaca48-6c0c-4084-904c-9262225729c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5dbaca48-6c0c-4084-904c-9262225729c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_247f570d-5f2d-4ee7-b811-961a268a7f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_247f570d-5f2d-4ee7-b811-961a268a7f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b0c80291-60fe-441d-a6c3-d9bf58d270fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b0c80291-60fe-441d-a6c3-d9bf58d270fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_d92eff0a-adc0-4c9a-8479-96063db6e327" xlink:href="pacb-20230331.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_StandardProductWarrantyPeriod_d92eff0a-adc0-4c9a-8479-96063db6e327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c606f2b3-6cda-494d-8cc1-a6f5c323c214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c606f2b3-6cda-494d-8cc1-a6f5c323c214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2528f19-3b40-457f-b320-1c680b5ee828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2528f19-3b40-457f-b320-1c680b5ee828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c12f5b5c-1cb2-4c78-b672-d91081f0a7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtInstrumentTerm_c12f5b5c-1cb2-4c78-b672-d91081f0a7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df4637e9-9c16-435d-958d-be0d64d5f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df4637e9-9c16-435d-958d-be0d64d5f0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentTermLoanElectiveOption_7bb6cdba-8b11-46ee-a24f-aad6e327532e" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentTermLoanElectiveOption"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_DebtInstrumentTermLoanElectiveOption_7bb6cdba-8b11-46ee-a24f-aad6e327532e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFeeToPrepayDebt_133e4e20-b310-4d68-9113-5f517ee21406" xlink:href="pacb-20230331.xsd#pacb_PercentageOfFeeToPrepayDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_pacb_PercentageOfFeeToPrepayDebt_133e4e20-b310-4d68-9113-5f517ee21406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_10b1ad73-17f8-4294-a980-8e58eb0478de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_10b1ad73-17f8-4294-a980-8e58eb0478de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c634da7a-fb9c-455c-aeff-2a12d0eef076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c634da7a-fb9c-455c-aeff-2a12d0eef076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_262709ed-ecb2-4d55-89dc-04f2be353fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_ShortTermBorrowings_262709ed-ecb2-4d55-89dc-04f2be353fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a0fd923b-e18d-4821-a31c-852afc9746b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_338f38f1-f45b-41a2-8334-a8c5104fa620" xlink:to="loc_us-gaap_InterestExpenseDebt_a0fd923b-e18d-4821-a31c-852afc9746b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74c65410-03b2-41d5-bad2-b62af9d95e5c" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_815a4515-6a83-40ff-9e5a-96e96055972d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74c65410-03b2-41d5-bad2-b62af9d95e5c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_815a4515-6a83-40ff-9e5a-96e96055972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5d31e91e-db69-49f6-a927-f441ebf64e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74c65410-03b2-41d5-bad2-b62af9d95e5c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5d31e91e-db69-49f6-a927-f441ebf64e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fd60f2a5-9b7e-4f61-b629-fd7cbe4cd757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74c65410-03b2-41d5-bad2-b62af9d95e5c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fd60f2a5-9b7e-4f61-b629-fd7cbe4cd757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bb630cd4-8ef7-4149-b794-0bc014c2a9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_74c65410-03b2-41d5-bad2-b62af9d95e5c" xlink:to="loc_us-gaap_InventoryNet_bb630cd4-8ef7-4149-b794-0bc014c2a9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_9ccd68b4-3da3-4269-96ec-29fcd23a7728" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82d829aa-60cc-4389-9d77-db3057964561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_9ccd68b4-3da3-4269-96ec-29fcd23a7728" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82d829aa-60cc-4389-9d77-db3057964561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eea87425-2f84-4144-9c5b-a487c75991a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82d829aa-60cc-4389-9d77-db3057964561" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eea87425-2f84-4144-9c5b-a487c75991a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8527761d-7662-4a74-84ef-486b2a19aa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eea87425-2f84-4144-9c5b-a487c75991a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8527761d-7662-4a74-84ef-486b2a19aa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_91cdfebe-4db4-497f-a4f5-17b756a235a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8527761d-7662-4a74-84ef-486b2a19aa9a" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_91cdfebe-4db4-497f-a4f5-17b756a235a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_7a9bbc66-f605-4f8b-aead-885205e61ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8527761d-7662-4a74-84ef-486b2a19aa9a" xlink:to="loc_us-gaap_CustomerRelationshipsMember_7a9bbc66-f605-4f8b-aead-885205e61ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82d829aa-60cc-4389-9d77-db3057964561" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a2ea28a-5767-4b6e-b06f-f884379bd5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a2ea28a-5767-4b6e-b06f-f884379bd5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_95a0387d-e84a-4bf5-b1f1-7adf869a2207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_95a0387d-e84a-4bf5-b1f1-7adf869a2207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ea1dfdbc-af37-46e1-a209-42cd02e9d41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ea1dfdbc-af37-46e1-a209-42cd02e9d41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ea2ba130-4ac7-4c64-8561-912d17d3a44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb451f5b-10db-4573-a985-43217c6e96e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ea2ba130-4ac7-4c64-8561-912d17d3a44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_cc2c01a8-1e27-440a-ac5e-a866ea6d0acb" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_fa54eb96-4924-4af7-a029-4a76efa0a915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_cc2c01a8-1e27-440a-ac5e-a866ea6d0acb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_fa54eb96-4924-4af7-a029-4a76efa0a915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_238204e5-f8f6-4874-829f-fb203aa91a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_cc2c01a8-1e27-440a-ac5e-a866ea6d0acb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_238204e5-f8f6-4874-829f-fb203aa91a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_934a42d5-ffdc-4f0e-85ee-36835a2662b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_cc2c01a8-1e27-440a-ac5e-a866ea6d0acb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_934a42d5-ffdc-4f0e-85ee-36835a2662b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bd922a7f-8d2c-4449-be91-18e00b7f1897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_cc2c01a8-1e27-440a-ac5e-a866ea6d0acb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bd922a7f-8d2c-4449-be91-18e00b7f1897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_473dc264-5cd7-41a4-9e3d-3b9cc83a438f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_cc2c01a8-1e27-440a-ac5e-a866ea6d0acb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_473dc264-5cd7-41a4-9e3d-3b9cc83a438f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_102d2fa4-c448-44a6-aafa-24e12fea6b8a" xlink:href="pacb-20230331.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_cc2c01a8-1e27-440a-ac5e-a866ea6d0acb" xlink:to="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_102d2fa4-c448-44a6-aafa-24e12fea6b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5ee2da4-be04-453e-8b9b-121400a27eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_cc2c01a8-1e27-440a-ac5e-a866ea6d0acb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5ee2da4-be04-453e-8b9b-121400a27eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_974c911c-324e-4bca-868f-3fc6c922b6da" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_399ea073-65a1-4f76-9ddc-775249996692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_974c911c-324e-4bca-868f-3fc6c922b6da" xlink:to="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_399ea073-65a1-4f76-9ddc-775249996692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_27677763-25f7-4376-91dd-9ae307d2e3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_399ea073-65a1-4f76-9ddc-775249996692" xlink:to="loc_us-gaap_ProductWarrantyAccrual_27677763-25f7-4376-91dd-9ae307d2e3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_d051a4b0-bdd5-48f3-87c6-2a6066506bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_399ea073-65a1-4f76-9ddc-775249996692" xlink:to="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_d051a4b0-bdd5-48f3-87c6-2a6066506bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments_5f2aa4e1-c5c8-4d6c-a01d-e461410d3123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_399ea073-65a1-4f76-9ddc-775249996692" xlink:to="loc_us-gaap_ProductWarrantyAccrualPayments_5f2aa4e1-c5c8-4d6c-a01d-e461410d3123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_e38f26ba-d740-4f7e-99a8-c4eb80a914ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_399ea073-65a1-4f76-9ddc-775249996692" xlink:to="loc_us-gaap_ProductWarrantyAccrual_e38f26ba-d740-4f7e-99a8-c4eb80a914ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_89b9c01e-f9fe-4599-95b1-4cffc79cc4c7" xlink:href="pacb-20230331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11142108-def6-4bb2-9050-e64ac23a8823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_89b9c01e-f9fe-4599-95b1-4cffc79cc4c7" xlink:to="loc_us-gaap_DebtInstrumentTable_11142108-def6-4bb2-9050-e64ac23a8823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d5bbcf6-dec2-417a-a9fa-7693366e18b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11142108-def6-4bb2-9050-e64ac23a8823" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d5bbcf6-dec2-417a-a9fa-7693366e18b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b043edbd-c5b6-4247-9b54-da0db65d17f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d5bbcf6-dec2-417a-a9fa-7693366e18b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b043edbd-c5b6-4247-9b54-da0db65d17f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TermLoansMember_d81ff23d-43e2-453d-9650-a23800965b11" xlink:href="pacb-20230331.xsd#pacb_TermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b043edbd-c5b6-4247-9b54-da0db65d17f4" xlink:to="loc_pacb_TermLoansMember_d81ff23d-43e2-453d-9650-a23800965b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_be2e4d2a-0297-4d92-9e2e-7ab73571f64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11142108-def6-4bb2-9050-e64ac23a8823" xlink:to="loc_us-gaap_DebtInstrumentLineItems_be2e4d2a-0297-4d92-9e2e-7ab73571f64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be2e4d2a-0297-4d92-9e2e-7ab73571f64e" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d4237607-f500-4d52-aa1c-f87c8d210635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d4237607-f500-4d52-aa1c-f87c8d210635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9a7874ec-e6b4-4872-a302-0c6a114c4f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9a7874ec-e6b4-4872-a302-0c6a114c4f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a1621712-d8e4-42ad-9273-6473304df6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7dbace20-69d5-4a0d-b9dc-a261b1224cfe" xlink:to="loc_us-gaap_LongTermDebt_a1621712-d8e4-42ad-9273-6473304df6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_37ecd8e4-26b0-42ae-ad00-c7a031a31f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_37ecd8e4-26b0-42ae-ad00-c7a031a31f35" xlink:to="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5c9f217-6178-4c5a-932c-c4362c9d4763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5c9f217-6178-4c5a-932c-c4362c9d4763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_41ecff23-d0cc-4da4-9666-284be42582b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5c9f217-6178-4c5a-932c-c4362c9d4763" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_41ecff23-d0cc-4da4-9666-284be42582b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_e7d8ca6b-ea83-461e-a4e5-fb6d816265cb" xlink:href="pacb-20230331.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41ecff23-d0cc-4da4-9666-284be42582b4" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_e7d8ca6b-ea83-461e-a4e5-fb6d816265cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_77b75d0c-5b08-4e05-aa18-adde7492599f" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_77b75d0c-5b08-4e05-aa18-adde7492599f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_0762c28c-67e0-4395-b389-546efb679a30" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_77b75d0c-5b08-4e05-aa18-adde7492599f" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_0762c28c-67e0-4395-b389-546efb679a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_25c485be-717b-4fdd-9415-204df69ca742" xlink:href="pacb-20230331.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_0762c28c-67e0-4395-b389-546efb679a30" xlink:to="loc_pacb_DebtConversionTermsOneMember_25c485be-717b-4fdd-9415-204df69ca742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_c5e073d0-552c-4649-af4a-eead596bdd32" xlink:href="pacb-20230331.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_0762c28c-67e0-4395-b389-546efb679a30" xlink:to="loc_pacb_DebtConversionTermsTwoMember_c5e073d0-552c-4649-af4a-eead596bdd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c5d863d0-bc68-4aeb-aa73-1132116bc6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c5d863d0-bc68-4aeb-aa73-1132116bc6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_560443db-454e-488c-bba1-23f8d72425cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c5d863d0-bc68-4aeb-aa73-1132116bc6ed" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_560443db-454e-488c-bba1-23f8d72425cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_df10cf01-97df-49d8-9cc3-d55ee9abdd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_560443db-454e-488c-bba1-23f8d72425cb" xlink:to="loc_us-gaap_ConvertibleDebtMember_df10cf01-97df-49d8-9cc3-d55ee9abdd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed75d4a2-c342-4d4b-aeac-426895635257" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_srt_RangeAxis_ed75d4a2-c342-4d4b-aeac-426895635257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b95ad07f-495c-46a7-ac35-207fb91b3a1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed75d4a2-c342-4d4b-aeac-426895635257" xlink:to="loc_srt_RangeMember_b95ad07f-495c-46a7-ac35-207fb91b3a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6228248a-94bf-4633-95ab-520ca9b29521" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b95ad07f-495c-46a7-ac35-207fb91b3a1a" xlink:to="loc_srt_MaximumMember_6228248a-94bf-4633-95ab-520ca9b29521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8065894f-c386-4c7b-b854-1a7d093f9676" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b95ad07f-495c-46a7-ac35-207fb91b3a1a" xlink:to="loc_srt_MinimumMember_8065894f-c386-4c7b-b854-1a7d093f9676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_232b24e6-179a-4601-a84f-f17300558c23" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c2ce29d7-b804-4cc3-b1b0-78f44c01a684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c2ce29d7-b804-4cc3-b1b0-78f44c01a684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11b2e0b9-7464-47fb-911e-891cc3d06908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11b2e0b9-7464-47fb-911e-891cc3d06908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_7f0ae6a3-0e22-4b7c-b61a-a2561ffaf0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_7f0ae6a3-0e22-4b7c-b61a-a2561ffaf0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3b99beeb-6ffa-4670-ba1e-b1be4e393a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3b99beeb-6ffa-4670-ba1e-b1be4e393a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_5243b008-28f8-4de7-b63e-701de2b29ba9" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_5243b008-28f8-4de7-b63e-701de2b29ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_8b97fe8d-ccbe-4f2f-acf3-702fc63e71e0" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_8b97fe8d-ccbe-4f2f-acf3-702fc63e71e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_615d37c5-a7fb-4982-8e62-92ce12368eef" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_615d37c5-a7fb-4982-8e62-92ce12368eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5868e62f-6d98-44dc-b0e7-b37784e6989e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5868e62f-6d98-44dc-b0e7-b37784e6989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_557f5cab-9542-4c7d-84d5-614088d642d1" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_557f5cab-9542-4c7d-84d5-614088d642d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_771622e0-de37-4c9f-ad9a-bbb69a53bfa9" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_771622e0-de37-4c9f-ad9a-bbb69a53bfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_8ee0c149-d0bf-4e11-8eea-dc1c63d3e135" xlink:href="pacb-20230331.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_8ee0c149-d0bf-4e11-8eea-dc1c63d3e135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_c77cb6a2-436b-4999-99ad-2b6f71040d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_c77cb6a2-436b-4999-99ad-2b6f71040d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_afad200b-8bc0-41b5-8cce-b2082152d5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_afad200b-8bc0-41b5-8cce-b2082152d5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_6c3d25da-9186-46af-9a51-3a58137a6593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3ef8d32b-d1b2-457a-b903-8a6a5066f19f" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_6c3d25da-9186-46af-9a51-3a58137a6593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2c6382aa-8f27-41dd-9ba7-a0169f855867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b6cb5da4-ed50-4507-9188-8f3ad2cca4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2c6382aa-8f27-41dd-9ba7-a0169f855867" xlink:to="loc_us-gaap_DebtInstrumentTable_b6cb5da4-ed50-4507-9188-8f3ad2cca4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6113efbe-f371-4232-8987-70d115d4543d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b6cb5da4-ed50-4507-9188-8f3ad2cca4f5" xlink:to="loc_us-gaap_DebtInstrumentAxis_6113efbe-f371-4232-8987-70d115d4543d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a5141def-68b7-4c4b-8928-26777f98c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6113efbe-f371-4232-8987-70d115d4543d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a5141def-68b7-4c4b-8928-26777f98c0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_3303d15a-76a4-4001-b5c3-f5f67cdd3fff" xlink:href="pacb-20230331.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a5141def-68b7-4c4b-8928-26777f98c0a5" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_3303d15a-76a4-4001-b5c3-f5f67cdd3fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b6cb5da4-ed50-4507-9188-8f3ad2cca4f5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a76fc755-2f3b-4b49-8264-343367646a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a76fc755-2f3b-4b49-8264-343367646a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5a8cde00-900e-4bba-bf17-aae1be81f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5a8cde00-900e-4bba-bf17-aae1be81f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3d138f83-320a-4c1c-8cb7-678c855ea074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_db0b29b0-aa14-4db2-bfc9-60f58b96f4cc" xlink:to="loc_us-gaap_LongTermDebt_3d138f83-320a-4c1c-8cb7-678c855ea074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0a0c7b69-dbb6-4332-9232-d27070794126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55591a31-94d9-4cf4-94fa-f8efe368fa50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0a0c7b69-dbb6-4332-9232-d27070794126" xlink:to="loc_us-gaap_DebtInstrumentTable_55591a31-94d9-4cf4-94fa-f8efe368fa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c388a253-2d54-4e1b-a3f1-07fa538e2694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55591a31-94d9-4cf4-94fa-f8efe368fa50" xlink:to="loc_us-gaap_DebtInstrumentAxis_c388a253-2d54-4e1b-a3f1-07fa538e2694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_881f824e-aa08-47d5-835f-eed5f9521695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c388a253-2d54-4e1b-a3f1-07fa538e2694" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_881f824e-aa08-47d5-835f-eed5f9521695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_6bbb2c76-eabf-4f71-8ed1-e9375d413030" xlink:href="pacb-20230331.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_881f824e-aa08-47d5-835f-eed5f9521695" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_6bbb2c76-eabf-4f71-8ed1-e9375d413030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55591a31-94d9-4cf4-94fa-f8efe368fa50" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_2e650731-1a4d-4789-b3f4-7371eae04b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_2e650731-1a4d-4789-b3f4-7371eae04b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_31a911d8-3d83-4bf1-a3e5-277afc825690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_31a911d8-3d83-4bf1-a3e5-277afc825690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_da224ac7-6bca-4d2a-a6af-593c28b79c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f5e1efbc-7f5e-42c9-b71c-08b24007a7e0" xlink:to="loc_us-gaap_InterestExpenseDebt_da224ac7-6bca-4d2a-a6af-593c28b79c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d06ce6b5-94c3-4b17-b4b8-881ac7b60191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d06ce6b5-94c3-4b17-b4b8-881ac7b60191" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_ba7eefa7-576f-4d96-a94e-c71f993d2807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_ba7eefa7-576f-4d96-a94e-c71f993d2807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c95ecb9a-eb27-4fac-856b-9c46ecf71815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_ba7eefa7-576f-4d96-a94e-c71f993d2807" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c95ecb9a-eb27-4fac-856b-9c46ecf71815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member_d14483c4-6025-47f1-a691-8aa74b9ecca6" xlink:href="pacb-20230331.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c95ecb9a-eb27-4fac-856b-9c46ecf71815" xlink:to="loc_pacb_EquityIncentivePlan2020Member_d14483c4-6025-47f1-a691-8aa74b9ecca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_aff4b342-623d-4a0a-a994-0cdb5ffd9b6e" xlink:href="pacb-20230331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c95ecb9a-eb27-4fac-856b-9c46ecf71815" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_aff4b342-623d-4a0a-a994-0cdb5ffd9b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fc0c7142-b915-47bb-b41e-ce164455c22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fc0c7142-b915-47bb-b41e-ce164455c22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdb40a4b-a6c2-4613-8c26-086ecf836a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc0c7142-b915-47bb-b41e-ce164455c22f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdb40a4b-a6c2-4613-8c26-086ecf836a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember_a1be7ae5-b7e1-416c-9c02-0387d8c689b0" xlink:href="pacb-20230331.xsd#pacb_ShelfOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdb40a4b-a6c2-4613-8c26-086ecf836a73" xlink:to="loc_pacb_ShelfOfferingMember_a1be7ae5-b7e1-416c-9c02-0387d8c689b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6911e6bc-6145-4a4a-9be6-06c22e33b93a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares_9eae216b-9aec-44d3-943e-9b582b9f32db" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_PublicOfferingShares_9eae216b-9aec-44d3-943e-9b582b9f32db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_33ba1c5f-a081-4e9b-9f68-6d8036224fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_33ba1c5f-a081-4e9b-9f68-6d8036224fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum_e13fa700-0011-4d9c-bb58-95c4f5a44442" xlink:href="pacb-20230331.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_OfferingShareAmountMaximum_e13fa700-0011-4d9c-bb58-95c4f5a44442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_934a5e24-665b-4673-8921-9a4a42a2e900" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_934a5e24-665b-4673-8921-9a4a42a2e900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_2fa8178e-08f1-4681-993b-7e1d62080cce" xlink:href="pacb-20230331.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_2fa8178e-08f1-4681-993b-7e1d62080cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eee46471-ebe8-4fa0-be12-e675033381ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eee46471-ebe8-4fa0-be12-e675033381ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_7469342f-57c1-4502-9ab2-c94dcf5d3d32" xlink:href="pacb-20230331.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_7469342f-57c1-4502-9ab2-c94dcf5d3d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_ddf4e3bc-930d-4bb2-a134-44c5cf4d105f" xlink:href="pacb-20230331.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_ddf4e3bc-930d-4bb2-a134-44c5cf4d105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_eb509944-4f4b-49c2-bb42-1803f95dcb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_eb509944-4f4b-49c2-bb42-1803f95dcb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f91f8306-0be1-4308-85fc-b3689d7539a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f91f8306-0be1-4308-85fc-b3689d7539a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_012ab02b-7641-41a6-9680-a03ec058b0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_012ab02b-7641-41a6-9680-a03ec058b0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d1347611-6d1a-4119-abb4-c82164591888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d1347611-6d1a-4119-abb4-c82164591888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_95c88b3a-5353-458d-b69e-1e1acb497ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_390f0dee-e356-441e-9573-b8941687c941" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_95c88b3a-5353-458d-b69e-1e1acb497ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_accf96d2-55ee-4161-9005-6095adce0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74104d4f-ae8b-4520-81ec-00302aae1a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_accf96d2-55ee-4161-9005-6095adce0e16" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74104d4f-ae8b-4520-81ec-00302aae1a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73f6b9b8-e464-4783-b307-5071ee69e691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74104d4f-ae8b-4520-81ec-00302aae1a59" xlink:to="loc_us-gaap_AwardTypeAxis_73f6b9b8-e464-4783-b307-5071ee69e691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00c82c47-bf14-495b-bd48-afebf5f75bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_73f6b9b8-e464-4783-b307-5071ee69e691" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00c82c47-bf14-495b-bd48-afebf5f75bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_44f6f963-d014-4e13-9a99-5e7b9fa1267e" xlink:href="pacb-20230331.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00c82c47-bf14-495b-bd48-afebf5f75bfa" xlink:to="loc_pacb_TimeBasedStockOptionMember_44f6f963-d014-4e13-9a99-5e7b9fa1267e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_871eea9b-331f-4484-aa46-abe283072a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74104d4f-ae8b-4520-81ec-00302aae1a59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_871eea9b-331f-4484-aa46-abe283072a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_871eea9b-331f-4484-aa46-abe283072a08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75add0df-a9f1-4ebd-823e-110c8fd8d812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75add0df-a9f1-4ebd-823e-110c8fd8d812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0d0a88b0-6fe7-4723-9900-bc7e79d6a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0d0a88b0-6fe7-4723-9900-bc7e79d6a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77d97da8-4f66-41cc-b6f3-73d590cfe6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77d97da8-4f66-41cc-b6f3-73d590cfe6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_145529a1-e491-4203-b55d-3f4c8d0d5616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_145529a1-e491-4203-b55d-3f4c8d0d5616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d3c66f0-94db-4f62-9f3e-08b5c09d0f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_da397af7-e01e-4571-8e08-b58692d55703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d3c66f0-94db-4f62-9f3e-08b5c09d0f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_871eea9b-331f-4484-aa46-abe283072a08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7739bade-f32c-4f99-919f-410ec6334a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7739bade-f32c-4f99-919f-410ec6334a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bdf1fdc3-039d-4372-9b5b-b3605c59eeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bdf1fdc3-039d-4372-9b5b-b3605c59eeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e3a2224-dcec-42e8-90ce-c43c3c872b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7e3a2224-dcec-42e8-90ce-c43c3c872b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72425018-ae85-4d0c-85db-f76e8f399d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72425018-ae85-4d0c-85db-f76e8f399d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e5d24203-2f62-4830-bfb3-20bfc78cd871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4fac2532-95ee-41fa-a2f3-049e063156ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e5d24203-2f62-4830-bfb3-20bfc78cd871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7592f947-3a60-4426-a3dc-0b1a81d631e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_f145c762-9357-40f4-babf-5c53da9485f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7592f947-3a60-4426-a3dc-0b1a81d631e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_f145c762-9357-40f4-babf-5c53da9485f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e139c2ae-096e-4b41-a3c7-85799eaaea0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_f145c762-9357-40f4-babf-5c53da9485f0" xlink:to="loc_us-gaap_AwardTypeAxis_e139c2ae-096e-4b41-a3c7-85799eaaea0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b813978-8c72-4b00-8cad-7523ac1d2b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e139c2ae-096e-4b41-a3c7-85799eaaea0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b813978-8c72-4b00-8cad-7523ac1d2b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_75ed6de9-4537-42a2-930d-fef672ab727a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b813978-8c72-4b00-8cad-7523ac1d2b8d" xlink:to="loc_us-gaap_PerformanceSharesMember_75ed6de9-4537-42a2-930d-fef672ab727a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d48378a0-3a5f-479e-bd91-250da3615820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_f145c762-9357-40f4-babf-5c53da9485f0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d48378a0-3a5f-479e-bd91-250da3615820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d48378a0-3a5f-479e-bd91-250da3615820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d568af0d-a230-475a-8685-3332bd8b5817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d568af0d-a230-475a-8685-3332bd8b5817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_806dbe2a-a6f0-4f82-87d9-d0391d185572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_806dbe2a-a6f0-4f82-87d9-d0391d185572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d13279e0-8807-4683-84fb-db668ca08104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d13279e0-8807-4683-84fb-db668ca08104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_23b96ac6-7e9d-4780-8f91-ad089c66c4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_23b96ac6-7e9d-4780-8f91-ad089c66c4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_47ff3e71-8a03-4500-8692-d1e9b70b10ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0196ac16-c6e3-4af5-bc70-9a70ff1764bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_47ff3e71-8a03-4500-8692-d1e9b70b10ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_d48378a0-3a5f-479e-bd91-250da3615820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1701daa2-878c-43a3-8eb2-a84153d7765e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1701daa2-878c-43a3-8eb2-a84153d7765e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40203ce5-6e1d-44b1-8ea3-60b81e5bfde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40203ce5-6e1d-44b1-8ea3-60b81e5bfde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1456e649-965d-4f4c-801b-6fe4db5cfa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1456e649-965d-4f4c-801b-6fe4db5cfa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_eafe7f3a-b220-49a5-bd72-d0d9e3403ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_eafe7f3a-b220-49a5-bd72-d0d9e3403ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_828fc4ed-42dd-452d-8172-15d7f7ef505a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18561610-e0f6-46dc-aa0c-d7c200abb33a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_828fc4ed-42dd-452d-8172-15d7f7ef505a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96483f87-9303-4033-a1c1-f93b274e239d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_316d6be6-960d-42d4-8e9a-02844f50a3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96483f87-9303-4033-a1c1-f93b274e239d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_316d6be6-960d-42d4-8e9a-02844f50a3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5fe1969f-267a-4a43-91c5-7fdf2b3409ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_316d6be6-960d-42d4-8e9a-02844f50a3b4" xlink:to="loc_us-gaap_AwardTypeAxis_5fe1969f-267a-4a43-91c5-7fdf2b3409ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0cc365-d8b2-4993-a332-72dfc7ff78fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5fe1969f-267a-4a43-91c5-7fdf2b3409ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0cc365-d8b2-4993-a332-72dfc7ff78fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_c37077d0-003d-40cd-a4ac-008084271395" xlink:href="pacb-20230331.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0cc365-d8b2-4993-a332-72dfc7ff78fd" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_c37077d0-003d-40cd-a4ac-008084271395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_815e56cd-fb9e-4089-aa16-4bfb325fe790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df0cc365-d8b2-4993-a332-72dfc7ff78fd" xlink:to="loc_us-gaap_PerformanceSharesMember_815e56cd-fb9e-4089-aa16-4bfb325fe790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7867f43-5264-4c05-861d-579171e2b6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_316d6be6-960d-42d4-8e9a-02844f50a3b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7867f43-5264-4c05-861d-579171e2b6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7867f43-5264-4c05-861d-579171e2b6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_376c906f-3df9-4b34-b64b-2c6e82579fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_376c906f-3df9-4b34-b64b-2c6e82579fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bdf8bd8-cf08-4a8d-a033-45aef6c63209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bdf8bd8-cf08-4a8d-a033-45aef6c63209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_968ecdaa-2222-43b3-989f-cf164b7adc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_968ecdaa-2222-43b3-989f-cf164b7adc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_56e6e884-2662-4618-8bbf-27497a5d2224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_56e6e884-2662-4618-8bbf-27497a5d2224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ecaac716-a4d7-49b4-84e7-94fdbe3744db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_6b8a0af7-6fb1-4785-815f-c596d3954e57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ecaac716-a4d7-49b4-84e7-94fdbe3744db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f7867f43-5264-4c05-861d-579171e2b6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb0a36e9-2e1c-464a-957f-61d5c5354bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb0a36e9-2e1c-464a-957f-61d5c5354bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a50aba96-bafd-408c-8480-167d6c879ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a50aba96-bafd-408c-8480-167d6c879ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0d9dd993-0194-4914-b9ca-7c045d4244b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0d9dd993-0194-4914-b9ca-7c045d4244b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2794b2b5-a526-4f62-8341-0d59c598cee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2794b2b5-a526-4f62-8341-0d59c598cee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ea3f9321-4141-474d-9f2a-1f4d7763f8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1f33285f-92fd-4e0e-af64-81b0ffec6a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ea3f9321-4141-474d-9f2a-1f4d7763f8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_602f2590-747f-4e9a-afea-1e960a44e2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91539f19-e40e-4daa-b252-efc34e53c74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_602f2590-747f-4e9a-afea-1e960a44e2c0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91539f19-e40e-4daa-b252-efc34e53c74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_994954b4-cec6-416d-86b9-62acab968578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91539f19-e40e-4daa-b252-efc34e53c74b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_994954b4-cec6-416d-86b9-62acab968578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_994954b4-cec6-416d-86b9-62acab968578" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_1d77b10a-f1eb-4747-95e1-916e68d53218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:to="loc_us-gaap_CostOfSalesMember_1d77b10a-f1eb-4747-95e1-916e68d53218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29d2ae17-e3b2-44b1-bc16-f098b8bdcfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29d2ae17-e3b2-44b1-bc16-f098b8bdcfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ad5b7b4-940c-4cbf-9f65-5478030e306b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a64e75e6-b9c7-41b8-8f8a-454c826b7200" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ad5b7b4-940c-4cbf-9f65-5478030e306b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d67598d7-9b3c-4d28-af42-d1e1e7f507c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_91539f19-e40e-4daa-b252-efc34e53c74b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d67598d7-9b3c-4d28-af42-d1e1e7f507c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e64f4fc-0c1e-478b-b99d-7386eb195e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d67598d7-9b3c-4d28-af42-d1e1e7f507c4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e64f4fc-0c1e-478b-b99d-7386eb195e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89b37f8c-d19a-409c-950e-66f1d8808184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89b37f8c-d19a-409c-950e-66f1d8808184" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ec28bf0f-afda-4c76-8e5b-152b0a80e812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:to="loc_us-gaap_AwardTypeAxis_ec28bf0f-afda-4c76-8e5b-152b0a80e812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47bc572e-093d-43dc-abeb-699445bb0191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ec28bf0f-afda-4c76-8e5b-152b0a80e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47bc572e-093d-43dc-abeb-699445bb0191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_ae8a2a79-37cd-4c17-960f-2b6098aa5295" xlink:href="pacb-20230331.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47bc572e-093d-43dc-abeb-699445bb0191" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_ae8a2a79-37cd-4c17-960f-2b6098aa5295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e2d14e1c-e6a9-410b-9441-24d5c8d21db7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:to="loc_srt_RangeAxis_e2d14e1c-e6a9-410b-9441-24d5c8d21db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6230a23b-c1ba-4fc4-86eb-954fc31ee136" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e2d14e1c-e6a9-410b-9441-24d5c8d21db7" xlink:to="loc_srt_RangeMember_6230a23b-c1ba-4fc4-86eb-954fc31ee136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_455c46cd-48c4-4c50-8fad-122c2daa559d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6230a23b-c1ba-4fc4-86eb-954fc31ee136" xlink:to="loc_srt_MinimumMember_455c46cd-48c4-4c50-8fad-122c2daa559d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c749948a-efb0-4ed2-ac21-94dbe85bb54b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6230a23b-c1ba-4fc4-86eb-954fc31ee136" xlink:to="loc_srt_MaximumMember_c749948a-efb0-4ed2-ac21-94dbe85bb54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06742f03-5b04-493d-9dd8-18698b796457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11537133-6c41-40ff-9794-9ffe62d5ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11537133-6c41-40ff-9794-9ffe62d5ae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_567c8b6d-300c-4137-84e9-3a72c41da464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_567c8b6d-300c-4137-84e9-3a72c41da464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_877dd10a-b594-43b6-9f2d-13b7911be462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_877dd10a-b594-43b6-9f2d-13b7911be462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dfda2e45-c729-4ca2-8725-bb3d081c5b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dfda2e45-c729-4ca2-8725-bb3d081c5b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2deec0b3-f8c7-4d32-b824-25807583bb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_996bed7e-86ba-4392-a4da-65ed767f5403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2deec0b3-f8c7-4d32-b824-25807583bb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21848803-7694-45ce-bca0-3dc74482d58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21848803-7694-45ce-bca0-3dc74482d58f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f06e5207-3475-4e64-a8f0-22d8c0b34115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f06e5207-3475-4e64-a8f0-22d8c0b34115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_db4af526-031a-4d95-b47a-806991aac9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f06e5207-3475-4e64-a8f0-22d8c0b34115" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_db4af526-031a-4d95-b47a-806991aac9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_0caa4d33-101b-4989-8167-b6f96d8a3a71" xlink:href="pacb-20230331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_db4af526-031a-4d95-b47a-806991aac9d3" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_0caa4d33-101b-4989-8167-b6f96d8a3a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b917b168-64f8-4a09-b6f0-0c65e403a247" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:to="loc_srt_RangeAxis_b917b168-64f8-4a09-b6f0-0c65e403a247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e498ec85-a7e3-4817-992e-ba515032416d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b917b168-64f8-4a09-b6f0-0c65e403a247" xlink:to="loc_srt_RangeMember_e498ec85-a7e3-4817-992e-ba515032416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f2921ba9-eec5-4448-8914-a141d0bc04dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e498ec85-a7e3-4817-992e-ba515032416d" xlink:to="loc_srt_MinimumMember_f2921ba9-eec5-4448-8914-a141d0bc04dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a8158e1c-4ad5-49ed-8130-b48da42b024e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e498ec85-a7e3-4817-992e-ba515032416d" xlink:to="loc_srt_MaximumMember_a8158e1c-4ad5-49ed-8130-b48da42b024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eaad28af-01a3-493d-8e59-4e00cfff8178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f43b2412-c0d7-4d1f-842b-2e174e9c191b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f43b2412-c0d7-4d1f-842b-2e174e9c191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4bcb6272-8dba-455c-a1d9-8668dda95f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4bcb6272-8dba-455c-a1d9-8668dda95f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_76cdb5dd-4a56-4d18-97b6-516265ccbe72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_76cdb5dd-4a56-4d18-97b6-516265ccbe72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a213179b-f311-4f68-ace2-df6a60d9eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a213179b-f311-4f68-ace2-df6a60d9eb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6d364e46-78a7-458d-ab2c-bd38234c8cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6d364e46-78a7-458d-ab2c-bd38234c8cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9dc5487f-610e-4341-93b1-f43674aecb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9dc5487f-610e-4341-93b1-f43674aecb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ae3facf-f283-4700-bfb1-ad5212083a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61c24ce9-aeef-4763-a953-7bb0ffc33c09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7ae3facf-f283-4700-bfb1-ad5212083a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_47036070-4fd8-42af-97db-3a04aac36b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_86eacb44-0ada-4710-a6a4-6287eb62e8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_47036070-4fd8-42af-97db-3a04aac36b2a" xlink:to="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_86eacb44-0ada-4710-a6a4-6287eb62e8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_6b9015fb-a0e4-4a98-9b3c-9f0fba2b1c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_86eacb44-0ada-4710-a6a4-6287eb62e8e9" xlink:to="loc_us-gaap_NetIncomeLossAbstract_6b9015fb-a0e4-4a98-9b3c-9f0fba2b1c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23bdbf3e-1f20-4004-9e6b-4c32fdef8a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6b9015fb-a0e4-4a98-9b3c-9f0fba2b1c4c" xlink:to="loc_us-gaap_NetIncomeLoss_23bdbf3e-1f20-4004-9e6b-4c32fdef8a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1c533f6-64f0-46d9-a813-fa4426ca0662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_86eacb44-0ada-4710-a6a4-6287eb62e8e9" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1c533f6-64f0-46d9-a813-fa4426ca0662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_11585108-1d80-4b8e-a30c-551fd26b0c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1c533f6-64f0-46d9-a813-fa4426ca0662" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_11585108-1d80-4b8e-a30c-551fd26b0c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8fe15ab4-273a-4093-bb25-62bec04e7add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_11585108-1d80-4b8e-a30c-551fd26b0c80" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8fe15ab4-273a-4093-bb25-62bec04e7add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_606e3173-416e-42eb-bc8b-6d108eb33c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_11585108-1d80-4b8e-a30c-551fd26b0c80" xlink:to="loc_us-gaap_EarningsPerShareBasic_606e3173-416e-42eb-bc8b-6d108eb33c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_fc90888e-4f9e-4527-8fe4-98585b510919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1c533f6-64f0-46d9-a813-fa4426ca0662" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_fc90888e-4f9e-4527-8fe4-98585b510919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a835b1a8-9b29-421d-9e8c-bdf40235481c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_fc90888e-4f9e-4527-8fe4-98585b510919" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a835b1a8-9b29-421d-9e8c-bdf40235481c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0ee03a5d-f888-4da9-a8ba-572b3666881e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_b1c533f6-64f0-46d9-a813-fa4426ca0662" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0ee03a5d-f888-4da9-a8ba-572b3666881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a5e48a9d-d371-4cea-ac4c-94ba0c8191bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ef4b39b0-2821-4a91-ab4e-7cdc61610258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5e48a9d-d371-4cea-ac4c-94ba0c8191bd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ef4b39b0-2821-4a91-ab4e-7cdc61610258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2eb8df3b-f103-4992-854a-3792ff497e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ef4b39b0-2821-4a91-ab4e-7cdc61610258" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2eb8df3b-f103-4992-854a-3792ff497e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a8a6d5d-8073-43fe-869e-36a15498f206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2eb8df3b-f103-4992-854a-3792ff497e0b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a8a6d5d-8073-43fe-869e-36a15498f206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_8f1fce8f-0155-4562-85ff-7337c405f361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a8a6d5d-8073-43fe-869e-36a15498f206" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_8f1fce8f-0155-4562-85ff-7337c405f361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_0783a799-54de-421f-9491-c31131eb46eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2a8a6d5d-8073-43fe-869e-36a15498f206" xlink:to="loc_us-gaap_StockCompensationPlanMember_0783a799-54de-421f-9491-c31131eb46eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0b12b7d-4012-448a-8605-f2aebf61a9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ef4b39b0-2821-4a91-ab4e-7cdc61610258" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0b12b7d-4012-448a-8605-f2aebf61a9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f2585a6-d741-4a67-b487-f51669522188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0b12b7d-4012-448a-8605-f2aebf61a9b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f2585a6-d741-4a67-b487-f51669522188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#REVENUEScheduleofRevenuebyGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eb2b197e-172a-4326-a089-e51d3c78eb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f664b19c-d259-40d9-9343-02dd80204b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eb2b197e-172a-4326-a089-e51d3c78eb7b" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f664b19c-d259-40d9-9343-02dd80204b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4fbd1aef-5baf-4172-9bdf-ad14924bdc45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f664b19c-d259-40d9-9343-02dd80204b3f" xlink:to="loc_srt_StatementGeographicalAxis_4fbd1aef-5baf-4172-9bdf-ad14924bdc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4fbd1aef-5baf-4172-9bdf-ad14924bdc45" xlink:to="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_a4e5df67-4236-4cf1-be02-462175d675d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:to="loc_srt_AmericasMember_a4e5df67-4236-4cf1-be02-462175d675d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_a3f4726a-37a8-4b55-a2a5-99d5adfe41a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:to="loc_us-gaap_EMEAMember_a3f4726a-37a8-4b55-a2a5-99d5adfe41a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_94e4dc6f-2436-4983-be05-451fdf4ee522" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8eb48c4e-3057-4324-a469-c2d233c8d810" xlink:to="loc_srt_AsiaPacificMember_94e4dc6f-2436-4983-be05-451fdf4ee522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_868bf935-6486-44b5-ab21-7094225d58c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f664b19c-d259-40d9-9343-02dd80204b3f" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_868bf935-6486-44b5-ab21-7094225d58c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20c60b2a-79e2-4d85-9892-4d8f800a3d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_868bf935-6486-44b5-ab21-7094225d58c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20c60b2a-79e2-4d85-9892-4d8f800a3d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20230331.xsd#REVENUESummaryofRevenuebyCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_30be751e-d763-44da-ac42-c0c6a737ba5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e51abd54-d416-46a0-b975-df15f5831900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_30be751e-d763-44da-ac42-c0c6a737ba5a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e51abd54-d416-46a0-b975-df15f5831900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_01ff6037-fd71-4c9b-a85f-f9fe3fda7660" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e51abd54-d416-46a0-b975-df15f5831900" xlink:to="loc_srt_ProductOrServiceAxis_01ff6037-fd71-4c9b-a85f-f9fe3fda7660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_01ff6037-fd71-4c9b-a85f-f9fe3fda7660" xlink:to="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_1a12a57d-9a0b-4296-8bbc-40d46062badc" xlink:href="pacb-20230331.xsd#pacb_InstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:to="loc_pacb_InstrumentMember_1a12a57d-9a0b-4296-8bbc-40d46062badc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_44e3ab99-bad4-4965-8a42-26bc09a11fbb" xlink:href="pacb-20230331.xsd#pacb_ConsumableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:to="loc_pacb_ConsumableMember_44e3ab99-bad4-4965-8a42-26bc09a11fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0e1cc631-0650-45a1-ab85-de9ecb84e68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:to="loc_us-gaap_ProductMember_0e1cc631-0650-45a1-ab85-de9ecb84e68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_83bb8e96-4842-41e4-9b45-a004912d5cbe" xlink:href="pacb-20230331.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56bc71cd-7c5b-488f-8fa7-e9d31754490d" xlink:to="loc_pacb_ServiceAndOtherMember_83bb8e96-4842-41e4-9b45-a004912d5cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_30194ced-4c6d-4b9b-b301-2c4975b4e5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e51abd54-d416-46a0-b975-df15f5831900" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_30194ced-4c6d-4b9b-b301-2c4975b4e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_efe3fd14-ffcf-4b0b-80b9-eaf5aa7f5f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_30194ced-4c6d-4b9b-b301-2c4975b4e5cd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_efe3fd14-ffcf-4b0b-80b9-eaf5aa7f5f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pacb-20230331_g1.jpg
<TEXT>
begin 644 pacb-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ 08# 2(  A$! Q$!_\0
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M^UZAYC//M."ZA& 53V)R<$$@=!]%? 7XW67QP\&C5X+4Z??02_9[RS9MWE2
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MHYSJ\(_4U]'@9<F&YNUS]KX6K/#Y![=*[CS/[CD?^%5^-?\ H3_$'_@KG_\
MB*?'\*/&\KK''X,\0/*YPJKI<Y8_0;:_=98UQ\J@#Z4[RQZ#\JX?[4E_*?,?
M\1 Q%M*$?O9^0GPC_84^*'Q*O(&U#2)/"&C,5,E]JZ%) O&0D!^<MCH"%!QC
M(K]0?@W\(- ^"/@:R\,^'X62WAS)-/)@RW$S8WR.1U8X_   <"NYVX]J.%&.
MU<&(Q=3$:/1'QN<<0XO.+1K/E@NB/Q)_:;UB;6_VA/B+<3%G=-<NK?+==D4A
MB4?]\H!^%?=G_!,3PG86'P;UK7TC5M2U'57ADFQ\WE1(FQ/IEG/_  *OC?\
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CJKDI:(^!XBX\K9G2>%P,>2#W;W?^2!!A<44H&**\ _)3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677738150192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pacific Biosciences of California, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1590339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1305 O&#8217;Brien Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">521-8000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PACB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,891,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001299130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737659920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 353,834<span></span>
</td>
<td class="nump">$ 325,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">521,058<span></span>
</td>
<td class="nump">447,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">29,589<span></span>
</td>
<td class="nump">18,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">61,955<span></span>
</td>
<td class="nump">50,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,375<span></span>
</td>
<td class="nump">10,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">981,111<span></span>
</td>
<td class="nump">852,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">40,833<span></span>
</td>
<td class="nump">41,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">38,247<span></span>
</td>
<td class="nump">39,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">2,922<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">410,011<span></span>
</td>
<td class="nump">410,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">409,974<span></span>
</td>
<td class="nump">409,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">13,319<span></span>
</td>
<td class="nump">10,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,896,417<span></span>
</td>
<td class="nump">1,767,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,390<span></span>
</td>
<td class="nump">12,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">19,380<span></span>
</td>
<td class="nump">32,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">30,866<span></span>
</td>
<td class="nump">30,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">9,018<span></span>
</td>
<td class="nump">8,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">4,670<span></span>
</td>
<td class="nump">7,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability, current</a></td>
<td class="nump">184,350<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">265,674<span></span>
</td>
<td class="nump">263,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">1,849<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">38,969<span></span>
</td>
<td class="nump">41,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="nump">896,839<span></span>
</td>
<td class="nump">896,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, non-current</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,204,300<span></span>
</td>
<td class="nump">1,204,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Authorized 50,000 shares; No shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized 1,000,000 shares; issued and outstanding 249,803 and 226,505 shares at March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,314,146<span></span>
</td>
<td class="nump">2,099,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,924)<span></span>
</td>
<td class="num">(4,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,620,355)<span></span>
</td>
<td class="num">(1,532,340)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">692,117<span></span>
</td>
<td class="nump">562,904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,896,417<span></span>
</td>
<td class="nump">$ 1,767,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677738069952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">249,803,000<span></span>
</td>
<td class="nump">226,505,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">249,803,000<span></span>
</td>
<td class="nump">226,505,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737026880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 38,900<span></span>
</td>
<td class="nump">$ 33,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangible assets</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">29,139<span></span>
</td>
<td class="nump">19,018<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">9,761<span></span>
</td>
<td class="nump">14,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">48,939<span></span>
</td>
<td class="nump">52,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">39,818<span></span>
</td>
<td class="nump">39,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="nump">12,256<span></span>
</td>
<td class="num">(1,063)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">101,013<span></span>
</td>
<td class="nump">91,678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(91,252)<span></span>
</td>
<td class="num">(77,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,630)<span></span>
</td>
<td class="num">(3,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">6,867<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before expense (benefit) from income taxes</a></td>
<td class="num">(88,015)<span></span>
</td>
<td class="num">(81,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Expense (benefit) from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,015)<span></span>
</td>
<td class="num">(81,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">2,841<span></span>
</td>
<td class="num">(2,998)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (85,174)<span></span>
</td>
<td class="num">$ (84,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeLossPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding used in calculating net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">242,032<span></span>
</td>
<td class="nump">222,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">242,032<span></span>
</td>
<td class="nump">222,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 34,654<span></span>
</td>
<td class="nump">$ 28,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">25,164<span></span>
</td>
<td class="nump">14,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">$ 3,792<span></span>
</td>
<td class="nump">$ 4,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677735943712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 790,987<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 2,009,945<span></span>
</td>
<td class="num">$ (1,087)<span></span>
</td>
<td class="num">$ (1,218,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(2,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">5,592<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">5,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">22,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 734,578<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">2,038,030<span></span>
</td>
<td class="num">(4,085)<span></span>
</td>
<td class="num">(1,299,591)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">226,505<span></span>
</td>
<td class="nump">226,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 562,904<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">2,099,782<span></span>
</td>
<td class="num">(4,765)<span></span>
</td>
<td class="num">(1,532,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">2,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs</a></td>
<td class="nump">189,200<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">189,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">7,235<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">7,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 17,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">249,803<span></span>
</td>
<td class="nump">249,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 692,117<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 2,314,146<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="num">$ (1,620,355)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737854832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,015)<span></span>
</td>
<td class="num">$ (81,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">2,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and financing costs</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">17,952<span></span>
</td>
<td class="nump">22,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accretion of discount and amortization of premium on marketable securities, net</a></td>
<td class="num">(2,155)<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="nump">12,256<span></span>
</td>
<td class="num">(1,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">3,521<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposition of equipment</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(10,803)<span></span>
</td>
<td class="num">(3,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(13,319)<span></span>
</td>
<td class="num">(6,661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(6,888)<span></span>
</td>
<td class="num">(1,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">5,068<span></span>
</td>
<td class="nump">6,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(13,186)<span></span>
</td>
<td class="num">(17,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">1,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,969)<span></span>
</td>
<td class="num">(1,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(2,455)<span></span>
</td>
<td class="num">(2,512)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(94,691)<span></span>
</td>
<td class="num">(79,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(3,721)<span></span>
</td>
<td class="num">(3,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(233,291)<span></span>
</td>
<td class="num">(76,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">163,864<span></span>
</td>
<td class="nump">122,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(72,553)<span></span>
</td>
<td class="nump">42,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under equity offerings, net of issuance costs</a></td>
<td class="nump">189,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock from equity plans</a></td>
<td class="nump">7,235<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Notes payable principal payoff</a></td>
<td class="num">(446)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">195,989<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">28,745<span></span>
</td>
<td class="num">(31,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">328,311<span></span>
</td>
<td class="nump">465,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">357,056<span></span>
</td>
<td class="nump">434,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">353,834<span></span>
</td>
<td class="nump">428,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash at end of period</a></td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">5,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">$ 357,056<span></span>
</td>
<td class="nump">$ 434,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677738033600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our existing HiFi long-read sequencing technology and our emerging short-read Sequencing by Binding (SBB</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) technology. Our products address solutions across a broad set of applications including human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2022 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to current period presentation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2023. Actual results could differ materially from these estimates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash and Investments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration and Other Risks </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, no customer represented 10% or greater of our total revenue during the period. For the three months ended March&#160;31, 2022, two customers accounted for approximately 14% and 11%, respectively, of total revenue during the period. No other customers exceeded 10% during those periods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, 49% of our accounts receivable were from domestic customers, compared to 57% as of December&#160;31, 2022. As of March&#160;31, 2023, no customer represented 10% or greater of our accounts receivable, while one customer represented approximately 10% of our net accounts receivable as of December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677742287376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">103,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">353,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">137,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">187,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">325,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">109,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">109,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">87,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">87,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">323,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">323,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">270,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">270,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">521,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">521,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">447,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">447,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">106,975&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">771,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">878,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">140,858&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">634,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">775,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration, which was incurred in connection with the acquisition of Omniome, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability by discounting the probability-weighted outcomes to present value using an estimate of our borrowing rate and the risk-free rate. The potential outcomes of milestone achievement dates are within the period from June&#160;30, 2023 to June&#160;30, 2025. A decrease in the probability of an earlier scenario within this range would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- and B credit rating, which ranges from 9.3% to 10.2%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as change in fair value of contingent consideration in the Condensed Consolidated Statement of Operations and Comprehensive Loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents and investments (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">353,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">353,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">323,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,813)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">521,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">876,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,840)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">874,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">127,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">127,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">274,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">270,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451,939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,720)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">447,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">777,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">772,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">634,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">771,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677743806992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text">BALANCE SHEET COMPONENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include acquired in-process research and development ("IPR&amp;D") of $400 million as a result of the Omniome acquisition in September 2021. The IPR&amp;D will remain on our Consolidated Balance Sheet as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development activities. During the development period following the acquisition, IPR&amp;D will not be amortized, but instead will be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. Upon completion of the development, we will begin to amortize the asset over the life of the product, or record an impairment charge if the asset is determined to be impaired.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, definite-lived intangible assets included the following (in thousands, except years): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,294)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,245&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review definite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2022, noting no impairment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, we entered into an Amended and Restated Development and Commercialization Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Invitae Corporation (&#8220;Invitae&#8221;). During the three months ended March&#160;31, 2023, Invitae did not purchase any of the instruments or consumables under the terms of the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated Agreement. As of March&#160;31, 2023 and December&#160;31, 2022, $21.4 million of deferred revenue, current, is recorded on the Condensed Consolidated Balance Sheet relating to all future performance obligations under the Amended and Restated Agreement. Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3 &#8211; Invitae Collaboration</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had a total of $32.7&#160;million of deferred revenue, $30.9&#160;million of which was recorded as deferred revenue, current, and primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae. The deferred revenue, non-current balance of $1.8&#160;million primarily relates to deferred service contract revenues and is scheduled to be recognized in the next 5 years. Revenue recorded in the three months ended March&#160;31, 2023 includes $3.5&#160;million of previously deferred revenue that was included in deferred revenue as of December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. There were no material changes in estimates for the periods presented below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term loans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Omniome, we acquired $1.3 million in short-term debt and $3.0 million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#8217;s purchases of equipment, which serves as collateral. Each term loan has a term of 43 months and bears a fixed interest rate of approximately 17% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month and before the 43</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month after the commencement date, is 4% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the carrying value of term loans outstanding was $1.9&#160;million. The related long-term portion of $0.2&#160;million was recorded as part of other liabilities, non-current and the short-term portion of $1.7&#160;million was recorded as part of other liabilities, current on the Condensed Consolidated Balance Sheet. The interest expense was $0.1&#160;million for the three months ended March 31, 2023, which was included as part of interest expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss.</span></div><div><span style="font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"/></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future principal payments on the term loans (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677742216144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE SENIOR NOTES</a></td>
<td class="text">CONVERTIBLE SENIOR NOTES On February&#160;9, 2021, we entered into an investment agreement (the &#8220;Investment Agreement&#8221;) with SB Northstar LP (the &#8220;Purchaser&#8221;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $900 million in aggregate principal amount of our 1.5% Convertible Senior Notes (the &#8220;Notes&#8221;). The Notes were issued on February&#160;16, 2021.<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are governed by an indenture (the &#8220;Indenture&#8221;) between the Company and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of 1.5% per annum. Interest on the Notes is payable semi-annually in arrears on February 15 and August 15 and commenced on August 15, 2021. The Notes will mature on February&#160;15, 2028, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the Notes (which is equal to an initial conversion price of $43.50 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after February 20, 2026, the Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges (a &#8220;Fundamental Change&#8221;), the holders of the Notes may require that we repurchase all or part of the principal amount of the Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the Notes at a rate equal to (i) 0.25% per annum of the principal amount of the Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the Notes shall be subject to acceleration as provided for in the Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the Notes were not issued at a premium; therefore, the Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the Notes of approximately $4.5 million, which were recorded as debt issuance cost and are presented as a reduction to the Notes on our Consolidated Balance Sheets and are </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortized to interest expense using the effective interest method over the term of the Notes, resulting in an effective interest rate of 1.6%. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the Notes is recorded as convertible senior notes, net, non-current in the Condensed Consolidated Balance Sheets as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">900,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">900,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, interest expense for the Notes was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>As of March&#160;31, 2023, the estimated fair value (Level 2) of the Notes was $693.0 million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677742230640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements, primarily relating to our corporate offices. See </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8 &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Leases&#8221;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for information regarding the Company&#8217;s maturity of lease liabilities under its lease agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idd15d706814f4821992e3c53513cc1e0_91" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings, in  Part II, Item 1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation </span></div>expense amounts. No additional liability associated with such indemnification obligations has been recorded as of March&#160;31, 2023 and December&#160;31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2127163<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2127197<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677740883024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Underwritten Public Equity Offering</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into an underwriting agreement, relating to the public offering of 17.5 million shares of our common stock, $0.001 par value per share, at a price to the public of $10.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2.6 million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold 20.1 million shares of our common stock. We paid a commission equal to 5.75% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $189.7&#160;million, excluding approximately $0.5&#160;million of offering expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information on the Company's underwritten public equity offerings and private placement of common stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had 12.8&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information on the Company's equity plans</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-based Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards (shares in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,618</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(250)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(362)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Stock Options</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for performance-based awards (shares in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (&#8220;RSU&#8221;) and Performance Stock Units ("PSU") </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We issue PSUs for which the number of shares issuable in the third year of the performance period based on performance relative to specified revenue targets and continued employment through the vesting period. The following table summarizes the time-based RSUs and PSUs activity (shares in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,535</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,640)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(465)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,771</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under our ESPP were 1,052,908 and 1,316,923 during the three months ended March&#160;31, 2023 and 2022, respectively. In February 2023, an additional 4.0&#160;million shares were reserved under the ESPP. As of March&#160;31, 2023, 12.9&#160;million shares of our common stock remain available for issuance under our ESPP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,952&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determining Fair Value</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, there were no employee stock options granted. The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.60</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.76%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6.66</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">97%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.89% &#8212; 5.20%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.60% &#8212; 1.31%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$5.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$5.42</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677742183760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHAREBasic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the convertible senior notes, using the if-converted method, and outstanding equity awards using the treasury stock method.       <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(88,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(81,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing basic net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">242,032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">222,289</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">242,032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">222,289</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,690</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,690</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,366</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,752</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Business Acquisitions </span>in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022, the contingently issuable shares would be due upon the achievement of a milestone.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677742151872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text">REVENUE<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows (in thousands): </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows (in thousands): </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,173&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677739168080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2022 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to current period presentation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2023. Actual results could differ materially from these estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents</a></td>
<td class="text">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677739491216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">103,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">353,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">137,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">187,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">325,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">109,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">109,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">87,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">87,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">323,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">323,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">270,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">270,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">521,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">521,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">447,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">447,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">106,975&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">771,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">878,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">140,858&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">634,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">775,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in the Estimated Fair Value of Contingent Consideration Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2023 were as follows (in thousands):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">172,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents and investments (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">353,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">353,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">323,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,813)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">521,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">876,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,840)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">874,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair<br/>Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">127,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">127,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">274,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">270,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451,939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,720)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">447,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">777,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">772,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">634,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">771,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677741130992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Definite-lived Intangible Assets from Business Acquisitions</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, definite-lived intangible assets included the following (in thousands, except years): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,294)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,245&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated Future Amortization Expense of Acquisition-Related Intangible Assets With Definite Lives</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Changes in Reserve for Product Warranties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Future Principal Payments, Fiscal Year Maturity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future principal payments on the term loans (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737642512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Net Carrying Amount</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the Notes is recorded as convertible senior notes, net, non-current in the Condensed Consolidated Balance Sheets as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">900,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">900,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, interest expense for the Notes was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Interest Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677739210960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards (shares in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,618</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(250)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(362)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for performance-based awards (shares in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Time-Based RSUs Activity</a></td>
<td class="text">The following table summarizes the time-based RSUs and PSUs activity (shares in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,535</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,341</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,640)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(465)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,771</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,952&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, there were no employee stock options granted. The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.60</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.76%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6.66</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Purchase Plan</a></td>
<td class="text">he fair value of shares to be issued under the ESPP was estimated using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">97%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.89% &#8212; 5.20%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.60% &#8212; 1.31%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$5.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$5.42</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677742100912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(88,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(81,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing basic net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">242,032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">222,289</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">242,032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">222,289</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,690</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,690</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,366</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,752</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677742290016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Location</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows (in thousands): </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenue by Category</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows (in thousands): </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,173&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677734285264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | One Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Two Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | One Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Domestic Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_DomesticCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_DomesticCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677736044672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 353,834<span></span>
</td>
<td class="nump">$ 325,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">521,058<span></span>
</td>
<td class="nump">447,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">2,922<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">878,114<span></span>
</td>
<td class="nump">775,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">184,350<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">184,350<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">109,873<span></span>
</td>
<td class="nump">127,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">87,381<span></span>
</td>
<td class="nump">49,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">323,804<span></span>
</td>
<td class="nump">270,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">103,753<span></span>
</td>
<td class="nump">137,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">2,922<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">106,975<span></span>
</td>
<td class="nump">140,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">250,081<span></span>
</td>
<td class="nump">187,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">521,058<span></span>
</td>
<td class="nump">447,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">771,139<span></span>
</td>
<td class="nump">634,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">109,873<span></span>
</td>
<td class="nump">127,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">87,381<span></span>
</td>
<td class="nump">49,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">323,804<span></span>
</td>
<td class="nump">270,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">184,350<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">184,350<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677739546448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Narrative (Details) - Measurement Input, Discount Rate<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">0.093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">0.102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_FinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_FinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677735899360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Changes in estimated fair value of contingent consideration (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 172,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in estimated fair value</a></td>
<td class="nump">12,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 184,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677734109200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 876,816<span></span>
</td>
<td class="nump">$ 777,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2,840)<span></span>
</td>
<td class="num">(4,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">874,892<span></span>
</td>
<td class="nump">772,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">2,922<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">353,837<span></span>
</td>
<td class="nump">325,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">353,834<span></span>
</td>
<td class="nump">325,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">522,979<span></span>
</td>
<td class="nump">451,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2,813)<span></span>
</td>
<td class="num">(4,720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">521,058<span></span>
</td>
<td class="nump">447,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">110,009<span></span>
</td>
<td class="nump">127,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">109,873<span></span>
</td>
<td class="nump">127,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">87,426<span></span>
</td>
<td class="nump">49,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(344)<span></span>
</td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">87,381<span></span>
</td>
<td class="nump">49,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">325,544<span></span>
</td>
<td class="nump">274,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2,316)<span></span>
</td>
<td class="num">(3,880)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 323,804<span></span>
</td>
<td class="nump">$ 270,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677738149872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 634,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Due after one year through five years</a></td>
<td class="nump">136,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 771,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737797824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">$ 30,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,498,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">$ 1,849,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,794,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StandardProductWarrantyPeriod', window );">Standard product warranty, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="nump">$ 3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_TermLoansMember', window );">Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Short- and long-term debt</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_TermLoansMember', window );">Term Loans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentTermLoanElectiveOption', window );">Debt instrument, term loan, elective option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_TermLoansMember', window );">Term Loans | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentTermLoanElectiveOption', window );">Debt instrument, term loan, elective option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">43 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_TermLoansMember', window );">Term Loans | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_TermLoansMember', window );">Term Loans | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">43 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfFeeToPrepayDebt', window );">Percentage of fee to prepay debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt, excluding current maturities</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Short term debt acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pacb_InvitaeCorporationMember', window );">Invitae Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Components [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentTermLoanElectiveOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term Loan, Elective Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentTermLoanElectiveOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfFeeToPrepayDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fee of the outstanding debt to prepay the debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfFeeToPrepayDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StandardProductWarrantyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standard Product Warranty, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StandardProductWarrantyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_InvitaeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_InvitaeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677735844400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Components of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Purchased materials</a></td>
<td class="nump">$ 25,475<span></span>
</td>
<td class="nump">$ 24,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">21,705<span></span>
</td>
<td class="nump">14,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">14,775<span></span>
</td>
<td class="nump">12,180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 61,955<span></span>
</td>
<td class="nump">$ 50,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737855296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Definite-lived Intangible Assets from Business Acquisitions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 11,539<span></span>
</td>
<td class="nump">$ 11,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,294)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 10,011<span></span>
</td>
<td class="nump">10,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 11,179<span></span>
</td>
<td class="nump">11,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,228)<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 9,951<span></span>
</td>
<td class="nump">10,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737663248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">2028 and thereafter</a></td>
<td class="nump">6,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 10,011<span></span>
</td>
<td class="nump">$ 10,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677739543840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward', window );"><strong>Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued', window );">Additions charged to cost of product revenue</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Repairs and replacements</a></td>
<td class="num">(631)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Balance at end of period</a></td>
<td class="nump">$ 1,624<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard and extended product warranty accrual from warranties issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677735856352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Future Principal Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 896,839<span></span>
</td>
<td class="nump">$ 896,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_TermLoansMember', window );">Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737747520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Narrative) (Details) - Convertible Senior Notes - Convertible Debt<br></strong></div></th>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0229885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 43.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice', window );">Debt redemption, percentage of conversion price</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceTradingDays', window );">Debt redemption, trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays', window );">Debt redemption, consecutive trading days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Debt Conversion Terms One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Debt Conversion Terms Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentAdditionalInterestInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentDebtDefaultCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Calendar Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentDebtDefaultCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentInterestInTheEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentInterestInTheEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677739543424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Schedule of Net Carrying Amount) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">$ (3,161)<span></span>
</td>
<td class="num">$ (3,317)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">896,839<span></span>
</td>
<td class="nump">896,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677915114944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Schedule of Interest Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">3,531<span></span>
</td>
<td class="nump">3,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 3,375<span></span>
</td>
<td class="nump">$ 3,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737959072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingShares', window );">Public offering (in shares)</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_OfferingShareAmountMaximum', window );">Offering share amount maximum (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod', window );">Public offering, option to purchase additional shares, period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares', window );">Public offering, option to purchase additional shares (in shares)</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering', window );">Percentage commission of gross proceeds on sale of common stock under at-the-market offering</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of stock</a></td>
<td class="nump">$ 189.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember', window );">Shelf Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,908<span></span>
</td>
<td class="nump">1,316,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OfferingShareAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Share Amount Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OfferingShareAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Option to Purchase Additional Shares, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Option to Purchase Additional Shares, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737656944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Summary of Time Based Options (Details) - Time-based stock option<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">14,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending (in shares) | shares</a></td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">3.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">17.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677738979184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Summary of Stock Option Activity (Details) - Performance-based stock options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(230,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending (in shares) | shares</a></td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">4.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677735960736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Summary of RSUs and PSUs Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">RSUs with time-based vesting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">8,535,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">6,341,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,640,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(465,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending (in shares) | shares</a></td>
<td class="nump">12,771,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">9.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">16.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">17.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">564,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending (in shares) | shares</a></td>
<td class="nump">564,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">9.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737709040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 17,952<span></span>
</td>
<td class="nump">$ 22,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,705<span></span>
</td>
<td class="nump">8,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,299<span></span>
</td>
<td class="nump">$ 11,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737788528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737690816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677731117712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Computation of Basic and Diluted Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,015)<span></span>
</td>
<td class="num">$ (81,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">242,032<span></span>
</td>
<td class="nump">222,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">242,032<span></span>
</td>
<td class="nump">222,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677741323584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Antidilutive Shares Excluded from Computation of Diluted Earnings per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Shares issuable upon conversion of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share (in shares)</a></td>
<td class="nump">20,690<span></span>
</td>
<td class="nump">20,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Equity Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share (in shares)</a></td>
<td class="nump">30,366<span></span>
</td>
<td class="nump">26,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737688832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Schedule of Revenue by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 38,900<span></span>
</td>
<td class="nump">$ 33,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">19,071<span></span>
</td>
<td class="nump">19,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">7,870<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia-Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 11,959<span></span>
</td>
<td class="nump">$ 8,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140677737911120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Summary of Revenue by Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 38,900<span></span>
</td>
<td class="nump">$ 33,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_InstrumentMember', window );">Instrument revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">20,700<span></span>
</td>
<td class="nump">15,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ConsumableMember', window );">Consumable revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13,954<span></span>
</td>
<td class="nump">12,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">34,654<span></span>
</td>
<td class="nump">28,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 4,246<span></span>
</td>
<td class="nump">$ 4,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_InstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_InstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ConsumableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ConsumableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>pacb-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pacb="http://www.pacificbiosciences.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pacb-20230331.xsd" xlink:type="simple"/>
    <context id="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i422efc39545048258818ad27173590cc_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="ib7391dc7425a48d1a68d124321e865b5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice0a062bee2249a4af687c1d872b4327_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib1cbb2936bb243b9a6592d611b169c16_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib4b86da148fb47efb77eed316c399b1d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5cf85b8a953e446a85fd97c4f01de732_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i05213693bb1c4eca878f5cc5112eeacb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53c21d7954bc458d83b1ff91758a8270_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idecc5bfef65744e09f272a78bcd68905_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecfc3de7424c4826b3f1731873d7f206_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1e0d15efe13435583148487cd4c04ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ide4390a867ed4ef08906ca95ade8cd55_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie48d42565d924ff9b4097dc043825527_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic2e7973ed88f4dc7822e42f6f9cada08_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ida601350d8e2486398e6f3e38ab85829_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie6cdbbe039cb4ef9af089ecc75fdb0cf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9e5013b2dc1b488db91c4bba79e8f7aa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c88663c018943f9969c82d3e25f57bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bf4cc431b7947788851e8ff3c3c2b54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39fce68f15da4941b559323699f4cc33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e3eb7fc88e14f23ab89fd860977e2c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib71260de6ee845f5827e04115b08241b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9c204295fa84994bdf6767d1c0daee1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i704c53f1332c4b5e8b25ccf4893f15dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i97cb8a03d16a448db1f7d245caca0d25_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if308a61785ca47938bc76410bbcfc128_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iddf6c8b89b524ea6a297d1dcd7650325_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i82e7c77b29bc4222a75d223c5aaf47c1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i232d2d8db0364677a249ba5c3d03501b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4568e4d90a544e3fa9b601fb92c24e7f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i170a5ddc0ff746bfba70414d856b57e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib74a70bcb48d4df6a79ecde68ca7040d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib90fd5a838bf4898b37389a8c2bf2e1c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd1f31512b50453585d88478dd9e32d0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f53c3bcf98f4143b2d656d33b41f1c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i774d705431d84bc8ad8c5a09742aa5c1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25920f50c4c04d77b9d0cd22fdc09393_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9ae391408ebf445da076c0866d88c4bd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie9967229d5414a46b6899d104fa4fcba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i22e1e2078c914a13a68381f4308c93a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i181aa9f4b31640dc8b14b6f82d70f240_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idae08cb548c441d3a91eba1de5219bd2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i849871cbc3cc45449d92adfe970af3c2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2a3125acf4ad4057b79910330fc7d13f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i65ab613bda3d44499a905662ecf1e971_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69ec8616bd37486dbff25977da4441f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i291b4bea01ad41c8963da94469fbd98f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i619b5be971f6439098c7aeac4e276a0d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49aeaa24126c489988a6ac04f57a2a00_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8ee96d635765436ca616328acee64b12_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9d490d8a9b4c43f9b0eb01ef5372cfe7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i94319df9941e4d4c9b28b64317ee7277_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d93184ef1de4f57bce4ecfe8206889f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idfa53ec2a0144c8dab9bfffe76c775ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a8af53f30ae4b7885dc2a7228d101d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4750e8e52de64b8ab4710c73414a1095_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54541305e5464edbb7c276c8782d6c2e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iebf211a0be2545bcb8bb2d83516598b9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if015623b8ea744f8818948cfc6f9cec7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i48b6553253ca455f8645230475b2cc61_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibe2a17ef15ba4c0cbedffc645c45aab6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iceb62135438a477dbd091a982c13e82b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55e15ba1dd7f452d855f284c62a7103b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4e23dae7b884c2d8e323afdc2202ec1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab42dea2b5104f92933733e4ae8b828c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id826230d5e794444a1100227d2df4064_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3f54406977384ecdbd22b1c966005bd1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i447b3166a1894e65ad053b4aca1c8396_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if2809d3f2dac4155af95932f49d85131_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf35d3b973c84f74991c106cc5541b89_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3b785e7e49a249b7975eb905979aa957_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if53a52cbc7e348799f5eb8078ff67bb2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i642d2faa764c497fb709bd8f7cf545ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f0aa7e818a540b4b3800563f1640bb5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c2165a552b2406aad1c18da3e5bcba1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7f0c2ed914b74450b0a466f80963c39e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4bed7d66a5a240dd880c5f2e196b2fb4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic6cf974ed2ad44f0b3a0fa6beaa4d15a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70ceb8bb0a3b41be9d4cc3b73a38fb83_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia15d8c644eec4080836b0b62648963ed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b8fbcede4404a2e8b1019f78237b47e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36c2bb89833b4cfcb9dcbf700eebd5b0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d7ed9bee28b4168b9214818a5a04afc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if2d5823f4ed048deabd8e0c7591c429c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16bd2f0eca824f1797f501f4e0391099_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3df88f6219dc43ce83dc501b125501a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icea01b3eb40349d587b12f4dca39ef4e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8ff3053e324549d69983b4ab416817c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3a16d74a89a48b188694cf52ea1bf6d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic22b2f234d3f44dea2cb7006091d3cfa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8484a2b1bd284e689338fd42dc179878_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3026c43f5474b3aaf648b1b685a4b02_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8dd1b10964904b3baf45a616d35f8e4a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibe51e70a3fcd4e399fbfdbb8e358e931_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6066f8de0b274e42940b04267565bdf7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2a4563e98c524b29afa46ed0121d04a2_I20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="i8b06909acc8846a687b88fb4008d393a_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="i87dcdd78b25e4f46a8ae756042953485_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="i82f01855a6084151a5dd9a070e4784b3_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="i20a09135868a48e4afb9690de6dd439c_D20210216-20210216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="i742c54bedefe423c93b513816a6c3979_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib40b2b69144d46d385bf12dbac4912ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i618edbbfddab4833a48509103c51d343_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i98efc311e4834a52b95558f1635f4df5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6f811a83540b4cdb8df5a2ca849b6ae0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i3539bf245d854192abfe418d43a09772_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="if0172c443e454bb9826a003845a4aa13_D20230131-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:ShelfOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i756aff43669a4bee98c53b5da2ad6ad6_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i6620f4b62a6245299f332889d2275280_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i638e0be2cf05429d9d48a17c3ad3afc4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia9475351ae4143b49d057e49d769bac5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifb8601e7bab34e959227a80dc0653b82_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i557fdaad292c4b3fb9316667a1bba49e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib5b211de82ab46bd9b8e7ecfb559c3d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4b260485f44645a2bd579bb81411474c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ife7d26135b95464faa9c223629b18165_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="id0a53ada800e4aa28d98cf54fcb50068_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ife8c470b6b7746deb6ce4dee0f7e41f1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i425ffb2f994b48168f939e71d5ba1ad5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb3065503208462293114ba3cebc247b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iab6e067725af44f990c3a8d3a8d5c108_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if4665a48d6d14296985783f51f19db3f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i197db529bcc44b64992d8392908d33c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6ceb564dadd349a3923864a97aebdd11_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i978408a314554860834dc737c3b1419c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i31f9e8f8b14e405e9c92d12a3b2a9e3c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i801b0f6773b4475bb9dd53e570abb778_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia7a1b740447c43f8a9ab44e87fa30129_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i04cac2e649ab434a97832d035f40bb55_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i14c86fb9249949768d1bdd6a89aac5c5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i22ec828e984b4ebc8d4bd50a11327be6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icb8e95a9d8854d71946cebeffe0b0fb3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib607a9972ac84fbcba2120fd9f7e766b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1641ad7927bc43fd949abadef487d0a9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d1a78f0fe194bdfb72bae3a006f6e4b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd4c824aaa2f49fc9e518b8402729d62_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1f27eacedc494a34b10e2794baf8cdf4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf52ec5feb514b609a102b910f6fa20e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7da4fe9d8e6343d5a93b936c584e420e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i978f0bc925a24496b995a232807ed9bb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie2efc93840c24155946c8e1c76fe58de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF8yLTEtMS0xLTQzMDA_cc1a71b4-1c91-4335-8a6b-2ebba91416c8">0001299130</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF8zLTEtMS0xLTQzMDA_6b761957-9e5a-4695-a7f2-cb9e0131c9b5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF80LTEtMS0xLTQzMDA_3089336f-e498-4c33-b32f-a0c37758825f">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF81LTEtMS0xLTQzMDA_fad77b81-6014-48a9-a35b-0b7e1be9ce77">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80L2ZyYWc6ZDBhMjU4MzhiY2M5NDVlYTk4NzRkYTAyZTk3OGM1YjgvdGFibGU6MjM3NmQ1MTY1NDFjNGRkMDgyNTI3YTMwMWExZGFmNjQvdGFibGVyYW5nZToyMzc2ZDUxNjU0MWM0ZGQwODI1MjdhMzAxYTFkYWY2NF82LTEtMS0xLTQzMDA_f3f739e1-9f95-4ed7-9397-8fab29606c3d">false</dei:AmendmentFlag>
    <pacb:StandardProductWarrantyPeriod
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80NzEvZnJhZzoxYjExODhkZjg3OTA0ZGNjOGNjYTJkMDgyNGQwMmZhNS90ZXh0cmVnaW9uOjFiMTE4OGRmODc5MDRkY2M4Y2NhMmQwODI0ZDAyZmE1XzQzOTgwNDY1MTExNTQ_2118f037-a144-4792-997d-43129fe3012f">P1Y</pacb:StandardProductWarrantyPeriod>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zNzUvZnJhZzphZGY2YzNjNzBmZWI0MmY1OGNkOTExMDQzMzIxOGVlYS90ZXh0cmVnaW9uOmFkZjZjM2M3MGZlYjQyZjU4Y2Q5MTEwNDMzMjE4ZWVhXzQzOTgwNDY1MTE2NjI_b7454d8a-5d4a-47ab-8f62-a63b3fd10e1b"
      unitRef="number">0.0229885</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTg3_fab373b2-88a0-4869-926d-0cbeec4aa942">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTkw_0efd8486-e4e5-4a53-8f29-e7f75ab081c8">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN180MTE_e9d70852-afd5-49e9-9709-2568688a6497">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTkx_419e52dd-8392-45a6-87b6-d8625fcd9cbc">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTky_912074ca-4968-46e5-a106-92bd5628fb02">001-34899</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTg4_e8e57be2-f016-4afa-8db8-2635d36735fe">Pacific Biosciences of California, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18wLTAtMS0xLTQzMDA_1c94b511-6128-4703-b3dc-df578ee1107e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18wLTEtMS0xLTQzMDA_e86fabbd-b02e-46c1-ac93-a6654417e2ed">16-1590339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18zLTAtMS0xLTQzMDAvdGV4dHJlZ2lvbjo5ODQ4YzE1ODcyZjc0ODJkOTQ2YTc2ZjdhY2FiYTM3M180_ea75ac88-2dd6-4005-b9f6-6ff03026fe92">1305 O&#x2019;Brien Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18zLTAtMS0xLTQzMDAvdGV4dHJlZ2lvbjo5ODQ4YzE1ODcyZjc0ODJkOTQ2YTc2ZjdhY2FiYTM3M183_f0b4b031-4c2f-4038-b2de-869b75da22ac">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18zLTAtMS0xLTQzMDAvdGV4dHJlZ2lvbjo5ODQ4YzE1ODcyZjc0ODJkOTQ2YTc2ZjdhY2FiYTM3M18xMQ_25c5c760-d5f7-4c32-9089-588b30481992">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OGE4ZTZlMTFhZTM5NDU2OThiNzMwMjk4MzE3OGU1MjcvdGFibGVyYW5nZTo4YThlNmUxMWFlMzk0NTY5OGI3MzAyOTgzMTc4ZTUyN18zLTEtMS0xLTQzMDA_0206dec8-4df2-4458-aa4c-c54dcf1f2999">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN184ODU_7c9ab157-67e9-4125-8ceb-aaa9e947502b">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN184ODk_b0b4a437-e24b-439a-b88a-dcf8ca4d6594">521-8000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OTlmOGYyOGFhMjY3NGI0NDhhYTI5OTUyN2U0MDAxMDgvdGFibGVyYW5nZTo5OWY4ZjI4YWEyNjc0YjQ0OGFhMjk5NTI3ZTQwMDEwOF8xLTAtMS0xLTQzMDA_4b776fb1-804c-459a-9df5-bc6371434a3a">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OTlmOGYyOGFhMjY3NGI0NDhhYTI5OTUyN2U0MDAxMDgvdGFibGVyYW5nZTo5OWY4ZjI4YWEyNjc0YjQ0OGFhMjk5NTI3ZTQwMDEwOF8xLTEtMS0xLTQzMDA_0664442b-f2f7-4496-80dc-8302e45e85aa">PACB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6OTlmOGYyOGFhMjY3NGI0NDhhYTI5OTUyN2U0MDAxMDgvdGFibGVyYW5nZTo5OWY4ZjI4YWEyNjc0YjQ0OGFhMjk5NTI3ZTQwMDEwOF8xLTItMS0xLTQzMDA_6ebdd1ef-8bbe-4cac-b803-ed0e15c2a880">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTkz_cc61d577-81c4-4914-b5ec-efce8762a2cd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN18yNTk0_9f940ed3-d95b-4722-956d-ca4c030dc34d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6MWE3ZjdmY2I4MzA2NDlmY2IxYzUwYjFkYmM4OWRiYTQvdGFibGVyYW5nZToxYTdmN2ZjYjgzMDY0OWZjYjFjNTBiMWRiYzg5ZGJhNF8wLTAtMS0xLTQzMDA_dcda34f1-16db-45a3-b182-64c5a90bff52">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6MWE3ZjdmY2I4MzA2NDlmY2IxYzUwYjFkYmM4OWRiYTQvdGFibGVyYW5nZToxYTdmN2ZjYjgzMDY0OWZjYjFjNTBiMWRiYzg5ZGJhNF8xLTMtMS0xLTQzMDA_b493bf97-58bc-4972-9bcf-1da463501c4d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGFibGU6MWE3ZjdmY2I4MzA2NDlmY2IxYzUwYjFkYmM4OWRiYTQvdGFibGVyYW5nZToxYTdmN2ZjYjgzMDY0OWZjYjFjNTBiMWRiYzg5ZGJhNF8yLTEtMS0xLTQzMDA_57a83cce-f111-4033-b55a-534241048377">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN180Mzk4MDQ2NTEzNzI2_9c83d0c7-5c69-4140-9a8b-13821d77bcbd">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i422efc39545048258818ad27173590cc_I20230430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xL2ZyYWc6Y2JmODQxYThiZjE2NGM3MjliOTQ1MzQwMGExODAwZDcvdGV4dHJlZ2lvbjpjYmY4NDFhOGJmMTY0YzcyOWI5NDUzNDAwYTE4MDBkN181NDk3NTU4MTY1MjE_4c037a88-8324-4f8b-8fd3-9207aa09c358"
      unitRef="shares">249891404</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMy0xLTEtMS00MzAw_3b8dccff-1567-42ac-bfe8-dad8af547ada"
      unitRef="usd">353834000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMy0zLTEtMS00MzAw_323016d3-bd80-441e-b2d9-4584a138bbd3"
      unitRef="usd">325089000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNC0xLTEtMS00MzAw_260c57c6-e0ce-43f0-826b-dfe87890a73b"
      unitRef="usd">521058000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNC0zLTEtMS00MzAw_6048e26f-54a8-42ee-95bb-0f419671077f"
      unitRef="usd">447229000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNS0xLTEtMS00MzAw_da55dafe-0611-48fa-a96e-5ddb1f398682"
      unitRef="usd">29589000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNS0zLTEtMS00MzAw_6c32e0ba-3921-4300-896d-9994f64b031c"
      unitRef="usd">18786000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNi0xLTEtMS00MzAw_bdf80c8e-60d7-4bad-8317-e9fd57bb2d02"
      unitRef="usd">61955000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNi0zLTEtMS00MzAw_43fe8338-730d-41c9-aa8d-186757183c21"
      unitRef="usd">50381000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNy0xLTEtMS00MzAw_b6d7054a-1153-4f49-996f-dc01d4ee7820"
      unitRef="usd">14375000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNy0zLTEtMS00MzAw_7ae56e80-411b-4b3a-9f1e-30310edabc17"
      unitRef="usd">10289000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfOC0xLTEtMS00MzAw_52a00a2f-bfbc-4a23-bffb-e4d8bc7ba264"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfOC0zLTEtMS00MzAw_86f98538-8292-438f-a1ff-4fc2d728ecdc"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfOS0xLTEtMS00MzAw_3d6bb2d0-76d6-48d5-ad11-57803dfecff2"
      unitRef="usd">981111000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfOS0zLTEtMS00MzAw_2317c2a2-3fd2-41ed-8a28-b16b74d10653"
      unitRef="usd">852074000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTAtMS0xLTEtNDMwMA_6c5919b0-6098-493b-afa3-bd7e01a70c35"
      unitRef="usd">40833000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTAtMy0xLTEtNDMwMA_039ec4b5-8610-4940-a321-7be18a69e11a"
      unitRef="usd">41580000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTEtMS0xLTEtNDMwMA_be9d1571-3eaf-4f78-82c2-4271cbd92333"
      unitRef="usd">38247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTEtMy0xLTEtNDMwMA_f6d0884d-e146-41df-a982-2c16f004384b"
      unitRef="usd">39763000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTItMS0xLTEtNDMwMA_4c36bd9a-f960-409e-ac7d-b5847eff3150"
      unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTItMy0xLTEtNDMwMA_a9d35f60-1a28-45a3-944a-bdc257c63429"
      unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTMtMS0xLTEtNDMwMA_468b474b-2ea6-49c6-8604-a0858dfed9a9"
      unitRef="usd">410011000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTMtMy0xLTEtNDMwMA_a2872eb8-e421-420f-b323-6c93e3abc16a"
      unitRef="usd">410245000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTQtMS0xLTEtNDMwMA_ad0a87b0-a44b-4ca7-bea3-155872672eaf"
      unitRef="usd">409974000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTQtMy0xLTEtNDMwMA_7ae94569-6510-4623-8139-297168192d73"
      unitRef="usd">409974000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTUtMS0xLTEtNDMwMA_6022b752-7a20-4e4a-8ee3-bce79da9a680"
      unitRef="usd">13319000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTUtMy0xLTEtNDMwMA_351cee04-6859-41df-b448-209d8e385d2b"
      unitRef="usd">10528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTYtMS0xLTEtNDMwMA_ede4d93c-31ce-4b89-93f8-e86fe5a70504"
      unitRef="usd">1896417000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTYtMy0xLTEtNDMwMA_80acc91e-0977-48f3-b412-5f8f377b9b45"
      unitRef="usd">1767086000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTktMS0xLTEtNDMwMA_6fafa35f-f2ee-4170-8d34-4906432ff0da"
      unitRef="usd">17390000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMTktMy0xLTEtNDMwMA_9df1df0e-bf97-449c-9fc9-4602c5d9b14b"
      unitRef="usd">12028000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjAtMS0xLTEtNDMwMA_92b43d69-5df5-4548-938b-a73e9fd9b298"
      unitRef="usd">19380000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjAtMy0xLTEtNDMwMA_a85ea509-8639-40fa-b65e-893bf341d119"
      unitRef="usd">32596000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjEtMS0xLTEtNDMwMA_33793ddd-7830-4d15-8ee4-5cbf410737f6"
      unitRef="usd">30866000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjEtMy0xLTEtNDMwMA_4e5936c3-23b2-4ad9-83f0-e7877159f33e"
      unitRef="usd">30498000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjItMS0xLTEtNDMwMA_2bc09d55-55d4-4eae-9ab4-6e25731184ee"
      unitRef="usd">9018000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjItMy0xLTEtNDMwMA_d54d7179-3cb5-441f-8d7c-dd31fea9019a"
      unitRef="usd">8886000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjMtMS0xLTEtNDMwMA_c55b4f9b-5a8d-4dc7-915c-b9f2fe680f37"
      unitRef="usd">4670000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjMtMy0xLTEtNDMwMA_b0229c24-2696-4211-a89c-971a29e28b4a"
      unitRef="usd">7233000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjQtMS0xLTEtMTE2OTU_5fa15ce3-a0dc-4673-b4f9-d902f74b544e"
      unitRef="usd">184350000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjQtMy0xLTEtMTE2OTU_a1044e90-7531-4791-92c7-8d138b7814d4"
      unitRef="usd">172094000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjQtMS0xLTEtNDMwMA_11f1e576-46d7-4fde-a267-0f9587b5845f"
      unitRef="usd">265674000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjQtMy0xLTEtNDMwMA_ab8e3b27-a4be-45a9-88c6-8c5b1683aaa6"
      unitRef="usd">263335000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjUtMS0xLTEtNDMwMA_6360faef-79e0-4ecf-8219-178ae4c9cbc0"
      unitRef="usd">1849000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjUtMy0xLTEtNDMwMA_c59cd294-9e2a-457e-95bd-2f3e0e04d25a"
      unitRef="usd">1794000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjctMS0xLTEtNDMwMA_f6616148-ce03-4a7c-ad96-310bb31f5a66"
      unitRef="usd">38969000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjctMy0xLTEtNDMwMA_51836437-530e-4e80-ae35-b7ca51cee92c"
      unitRef="usd">41070000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjgtMS0xLTEtNDMwMA_f3dd3991-4bf5-46d3-ada4-fff96eb03e45"
      unitRef="usd">896839000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjgtMy0xLTEtNDMwMA_8b3c45a2-db7e-4551-9651-38dd413e10a4"
      unitRef="usd">896683000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjktMS0xLTEtNDMwMA_3b5c16ca-e745-4e71-bd3b-57ad9b1f6cea"
      unitRef="usd">969000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMjktMy0xLTEtNDMwMA_74322a3c-b668-4d3c-9af0-470867ebecd1"
      unitRef="usd">1300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzAtMS0xLTEtNDMwMA_a1800873-209a-49fd-91f3-80dc0ebe1dc1"
      unitRef="usd">1204300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzAtMy0xLTEtNDMwMA_8a11ae89-85fd-4013-b370-2f85ac43edee"
      unitRef="usd">1204182000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzItMS0xLTEtNDMwMA_36a5011c-8a8c-4dd1-90e4-b2abbeeb6181"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzItMy0xLTEtNDMwMA_2d4f3d7b-1a50-432e-9902-4385b9c88bd2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzUtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjZhNmRiMGMxZDIxNTQwOGM4ODMzZmU0NTkzNGYzN2Q4XzIx_82cde825-87dc-45de-9336-bba9aea096bf"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzUtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjZhNmRiMGMxZDIxNTQwOGM4ODMzZmU0NTkzNGYzN2Q4XzIx_ea5af7e0-16e8-456a-8e8d-77e39ea70ad9"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzE1_43caa508-c568-48a0-b862-3c4e30543f67"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzE1_e8326259-d75c-4915-8815-f882ae85f3d8"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzI2_22967be3-ea50-4b7c-8874-d5a968f67263"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzI2_ca00ae88-fcdc-4066-a6b4-043f40015619"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzI2_e2b6b06f-de30-43be-9208-04748431c64c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmMxZDM1YzY4YWFlZDRhZjZhYzU3MWY4ODVlNGI5YTdkXzI2_ee17f3f1-fa5a-45d6-a137-0d8c3ba5df32"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMS0xLTEtNDMwMA_10a19777-d5f2-4370-a7b6-14ea649a910c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzYtMy0xLTEtNDMwMA_be09306a-d0ed-4640-b545-730a82801352"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzctMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmM1NjNlNDg5YTk2NDQ3NzhhMzE4ODlhMzRjNGM5YWY5XzE4_703766d5-bf18-4620-8c82-e4d9b074a09a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzctMC0xLTEtNDMwMC90ZXh0cmVnaW9uOmM1NjNlNDg5YTk2NDQ3NzhhMzE4ODlhMzRjNGM5YWY5XzE4_fe658025-6653-4072-81a0-e3abf4bf5ce9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzE1_24cec4f5-1c8b-44b4-8210-bbd49921e83d"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzE1_9afdc7fb-7313-4a54-ac9b-f8364584c71f"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzQ5_83235359-c8fb-4249-93fa-67ecd0d0db71"
      unitRef="shares">249803000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzQ5_8bc94636-474b-43c0-9249-8cdeef38da3b"
      unitRef="shares">249803000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzU2_4ceb4e11-173e-4529-bbe4-df55f281110e"
      unitRef="shares">226505000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMC0xLTEtNDMwMC90ZXh0cmVnaW9uOjc2ZmY5Y2U1MTZkZjQ5NmE4OWMxMDc0OGU3NzQ5YWIyXzU2_acfef713-e347-42cc-8b92-7267c0e042c3"
      unitRef="shares">226505000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMS0xLTEtNDMwMA_fbaf0a74-e211-40a9-83d1-9eb706b672e8"
      unitRef="usd">250000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzgtMy0xLTEtNDMwMA_cc619268-2722-44fd-b57d-0cfc5ae4941a"
      unitRef="usd">227000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzktMS0xLTEtNDMwMA_6e74a93b-2021-4f7d-806c-512e08d1eea3"
      unitRef="usd">2314146000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfMzktMy0xLTEtNDMwMA_54509824-6191-4c76-984d-2cb8d63e71f7"
      unitRef="usd">2099782000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDAtMS0xLTEtNDMwMA_1c5273de-2027-42c7-a31e-e9168b54ed1f"
      unitRef="usd">-1924000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDAtMy0xLTEtNDMwMA_4677c20b-04dc-4069-9213-15a2170917ce"
      unitRef="usd">-4765000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDEtMS0xLTEtNDMwMA_cfc34bc8-aaa2-4b1f-b49b-b5fd7d07290a"
      unitRef="usd">-1620355000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDEtMy0xLTEtNDMwMA_df230a6f-de97-4de0-bd7d-fb22cd8bfa64"
      unitRef="usd">-1532340000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDItMS0xLTEtNDMwMA_794136c9-ce67-4753-b413-bd8680052956"
      unitRef="usd">692117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDItMy0xLTEtNDMwMA_923ee174-9652-4f7b-acfd-5b8951374200"
      unitRef="usd">562904000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDMtMS0xLTEtNDMwMA_02871ece-620a-48d2-a65e-d87699f25aa9"
      unitRef="usd">1896417000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xNi9mcmFnOjcxZmQ2NDI5ZDUxNTQxYWNhODVjZTcwNzYzNWJhNzM3L3RhYmxlOmIwMTIyNzc1YzEwZTRmOGNhN2NlN2FmZTI1ZTc0OTdhL3RhYmxlcmFuZ2U6YjAxMjI3NzVjMTBlNGY4Y2E3Y2U3YWZlMjVlNzQ5N2FfNDMtMy0xLTEtNDMwMA_2950a0c7-0e82-4026-aa26-3dc1570f8a7a"
      unitRef="usd">1767086000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice0a062bee2249a4af687c1d872b4327_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMy0xLTEtMS00MzAw_ddb8c995-460d-4bf8-bd11-c7f37b551975"
      unitRef="usd">34654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1cbb2936bb243b9a6592d611b169c16_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMy0zLTEtMS00MzAw_372c70ab-74aa-416f-a374-ce015dab1cff"
      unitRef="usd">28244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4b86da148fb47efb77eed316c399b1d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNC0xLTEtMS00MzAw_2b82682a-d88d-4df7-b50a-3fc2a60d93de"
      unitRef="usd">4246000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cf85b8a953e446a85fd97c4f01de732_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNC0zLTEtMS00MzAw_22a88a47-f645-4b80-a5f1-7513b63241d1"
      unitRef="usd">4929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNS0xLTEtMS00MzAw_fd864fa8-d196-4c14-b888-eb7cadd3284c"
      unitRef="usd">38900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNS0zLTEtMS00MzAw_afb79b86-8d47-4abd-bb78-b2c8ec6e5c8c"
      unitRef="usd">33173000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ice0a062bee2249a4af687c1d872b4327_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNy0xLTEtMS00MzAw_df32780d-bd14-41de-af61-06c4d95ab63d"
      unitRef="usd">25164000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ib1cbb2936bb243b9a6592d611b169c16_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfNy0zLTEtMS00MzAw_9730fa64-c838-4e7f-ac16-e1c8576034c2"
      unitRef="usd">14820000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ib4b86da148fb47efb77eed316c399b1d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfOC0xLTEtMS00MzAw_077bc0b5-1acf-4eed-bbca-37a1089705a7"
      unitRef="usd">3792000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i5cf85b8a953e446a85fd97c4f01de732_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfOC0zLTEtMS00MzAw_9bcc9939-39f7-4281-a601-09ea87eea5ec"
      unitRef="usd">4015000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfOS0xLTEtMS00MzAw_a0646517-1c53-4972-89e0-b48a2b189e2a"
      unitRef="usd">183000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfOS0zLTEtMS00MzAw_589eb5f8-86be-40a8-a6aa-2f02dbf10a7f"
      unitRef="usd">183000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfRevenue
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTAtMS0xLTEtNDMwMA_909a52e8-46c3-4b6f-adc1-06be01b2c47e"
      unitRef="usd">29139000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTAtMy0xLTEtNDMwMA_520d036d-7eaf-42f4-a696-a766fd74b399"
      unitRef="usd">19018000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTEtMS0xLTEtNDMwMA_4de561a5-d5c4-4d3d-b5e7-54927bbae443"
      unitRef="usd">9761000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTEtMy0xLTEtNDMwMA_29802217-cb9a-4f46-83c8-1d3bf153a4f3"
      unitRef="usd">14155000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTMtMS0xLTEtNDMwMA_e1e05540-9101-4442-b2f0-a6893b6936f5"
      unitRef="usd">48939000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTMtMy0xLTEtNDMwMA_075f03cc-548f-4f07-9d14-4c29f67b4b6d"
      unitRef="usd">52937000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTQtMS0xLTEtNDMwMA_3e893984-87e1-4af3-b4c0-f483e5ab7181"
      unitRef="usd">39818000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTQtMy0xLTEtNDMwMA_77f8c815-a420-4a3c-b097-144d36c35ee0"
      unitRef="usd">39804000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTYtMS0xLTEtNDMwMA_4b075441-c5e8-4eeb-8c41-84a6450d1bf0"
      unitRef="usd">12256000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTYtMy0xLTEtNDMwMA_47a6a3c1-464a-43b3-86d6-1ed7109cb5fd"
      unitRef="usd">-1063000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTctMS0xLTEtNDMwMA_32eb7687-4a31-46d4-8960-812611a351fb"
      unitRef="usd">101013000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTctMy0xLTEtNDMwMA_1811ebdf-e6ca-4752-9446-47923c3d55fa"
      unitRef="usd">91678000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTgtMS0xLTEtNDMwMA_3415dde4-eb50-45d5-8f97-e19bcb450275"
      unitRef="usd">-91252000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMTgtMy0xLTEtNDMwMA_799fc533-c4bd-4a74-bc6b-40f229751056"
      unitRef="usd">-77523000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjAtMS0xLTEtNDMwMA_9952b8b2-3067-4a06-ada6-ebc58f988cf0"
      unitRef="usd">3630000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjAtMy0xLTEtNDMwMA_e7bc6fae-48c5-4142-8202-e87a546854c6"
      unitRef="usd">3697000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjEtMS0xLTEtNDMwMA_7baeb22d-54c2-4dfe-93bf-fb74f18c5ac1"
      unitRef="usd">6867000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjEtMy0xLTEtNDMwMA_8cf3815f-c207-49de-901a-e2386f5e5e98"
      unitRef="usd">-279000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjItMS0xLTEtNDMwMA_04099700-12f7-4f19-a346-3f2a3d0e8d60"
      unitRef="usd">-88015000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjItMy0xLTEtNDMwMA_57d256eb-73fe-43f8-bec5-c6d1ff3d62a6"
      unitRef="usd">-81499000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjMtMS0xLTEtNDMwMA_8f01c3e4-fa02-4a4b-a11f-1fc9462c7a01"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjMtMy0xLTEtNDMwMA_f6a4c4eb-8bf9-4c12-9cd2-a1ac771e17c7"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjQtMS0xLTEtNDMwMA_06953f18-ec92-4d6e-9fff-367dbdb5d2d8"
      unitRef="usd">-88015000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjQtMy0xLTEtNDMwMA_05709cf7-9337-410e-966d-b996b7879470"
      unitRef="usd">-81499000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjYtMS0xLTEtNDMwMA_4004ac07-507e-4acd-bbcc-fa550e5b05f8"
      unitRef="usd">2841000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjYtMy0xLTEtNDMwMA_69b4c6a7-75ca-434f-8684-50b4c396b449"
      unitRef="usd">-2998000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjctMS0xLTEtNDMwMA_1eccc67c-9540-418e-bc3e-a6512874bb25"
      unitRef="usd">-85174000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjctMy0xLTEtNDMwMA_a123948b-69d5-4f65-b323-f1f1c10fee6b"
      unitRef="usd">-84497000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjktMS0xLTEtNDMwMA_6182ba1f-b114-4c02-9ac7-7b0a8c7fc2d7"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMjktMy0xLTEtNDMwMA_b1d8b20f-1913-4797-bef0-1229310d1c88"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzAtMS0xLTEtNDMwMA_84d3ea7e-70f7-4a34-860c-ff006ba06a62"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzAtMy0xLTEtNDMwMA_a03a3768-bd2e-4a0b-9b0f-b0f20f697030"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzMtMS0xLTEtNDMwMA_7f21c096-30d3-438d-8665-03d3d4f55f1c"
      unitRef="shares">242032000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzMtMy0xLTEtNDMwMA_7637772b-4b1e-4d7e-adee-c031f0980950"
      unitRef="shares">222289000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzQtMS0xLTEtNDMwMA_035e87a1-145b-4b4c-a618-2445d7930e02"
      unitRef="shares">242032000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8xOS9mcmFnOjc2M2E5MmEzZTQ0NTRmNjM5YWUzYmYxYzQ5MjA1NWU2L3RhYmxlOjdmNWQ2ZTdmN2FlZDQwMjVhYzcxMWVmZmVmNWFlNWVhL3RhYmxlcmFuZ2U6N2Y1ZDZlN2Y3YWVkNDAyNWFjNzExZWZmZWY1YWU1ZWFfMzQtMy0xLTEtNDMwMA_5163c46f-7ec6-42c6-8659-7efa6e6a2f45"
      unitRef="shares">222289000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i05213693bb1c4eca878f5cc5112eeacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy0xLTEtMS00MzAw_e895f32e-9d4c-42b4-b583-c63f38895bfc"
      unitRef="shares">226505000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i05213693bb1c4eca878f5cc5112eeacb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy0zLTEtMS00MzAw_ac156ba1-7536-404b-850d-8c867336c883"
      unitRef="usd">227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53c21d7954bc458d83b1ff91758a8270_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy01LTEtMS00MzAw_97b56c0d-5b13-44e5-98c4-c16a98893c7d"
      unitRef="usd">2099782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idecc5bfef65744e09f272a78bcd68905_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy03LTEtMS00MzAw_6f5155a0-e9c8-45c4-a4bf-1390cb4ed5a6"
      unitRef="usd">-4765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecfc3de7424c4826b3f1731873d7f206_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy05LTEtMS00MzAw_723ddc28-4678-491e-9f0b-211bf03b5e96"
      unitRef="usd">-1532340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMy0xMS0xLTEtNDMwMA_45a06ddf-7d45-4871-b815-3d828bbff286"
      unitRef="usd">562904000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id1e0d15efe13435583148487cd4c04ed_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNC05LTEtMS00MzAw_5fe709e1-6886-4515-9276-a7bae8eecd78"
      unitRef="usd">-88015000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNC0xMS0xLTEtNDMwMA_fdf00655-1a0d-4af5-8fc8-55b79ba38c5a"
      unitRef="usd">-88015000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ide4390a867ed4ef08906ca95ade8cd55_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNS03LTEtMS00MzAw_a4b8c12c-ebd0-4992-a385-7eb435719161"
      unitRef="usd">2841000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNS0xMS0xLTEtNDMwMA_facc5415-ce32-43b5-b179-2f1f75ef78c7"
      unitRef="usd">2841000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0xLTEtMS0xMDQ1OQ_f5f3b3b4-daac-4ffe-b095-29d65169951c"
      unitRef="shares">20125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0zLTEtMS0xMDQ1OQ_8b48ae98-090c-4726-b586-a61fc885ab95"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie48d42565d924ff9b4097dc043825527_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi01LTEtMS0xMDQ1OQ_0751db7e-0b09-4330-80af-0ab18e050fd6"
      unitRef="usd">189180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0xMS0xLTEtMTA0NTk_b13f5a40-533e-416a-a1dc-0b1797d89753"
      unitRef="usd">189200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0xLTEtMS00MzAw_d2307645-009f-40e5-87e4-93463f71c022"
      unitRef="shares">3173000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic729f140dc8f4a5c8a8ca401d4eb6aa2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0zLTEtMS00MzAw_5c7c119f-be65-4a70-a616-2c7b18a40474"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie48d42565d924ff9b4097dc043825527_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi01LTEtMS00MzAw_d60c02ac-7e55-4cb4-a93e-9aaf9be598f9"
      unitRef="usd">7232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNi0xMS0xLTEtNDMwMA_e7cf0f3c-693f-427d-8d77-1ab8cf323aaa"
      unitRef="usd">7235000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie48d42565d924ff9b4097dc043825527_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNy01LTEtMS00MzAw_0bb81167-8b3a-4469-a12c-bbc493c9e73e"
      unitRef="usd">17952000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfNy0xMS0xLTEtNDMwMA_15dca762-8b79-4590-8a2e-ba36906955b4"
      unitRef="usd">17952000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic2e7973ed88f4dc7822e42f6f9cada08_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC0xLTEtMS00MzAw_c91ae889-bcac-4130-b3fe-d16eabd7193d"
      unitRef="shares">249803000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic2e7973ed88f4dc7822e42f6f9cada08_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC0zLTEtMS00MzAw_73da4f07-62aa-4334-af7e-8340ec0661e5"
      unitRef="usd">250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida601350d8e2486398e6f3e38ab85829_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC01LTEtMS00MzAw_eb63e0ae-7a57-40a3-b0ff-636f6a0261c1"
      unitRef="usd">2314146000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6cdbbe039cb4ef9af089ecc75fdb0cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC03LTEtMS00MzAw_d67cd4e7-8ade-433b-9779-23a05c50b8f7"
      unitRef="usd">-1924000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e5013b2dc1b488db91c4bba79e8f7aa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC05LTEtMS00MzAw_b18190d2-a6e2-48da-be4c-3074c0dfcad5"
      unitRef="usd">-1620355000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfOC0xMS0xLTEtNDMwMA_8b5a2855-a925-4d24-86c4-93fe5b297462"
      unitRef="usd">692117000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0c88663c018943f9969c82d3e25f57bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtMS0xLTEtNDMwMA_a0cd8d89-4c35-417d-8996-6b7c61a52931"
      unitRef="shares">220978000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0c88663c018943f9969c82d3e25f57bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtMy0xLTEtNDMwMA_be85f10a-4b84-4745-9b90-a09adad9bb65"
      unitRef="usd">221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6bf4cc431b7947788851e8ff3c3c2b54_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtNS0xLTEtNDMwMA_e1508e73-51d0-491e-a7a8-29e4c7635868"
      unitRef="usd">2009945000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39fce68f15da4941b559323699f4cc33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtNy0xLTEtNDMwMA_211be74f-43ef-4545-9309-28baea8b2a41"
      unitRef="usd">-1087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e3eb7fc88e14f23ab89fd860977e2c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtOS0xLTEtNDMwMA_6124670d-1b03-465e-87e3-3faa34645605"
      unitRef="usd">-1218092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib71260de6ee845f5827e04115b08241b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTEtMTEtMS0xLTQzMDA_875ef941-072a-4d6a-b168-b2fa169c6362"
      unitRef="usd">790987000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id9c204295fa84994bdf6767d1c0daee1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTItOS0xLTEtNDMwMA_08159ae4-7a27-493a-9f0e-3364aa2039d8"
      unitRef="usd">-81499000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTItMTEtMS0xLTQzMDA_789a306a-2f8e-43c9-91ae-156f2796b8d8"
      unitRef="usd">-81499000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i704c53f1332c4b5e8b25ccf4893f15dc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTMtNy0xLTEtNDMwMA_700f64c0-a023-4e3b-90b0-8a7f1dbf97c6"
      unitRef="usd">-2998000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTMtMTEtMS0xLTQzMDA_e6a01153-9e30-4ca5-bfb5-9e6ef063d96b"
      unitRef="usd">-2998000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i97cb8a03d16a448db1f7d245caca0d25_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTQtMS0xLTEtNDMwMA_c157fae7-5aa7-48fa-8864-988f164eee06"
      unitRef="shares">3351000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i97cb8a03d16a448db1f7d245caca0d25_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTQtMy0xLTEtNDMwMA_f5d6ddbd-52bc-4c44-be52-22936024eabd"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if308a61785ca47938bc76410bbcfc128_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTQtNS0xLTEtNDMwMA_f0c9d9e9-6427-4f14-ac93-93b7a87f3630"
      unitRef="usd">5589000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTQtMTEtMS0xLTQzMDA_b0dca983-92c0-44c5-ae66-794d57f73f78"
      unitRef="usd">5592000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if308a61785ca47938bc76410bbcfc128_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTctNS0xLTEtNDMwMA_bac86a4a-b32b-4e67-878f-6f0b8d7f550d"
      unitRef="usd">22496000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTctMTEtMS0xLTQzMDA_6c5fd260-65e1-4337-bf40-205de7185c56"
      unitRef="usd">22496000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iddf6c8b89b524ea6a297d1dcd7650325_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtMS0xLTEtNDMwMA_f55f0a97-675d-47aa-b244-58b8f00b71ad"
      unitRef="shares">224329000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iddf6c8b89b524ea6a297d1dcd7650325_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtMy0xLTEtNDMwMA_af9a094b-6044-446e-82ab-a85a51c9a549"
      unitRef="usd">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i82e7c77b29bc4222a75d223c5aaf47c1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtNS0xLTEtNDMwMA_4fb1ddca-ee30-4cbe-b0f1-f0091f15a6e1"
      unitRef="usd">2038030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i232d2d8db0364677a249ba5c3d03501b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtNy0xLTEtNDMwMA_8e217a8b-fc61-400d-ad25-9854980048d7"
      unitRef="usd">-4085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4568e4d90a544e3fa9b601fb92c24e7f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtOS0xLTEtNDMwMA_24306674-d429-41fc-9ac1-c95c3ee963fa"
      unitRef="usd">-1299591000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yMi9mcmFnOmM5Mjc4MWU1OGIxYTRkZDY4ZDEzZWQ4YjVkMTI4YTQzL3RhYmxlOjE1MjJmZDhhYjFmNzRkOTg4Y2I0M2Y3ZjViMjA3NTY5L3RhYmxlcmFuZ2U6MTUyMmZkOGFiMWY3NGQ5ODhjYjQzZjdmNWIyMDc1NjlfMTgtMTEtMS0xLTQzMDA_3e343713-cb46-44bd-9ebd-5c15e0fe9843"
      unitRef="usd">734578000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMy0xLTEtMS00MzAw_4f381adb-d6a8-4830-915b-ac9a412692f4"
      unitRef="usd">-88015000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMy0zLTEtMS00MzAw_d7cbac56-3edd-42f1-ab22-0c50dcd6aa83"
      unitRef="usd">-81499000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNi0xLTEtMS00MzAw_1097e806-b30f-4f27-87ce-e2653b99bb2f"
      unitRef="usd">2755000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNi0zLTEtMS00MzAw_02ed4f01-9397-4bdd-b388-4436a0ec9b6b"
      unitRef="usd">2268000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNy0xLTEtMS00MzAw_b6734583-85e5-4592-9601-ea295b49b3b3"
      unitRef="usd">234000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNy0zLTEtMS00MzAw_ffab12a0-31bd-49d9-a7e7-6ba203b2433f"
      unitRef="usd">228000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfOC0xLTEtMS00MzAw_794b4980-c3d5-468f-afdb-f7c94418571c"
      unitRef="usd">1527000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfOC0zLTEtMS00MzAw_b5381c35-37a1-4434-922b-4d15d0e1e1d8"
      unitRef="usd">1696000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfOS0xLTEtMS00MzAw_cfbb7612-63dc-4139-935b-af36b1f0597e"
      unitRef="usd">162000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfOS0zLTEtMS00MzAw_f471f133-3124-46fd-89bf-d12c4b08fce3"
      unitRef="usd">159000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTAtMS0xLTEtNDMwMA_31f782d2-f3df-4ac1-8a7f-0ab9edd57c71"
      unitRef="usd">17952000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTAtMy0xLTEtNDMwMA_a7a7b6fc-1e55-4185-b7c9-96c6b520fc2c"
      unitRef="usd">22703000</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTEtMS0xLTEtNDMwMA_862d29ae-76e0-46bc-ac7d-22689319d707"
      unitRef="usd">2155000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTEtMy0xLTEtNDMwMA_229551ac-a3cb-43fb-85fe-25165583e9f5"
      unitRef="usd">-758000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTMtMS0xLTEtNDMwMA_b2e26d91-3d08-4339-9390-fe7e94425ec8"
      unitRef="usd">12256000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTMtMy0xLTEtNDMwMA_ea02f361-b8f5-458b-b6bc-8259a956a5b6"
      unitRef="usd">-1063000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InventoryWriteDown
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTItMS0xLTEtMTU3ODA_4d8d584a-ad3d-49a5-9e13-5535847ac2d6"
      unitRef="usd">3521000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTItMy0xLTEtMTU3ODA_35667819-e2c5-40cf-b278-6cc4cee1ca00"
      unitRef="usd">386000</us-gaap:InventoryWriteDown>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTQtMS0xLTEtNDMwMA_9083e5e4-5543-4188-990b-fafd63f84f9f"
      unitRef="usd">-201000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTQtMy0xLTEtNDMwMA_8408cd34-31e6-4cc1-8c16-1c9b46d5a308"
      unitRef="usd">-100000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTYtMS0xLTEtNDMwMA_e8222ba8-4133-423c-ad63-06135b5e223a"
      unitRef="usd">10803000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTYtMy0xLTEtNDMwMA_c51ce9bb-d466-450d-9e06-17a3276a573d"
      unitRef="usd">3611000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTctMS0xLTEtNDMwMA_e22daf40-87da-4c6d-9ccd-c48782a3fb4b"
      unitRef="usd">13319000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTctMy0xLTEtNDMwMA_6e42e907-8c14-497f-bf92-57498ea1c68f"
      unitRef="usd">6661000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTgtMS0xLTEtNDMwMA_927accd3-217c-4a43-a374-e6dac9166ed8"
      unitRef="usd">6888000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTgtMy0xLTEtNDMwMA_5b987294-80f1-453a-8ce2-0b27ee2e3059"
      unitRef="usd">1185000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTktMS0xLTEtNDMwMA_d2c461e7-6e9e-4f16-b509-3ae0bc45a1b8"
      unitRef="usd">5068000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMTktMy0xLTEtNDMwMA_eaf366af-e6c2-4428-836a-e5c4d6121016"
      unitRef="usd">6373000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjAtMS0xLTEtNDMwMA_cd125785-b5bc-4354-b8a3-05511c300906"
      unitRef="usd">-13186000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjAtMy0xLTEtNDMwMA_2e494476-f731-4622-8c9e-864b34e31f65"
      unitRef="usd">-17234000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjEtMS0xLTEtNDMwMA_6ba867c4-aa5b-4117-a4e3-550e856f01b9"
      unitRef="usd">423000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjEtMy0xLTEtNDMwMA_9a3da53c-08d7-450a-b213-aa23e13f469b"
      unitRef="usd">1949000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjItMS0xLTEtNDMwMA_56151c3c-de61-4243-bc5b-9d758cc7e35c"
      unitRef="usd">-1969000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjItMy0xLTEtNDMwMA_cc6009ea-a138-48ec-add1-9b27e0b2c134"
      unitRef="usd">-1884000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjMtMS0xLTEtNDMwMA_9dacf042-75a3-4b4e-8966-91863b2f8a32"
      unitRef="usd">-2455000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjMtMy0xLTEtNDMwMA_1da7a06b-0940-4d36-96b9-75db1ba4ba6d"
      unitRef="usd">-2512000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjQtMS0xLTEtNDMwMA_f756a93b-4303-4a79-9695-d032c76427db"
      unitRef="usd">-94691000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjQtMy0xLTEtNDMwMA_a385a387-17a2-49b4-af2a-fd19e42dacd7"
      unitRef="usd">-79029000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjYtMS0xLTEtNDMwMA_3d071a97-e570-44bd-8a9b-3ccce9c2ae25"
      unitRef="usd">3721000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjYtMy0xLTEtNDMwMA_05fee4f2-8662-4e92-b9b2-a833395f19c5"
      unitRef="usd">3638000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjktMS0xLTEtNDMwMA_c464c446-0dd9-4b67-bb1f-aeb26fad06c7"
      unitRef="usd">233291000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMjktMy0xLTEtNDMwMA_335df0d7-df91-46c2-9ea9-62f4265110c9"
      unitRef="usd">76369000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzAtMS0xLTEtNDMwMA_32752973-075f-4715-803a-4f9857d6f18c"
      unitRef="usd">595000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzAtMy0xLTEtNDMwMA_348c169f-03e0-4123-b425-9394109373a5"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzEtMS0xLTEtNDMwMA_accf3ea0-3f4a-4b55-8d7f-e8549581e062"
      unitRef="usd">163864000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzEtMy0xLTEtNDMwMA_a47c5af9-8aad-4381-bdfb-e7a8e8fbc458"
      unitRef="usd">122060000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzItMS0xLTEtNDMwMA_2331fc5a-b2e5-41fa-bf38-2da3cf7bc493"
      unitRef="usd">-72553000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzItMy0xLTEtNDMwMA_bfa81e12-8ccd-4248-8329-fec61846ad55"
      unitRef="usd">42053000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzYtMS0xLTEtNDMwMA_9489bdf7-84fe-4ab9-be75-53134bea21db"
      unitRef="usd">189200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzYtMy0xLTEtNDMwMA_c6a14c2b-f4d3-4f53-9e77-f3ef5e616eac"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzctMS0xLTEtNDMwMA_d00ac8eb-9857-473a-9911-dd50261765dd"
      unitRef="usd">7235000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzctMy0xLTEtNDMwMA_82a27098-7fe2-4328-aab0-fcdcad9b2903"
      unitRef="usd">5592000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzgtMS0xLTEtNDMwMA_7e48cb49-61ba-4636-9e05-5440d3a17e33"
      unitRef="usd">446000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfMzgtMy0xLTEtNDMwMA_279ad2a3-f773-4d22-b501-2e942577044a"
      unitRef="usd">377000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDAtMS0xLTEtNDMwMA_311418f8-af87-4b58-9f4e-b40abb9665be"
      unitRef="usd">195989000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDAtMy0xLTEtNDMwMA_a40381e5-b8b7-4aac-904a-fc6d7143d99d"
      unitRef="usd">5215000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDEtMS0xLTEtNDMwMA_cb3ba9c4-24ad-41c8-bb07-a6bc93cf304a"
      unitRef="usd">28745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDEtMy0xLTEtNDMwMA_5ee28d40-5f44-4a3d-9340-4116dcca7e27"
      unitRef="usd">-31761000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDItMS0xLTEtNDMwMA_1d6748d9-9403-49e2-8a6c-e678fd09e12d"
      unitRef="usd">328311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib71260de6ee845f5827e04115b08241b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDItMy0xLTEtNDMwMA_e8a651bb-e3a4-44f6-bcaa-ecd2f3232a0f"
      unitRef="usd">465817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDMtMS0xLTEtNDMwMA_4b35734d-9f69-4a65-9dee-3a2cfae9fa80"
      unitRef="usd">357056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDMtMy0xLTEtNDMwMA_c85909ba-2116-43bd-a56b-7d6837a65c24"
      unitRef="usd">434056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDQtMS0xLTEtNDMwMA_c8ce9941-20b1-43a7-96e4-ee4bcabd7059"
      unitRef="usd">353834000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDQtMy0xLTEtNDMwMA_708ac36c-41b0-42ba-8535-5bdb08c8ce7e"
      unitRef="usd">428574000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDUtMS0xLTEtNDMwMA_7a79132a-b043-44e5-8fe1-2d68513c04f1"
      unitRef="usd">3222000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDUtMy0xLTEtNDMwMA_af882460-122d-41a1-8779-c1156dea9e50"
      unitRef="usd">5482000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDYtMS0xLTEtNDMwMA_7a1ab5f4-9e09-4037-baf9-e3b12bbb7a38"
      unitRef="usd">357056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8yNS9mcmFnOmE1NTk1ZjEyNmRlZjQ3MDA5NzYwZWY3OGJkY2QyOGZhL3RhYmxlOjU2NzYyZmRkNmY1ZjQxMGE4Y2QwYmQzNDc1YTNjN2NkL3RhYmxlcmFuZ2U6NTY3NjJmZGQ2ZjVmNDEwYThjZDBiZDM0NzVhM2M3Y2RfNDYtMy0xLTEtNDMwMA_d262a2f1-0064-4c8c-b71d-4a89ed4cf202"
      unitRef="usd">434056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU4MA_a7f3991a-2e5d-4576-a245-c60f64883721">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We are a life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our existing HiFi long-read sequencing technology and our emerging short-read Sequencing by Binding (SBB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;) technology. Our products address solutions across a broad set of applications including human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on providing our customers with advanced sequencing technologies with higher throughput and improved workflows that we believe will enable dramatic advancements in routine healthcare. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in this report to &#x201c;PacBio,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; and &#x201c;our&#x201d; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2022 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2023. Actual results could differ materially from these estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash and Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration and Other Risks &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023, no customer represented 10% or greater of our total revenue during the period. For the three months ended March&#160;31, 2022, two customers accounted for approximately 14% and 11%, respectively, of total revenue during the period. No other customers exceeded 10% during those periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, 49% of our accounts receivable were from domestic customers, compared to 57% as of December&#160;31, 2022. As of March&#160;31, 2023, no customer represented 10% or greater of our accounts receivable, while one customer represented approximately 10% of our net accounts receivable as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to our significant accounting policies as disclosed in the Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU4Mg_9c4bd387-ae80-4120-9991-e9b4484b0185">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2022 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to current period presentation.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU3OQ_06cfa062-bc03-444f-9ae5-1e7e6abe8701">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2023. Actual results could differ materially from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU4Mw_cd36157f-d442-4d4e-98ab-ca40af09d79d">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNDM5ODA0NjU0NDc5NA_000cae07-1beb-4f58-9639-2de2148bbe52">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNDM5ODA0NjU0NDc5Mw_8fe94546-7b32-424c-b201-b7903899bd82">Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib74a70bcb48d4df6a79ecde68ca7040d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNTgwMw_27e7e558-1408-4728-b517-6f1ea2ef4e5a"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib90fd5a838bf4898b37389a8c2bf2e1c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfODI0NjMzNzI0MzIxMA_68c65357-6fae-41bd-bfb3-86c430ebe7fc"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idd1f31512b50453585d88478dd9e32d0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNTkxNQ_04696958-8867-44bc-9616-4dcd1f0fe4d1"
      unitRef="number">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3f53c3bcf98f4143b2d656d33b41f1c4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNTk4Nw_aedb9f39-32cb-4875-bb1c-364c70a6c98b"
      unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i774d705431d84bc8ad8c5a09742aa5c1_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfMTA5OTUxMTY0OTcxOA_b3850014-f4e5-45f1-9369-0c9af146bb6a"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF8zMS9mcmFnOjY5N2IxN2VhMmQ1OTQ3YjVhN2IzYzNlMDZmYzMwYzdhL3RleHRyZWdpb246Njk3YjE3ZWEyZDU5NDdiNWE3YjNjM2UwNmZjMzBjN2FfNzU4NQ_b1d60dc1-321b-482f-bfad-5115e37e74ba">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNjU5NzA2OTc3Njk3OQ_5f8f9c58-5e06-415c-b6ff-f6ab1165b8fc">FINANCIAL INSTRUMENTS&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;103,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;250,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;353,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;187,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;325,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;109,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;109,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;87,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;87,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;323,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;323,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;521,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;521,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;106,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;771,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;878,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;140,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;634,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;775,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify contingent consideration, which was incurred in connection with the acquisition of Omniome, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of the contingent consideration liability by discounting the probability-weighted outcomes to present value using an estimate of our borrowing rate and the risk-free rate. The potential outcomes of milestone achievement dates are within the period from June&#160;30, 2023 to June&#160;30, 2025. A decrease in the probability of an earlier scenario within this range would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- and B credit rating, which ranges from 9.3% to 10.2%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ending balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the fair value are recorded as change in fair value of contingent consideration in the Condensed Consolidated Statement of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash, cash equivalents and investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;353,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;353,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;110,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;109,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;325,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;323,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;522,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;521,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;876,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;874,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;325,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;325,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;127,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;274,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;777,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;772,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;634,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after one year through five years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;136,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;771,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTExOQ_2933d98e-f7a2-4e2f-9ab6-4580558b5570">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTEyMA_02a2d488-c965-4a51-9409-0d25c8dc8962">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;103,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;250,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;353,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;187,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;325,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;109,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;109,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;87,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;87,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;323,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;323,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;521,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;521,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;106,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;771,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;878,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;140,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;634,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;775,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0xLTEtMS00MzAw_0dda0c17-d01c-4af5-b388-620e78c0f298"
      unitRef="usd">103753000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0zLTEtMS00MzAw_3fd84e3e-bfee-4061-9566-f5b2656d4dd2"
      unitRef="usd">250081000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy01LTEtMS00MzAw_d7578961-ab0d-4d6b-b4c5-d4b68055c5e2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy03LTEtMS00MzAw_8e6c35fd-c2e4-4175-b72d-da83d7be66d2"
      unitRef="usd">353834000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy05LTEtMS00MzAw_776331a3-f490-4288-b5f8-9290d77ebe0a"
      unitRef="usd">137636000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0xMS0xLTEtNDMwMA_ae46ac32-cbd8-47e0-adec-bbdb6850c58b"
      unitRef="usd">187453000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0xMy0xLTEtNDMwMA_12001456-0f3e-47e6-89f5-65440ea695df"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMy0xNS0xLTEtNDMwMA_7de2cb93-8554-42b8-86c6-87ab9a54bf33"
      unitRef="usd">325089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i181aa9f4b31640dc8b14b6f82d70f240_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0xLTEtMS00MzAw_7702b825-c29a-4751-aed0-a71f95b26019"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idae08cb548c441d3a91eba1de5219bd2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0zLTEtMS00MzAw_2fcf9fb4-e272-46d0-8507-77e5b14fa572"
      unitRef="usd">109873000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i849871cbc3cc45449d92adfe970af3c2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS01LTEtMS00MzAw_54a71b6c-dff4-4333-aac4-46fd8f0bfea0"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2a3125acf4ad4057b79910330fc7d13f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS03LTEtMS00MzAw_d564883c-f1bb-4116-93ae-f55fc645bab9"
      unitRef="usd">109873000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i65ab613bda3d44499a905662ecf1e971_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS05LTEtMS00MzAw_600acaf4-eadb-45e7-9039-92579b1aa529"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i69ec8616bd37486dbff25977da4441f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0xMS0xLTEtNDMwMA_394a6060-ebba-41ae-9f74-7d6764fa0068"
      unitRef="usd">127302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i291b4bea01ad41c8963da94469fbd98f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0xMy0xLTEtNDMwMA_d7f31589-5bb8-4b85-babf-860d0b47a549"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i619b5be971f6439098c7aeac4e276a0d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNS0xNS0xLTEtNDMwMA_4052dde3-27ff-43f0-9ef1-9b77dc02e063"
      unitRef="usd">127302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i49aeaa24126c489988a6ac04f57a2a00_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0xLTEtMS00MzAw_53de9f29-202d-4874-b3f9-817fb860c136"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8ee96d635765436ca616328acee64b12_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0zLTEtMS00MzAw_384ed3f7-4cc9-4943-a143-4ac685816569"
      unitRef="usd">87381000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9d490d8a9b4c43f9b0eb01ef5372cfe7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi01LTEtMS00MzAw_63686101-787a-49da-8cc2-e8161899adf4"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i94319df9941e4d4c9b28b64317ee7277_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi03LTEtMS00MzAw_51acd9da-779f-40c6-bd9b-d123d0d9e181"
      unitRef="usd">87381000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7d93184ef1de4f57bce4ecfe8206889f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi05LTEtMS00MzAw_6c1afbe2-a838-482a-93ed-48f8a8e005de"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idfa53ec2a0144c8dab9bfffe76c775ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0xMS0xLTEtNDMwMA_12efad5f-4214-4801-88ee-1210f999cc44"
      unitRef="usd">49491000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5a8af53f30ae4b7885dc2a7228d101d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0xMy0xLTEtNDMwMA_6aec199c-5418-4ca3-a29d-c506e6721947"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4750e8e52de64b8ab4710c73414a1095_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNi0xNS0xLTEtNDMwMA_63e3e5b0-a88d-4703-ba4d-2b638ff01d26"
      unitRef="usd">49491000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i54541305e5464edbb7c276c8782d6c2e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0xLTEtMS00MzAw_b7fc7491-7ce7-46dd-9172-6d782265b823"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iebf211a0be2545bcb8bb2d83516598b9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0zLTEtMS00MzAw_7efd3a2e-f1f6-4260-bc7b-e9f1dc7f1e0c"
      unitRef="usd">323804000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if015623b8ea744f8818948cfc6f9cec7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy01LTEtMS00MzAw_ddaf2c75-8614-4648-ba73-88021fdb6908"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i48b6553253ca455f8645230475b2cc61_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy03LTEtMS00MzAw_4a86e2b6-23ab-49c9-9a0f-07bd4b5399f4"
      unitRef="usd">323804000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibe2a17ef15ba4c0cbedffc645c45aab6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy05LTEtMS00MzAw_62fd167e-85c7-49e7-9532-2886e3dd6955"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iceb62135438a477dbd091a982c13e82b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0xMS0xLTEtNDMwMA_68c384db-d8eb-447f-bcbf-ef3fa667856c"
      unitRef="usd">270436000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i55e15ba1dd7f452d855f284c62a7103b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0xMy0xLTEtNDMwMA_33b5ea39-ac59-46f2-b77f-22049d107b0c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia4e23dae7b884c2d8e323afdc2202ec1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfNy0xNS0xLTEtNDMwMA_686fc195-4f58-4560-ba28-34c81b1a3788"
      unitRef="usd">270436000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0xLTEtMS00MzAw_e35382d6-f980-4925-b0b8-36a278436695"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0zLTEtMS00MzAw_2f3b6927-de81-4177-aa2f-99855feeec53"
      unitRef="usd">521058000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC01LTEtMS00MzAw_5d821d88-feee-4106-ae48-86828e44d0ad"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC03LTEtMS00MzAw_8d0243e1-f86a-439b-a16c-4199b34928f6"
      unitRef="usd">521058000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC05LTEtMS00MzAw_daacbaaa-e25f-4146-b803-6926d699422a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0xMS0xLTEtNDMwMA_69c47a93-2f10-43cb-99e8-5a882ba18a3d"
      unitRef="usd">447229000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0xMy0xLTEtNDMwMA_398948bc-ea5c-46b1-84ca-8ec38ad4641e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfOC0xNS0xLTEtNDMwMA_d891c9f9-d4ef-4362-8624-3920f471794f"
      unitRef="usd">447229000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:RestrictedCashCurrent
      contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMS0xLTEtNDMwMA_ca5bdf7f-1e5a-4692-9a9e-6af3726ab20a"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMy0xLTEtNDMwMA_86718bab-904d-49b5-92bf-f127399b31a0"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtNS0xLTEtNDMwMA_db29743b-164a-483e-80ba-4fa851922dbd"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtNy0xLTEtNDMwMA_0435bc91-caef-4a4c-8e50-4e4f59012929"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtOS0xLTEtNDMwMA_f1d7c67e-019a-411c-adc0-1a584051f8e4"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMTEtMS0xLTQzMDA_75cc0302-1d51-4dfb-8ab6-8d9381f849f2"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMTMtMS0xLTQzMDA_dcfc8c48-4c70-4381-a719-d39c6b3547ee"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTAtMTUtMS0xLTQzMDA_20aea589-9827-46e4-996c-6afda7481cd5"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMS0xLTEtNDMwMA_e1a60f65-5225-4d6e-82c8-44da103b35b4"
      unitRef="usd">2922000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMy0xLTEtNDMwMA_1593c891-ddd4-44a0-ac9a-c1b5f0ccdcb8"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtNS0xLTEtNDMwMA_c1628a64-85b4-4b22-9ab4-30455cc72118"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtNy0xLTEtNDMwMA_994ee833-60ca-49eb-94b6-f0019d531304"
      unitRef="usd">2922000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtOS0xLTEtNDMwMA_0b9cfd5e-9dc4-4821-b862-7ac24ab8072b"
      unitRef="usd">2922000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMTEtMS0xLTQzMDA_8b76cbcb-6a7a-4511-9d35-beb0def85d63"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMTMtMS0xLTQzMDA_b2fd2510-bc69-4141-8d82-531a47d1e062"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTEtMTUtMS0xLTQzMDA_d165e0e2-430e-438e-b99f-4b4d2b02a98d"
      unitRef="usd">2922000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMS0xLTEtNDMwMA_f3a9419f-4cb9-4197-8580-220d9aaa5878"
      unitRef="usd">106975000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMy0xLTEtNDMwMA_3bba5e99-449a-4ec5-b8ba-a269dcbd261b"
      unitRef="usd">771139000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItNS0xLTEtNDMwMA_d42c72dc-d9a3-453c-a3e7-66403d56a6fa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItNy0xLTEtNDMwMA_b3d97c68-38ef-4aa6-b5a7-5adc981cef06"
      unitRef="usd">878114000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItOS0xLTEtNDMwMA_522ee2fa-dcec-4583-b302-d09b4f9ab3ca"
      unitRef="usd">140858000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMTEtMS0xLTQzMDA_e3bc0abc-df49-4aa0-901d-35cbe9a28d94"
      unitRef="usd">634682000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMTMtMS0xLTQzMDA_26dda997-985e-40d7-8530-4c9047d4591b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTItMTUtMS0xLTQzMDA_5184b603-d22c-4344-9a18-acd95322d1d8"
      unitRef="usd">775540000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMS0xLTEtNDMwMA_f5b55168-39d8-419d-a255-a6ff153ebd39"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMy0xLTEtNDMwMA_31350c3b-edcc-45ec-ab46-3902b824c8b4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtNS0xLTEtNDMwMA_cf17dc32-46e6-47db-8a96-c455043ffdb4"
      unitRef="usd">184350000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtNy0xLTEtNDMwMA_1a1c62f2-a258-4b37-886a-2679717f4d54"
      unitRef="usd">184350000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtOS0xLTEtNDMwMA_a01d2afd-92e3-4118-86ae-122f3e014f90"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMTEtMS0xLTQzMDA_f0f8a67d-dfed-40b3-9538-d8244abac040"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMTMtMS0xLTQzMDA_7a100df7-000f-4ada-b90c-b41deb93c3df"
      unitRef="usd">172094000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTUtMTUtMS0xLTQzMDA_6885b67e-608c-4e44-bea4-83a24da8b167"
      unitRef="usd">172094000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i25920f50c4c04d77b9d0cd22fdc09393_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMS0xLTEtNDMwMA_55ce118b-f84c-4dd9-85a9-0ee6bdf86ab3"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9ae391408ebf445da076c0866d88c4bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMy0xLTEtNDMwMA_3cc8dbf5-f8fd-4058-a7b9-78dfbaac81df"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie9967229d5414a46b6899d104fa4fcba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtNS0xLTEtNDMwMA_e0dda820-b6ae-4221-84d0-c83bd0937153"
      unitRef="usd">184350000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtNy0xLTEtNDMwMA_448a4a32-eff5-4047-8231-8ab6986440f2"
      unitRef="usd">184350000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i22e1e2078c914a13a68381f4308c93a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtOS0xLTEtNDMwMA_c2c44da8-d5fc-4750-baa1-5fc1d2a6c8d0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ice0b5b7475eb4dbdb6315f049052a2c5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMTEtMS0xLTQzMDA_4191045b-d0a2-45d1-9945-e2f65b6538ea"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7e5bfade3a5f42a4b09bc55969df3a96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMTMtMS0xLTQzMDA_f59d8159-ca23-4539-bc0a-b2b3e686a0ac"
      unitRef="usd">172094000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjEzNTY5MDJhZmU5NDRhMTQ5YzY5MjNiNTA5Njg1N2U5L3RhYmxlcmFuZ2U6MTM1NjkwMmFmZTk0NGExNDljNjkyM2I1MDk2ODU3ZTlfMTYtMTUtMS0xLTQzMDA_88a437d4-0c12-4036-b823-433f780c54ad"
      unitRef="usd">172094000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iab42dea2b5104f92933733e4ae8b828c_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTQ5NzU1ODE5MjYz_21d7efe8-ce7e-44be-9b73-2e6c7ad8b45b"
      unitRef="number">0.093</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id826230d5e794444a1100227d2df4064_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTQ5NzU1ODE5MjY3_c3c0413f-ba12-4983-b5b7-1792c96617cb"
      unitRef="number">0.102</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNTEyMQ_00d158f1-8463-43f9-9942-3817efdba4f5">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ending balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOmQxN2Q4MTRmZTUyOTRkNzFiMDFkYmMwMzhmOGEyYzUzL3RhYmxlcmFuZ2U6ZDE3ZDgxNGZlNTI5NGQ3MWIwMWRiYzAzOGY4YTJjNTNfMS0xLTEtMS00MzAw_3c24fcb0-04dd-4cf5-93a1-c847c2c67a22"
      unitRef="usd">172094000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOmQxN2Q4MTRmZTUyOTRkNzFiMDFkYmMwMzhmOGEyYzUzL3RhYmxlcmFuZ2U6ZDE3ZDgxNGZlNTI5NGQ3MWIwMWRiYzAzOGY4YTJjNTNfMi0xLTEtMS00MzAw_10cd08f5-6aa2-4241-a7ef-9c54fb3b5f96"
      unitRef="usd">12256000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOmQxN2Q4MTRmZTUyOTRkNzFiMDFkYmMwMzhmOGEyYzUzL3RhYmxlcmFuZ2U6ZDE3ZDgxNGZlNTI5NGQ3MWIwMWRiYzAzOGY4YTJjNTNfMy0xLTEtMS00MzAw_9602d317-8a4b-47ad-b5fd-d66f2ed82308"
      unitRef="usd">184350000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RleHRyZWdpb246Y2ZjNDM5N2RlZjllNDBhNjgxZjU2YjVlZmEyMjkyZTZfNDM5ODA0NjUyMTQyOA_ce58661a-df33-4ad8-b192-58c6ad906ef6">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash, cash equivalents and investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;353,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;353,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;110,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;109,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;325,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;323,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;522,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;521,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;876,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;874,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;325,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;325,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;127,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;274,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;777,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;772,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;634,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after one year through five years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;136,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;771,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i3f54406977384ecdbd22b1c966005bd1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMy0xLTEtMS03MTM4_3a03aad5-de6b-4b7c-bb05-97c3f2b5a7f2"
      unitRef="usd">353837000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3f54406977384ecdbd22b1c966005bd1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMy0zLTEtMS03MTM4_3b31d76e-041f-405d-8344-fc271f68b96e"
      unitRef="usd">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f54406977384ecdbd22b1c966005bd1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMy01LTEtMS03MTM4_527ee8e0-04af-423e-b379-6d558e65cbda"
      unitRef="usd">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3f54406977384ecdbd22b1c966005bd1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMy03LTEtMS03MTM4_02dcd670-ee7b-4053-96b1-15a84cbeb775"
      unitRef="usd">353834000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i447b3166a1894e65ad053b4aca1c8396_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNS0xLTEtMS03MTM4_f2cba353-cf19-445d-b658-e81fe9c8b1f2"
      unitRef="usd">110009000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i447b3166a1894e65ad053b4aca1c8396_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNS0zLTEtMS03MTM4_514aef82-d60e-4cc7-be73-99ae0941b51c"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i447b3166a1894e65ad053b4aca1c8396_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNS01LTEtMS03MTM4_8f1af1b9-d4e4-450f-bdf9-40b170fc40f2"
      unitRef="usd">153000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i447b3166a1894e65ad053b4aca1c8396_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNS03LTEtMS03MTM4_5eac8a01-e377-4cb1-abbe-1a0925c9c75b"
      unitRef="usd">109873000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="if2809d3f2dac4155af95932f49d85131_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNi0xLTEtMS03MTM4_602ad263-0383-4dbe-89d9-1d346c8915ff"
      unitRef="usd">87426000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if2809d3f2dac4155af95932f49d85131_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNi0zLTEtMS03MTM4_892e195d-cdeb-4e7a-86cb-8da6e13ce360"
      unitRef="usd">299000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if2809d3f2dac4155af95932f49d85131_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNi01LTEtMS03MTM4_6f024b80-6602-4b15-a4f4-621990e6cb23"
      unitRef="usd">344000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if2809d3f2dac4155af95932f49d85131_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNi03LTEtMS03MTM4_3a9ad227-3f76-4a52-82e2-afc771e344df"
      unitRef="usd">87381000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iaf35d3b973c84f74991c106cc5541b89_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNy0xLTEtMS03MTM4_4794fb58-a139-4976-b053-f77ea7775c7b"
      unitRef="usd">325544000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf35d3b973c84f74991c106cc5541b89_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNy0zLTEtMS03MTM4_88f94ff1-c855-49e4-a0b2-5e7b842c9f18"
      unitRef="usd">576000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf35d3b973c84f74991c106cc5541b89_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNy01LTEtMS03MTM4_03d9adb3-1622-477f-a736-7ef08ff96e4b"
      unitRef="usd">2316000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaf35d3b973c84f74991c106cc5541b89_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfNy03LTEtMS03MTM4_7b449acc-e5da-41a1-a8f3-9cd131be83d0"
      unitRef="usd">323804000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i3b785e7e49a249b7975eb905979aa957_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOC0xLTEtMS03MTM4_80928ca6-d7c1-412f-81c8-ae645bccc2d5"
      unitRef="usd">522979000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3b785e7e49a249b7975eb905979aa957_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOC0zLTEtMS03MTM4_d79f1d21-393a-4e7f-a060-c5134da2c1ac"
      unitRef="usd">892000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3b785e7e49a249b7975eb905979aa957_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOC01LTEtMS03MTM4_5ab3a38d-dabd-4908-928b-09918cb6f9d3"
      unitRef="usd">2813000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3b785e7e49a249b7975eb905979aa957_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOC03LTEtMS03MTM4_dbc58289-eb79-4c1a-a069-1879ad923ec1"
      unitRef="usd">521058000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOS0xLTEtMS03MTM4_a2770f20-b64f-4365-b517-9058eb47083e"
      unitRef="usd">876816000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOS0zLTEtMS03MTM4_6b0f95f6-7cfa-4e16-ac9e-661277a70da6"
      unitRef="usd">916000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOS01LTEtMS03MTM4_e7300343-4be4-4cf1-840b-48fe63159f97"
      unitRef="usd">2840000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfOS03LTEtMS03MTM4_762d6421-2102-4ccd-8b33-ca352cc82e07"
      unitRef="usd">874892000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTEtMS0xLTEtNzEzOA_56d236a3-23e5-499e-96d6-9ab1e8edb63e"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTEtNy0xLTEtNzEzOA_5ad2443a-c4e8-4504-8f57-be5f105fbdfd"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTItMS0xLTEtNzEzOA_c4f5d857-848f-43c5-a986-a26f84c272c5"
      unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTItNy0xLTEtNzEzOA_fdb29764-2835-4ed1-aea9-f58f9011748e"
      unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="if53a52cbc7e348799f5eb8078ff67bb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTgtMS0xLTEtNzEzOA_9078c4ad-7ab8-4abe-80a4-ea3b44fba141"
      unitRef="usd">325144000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if53a52cbc7e348799f5eb8078ff67bb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTgtMy0xLTEtNzEzOA_931a0c34-2528-46e0-a713-4ec4ac1a14f6"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if53a52cbc7e348799f5eb8078ff67bb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTgtNS0xLTEtNzEzOA_a9c63193-1593-409a-ab76-7f802e42ad33"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if53a52cbc7e348799f5eb8078ff67bb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMTgtNy0xLTEtNzEzOA_d6ab364e-9683-42d2-a3e3-ac80480cdaea"
      unitRef="usd">325089000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i642d2faa764c497fb709bd8f7cf545ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjAtMS0xLTEtNzEzOA_400d3cab-5e31-434a-b586-a2b03c065cbf"
      unitRef="usd">127626000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i642d2faa764c497fb709bd8f7cf545ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjAtMy0xLTEtNzEzOA_00303518-c3ea-4fa7-af0b-cc593f3e9f61"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i642d2faa764c497fb709bd8f7cf545ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjAtNS0xLTEtNzEzOA_945f621d-a395-4b94-bac4-1e372a92666a"
      unitRef="usd">333000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i642d2faa764c497fb709bd8f7cf545ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjAtNy0xLTEtNzEzOA_64ea8864-5b81-466c-9b0a-c9f7f5576fec"
      unitRef="usd">127302000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjEtMS0xLTEtNzEzOA_2eb007bc-f825-4b5a-a9cc-2d6defac4cbb"
      unitRef="usd">49998000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjEtMy0xLTEtNzEzOA_b00376d8-a7e7-4e23-a04f-7e63eabeb618"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjEtNS0xLTEtNzEzOA_5507f721-9cfa-47fe-8a23-65e51251095a"
      unitRef="usd">507000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iee27a6b495d34ac280f6547e7d3d1dcf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjEtNy0xLTEtNzEzOA_21acc481-8f15-40f7-b4fb-a9c6d9962c93"
      unitRef="usd">49491000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i7f0aa7e818a540b4b3800563f1640bb5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjItMS0xLTEtNzEzOA_12cfabc3-916c-416b-8a45-82139c99a826"
      unitRef="usd">274315000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f0aa7e818a540b4b3800563f1640bb5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjItMy0xLTEtNzEzOA_cf0171ad-ea15-4cb4-95de-ef574f03e469"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f0aa7e818a540b4b3800563f1640bb5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjItNS0xLTEtNzEzOA_3c3fd9e4-9334-4234-bec3-64380d3a5a4c"
      unitRef="usd">3880000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7f0aa7e818a540b4b3800563f1640bb5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjItNy0xLTEtNzEzOA_efbb8970-218b-453f-aa64-d855ef151ee8"
      unitRef="usd">270436000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjMtMS0xLTEtNzEzOA_270a938b-f458-4cbc-8032-68da39a508c9"
      unitRef="usd">451939000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjMtMy0xLTEtNzEzOA_dbec8d04-5546-4184-ac2a-c1448023964a"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjMtNS0xLTEtNzEzOA_c0447548-a2ec-423d-9119-3d6e74e919f6"
      unitRef="usd">4720000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i95eb269f6e6a4f24b08f5751caf9bbc1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjMtNy0xLTEtNzEzOA_9d0506f3-a119-4f6b-a970-791396dc2abf"
      unitRef="usd">447229000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjQtMS0xLTEtNzEzOA_903b61d2-852f-48d2-bde9-3e4a7e05d779"
      unitRef="usd">777083000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjQtMy0xLTEtNzEzOA_6d61209c-d6cc-4176-9eae-c4c6875c5dc3"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjQtNS0xLTEtNzEzOA_4c43532c-057b-4656-8fcc-1c32fe02d516"
      unitRef="usd">4781000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjQtNy0xLTEtNzEzOA_9899fe18-6193-44f9-9ff0-e9f820561366"
      unitRef="usd">772318000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RestrictedCashCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjYtMS0xLTEtNzEzOA_be4ef5c8-68d6-4de9-9abc-eb0942d44c88"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjYtNy0xLTEtNzEzOA_f9f05628-386b-4088-860b-b97289b2e2e6"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjctMS0xLTEtNzEzOA_71b92477-8424-4e9d-93fa-da922f026462"
      unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjhkNTM2MWVkZjhlZjQ1YmM5OGFkYzVkODgyZjdkMzZkL3RhYmxlcmFuZ2U6OGQ1MzYxZWRmOGVmNDViYzk4YWRjNWQ4ODJmN2QzNmRfMjctNy0xLTEtNzEzOA_6b938c39-dacb-4a60-8da9-846e1f1d810f"
      unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjJjNjY1MzFkMTczNTQwOTI5YWI0NTQ5NzkwOTBkMDk0L3RhYmxlcmFuZ2U6MmM2NjUzMWQxNzM1NDA5MjlhYjQ1NDk3OTA5MGQwOTRfMS0xLTEtMS00MzAw_d98ef60d-ff29-4865-a877-03f3a9924247"
      unitRef="usd">634191000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjJjNjY1MzFkMTczNTQwOTI5YWI0NTQ5NzkwOTBkMDk0L3RhYmxlcmFuZ2U6MmM2NjUzMWQxNzM1NDA5MjlhYjQ1NDk3OTA5MGQwOTRfMi0xLTEtMS00MzAw_c70b9404-2154-4a70-8a54-828abdc9f65e"
      unitRef="usd">136948000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80My9mcmFnOmNmYzQzOTdkZWY5ZTQwYTY4MWY1NmI1ZWZhMjI5MmU2L3RhYmxlOjJjNjY1MzFkMTczNTQwOTI5YWI0NTQ5NzkwOTBkMDk0L3RhYmxlcmFuZ2U6MmM2NjUzMWQxNzM1NDA5MjlhYjQ1NDk3OTA5MGQwOTRfMy0xLTEtMS00MzAw_2681ed65-0bdd-4c46-8322-0e82f3f7f1d1"
      unitRef="usd">771139000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM4OQ_7eb0fcbf-0fc1-4c82-8428-071178572618">BALANCE SHEET COMPONENTS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our inventory, net, consisted of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include acquired in-process research and development ("IPR&amp;amp;D") of $400 million as a result of the Omniome acquisition in September 2021. The IPR&amp;amp;D will remain on our Consolidated Balance Sheet as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development activities. During the development period following the acquisition, IPR&amp;amp;D will not be amortized, but instead will be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. Upon completion of the development, we will begin to amortize the asset over the life of the product, or record an impairment charge if the asset is determined to be impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, definite-lived intangible assets included the following (in thousands, except years): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review definite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2022, noting no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, we entered into an Amended and Restated Development and Commercialization Agreement (the &#x201c;Amended and Restated Agreement&#x201d;) with Invitae Corporation (&#x201c;Invitae&#x201d;). During the three months ended March&#160;31, 2023, Invitae did not purchase any of the instruments or consumables under the terms of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amended and Restated Agreement. As of March&#160;31, 2023 and December&#160;31, 2022, $21.4 million of deferred revenue, current, is recorded on the Condensed Consolidated Balance Sheet relating to all future performance obligations under the Amended and Restated Agreement. Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3 &#x2013; Invitae Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, we had a total of $32.7&#160;million of deferred revenue, $30.9&#160;million of which was recorded as deferred revenue, current, and primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae. The deferred revenue, non-current balance of $1.8&#160;million primarily relates to deferred service contract revenues and is scheduled to be recognized in the next 5 years. Revenue recorded in the three months ended March&#160;31, 2023 includes $3.5&#160;million of previously deferred revenue that was included in deferred revenue as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Warranties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. There were no material changes in estimates for the periods presented below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Term loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Omniome, we acquired $1.3 million in short-term debt and $3.0 million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#x2019;s purchases of equipment, which serves as collateral. Each term loan has a term of 43 months and bears a fixed interest rate of approximately 17% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; month and before the 43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;rd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; month after the commencement date, is 4% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the carrying value of term loans outstanding was $1.9&#160;million. The related long-term portion of $0.2&#160;million was recorded as part of other liabilities, non-current and the short-term portion of $1.7&#160;million was recorded as part of other liabilities, current on the Condensed Consolidated Balance Sheet. The interest expense was $0.1&#160;million for the three months ended March 31, 2023, which was included as part of interest expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"/&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the future principal payments on the term loans (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5MA_5d50449f-4e01-4dfa-91b3-6fc41785f61a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our inventory, net, consisted of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMS0xLTEtMS00MzAw_affc274d-d77d-42a2-aea5-0be762de9e79"
      unitRef="usd">25475000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMS0zLTEtMS00MzAw_304a41d9-6c62-49fc-bcc7-e1fdf88c744d"
      unitRef="usd">24139000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMi0xLTEtMS00MzAw_d69ea7b5-de37-4de8-9c7d-bee3a4090ff9"
      unitRef="usd">21705000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMi0zLTEtMS00MzAw_ad42539b-94df-417a-9910-9f0e7602d51f"
      unitRef="usd">14062000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMy0xLTEtMS00MzAw_1821144f-98b3-4144-9520-65ed2ea45fe2"
      unitRef="usd">14775000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfMy0zLTEtMS00MzAw_99970a5d-1ce7-455b-a2ce-2ca8e50e64cf"
      unitRef="usd">12180000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfNC0xLTEtMS00MzAw_3eb7e261-b00b-4ce5-808b-36f09a24c02b"
      unitRef="usd">61955000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmIyYmQ5YTNjY2NjOTQzZjU5NTFmZmVlYTZiNjU3ZmI5L3RhYmxlcmFuZ2U6YjJiZDlhM2NjY2M5NDNmNTk1MWZmZWVhNmI2NTdmYjlfNC0zLTEtMS00MzAw_9027736c-b7f9-4ff0-af99-c267c9f295fc"
      unitRef="usd">50381000</us-gaap:InventoryNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4c2165a552b2406aad1c18da3e5bcba1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfMTQ5NA_9f960b06-44dc-455e-82e1-db9e1c059a3e"
      unitRef="usd">400000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5MQ_eac39a1f-7f74-4057-be80-2ef4acff48c9">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, definite-lived intangible assets included the following (in thousands, except years): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7f0c2ed914b74450b0a466f80963c39e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi0xLTEtMS00MzAw_8338f8dc-f90d-428d-99f0-0491e4c14c16">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4bed7d66a5a240dd880c5f2e196b2fb4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi0zLTEtMS00MzAw_4a205d7d-d0e8-478d-b4e6-849c864ac43f"
      unitRef="usd">11179000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4bed7d66a5a240dd880c5f2e196b2fb4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi01LTEtMS00MzAw_beaa7b5f-2fe2-4d6b-8d1d-c1f0a461ffe8"
      unitRef="usd">1228000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4bed7d66a5a240dd880c5f2e196b2fb4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi03LTEtMS00MzAw_6725a6b8-772c-4c47-8d21-bf5510936b8d"
      unitRef="usd">9951000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic6cf974ed2ad44f0b3a0fa6beaa4d15a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi05LTEtMS00MzAw_7a1d1b51-5472-4a6f-8990-c28f13c2774c"
      unitRef="usd">11179000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic6cf974ed2ad44f0b3a0fa6beaa4d15a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi0xMS0xLTEtNDMwMA_61a6d471-be0d-4636-8b83-f41082e57786"
      unitRef="usd">1039000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic6cf974ed2ad44f0b3a0fa6beaa4d15a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMi0xMy0xLTEtNDMwMA_572726a8-33ab-4386-aca8-f204a80646c1"
      unitRef="usd">10140000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i70ceb8bb0a3b41be9d4cc3b73a38fb83_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy0xLTEtMS00MzAw_81b1e520-5dba-42b9-aa7d-beb988c9e7f4">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia15d8c644eec4080836b0b62648963ed_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy0zLTEtMS00MzAw_cf731d52-ea83-47c0-b196-874a6d8f958d"
      unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia15d8c644eec4080836b0b62648963ed_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy01LTEtMS00MzAw_7a78fd51-4dea-4518-a3f3-aa09f04d1ad6"
      unitRef="usd">300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia15d8c644eec4080836b0b62648963ed_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy03LTEtMS00MzAw_2fc3fef1-6a0a-4158-86e8-fea4e0d5c4f8"
      unitRef="usd">60000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4b8fbcede4404a2e8b1019f78237b47e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy05LTEtMS00MzAw_55364284-cd5f-444e-9802-db7bef4ef752"
      unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4b8fbcede4404a2e8b1019f78237b47e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy0xMS0xLTEtNDMwMA_5e519b5d-bc41-40d6-a6f9-8699718ecf4e"
      unitRef="usd">255000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4b8fbcede4404a2e8b1019f78237b47e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfMy0xMy0xLTEtNDMwMA_5ce003e2-cba6-4ac8-adba-1fe5aeea8aad"
      unitRef="usd">105000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC0zLTEtMS00MzAw_7dbd08b0-e48b-4432-9a3f-fca605f91142"
      unitRef="usd">11539000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC01LTEtMS00MzAw_011b3587-2f92-4a46-8529-14fd8173f46d"
      unitRef="usd">1528000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC03LTEtMS00MzAw_00221f47-55ed-42fb-a499-c3458636f232"
      unitRef="usd">10011000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC05LTEtMS00MzAw_f88e9be5-fad1-406b-ad54-0ce34e5fd423"
      unitRef="usd">11539000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC0xMS0xLTEtNDMwMA_d3474e28-8cca-49c8-a0eb-cabc3ec001fc"
      unitRef="usd">1294000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjA1ZTRmZDAxMWJhMjRlNDI5YWVlNDMwZTc1YTNhNTMwL3RhYmxlcmFuZ2U6MDVlNGZkMDExYmEyNGU0MjlhZWU0MzBlNzVhM2E1MzBfNC0xMy0xLTEtNDMwMA_cd055242-3e8b-4504-a158-dc48896f4241"
      unitRef="usd">10245000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5Mg_452cb624-23cc-456a-a6d5-aea3cc265b99">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfMC0xLTEtMS00MzAw_8352bdad-3860-4098-9fa7-0d63796bdde1"
      unitRef="usd">619000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfMS0xLTEtMS00MzAw_4a093009-81af-48dc-91f1-35444cb510f0"
      unitRef="usd">745000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfMi0xLTEtMS00MzAw_0bc756e9-9dc0-4d7b-8641-ecd39226bf60"
      unitRef="usd">745000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfMy0xLTEtMS00MzAw_dd0e5af3-ee7a-4626-b476-2046137cfa9e"
      unitRef="usd">745000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfNC0xLTEtMS00MzAw_913e8ac2-42f0-45b7-b1ae-82598564a0a3"
      unitRef="usd">746000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfNS0xLTEtMS00MzAw_57ec7340-3488-4841-b93f-95066f267b6a"
      unitRef="usd">6411000</pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOmUyNjJjMmJkYmVkNzQ5ZmM5YjUyZWFlOWQxN2VmMGJiL3RhYmxlcmFuZ2U6ZTI2MmMyYmRiZWQ3NDlmYzliNTJlYWU5ZDE3ZWYwYmJfNi0xLTEtMS00MzAw_6a403dbe-aeac-403a-bfa1-a0d1eb18c78d"
      unitRef="usd">10011000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i36c2bb89833b4cfcb9dcbf700eebd5b0_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfMjg4OA_4e3afcca-8192-478a-962d-a1e0e1d12d4e"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8d7ed9bee28b4168b9214818a5a04afc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODMwOTI1_9ded0fd7-3d3d-4cbe-9523-884462230880"
      unitRef="usd">21400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if2d5823f4ed048deabd8e0c7591c429c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODMwOTI1_e46ac36c-59b7-421c-b446-15c26f5e921f"
      unitRef="usd">21400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODIxNzIy_4f3ce485-dbc0-4ada-ab5a-36dbc20ffc56"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDk0NzgwMjM0MDIzMw_41cff15a-df52-4ca9-8368-8a2256800510"
      unitRef="usd">30900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i16bd2f0eca824f1797f501f4e0391099_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODIyMDYy_16547383-7f95-46ab-b64f-3f4d7b4eeb12"
      unitRef="usd">1800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODIyMDYy_64d3b224-bc94-4b71-a93d-dad3eed5175b"
      unitRef="usd">1800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i16bd2f0eca824f1797f501f4e0391099_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfMzM5MA_ebb8b7cc-4bea-4afb-ae47-bf47be3cd1a6">P5Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i3df88f6219dc43ce83dc501b125501a1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODIyMDcw_9e63e505-d07b-4b18-902d-42ac39b5fa63"
      unitRef="usd">3500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5Mw_84ca569c-540a-4b59-b86a-6977a6c4bb28">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ProductWarrantyAccrual
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfMi0xLTEtMS00MzAw_f020ccb5-bb66-4708-9c96-71be6f5113b8"
      unitRef="usd">1651000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="ib71260de6ee845f5827e04115b08241b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfMi0zLTEtMS00MzAw_a48ada63-bb66-4804-9dcd-7cd11ec43187"
      unitRef="usd">594000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfMy0xLTEtMS00MzAw_17be0ecf-18d8-42fe-b88c-255f72fd89b9"
      unitRef="usd">604000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfMy0zLTEtMS00MzAw_f645aa00-298c-4736-87f4-8f58c481f8b6"
      unitRef="usd">953000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualPayments
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfNC0xLTEtMS00MzAw_abcf382f-a993-4353-af20-f6d3176b2445"
      unitRef="usd">631000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfNC0zLTEtMS00MzAw_974aaeff-b0a9-4f6c-9f6b-bc39b0ca364a"
      unitRef="usd">373000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrual
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfNS0xLTEtMS00MzAw_3cbf431a-67ea-4f7d-85c7-9ec7056b797d"
      unitRef="usd">1624000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="i170a5ddc0ff746bfba70414d856b57e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjUxOWE1MWNkYmU4NTRlZTZiNzYwNmE1ZDRiM2RmYWMzL3RhYmxlcmFuZ2U6NTE5YTUxY2RiZTg1NGVlNmI3NjA2YTVkNGIzZGZhYzNfNS0zLTEtMS00MzAw_f121997e-a152-48b5-8e78-a5562a3dc6d1"
      unitRef="usd">1174000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="icea01b3eb40349d587b12f4dca39ef4e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDY2NA_d58b4f81-01e8-4a7e-9e9f-08eb79f97689"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="icea01b3eb40349d587b12f4dca39ef4e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDY5MA_6dd77d35-8290-43df-b617-ec821fbc6dd0"
      unitRef="usd">3000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="i8ff3053e324549d69983b4ab416817c9_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDkyNw_06e55dd9-8427-4577-bdd5-06d57871b118">P43M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3a16d74a89a48b188694cf52ea1bf6d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDk3OQ_d950eac6-b596-4199-92dd-260905372e26"
      unitRef="number">0.17</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <pacb:DebtInstrumentTermLoanElectiveOption
      contextRef="ic22b2f234d3f44dea2cb7006091d3cfa_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDM5ODA0NjUyOTcwMg_b92c82ee-2825-436d-b894-5d9902a801a1">P24M</pacb:DebtInstrumentTermLoanElectiveOption>
    <pacb:DebtInstrumentTermLoanElectiveOption
      contextRef="i8484a2b1bd284e689338fd42dc179878_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDM5ODA0NjUyOTcwNg_0d229de3-5cc5-468d-ab9d-ce8a2b3ea7c0">P43M</pacb:DebtInstrumentTermLoanElectiveOption>
    <pacb:PercentageOfFeeToPrepayDebt
      contextRef="i8ff3053e324549d69983b4ab416817c9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTE3Nw_a15a11b3-609f-49e5-b8dc-92daf71c8e27"
      unitRef="number">0.04</pacb:PercentageOfFeeToPrepayDebt>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="id3026c43f5474b3aaf648b1b685a4b02_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNDM5ODA0NjUyNjMzMA_28cac3d8-1f52-4ef1-bf34-b928335f7b8a"
      unitRef="usd">1900000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8dd1b10964904b3baf45a616d35f8e4a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODI5MDQ5_ab22a5a1-ecbc-4619-acc5-f343d77ac9ab"
      unitRef="usd">200000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="ibe51e70a3fcd4e399fbfdbb8e358e931_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODI5MDQ1_f83bc244-d3d8-49ba-bde7-8e0cebbc526f"
      unitRef="usd">1700000</us-gaap:ShortTermBorrowings>
    <us-gaap:InterestExpenseDebt
      contextRef="i6066f8de0b274e42940b04267565bdf7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTQ5NzU1ODI5MTAz_f3764b9c-4bcd-4730-8474-2a73fddcd459"
      unitRef="usd">100000</us-gaap:InterestExpenseDebt>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RleHRyZWdpb246ZTQ4Yzg1NTY4MjUyNGNmNGI0NTA3ZjdmNzAzYzJiN2ZfNTM5NA_82359371-d1d5-43a0-8a17-8e2aeb04ef0c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the future principal payments on the term loans (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="id3026c43f5474b3aaf648b1b685a4b02_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjIyNDZkMjliMDU4MjQwYzI4ZTFjMDJkNmEwNzJkZWJkL3RhYmxlcmFuZ2U6MjI0NmQyOWIwNTgyNDBjMjhlMWMwMmQ2YTA3MmRlYmRfMC0xLTEtMS00MzAw_913b3c38-ca05-4b2e-b1fb-644df1dbe671"
      unitRef="usd">1395000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="id3026c43f5474b3aaf648b1b685a4b02_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjIyNDZkMjliMDU4MjQwYzI4ZTFjMDJkNmEwNzJkZWJkL3RhYmxlcmFuZ2U6MjI0NmQyOWIwNTgyNDBjMjhlMWMwMmQ2YTA3MmRlYmRfMS0xLTEtMS00MzAw_8149a690-709b-4f24-96b4-8b2251bda600"
      unitRef="usd">490000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt
      contextRef="id3026c43f5474b3aaf648b1b685a4b02_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80Ni9mcmFnOmU0OGM4NTU2ODI1MjRjZjRiNDUwN2Y3ZjcwM2MyYjdmL3RhYmxlOjIyNDZkMjliMDU4MjQwYzI4ZTFjMDJkNmEwNzJkZWJkL3RhYmxlcmFuZ2U6MjI0NmQyOWIwNTgyNDBjMjhlMWMwMmQ2YTA3MmRlYmRfMy0xLTEtMS00MzAw_a1e89c7d-122e-4c29-94df-39e735fbcabd"
      unitRef="usd">1885000</us-gaap:LongTermDebt>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNjQzNQ_a8950d4e-0174-440d-81ed-e7cc564a9465">CONVERTIBLE SENIOR NOTES On February&#160;9, 2021, we entered into an investment agreement (the &#x201c;Investment Agreement&#x201d;) with SB Northstar LP (the &#x201c;Purchaser&#x201d;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $900 million in aggregate principal amount of our 1.5% Convertible Senior Notes (the &#x201c;Notes&#x201d;). The Notes were issued on February&#160;16, 2021.&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are governed by an indenture (the &#x201c;Indenture&#x201d;) between the Company and U.S. Bank National Association, as trustee. The Notes bear interest at a rate of 1.5% per annum. Interest on the Notes is payable semi-annually in arrears on February 15 and August 15 and commenced on August 15, 2021. The Notes will mature on February&#160;15, 2028, subject to earlier conversion, redemption or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the Notes (which is equal to an initial conversion price of $43.50 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after February 20, 2026, the Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges (a &#x201c;Fundamental Change&#x201d;), the holders of the Notes may require that we repurchase all or part of the principal amount of the Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the Notes at a rate equal to (i) 0.25% per annum of the principal amount of the Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the Notes shall be subject to acceleration as provided for in the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the Notes were not issued at a premium; therefore, the Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the Notes of approximately $4.5 million, which were recorded as debt issuance cost and are presented as a reduction to the Notes on our Consolidated Balance Sheets and are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortized to interest expense using the effective interest method over the term of the Notes, resulting in an effective interest rate of 1.6%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the Notes is recorded as convertible senior notes, net, non-current in the Condensed Consolidated Balance Sheets as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;900,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;900,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;896,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;896,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, interest expense for the Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of March&#160;31, 2023, the estimated fair value (Level 2) of the Notes was $693.0 million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMjQ3_36eb7339-f1a7-42a8-bee2-eb07e9374565"
      unitRef="usd">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMjg3_0d524ada-6ab7-4254-bec0-044d80a443df"
      unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNTIx_62557857-bebe-4826-b2c5-fd00db9935d4"
      unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTE0Mw_667dd665-4d80-4956-99b3-0713970bc1e3"
      unitRef="usdPerShare">43.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTU2Ng_6bfe6e0a-aabe-49c6-8b3a-e7b9e8062b48"
      unitRef="number">1.50</pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice>
    <pacb:DebtInstrumentRedemptionPriceTradingDays
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTYyMQ_07ddbb65-7133-48fe-82db-b65a6c7042fd">P20D</pacb:DebtInstrumentRedemptionPriceTradingDays>
    <pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTY3Nw_095fc2c9-2317-4c77-b8ec-be32b955de4a">P30D</pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMTg5OQ_0b7b0941-8d21-4dc6-9bc4-097fe1fa0212"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk1Mw_20814e47-a2ac-4697-aa89-2d806269533d">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMjkzMQ_3d42305f-0abd-4c32-bd5b-903f00304216"
      unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays
      contextRef="i8b06909acc8846a687b88fb4008d393a_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk2Mw_6ada062b-c57e-4e92-a748-d6fa79cc787f">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk1OA_46c617c5-6e98-45c1-a485-2269cf65ba4d">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault
      contextRef="ia1b493f5877b44928f8d86eedcad7057_D20210216-20210216"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfMzI0Nw_6d61c34a-767d-46d4-9372-4b4c79825802"
      unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays
      contextRef="i87dcdd78b25e4f46a8ae756042953485_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk4Mw_cbfb0154-5a00-40d8-974e-cdef40930743">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays
      contextRef="i82f01855a6084151a5dd9a070e4784b3_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk3OA_716a4ef6-1322-4893-b1f6-f26effe7ea22">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays
      contextRef="i20a09135868a48e4afb9690de6dd439c_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk3Mw_b208c9ad-370d-4a11-8c24-ed684e8f46bf">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays
      contextRef="i20a09135868a48e4afb9690de6dd439c_D20210216-20210216"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNDM5ODA0NjUyMzk2OA_55978d04-9014-4bb4-9b15-8e1632ed1372">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNTY1MA_98cb7a64-3de6-4720-9f66-9bb33ab8eae3"
      unitRef="usd">4500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2a4563e98c524b29afa46ed0121d04a2_I20210216"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNTkyMg_610d7dca-d39b-4cdd-b2da-4c077daa11d2"
      unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNjQzNg_4d8d8674-2153-4b6c-9aaf-c2af00d1b43c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the Notes is recorded as convertible senior notes, net, non-current in the Condensed Consolidated Balance Sheets as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;900,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;900,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;896,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;896,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i742c54bedefe423c93b513816a6c3979_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMS0xLTEtMS00MzAw_48c1dcfe-45a6-4594-8dd5-d1008c433a43"
      unitRef="usd">900000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib40b2b69144d46d385bf12dbac4912ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMS0zLTEtMS00MzAw_349162f8-db85-492e-a2b8-76e7615d7ff0"
      unitRef="usd">900000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMi0xLTEtMS00MzAw_97b488b9-daa5-4c4f-9bde-b35fa23206f3"
      unitRef="usd">3161000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMi0zLTEtMS00MzAw_1cacd164-f999-414f-8aa2-b4ffba639333"
      unitRef="usd">3317000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ib7391dc7425a48d1a68d124321e865b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMy0xLTEtMS00MzAw_ee3047ad-e7b4-4810-b0c6-cfc2a520a17d"
      unitRef="usd">896839000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie27fe1fa4ecc4067a7d326349cbf168c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjBhOTk4MDBkYzBkODQ5YTU4NWY0MTlkNzVlMDI4OGI2L3RhYmxlcmFuZ2U6MGE5OTgwMGRjMGQ4NDlhNTg1ZjQxOWQ3NWUwMjg4YjZfMy0zLTEtMS00MzAw_8fddfb31-fb56-49ff-b3b1-94f3937c14ab"
      unitRef="usd">896683000</us-gaap:LongTermDebt>
    <pacb:ScheduleOfInterestExpenseTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNjQzNA_8f5cae5a-e231-4a81-839a-581ddfbe2dea">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, interest expense for the Notes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ScheduleOfInterestExpenseTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i618edbbfddab4833a48509103c51d343_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfMi0xLTEtMS00MzAw_d81813f7-47fd-4d60-9a12-1b889f866080"
      unitRef="usd">3375000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i98efc311e4834a52b95558f1635f4df5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfMi0zLTEtMS00MzAw_da8ba35e-c6d0-4840-8011-470914481eba"
      unitRef="usd">3375000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfMy0xLTEtMS00MzAw_a99a375e-fb73-4911-b45d-a42308947fd2"
      unitRef="usd">156000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfMy0zLTEtMS00MzAw_2c5e4106-382e-4c53-b12e-7b48c833554c"
      unitRef="usd">153000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfNC0xLTEtMS00MzAw_79bcd4ff-335a-4028-947e-8479f9ee4c1c"
      unitRef="usd">3531000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RhYmxlOjVmNTc1NjBjMzg1YTRmZjNiNWE3NDI1NTI4Y2FkNThmL3RhYmxlcmFuZ2U6NWY1NzU2MGMzODVhNGZmM2I1YTc0MjU1MjhjYWQ1OGZfNC0zLTEtMS00MzAw_be82ff3c-fe47-4e40-8bfb-d46ab7a8f9c0"
      unitRef="usd">3528000</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i6f811a83540b4cdb8df5a2ca849b6ae0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF80OS9mcmFnOmQyMGMwZjZkZjJhMDQxZDlhMmJhMmEwY2RmZjk4ZGRkL3RleHRyZWdpb246ZDIwYzBmNmRmMmEwNDFkOWEyYmEyYTBjZGZmOThkZGRfNjI3Mw_238ab663-8bd1-4e67-93df-79a720da8f3c"
      unitRef="usd">693000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:LossContingencyDisclosures
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81Mi9mcmFnOjBlOWJmNWRlMmZiNTQ0YjZhMTJlYzdhZWIzYmNkYTQxL3RleHRyZWdpb246MGU5YmY1ZGUyZmI1NDRiNmExMmVjN2FlYjNiY2RhNDFfNjUzOA_1b54d1d4-5055-4c43-b0e1-1fda73f97109">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various operating lease agreements, primarily relating to our corporate offices. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8 &#x2013; Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, subsection titled &#x201c;Leases&#x201d;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for information regarding the Company&#x2019;s maturity of lease liabilities under its lease agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see subsection titled &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#idd15d706814f4821992e3c53513cc1e0_91" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Legal Proceedings, in  Part II, Item 1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation &lt;/span&gt;&lt;/div&gt;expense amounts. No additional liability associated with such indemnification obligations has been recorded as of March&#160;31, 2023 and December&#160;31, 2022.</us-gaap:LossContingencyDisclosures>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQ2OQ_a41db0fa-335d-4bad-a1e0-aed100eac3f6">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Underwritten Public Equity Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we entered into an underwriting agreement, relating to the public offering of 17.5 million shares of our common stock, $0.001 par value per share, at a price to the public of $10.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2.6 million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold 20.1 million shares of our common stock. We paid a commission equal to 5.75% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $189.7&#160;million, excluding approximately $0.5&#160;million of offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10 &#x2013; Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information on the Company's underwritten public equity offerings and private placement of common stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2023, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;), the 2020 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#x201c;Omniome Plan&#x201d;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, we had 12.8&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10 &#x2013; Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2022 for more information on the Company's equity plans&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Time-based Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for time-based awards (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for performance-based awards (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units (&#x201c;RSU&#x201d;) and Performance Stock Units ("PSU") &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We issue PSUs for which the number of shares issuable in the third year of the performance period based on performance relative to specified revenue targets and continued employment through the vesting period. The following table summarizes the time-based RSUs and PSUs activity (shares in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units (RSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Performance Stock Units (PSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,535&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,640)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,771&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued under our ESPP were 1,052,908 and 1,316,923 during the three months ended March&#160;31, 2023 and 2022, respectively. In February 2023, an additional 4.0&#160;million shares were reserved under the ESPP. As of March&#160;31, 2023, 12.9&#160;million shares of our common stock remain available for issuance under our ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Determining Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023, there were no employee stock options granted. The fair value of employee stock options was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$6.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;97%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.89% &#x2014; 5.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.60% &#x2014; 1.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$5.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pacb:PublicOfferingShares
      contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTM4Mw_f4399b0a-0517-4d3c-9d86-854beff15ed4"
      unitRef="shares">17500000</pacb:PublicOfferingShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3539bf245d854192abfe418d43a09772_I20230131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQ2Mg_b7b5e57c-0d1f-4149-bf35-9ea743a6fbe9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pacb:OfferingShareAmountMaximum
      contextRef="i3539bf245d854192abfe418d43a09772_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQwMg_a502455b-b063-4d0d-b177-da58ce87a670"
      unitRef="usdPerShare">10.00</pacb:OfferingShareAmountMaximum>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod
      contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQxMA_6fafa168-3ff7-4781-bc42-14529c07b87d">P30D</pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares
      contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQ1MQ_01642c19-8361-41e9-a64d-9ba48028329b"
      unitRef="shares">2600000</pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if0172c443e454bb9826a003845a4aa13_D20230131-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDM5ODA0NjUyOTU1OQ_0d297a57-fea5-4c34-a628-85ae098d67d7"
      unitRef="shares">20100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering
      contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQxNA_89181e91-f590-4678-810c-da1888602dc4"
      unitRef="number">0.0575</pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQyMQ_7f7d3c7a-dbdf-4782-856f-1e0e27356028"
      unitRef="usd">189700000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i756aff43669a4bee98c53b5da2ad6ad6_D20230101-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNDk0NzgwMjM1OTQzNw_8037f472-1081-4a5a-a56a-ad3c28528cbc"
      unitRef="usd">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6620f4b62a6245299f332889d2275280_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMjQ0OA_6fcd9158-c4f9-4cfd-ad9c-6f32a4fce5e2"
      unitRef="shares">12800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwOQ_bb48220e-a361-4cc8-b96a-401e75bf55af">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for time-based awards (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for performance-based awards (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;258&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i638e0be2cf05429d9d48a17c3ad3afc4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMS0xLTEtMS00MzAw_9e533998-700b-4ee2-beb2-42e1c2c5d24b"
      unitRef="shares">14618000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i638e0be2cf05429d9d48a17c3ad3afc4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMS01LTEtMS00MzAw_9046031d-a0e5-44db-becf-a96e63bc82b0"
      unitRef="usdPerShare">10.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMi0xLTEtMS00MzAw_74e89dcf-85b2-48fb-8689-f6884e8501cb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMi01LTEtMS00MzAw_2897967e-92f1-4dd7-aa30-0f5fb687499a"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMy0xLTEtMS00MzAw_5c1397ae-de5b-4556-91d0-577765e3b5a7"
      unitRef="shares">250000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfMy01LTEtMS00MzAw_616e2224-e5f3-42ef-ae87-fd557eb81dcc"
      unitRef="usdPerShare">3.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfNC0xLTEtMS00MzAw_61b31b8c-4bbf-4b9f-95c7-8db3ab29a64d"
      unitRef="shares">362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0c104658d4054c9398ae4c51b4bcb990_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfNC01LTEtMS00MzAw_db757128-dd83-4ce1-84ff-16cf179700f0"
      unitRef="usdPerShare">17.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia9475351ae4143b49d057e49d769bac5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfNS0xLTEtMS00MzAw_27bbab0b-4046-4ac9-b327-56c0527a9a2c"
      unitRef="shares">14006000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia9475351ae4143b49d057e49d769bac5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjNhNGFiNzA5NGQxNjQ5YTdhNmM0YjBlYzJiOTk1OGJjL3RhYmxlcmFuZ2U6M2E0YWI3MDk0ZDE2NDlhN2E2YzRiMGVjMmI5OTU4YmNfNS01LTEtMS00MzAw_ba3138c3-3ace-4422-b83e-a7ee66db05ec"
      unitRef="usdPerShare">10.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMS0xLTEtMS00MzAw_497b9ec6-3c68-4dcd-9442-764dc61c739d"
      unitRef="shares">258000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMS01LTEtMS00MzAw_7af5fe54-636b-47cc-90e0-10efaf167c22"
      unitRef="usdPerShare">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMi0xLTEtMS00MzAw_2f327b30-947b-45bd-9c05-a0b5b09b2f3e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMi01LTEtMS00MzAw_c488a93f-7049-4f1d-99ed-2faf57a0abd1"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMy0xLTEtMS00MzAw_1d12e70c-ec76-4b14-be34-b0816559ffb6"
      unitRef="shares">230000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfMy01LTEtMS00MzAw_a5353ebe-e751-404d-a7ba-08f2d064d9c5"
      unitRef="usdPerShare">4.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfNC0xLTEtMS00MzAw_6a49b66c-f74e-4075-bac3-82f2ac1951d6"
      unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfNC01LTEtMS00MzAw_e14092e6-de58-4103-9ff9-1763ec7e19ec"
      unitRef="usdPerShare">4.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifb8601e7bab34e959227a80dc0653b82_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfNS0xLTEtMS00MzAw_9f273bde-0841-4a80-828a-a63061d27120"
      unitRef="shares">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifb8601e7bab34e959227a80dc0653b82_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjJmYzU4NDBkZWUxNjQ0NmJhZDcwMDk5Y2RmZmFkZGZlL3RhYmxlcmFuZ2U6MmZjNTg0MGRlZTE2NDQ2YmFkNzAwOTljZGZmYWRkZmVfNS01LTEtMS00MzAw_c1e80011-5969-4814-bf52-a2a1255ddaf1"
      unitRef="usdPerShare">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwNA_36a6a81d-ad54-4254-972b-6fe73e056951">The following table summarizes the time-based RSUs and PSUs activity (shares in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units (RSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Performance Stock Units (PSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,535&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,341&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,640)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,771&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i557fdaad292c4b3fb9316667a1bba49e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMS0xLTEtMS00MzAw_9ed01f4d-d54d-48c7-8bbd-824bfd0e3b84"
      unitRef="shares">8535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMS0zLTEtMS0xNDMwNg_35f705a7-f190-43c2-977a-76282eafe6c4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i557fdaad292c4b3fb9316667a1bba49e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMS0zLTEtMS00MzAw_6de99fbd-1bef-4784-932f-94dfc3b58fe2"
      unitRef="usdPerShare">15.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3d55f5d1f2ab4ed397287f639f4978b7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMS03LTEtMS0xNDMxMA_417b6aa6-2669-4901-b822-8261b0c5df33"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMi0xLTEtMS00MzAw_deee4680-f8ce-4deb-a4d6-cab469239cd9"
      unitRef="shares">6341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMi0zLTEtMS0xNDMwNg_2901f7a4-ee99-43cb-b560-b2f30a5edba0"
      unitRef="shares">564000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMi0zLTEtMS00MzAw_8a622dd0-bca6-49a7-8166-fe76ec6adbd9"
      unitRef="usdPerShare">9.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMi03LTEtMS0xNDMxMA_2e6e4029-cdd3-4c0a-a5d9-970902277a53"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMy0xLTEtMS00MzAw_39e44cab-d909-4b0e-91fe-f96e99c351d1"
      unitRef="shares">1640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMy0zLTEtMS0xNDMwNg_716a472f-556f-4bcc-bfa1-f06d1f8449a0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMy0zLTEtMS00MzAw_d206cd40-a894-4852-9d48-9cdde4f2369d"
      unitRef="usdPerShare">16.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfMy03LTEtMS0xNDMxMA_8b7c1696-3be5-4d0a-a038-ff966b167208"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNC0xLTEtMS00MzAw_7661da59-3f50-4e83-b70a-4b37ac709322"
      unitRef="shares">465000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNC0zLTEtMS0xNDMwNg_9ee96ff3-4137-4b98-9800-9b2bd444d99c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie0ec8fe5488748e6a8f22d25a217ca58_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNC0zLTEtMS00MzAw_bc23f895-2994-4332-89ab-c483825e1e43"
      unitRef="usdPerShare">17.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1e83b9026246461ab11f492eafcb95ca_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNC03LTEtMS0xNDMxMA_358a6be1-473c-4757-877f-6e24159996db"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib5b211de82ab46bd9b8e7ecfb559c3d6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNS0xLTEtMS00MzAw_f88918e7-aa90-4fe1-82d7-aebb13445c2f"
      unitRef="shares">12771000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifb8601e7bab34e959227a80dc0653b82_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNS0zLTEtMS0xNDMwNg_2bba6925-4d01-47bf-9686-2ba384421564"
      unitRef="shares">564000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib5b211de82ab46bd9b8e7ecfb559c3d6_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNS0zLTEtMS00MzAw_c20930ee-2728-4333-8b5b-eff2566857ce"
      unitRef="usdPerShare">12.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifb8601e7bab34e959227a80dc0653b82_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjliZDlmNzZkZjNiYTQzNzhiNzg3NWU1MWY3ZmMyOTMxL3RhYmxlcmFuZ2U6OWJkOWY3NmRmM2JhNDM3OGI3ODc1ZTUxZjdmYzI5MzFfNS03LTEtMS0xNDMxMA_25571dba-b3c9-4580-bcd6-e435f8dfd25c"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMzQwOQ_f78d87eb-ff80-44bb-88a4-25d5f145cb32"
      unitRef="shares">1052908</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMzQxNg_082bbb73-b54a-4008-91e4-6b6311d2a1a5"
      unitRef="shares">1316923</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ife7d26135b95464faa9c223629b18165_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMzQ5Mg_34d58d90-296c-4d2e-9e37-ea0682496204"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id0a53ada800e4aa28d98cf54fcb50068_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfMzU0Mg_c47224f9-6e00-4dfa-bc7a-3222189da045"
      unitRef="shares">12900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwNQ_352560de-3e72-48e3-873d-d9da1e0fe2b0">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife8c470b6b7746deb6ce4dee0f7e41f1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfMi0xLTEtMS00MzAw_7e8cf663-45c3-4fa3-b594-bb7e4b3f51cf"
      unitRef="usd">1949000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i425ffb2f994b48168f939e71d5ba1ad5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfMi0zLTEtMS00MzAw_d80efa3f-9402-4ff0-91b5-6a002ef71889"
      unitRef="usd">1758000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb3065503208462293114ba3cebc247b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfMy0xLTEtMS00MzAw_0ff410a7-b8dc-49ec-ac50-82f4ccf06979"
      unitRef="usd">6705000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iab6e067725af44f990c3a8d3a8d5c108_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfMy0zLTEtMS00MzAw_4483cb7f-d486-4cee-8b1d-23a4315d5585"
      unitRef="usd">8965000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4665a48d6d14296985783f51f19db3f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfNC0xLTEtMS00MzAw_00f309b1-50c1-4206-a260-c3fdb6d5fa40"
      unitRef="usd">9299000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i197db529bcc44b64992d8392908d33c9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfNC0zLTEtMS00MzAw_001993c3-0222-4149-b2f7-989fbcbfa8cf"
      unitRef="usd">11980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfOS0xLTEtMS00MzAw_d5b73f30-1316-49b0-b4c0-7e17ac490222"
      unitRef="usd">17952000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjU3MTJkOWZjNzU2MzQyYzlhMTQ3Y2VhNDMzN2M4YmYzL3RhYmxlcmFuZ2U6NTcxMmQ5ZmM3NTYzNDJjOWExNDdjZWE0MzM3YzhiZjNfOS0zLTEtMS00MzAw_4242e586-3f69-4a2b-a777-f06ccd6c021e"
      unitRef="usd">22703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNTQ5NQ_c135bd2c-6bbc-4ef0-a470-d9069f1216a7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwNg_1d00935b-f990-49d5-849c-ce3737fd5922">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023, there were no employee stock options granted. The fair value of employee stock options was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$6.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfMi0zLTEtMS0xNTUwMQ_3bf12d9b-8f04-4e2a-9838-b7685d6c146b">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfMy0zLTEtMS0xNTUwMQ_b2a4b612-bafe-433e-8ffd-006d127286f8"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfNC0zLTEtMS0xNTUwMQ_2f3307f6-7924-45fb-8f8c-a9e59b9a5b66"
      unitRef="number">0.0176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfNS0zLTEtMS0xNTUwMQ_2a17db88-899f-49e7-b71b-cbb6200fc4fd"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i87cda0291620443e8aecca5e2324bb78_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjVjY2YxMWFiZDlmMjRhZGFhZjY5NDk4MmVlYzFiMDRjL3RhYmxlcmFuZ2U6NWNjZjExYWJkOWYyNGFkYWFmNjk0OTgyZWVjMWIwNGNfNi0zLTEtMS0xNTUwMQ_b29debb1-d6c5-4461-9109-91cb44e4fd70"
      unitRef="usdPerShare">6.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RleHRyZWdpb246OGJlZmM4ODcyZmZjNGQ2ZTk4YmM1NzY2ZDBkOWFiZDhfNjAwNw_e378159b-0f7e-4cea-9784-75785c02bd20">he fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;97%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.89% &#x2014; 5.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.60% &#x2014; 1.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$5.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6ceb564dadd349a3923864a97aebdd11_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMi0xLTEtMS00MzAwL3RleHRyZWdpb246NTE3NTgwMTJhNjAyNGMyN2I1NDhiMzdjMTY1NzBkNmVfNA_4f1d9836-0849-4d00-a6e3-d8dd858d3903">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i978408a314554860834dc737c3b1419c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMi0xLTEtMS00MzAwL3RleHRyZWdpb246NTE3NTgwMTJhNjAyNGMyN2I1NDhiMzdjMTY1NzBkNmVfOQ_80b1f725-ec81-4818-94a5-391481ed32a5">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i31f9e8f8b14e405e9c92d12a3b2a9e3c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMi0zLTEtMS00MzAwL3RleHRyZWdpb246N2UyZTJhZGNjNzVkNDQ2NDk1MjYyNWRmMjYzNDhiYTJfNA_b876815c-220c-41e1-ba2d-3a9ea6f882b3">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i801b0f6773b4475bb9dd53e570abb778_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMi0zLTEtMS00MzAwL3RleHRyZWdpb246N2UyZTJhZGNjNzVkNDQ2NDk1MjYyNWRmMjYzNDhiYTJfOQ_4962eeeb-a3c7-409c-8f39-0e2f7ac94318">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMy0xLTEtMS00MzAw_8cbc5d63-c5ab-47d0-9dd9-7a4b3e778556"
      unitRef="number">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfMy0zLTEtMS00MzAw_7547a740-404b-4ee0-b0eb-1a45da5f301a"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNC0xLTEtMS00MzAwL3RleHRyZWdpb246ZTdhMjg5ZDQ3OWVkNDg1MGEzN2JkNjRkYTdlMTUxYjNfNA_1afc6d03-d71c-4b02-86d6-0bd33d6195e0"
      unitRef="number">0.0489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNC0xLTEtMS00MzAwL3RleHRyZWdpb246ZTdhMjg5ZDQ3OWVkNDg1MGEzN2JkNjRkYTdlMTUxYjNfOQ_f46720d5-548b-463b-ab20-ace8006f6d38"
      unitRef="number">0.0520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNC0zLTEtMS00MzAwL3RleHRyZWdpb246Nzg5M2ZlYTk5NjE1NDIwMDk1OGZmZjlhOTUwNTQzN2VfNA_a53f8558-9309-43b3-9ca9-40b18b1812b4"
      unitRef="number">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNC0zLTEtMS00MzAwL3RleHRyZWdpb246Nzg5M2ZlYTk5NjE1NDIwMDk1OGZmZjlhOTUwNTQzN2VfOQ_e95669a7-933b-4be9-a840-b32c5872edec"
      unitRef="number">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNS0xLTEtMS00MzAw_a35bf2f2-6f41-4b65-bb76-a23e301db336"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNS0zLTEtMS00MzAw_7440db0d-82d6-4c00-b255-649d82de9ba8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNi0xLTEtMS00MzAw_80e8a01d-479a-4fe8-873e-2f2ca055fac3"
      unitRef="usdPerShare">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4b260485f44645a2bd579bb81411474c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81NS9mcmFnOjhiZWZjODg3MmZmYzRkNmU5OGJjNTc2NmQwZDlhYmQ4L3RhYmxlOjAxOGIyY2FiOTg0YTRiYmFiOGI0YjJlMDQ0NmY0NmM0L3RhYmxlcmFuZ2U6MDE4YjJjYWI5ODRhNGJiYWI4YjRiMmUwNDQ2ZjQ2YzRfNi0zLTEtMS00MzAw_d9fe509c-9e77-455b-a191-6319c8f99d55"
      unitRef="usdPerShare">5.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RleHRyZWdpb246N2IyY2JhZDcxMjgyNDE5Zjk4YjNkZDQ0ZTQzYzY4OTZfMTYyMg_2105ff8b-f714-4693-8b85-872d04ee5705">NET LOSS PER SHAREBasic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the convertible senior notes, using the if-converted method, and outstanding equity awards using the treasury stock method.       &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(88,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(81,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing basic net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;242,032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;222,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;242,032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;222,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares issuable upon conversion of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,752&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2. Business Acquisitions &lt;/span&gt;in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022, the contingently issuable shares would be due upon the achievement of a milestone.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RleHRyZWdpb246N2IyY2JhZDcxMjgyNDE5Zjk4YjNkZDQ0ZTQzYzY4OTZfMTYyMw_f1a584ad-d893-47be-9005-fd3f6e44f339">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(88,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(81,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing basic net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;242,032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;222,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;242,032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;222,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMy0xLTEtMS00MzAw_180ac82d-7879-45e7-b0ba-7e446f74f323"
      unitRef="usd">-88015000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMy0zLTEtMS00MzAw_1037df71-c58f-4685-b84c-026b0e4042c1"
      unitRef="usd">-81499000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfNy0xLTEtMS00MzAw_90e6e9a6-cf74-43f8-ac8a-f9e0b1e72b64"
      unitRef="shares">242032000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfNy0zLTEtMS00MzAw_f75848ca-c31c-4ff1-9997-9e11cb83d017"
      unitRef="shares">222289000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfOC0xLTEtMS00MzAw_5b0f7cf3-5049-48cb-a87b-282b97dd3b2c"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfOC0zLTEtMS00MzAw_788e6681-0099-4acd-a76c-9555ab11ac6f"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMTUtMS0xLTEtNDMwMA_67531178-09f0-440a-a020-eaceddafb1d9"
      unitRef="shares">242032000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMTUtMy0xLTEtNDMwMA_8a559b42-d772-48fe-b8cc-2931e87fc2ad"
      unitRef="shares">222289000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMTYtMS0xLTEtNDMwMA_a7c7ef44-2b58-4331-a668-0393eb792926"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjY5OTkwYmIzYmZlZjRkOGJhYzVhMzViMWEyOGQ1MGIxL3RhYmxlcmFuZ2U6Njk5OTBiYjNiZmVmNGQ4YmFjNWEzNWIxYTI4ZDUwYjFfMTYtMy0xLTEtNDMwMA_5ae5f6d9-ddc4-4ca1-b717-e1b2414f6718"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RleHRyZWdpb246N2IyY2JhZDcxMjgyNDE5Zjk4YjNkZDQ0ZTQzYzY4OTZfMTYyNA_e13d8086-6dea-4cf4-9f38-0f13acc20ef6">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares issuable upon conversion of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,752&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia7a1b740447c43f8a9ab44e87fa30129_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjA2YWEwMTc1ODNkMDRhMjBhNWQ5Nzg0N2FmMjZkZjRkL3RhYmxlcmFuZ2U6MDZhYTAxNzU4M2QwNGEyMGE1ZDk3ODQ3YWYyNmRmNGRfMi0xLTEtMS00MzAw_f95c3b46-a3d5-471c-b036-dd36e73d8178"
      unitRef="shares">20690000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i04cac2e649ab434a97832d035f40bb55_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjA2YWEwMTc1ODNkMDRhMjBhNWQ5Nzg0N2FmMjZkZjRkL3RhYmxlcmFuZ2U6MDZhYTAxNzU4M2QwNGEyMGE1ZDk3ODQ3YWYyNmRmNGRfMi0zLTEtMS00MzAw_bc7b53e3-1f76-4ae9-9b84-ffb0e492a75a"
      unitRef="shares">20690000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i14c86fb9249949768d1bdd6a89aac5c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjA2YWEwMTc1ODNkMDRhMjBhNWQ5Nzg0N2FmMjZkZjRkL3RhYmxlcmFuZ2U6MDZhYTAxNzU4M2QwNGEyMGE1ZDk3ODQ3YWYyNmRmNGRfNy0xLTEtMS0xNDQ3Nw_0989d2cf-356a-4c78-8c64-c41f97e51b56"
      unitRef="shares">30366000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i22ec828e984b4ebc8d4bd50a11327be6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF81OC9mcmFnOjdiMmNiYWQ3MTI4MjQxOWY5OGIzZGQ0NGU0M2M2ODk2L3RhYmxlOjA2YWEwMTc1ODNkMDRhMjBhNWQ5Nzg0N2FmMjZkZjRkL3RhYmxlcmFuZ2U6MDZhYTAxNzU4M2QwNGEyMGE1ZDk3ODQ3YWYyNmRmNGRfNy0zLTEtMS0xNDQ3Nw_3cb4e55b-1e35-4ea3-b53e-33f63f58b34e"
      unitRef="shares">26752000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RleHRyZWdpb246NjMyNzU0NTJlNTVlNDc4MzgzOWJmZjcxMDlkNGM2YTBfMjQ3_921f247c-6b0d-4cf4-9564-7ad391166971">REVENUE&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RleHRyZWdpb246NjMyNzU0NTJlNTVlNDc4MzgzOWJmZjcxMDlkNGM2YTBfMjQ4_8cffd165-7288-4a96-be43-382bb9d291aa">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb8e95a9d8854d71946cebeffe0b0fb3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfMi0xLTEtMS00MzAw_79753edd-d517-4eda-8217-a362dc851467"
      unitRef="usd">19071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib607a9972ac84fbcba2120fd9f7e766b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfMi0zLTEtMS00MzAw_fd3004e0-ac32-4d2b-a6b7-972deec0706a"
      unitRef="usd">19082000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1641ad7927bc43fd949abadef487d0a9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfMy0xLTEtMS00MzAw_00922382-7ea7-4b5f-993a-73b9bdaba8d6"
      unitRef="usd">7870000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d1a78f0fe194bdfb72bae3a006f6e4b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfMy0zLTEtMS00MzAw_1463065f-88ee-4bb3-8194-44a17bb73965"
      unitRef="usd">5700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd4c824aaa2f49fc9e518b8402729d62_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfNC0xLTEtMS00MzAw_411be84c-d92a-4e80-b6c4-70c029aaca7e"
      unitRef="usd">11959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f27eacedc494a34b10e2794baf8cdf4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfNC0zLTEtMS00MzAw_1096c3b5-08e7-4de0-a25b-e539a8c1892b"
      unitRef="usd">8391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfNS0xLTEtMS00MzAw_4f0de8c1-126f-4659-a5c8-66f65817cb9b"
      unitRef="usd">38900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOmJmYjVjOTczMjgyOTQyZDU4YjA2MmU1MWRiY2MzOGExL3RhYmxlcmFuZ2U6YmZiNWM5NzMyODI5NDJkNThiMDYyZTUxZGJjYzM4YTFfNS0zLTEtMS00MzAw_1c5af888-5022-4921-a3b2-bd6310900903"
      unitRef="usd">33173000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RleHRyZWdpb246NjMyNzU0NTJlNTVlNDc4MzgzOWJmZjcxMDlkNGM2YTBfMjQ5_ea2d2866-ab70-4ce9-9bfb-1aac254a9180">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf52ec5feb514b609a102b910f6fa20e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfMi0xLTEtMS00MzAw_3bb73a0c-cca3-4650-b654-c9f052abdf61"
      unitRef="usd">20700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7da4fe9d8e6343d5a93b936c584e420e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfMi0zLTEtMS00MzAw_08b87121-9fd0-4097-9a67-9922a133dec2"
      unitRef="usd">15550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i978f0bc925a24496b995a232807ed9bb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfMy0xLTEtMS00MzAw_2ec9aec0-7171-4106-a3b8-4865e916d0c3"
      unitRef="usd">13954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2efc93840c24155946c8e1c76fe58de_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfMy0zLTEtMS00MzAw_95d3591b-d8d3-43e5-a8b5-c7fdd84b899b"
      unitRef="usd">12694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice0a062bee2249a4af687c1d872b4327_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNC0xLTEtMS00MzAw_c2c2db87-da3c-4185-b07e-06fe6c37a9da"
      unitRef="usd">34654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1cbb2936bb243b9a6592d611b169c16_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNC0zLTEtMS00MzAw_964b21d8-3502-46f0-82a9-ac7148dcdd5d"
      unitRef="usd">28244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4b86da148fb47efb77eed316c399b1d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNS0xLTEtMS00MzAw_d1d2e5a0-ff86-4192-a539-0ddefd792449"
      unitRef="usd">4246000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cf85b8a953e446a85fd97c4f01de732_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNS0zLTEtMS00MzAw_5d35f0e5-5a6f-4847-b925-4a829045d0ae"
      unitRef="usd">4929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i771ebf8299794c3cb53f7fd659514061_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNi0xLTEtMS00MzAw_8544ac08-73fa-4454-84d6-936855f488be"
      unitRef="usd">38900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1376ccb3510e48df9a6f47085ecff816_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMTVkNzA2ODE0ZjQ4MjE5OTJlM2M1MzUxM2NjMWUwL3NlYzpkZDE1ZDcwNjgxNGY0ODIxOTkyZTNjNTM1MTNjYzFlMF82MS9mcmFnOjYzMjc1NDUyZTU1ZTQ3ODM4MzliZmY3MTA5ZDRjNmEwL3RhYmxlOjkyMTg1MjM4YTJkMTQ3YzU5NmJlNDgwYTdlNGYxOGM0L3RhYmxlcmFuZ2U6OTIxODUyMzhhMmQxNDdjNTk2YmU0ODBhN2U0ZjE4YzRfNi0zLTEtMS00MzAw_bdf57662-46fd-482c-939d-34104590ddc9"
      unitRef="usd">33173000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2J3>84CW&16*B>@%/;"4"V7"LTLID9DJQ;-&-<0[*_'.#L.;,A'R0/="!..
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M[<L<FOWCV;L=8&N;7F"@:<PC/PGR=HDW4F3?MZ)0=;UY_4N"4?RNW=/*!VO
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M4*X%U.\KQN3A1K^@.:I?_ M02P,$%     @ 3H6D5I&M?=Q5!@  4R@  !@
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M9^RY,XF^B%9O5?0O0%"=KU^ %8,I^,F43SBH\ N5[R."WD4XQL2!9WWY<AR
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M._M*J^<638QM^5%;)4L;.N<RZ8C8J6^0X!CVUGHC;B?M%0(D CR$PM9;K19
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M)/5SPPXV5 J"-C?S.-A/QNU<:8_"/^A2&N6VYX&?#&F@0 P2$Z6!Y.D2X2S
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M\@F,9#O20:I#"_+NAX2E;Q:3)\56T1#B'[IJ:-#6-2$\?J2-"07PYD[_N64
M+45,=UV),C+@2!W8-^<]$W4U&$ ,@P#'"(:3&-X,1E@4VP5:>IE^W!UA#&??
M+04=VFEMC[Z^8YBTP!EL^>I,:==WS_N#7QK0MUW\>PINXJHH/SKH5KN?;$SE
MEPK]=OF]!_+:DN!,:18X>C#Y^?E(.O_V(;J:?[< MX([\,<"9=AXVH#W-*YN
M'XA!]T.6X_\!4$L#!!0    ( $Z%I%:\"'? K0L  $0A   8    >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&ULQ5K9;MM(%OV5@CO=L ':%A=M3F+ 3G>Z,\B&
M..E^&,Q#B2Q)->:6*E*.YNOGW%LD16V..QA@7F0N57=?SBWZQ4-A[NU2J4I\
MR]+<OCQ95E5Y=7EIXZ7*I+TH2I7CS;PPF:QP:Q:7MC1*)KPI2R^#P6!TF4F=
MGUR_X&<?S?6+HJY2G:N/1M@ZRZ19WZJT>'AYXI^T#S[IQ;*B!Y?7+TJY4'>J
M^E)^-+B[[*@D.E.YU44NC)J_/+GQKVXC6L\+_M3JP?:N!6DR*XI[NGF3O#P9
MD$ J57%%%"3^K-0KE:9$"&)\;6B>="QI8_^ZI?Z:=8<N,VG5JR+]2R?5\N7)
MY$0D:B[KM/I4//RA&GV&1"\N4LN_XL&MC48G(JYM563-9DB0Z=S]E=\:._0V
M3 9'-@3-AH#E=HQ8RE]E):]?F.)!&%H-:G3!JO)N"*=S<LI=9?!68U]U_?K-
M^YOWK][<O!5OWM]]_O3EW6_O/]^]N*Q FA9<Q@V96T<F.$(F%.^*O%I:\5N>
MJ&1[_R5$ZN0*6KEN@T<)OI/F0H2^)X)!$#Y"+^ST#)E>>(3>FWRE;(5HJJPG
M;M)4?*B6RHC>8_'/FYFM#,+D7X?T=^2CP^0I=:YL*6/U\@2Y8959J9/K7W[R
M1X/GCP@?=<)'CU%_NI-^@(QX+;41?\JT5J*8B]<ZEWFL90K3P!JU,PVO6?$:
M;04L)]2W>"GSA1*ET;'"(UDA_^HT$3.%9(T5<BT152&0@*F02#]K46(*(TJI
M^05,G=LY?"!%JN5,I[I:"YW3VL(DRJ1KMT2Z])VIZD&I'+%O[D&HE*;2L2XE
MB0?>)%.FI*V-(I%%(BMU(3[CZ7PC^U(K(TV\7 LX7<Y2C;Q)1(V0->+WFYN/
M$/QKK>$_$@)42")(BG33F?Z/8B:U93L5,W(R:, B>5F3$'E"";JWLL[WUSXL
M21,65^>+GHA.Y&IIE!*I6JG4$HEF%QLYDVLR,8BS%1N=^UI*W$HKYD6*BFNO
MQ"\_38)@]%R\)7K"OQ)?ZZ+";O:<99-S:6Q,2SN-T GI'R,.V'&6/->Z22O[
M?(=J<-4*67!>0=2\9>CD)JDVAO"$TKPP@;GC"KXFGGE[YZ%)Q$O2XBFR6M@\
ME>:PI-X.B6WEOK>;.+:L.C7RHFK$\&BYT[COHVU=:4TL*8)%7!A3S HC2:#9
MNK^HB6O$K71*U:A&B&ZD(F4"!7*-3*J4R2@DZ,$1SU @;GLGO#H8A9VLMB[+
MPC0R@4SEA,Z+5BK6EK*!:&^VZ46NY[ C\HT2>CO9'A/R0OQ%QD!KI]23.UXE
MOQ<YB8E$T8B#7AUP#NP(]^G"G'%<&V070@LZS2&:IEHPI[16>>S$7Q4IJAH)
M7)IB!0$X,B@-=>Y #I6;PA6B?%'0&_1]#:%?%6@7!A4- ?J@Q(I !U:A9#XN
M/N+#I>4<&YZHC,?/FZ!MHP[J&6C$8><*+P6W=+16 %4[8=,D6;&BE 26HGTR
M@U:MJ)F\AT)PAQ.QA$E %^$)%C5%0'Y>*L-FR<'-:'O/S#D&J QB45S4.<*2
M*C*D1G]H'8MX@@T213&+P@BNVR'"M:V?;.0>%R\>2K$M%9LU7;MP2?%*S]>.
MI[1+4"X+J]O2"Y.O6[7FJ.DN#O2F##4!>; ?S%0LJ5YCP9JMS0O0&ZQS?WZ/
MGY1LP*'<E)2V%[&3]H74/7"!F&@J)1YO&BL!RH2"K4>*.))&KJ[LI2WS2=!#
M.2!:?C)?M_[HL]TR0?B8"2[$C<M48MUW2M-A$NJR.UVFX:Z=HT$9;ZFR&H5D
M[%0CCNA$D,FU-*>'"R%$R^-5I-?3+\2'VI5I:[G'-]IL",1<=60##FJJZ@TO
M1]?)=H3\IODCUC&/\#/N_O=*_+M.%HTC89ZN<LV1QP4J#H4JB= RVD]GU]AC
M:<R:_9M1TK0>DS'GD&V DVN0P)$,E=0W#&"6&ID+B*8&=(G2;2[EVNW$$T/!
MV^[L1=-68^RJ"><], [ROF^<I%:-0GADE^@0,$8%R.)*>"]>WO;BY5TO7OK8
M$@55?%+$DPQP2Q75X3/&*5P=.,IMT]:KY8&.0M::=Q!5'HY8!T:IH'6QR]Q-
MQYWKN3CEH"UJ"P+V[$J\HT3HA@[Q*YR1S6"TYDG059(VD]NT^HP:G'[G;6.M
M5U2X.(;H@B(.NG%@/1/^(/3&PQ!7P7#@#28^KJB1^\%S7(7#T)N$$:T+Q]XH
M'-'59.Q%O*.W+AAB[[0_VERA<V69,FRT4J*B=^O]P=2;C,/C]\'8"P?!WOVK
MPI2,8U"%9Q6<%C=QT:V$:"%4.'(;3;UHNG?[Y>+N0BRH7>6<?K_(K 2@67#S
M/L C#&"3073T/A@/O B6VKUW+ND7RG;%,/"]P7!R]#Z*QEX03/?N[R@]SAF=
MH814*./4(-C)X6#0+>\$Q;-CS]^B/Q^F%'C3(-C;XYX^]LZIVV3+D7I.X3?R
MIN,AKL9CW_/#Z5983<83S_<Y_**!-X%)GHE1&'FC2;"U;CP>>L-HL%42@)LJ
MI!UYM"V=#F7U-VZN_$GDA</!UM7!=>/ &TRCWI53] G=ZW_-N-_ZXR/:>@T<
M?) T5G#QY;Z)17ES1L7(E1M(C,H ;,-0="X^9+DN,I3VG7Y.8U[3@MJ!,*%7
M1>GZG:U<40>)GO)@GM; O8_.!(0NMN:"0Z/ =Z< !BN=&(<GA&/VZ@%[L$^T
MY3[7PDATK%GS^OR!S]ZHS-=5##M9A^Z5)9J.EP-R--;W;$+=9$8C&;<?KF9N
MP'%(]WQ.8[CI3A)*@#Y&UAL^((+I$30)\,L8:&JU.7]PN+UQ&<NLC"X2S"-%
M)OY18T<X:'H-Y.T_&**[PI.Q0?0JT>[>:,PP![I(DP*_"1NK7(+TAA>ZF^'C
M&7<F U/4:<7C\Q[9?8?L@);6\FR))M!(,<9>=3>-<NW>-EMGS=;H"<TGA4G0
MP;FH(0,TPHR/DWD6NCWG/;?M*XJ$?-%F#JMDG?VF%^'/9#9_<!'\C-%LZ=Y!
M*?+JDQC24+ZQ3+RA\*-Q2G+R',5XU^RPHY.;GB-H;G2>2'J13AR9ZI9*VS;\
MH11J)TUWMI2YTUI%I[6[N(>1T^8 :0\FM<7G5BUTGCLXQ:,1#[[S [AI4R>=
M3J32077\P N&(SI$WB>[(^6F1K=VVA\>*$H!^N@XD0;+QL7$?=N$1\W7F![]
M*R$DG="5+5*=L.!WF+Q5.XE\*)M-#H\"<,'K2_IZL5)HZ1: ^?537> U1P;L
MB7QS5&J[4] &:WHMV.2A?-,5#IUD89QPM7R[$QY"QIZ;&&JS"4=1J7B9ZZ\T
MM7?#IS,G*B$&+M=]FC,+L%XK.L$_ /!M\P&(CDG;4=[;A\,D01^@[4;AS:&@
MN,F@(@@GXG<#DS>_/(4<!]X.6(]%$(G38'S6 >W' ;3O Z(/IHAL<>H/P[,.
M.1]'Q@36@Y$(IE-Q&D;168N)GXIZ"=D/HT@,QR-(ZH7^Z*Q#O/N(=A@ _(VG
M8C(-:/7$AXPMFG6KGVAYPGXC[*>!8\J_1"X:G/&;R",&C\#?9PQJ#P.IQ^'N
MLP:^'M[KWMT<*3D_%@DPL \#P[PC_^R)DQ1-1".XE9P:4AQ\=T+"L#.=;D:*
MT^$ 4?<W)Z  A@_](<;-4P3 !,XX/MM$0]^; L[[ W$:>>, B]NQY6\&PG@\
MAD6X^'(<@-K$/^,7%(^3_U\<'#Q):.N,[9HD?=ZKH?'F'*,[Q3RDO5Q)G1*M
M<[3/<RL9)_<^)*IOA*2)X_[QHW>X;^W6L=X1R:^,S?GLF*HG%W!E;3-H^8@.
M6B'G%1T+MHO03(IZL11SZC/TQ H_Q" 7M5F^&>=N]G0G2)+H.7V%8U!UQ$3M
MZ:BVMJ8N1-N6<J4:I SL3;4_EFGJ#J95*>G;1JH734<D7 K,O+.$ [P$=$WY
M0.G0A]++WI=MI-V"O]];=^3L/G)W3[M_$;AQ7\8WR]W_%\ /P"L6)IUCZ^!B
M/#QQLK<W55'R=_)9455%QI=+X#9E: '>SPO@_^:&&'3_.'']7U!+ P04
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MM:=>I$@E[ZF#B5<.U-"5=!/$1W[^W'03,_86)>_*U@0A&;CC8[:,AQ^:!K@
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M8S[6<,^TX)N20$<:2!):S5S3>?QK_\2.5I5T?XA OSL+E<@"?8VN),*#S$V
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MON)EB>,N.5Z ]PN+C]'VA@-L#] G_P)02P,$%     @ 3H6D5D4#:++\"@
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M$>#A,'M.[X:3P2OJ'Y+))L=U7R-VF%D"N_%8G"K+((/.7PO8\A[AOQBWP9A
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M\1Z)Z)2$>R6+\"SA#9.7$ 4NA'X8G>&+NL@BRQ>]%1D^854C9%*4<$5:);T
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M;FC R7%8$WNDIA]:$U'N=\DMPVLF$QVUY^K0AXZVXW4\1:U"Z<ZWG%>#EF-
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M.X[>TGS['@' %_%3WQX.@9Q8[M$Y"2SL0J9>SJLC23OWMI'PB(TM+SPZ=]T
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MY35QI^N'HUY8M?7->J4LM7X_+>BM1>T$Z'RMZ+*;A3/0OMZC?P%02P,$%
M  @ 3H6D5D3*WJ5'!0  20\  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&ULM5=M;]LV$/XK![<I$L"5]2X[30SDQ5F+K8L7)RV&81]HZVP+D42/I.-D
MOWYWE*TXK:,40?=%XLOQ[GC/<T?R:"75K9XC&K@O\E(?M^;&+ X['3V98R&T
M(Q=8TLQ4JD(8ZJI91R\4BM0N*O*.[[IQIQ!9V>H?V;&AZA_)I<FS$H<*]+(H
MA'HXQ5RNCEM>:S-PE<WFA@<Z_:.%F.$(S<UBJ*C7J;6D68&ESF0)"J?'K1/O
M\+3+\E;@2X8KO=4&WLE8REON?$J/6RX[A#E.#&L0]+O#,\QS5D1N_+/6V:I-
M\L+M]D;[A=T[[64L-)[)_&N6FOEQJ]N"%*=BF9LKN?J(Z_U$K&\B<VV_L*ID
MHZ@%DZ4VLE@O)@^*K*S^XGX=AZT%7?>9!?YZ@6_]K@Q9+\^%$?TC)5>@6)JT
M<<-NU:XFY[*201D91;,9K3/]T?7EV:\?+W\['UR-WKWI^E[R 09_W'RZ_A/V
MK\4X1WUPU#%DB,4[D[72TTJI_XS2 #[+TLPU#,H4TZ?K.^1@[:6_\?+4;U3X
M62@' J\-ONL'#?J">M>!U1<\M^NY4/C^E-!,82@>B&0&3I02Y0QM^Z^3L3:*
M&//WKLU7NL/=NCF+#O5"3/"X16FB4=UAJ__NC1>['QH\#VO/PR;M_5&5/""G
M,#)R<@N7"\ON$V9W9AYV^=NH<;>_UW.$J<PI9;-R!H:)L,[;[%_4H*UIN7A,
M+#)-"Q08RMCW8QM8L1(JU;"O.=@:LA+,7"ZU*%-]< B_+XLQ*OAJTX:D+Y=&
M&YIC>\+ .4[0"JQ1]\$+V['7A;?@N4[LPB^$%J^SI/4_U/_!/:I)QO;W_<@]
M@,!)(C@3Y80* 8T%L7\ 7N)X\;<6B6.3>4TR-D=UK3(71?#J@"Q0V=))#OP_
M<?$C#DKH)-X/Q22@F%CAQYB$ZY'F@/CAQDP#C:.:QM&/TOB:&5.EXM7H1C<R
MN5'IJYAL:'J+L]8#"@$,;6,#Y#-872%5B6S"(:^2\:;,#"%+6@Y@^ C\T]DA
MS];XBCM4=/K!C+&#5!AD)]C^R]!WVU$0U2@352/F]=MZ9,.'N!V$'D1Q"#TG
M3/@3P!?RG<'WVG%(E-@L\6*6V/3HX)MB9N7".-J22IRN6_=>2"2_G225=?+0
M=]R$_M:%!A[%-8_B9A[1)25=$J2;>KAFTIDLZ-JBA<W'P3VW<1>A&K6_KC3:
MHZ5BTV3;"ZR\@/UO2'0]5XA/#LSO,H^Q/I/:\"X5WF&Y1(YENQ?V[#^A$D!<
M1+N,V9N24"X7]BR+VXD;$55Z<00C00=Z&V98$NER*RI2NE5D?-KQ]0AZ;;_7
M X]T$\#7TI#4BSLB%Y)V+_*IX1/8;B.R28UL\L/(7HA,P1>1+VUO4"QR^8#X
MY #4N]!MMG#!QQ6GOP6@J # '0"T64PAK/A32L"- ]M57U<9C*E3G17L\MW&
MY6=6K 09U%1^!*?84EM"/:&7T$2M2OIEIOB6Z;8<&50%5ZL'XH2FJDT'9CUW
M)W/"+^>ZEKA[<)7IV_=3UIR1^T1S XJKD.<D\1Z<4P%,*2CPD&'^>+(TE:^M
MK=/A5]$'WL9.'#?0HEO3HOMS:#%<4F2(LS#,1;F+',UVOH-P?0(8"6.*%,'"
MB!$&%8<&H^'P9\,9-&)*MY(:#2JJW_5WP=U+]AHA#YUN;Z_6$CD^R?)EZW',
M<P+O65*\GAR1X[K\#?U=%.EL/6\*5#/[B--4BY:EJ5XZ]6C]3CRIGD>/XM4C
MDP(\RRCS<IS24I?NABU0U<.MZABYL(^EL33T]++-.;UU4;$ S4^E-)L.&ZA?
MS_W_ %!+ P04    " !.A:16O1);Z<4#  !I"0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6R55FV/XC80_BNCM*H6"6U">%F6 A+L4EVENSVT;'L?
MJGXPR818E]@YVUGV_GW'=DCA#NCU"SCVS#//,Y[)9+J7ZK/.$0V\E870LR W
MIIJ$H4YR+)F^E14*.LFD*IFA1[4+=:60I<ZI+,(XBD9AR;@(YE.WMU;SJ:Q-
MP06N%>BZ+)GZNL1"[F=!+SAL//-=;NQ&.)]6;(<;-']4:T5/88N2\A*%YE*
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M75DRGF.I3OG*%1L.>&&"\LP-/*_KYIA09]@W95,^[+.MS B%*4=BF^>8?W^
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ME_4!^OL'(=3K1IU@L^K@^&]02P,$%     @ 3H6D5IVU-W>J @  _ 8  !D
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MZJ<XEUS=)4HGO>'@=G _FJ#Y]62R0*.'N^G#_>1^,4?G:"(D476" %VE,N6
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M.A#E+59V%,^*BV#!E;Y6BN9:7_PH3(!^O^2Z/*N.N5OJ3XGP-U!+ P04
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M&![_/M"V1_,,&QZ'_D<T YW50&>M ?7=IE?M%;I&H7\7@-5E02'2")LXSOY
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M2D-=)9[U4-E"LM3T+2,F51=DIE/5=P+7&]3[,6-RN= !BDXV^ M02P,$%
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MPP7?83O?O>Q DQEK'5!O!?%A._$=.<QDVG\>9OP*6 7983O9'3>_X-W/KZI
M%62&[9]>1X\N>/=KK I402G83BDO.+9DECKV1+JETZN8\KDYHQ,P9:M$I@=9
M^=/\''"0GGX5R]-#Q&O"57,(B.A,B7KUMHH,3\_ETAO)EN8L;,*D9+&Y7% 2
M4*X7J/<SQN3V1AO(3T?[_P!02P,$%     @ 3H6D5F_B 2^; P  Y X  !D
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MU[OZO/C[P^>/Y\N5]^;5Q#+'[\GRR_7%U7=R3#PLFF ; V%KXDGFWQ[/4;&
M+%B"921HGHCEG5H#>7L.DD:Q>(>.U]XY>?OZ'7E-HI1<A6PK:!J(J2Z1L?JN
M[I?LY@4[ZPEV-OG$4AD*LDP#")K^.D9:A6O=ASNW.@$_47Y";/.(6(9EM_!9
M_+J[U4''KM2W<SS[";QEDL7L)P#Q@.\B'Y\AY7!\\TCE(W(6Q\PO%,=LK,!G
MFS3Z#\TN@4=,60LIR#\?\0OD0D(B_FV3NZ S:*>CKHQ3D5$?9AK>"0(Y@>:^
M>66.C/=M6O4$UE!N4"DWZ$)WKYBD,1%Y419R^?6BA*(HVR0H<$<YKKKD=JXY
M=H:8S5T]ML=6EC4V[,JJ07I8D1YVDE8Y4MGCL(-TV\JN$^"Y">H)K!'KJ(IU
M]+)*>]2G<CV!-90;5\J-_U!I%[C#>FD[ ^>@LEN,QL-)>V%/*LJ33LHK%(%R
M/R1XS>./Z Z[@PQ_ZV4;R4ZDY^:I)[!&T$X5M/.R*MSI4[F>P!K*F<9#UV'\
MH1HO@>OU.QH;PX,B;[&:.*-A>Y6;M6;)[*3MT1C$$=E "ASYJVJG 79ED9"<
MJGZTE7$GYG/SUA=:4P'K00'K915]R:<O]7I":ZKWT.Z9G3W1[Y2]_:@A<2SG
M\&YOL3)-9V(<U+U>FQ<2X)M\C!+(99O*HI>N3JM1[2P?4 [.YVJ$R^>0!YAB
M_L-.>1.E@L2P1DCC9(S_BKP8J8J-9%D^E=PPB3-.O@QQ# 6N#/#]FC%YOU$?
MJ 9;]W]02P,$%     @ 3H6D5O9L<JN" P  HPL  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&ULQ5;;;MLX$/V5@5H4+;")+G9D)[4-Q(Z+!MLBV;@7
M+!;[P%ACBP@EJB1MQW_?(26K=E81:B# OM@DQ7-XSG!(SF CU8-.$0T\9B+7
M0R\UIKCP?3U/,6/Z5!:8TY>%5!DSU%5+7Q<*6>) F?"C((C]C/'<&PW<V*T:
M#>3*")[CK0*]RC*FMF,4<C/T0F\W<,>7J;$#_FA0L"7.T'PM;A7U_)HEX1GF
MFLL<%"Z&WF5X,0D#"W SOG'<Z+TV6"OW4C[8SG4R] *K" 7.C:5@]+?&"0IA
MF4C'CXK4J]>TP/WVCOV#,T]F[IG&B13?>6+2H=?W(,$%6PES)S<?L3)T9OGF
M4FCW"YMJ;N#!?*6-S"HP*<AX7OZSQRH0>P#B:09$%2!Z HBZSP Z%:#CC);*
MG*TK9MAHH.0&E)U-;+;A8N/0Y(;G=AMG1M%73C@SFGVYF?SY\>;3U?1N]N95
M/PI[[V'ZU]?K+W_#"<PH:9*50) +^,"X@F],K%QOFA5";A%A9N3\ 6X*NR<:
MWEZA85SH=P1^#3[HE"G4 ]^04KN>/Z]4C4M5T3.J.O!9YB;5,,T33 [Q/CFL
M;48[F^.HE? S4Z?0"?^ *(@Z#7HFOP^/6N1TZJAW'%_GN:C;N)R,*?T2F,B,
MSJ1F+JLOE6+Y$NF<&+C?POZ\6[9UPY<;IA+XYQ-1PK7!3/_;%-]R_6[S^O9N
MN- %F^/0H\.O4:W1&[UY%<;!^Z;@O!#90:BZ=:BZ;>RC*[[F">8);#F*I,EJ
MB3]W>'MKK4?!P%_OZV^;<2#JK!9UUBIJE^]&0K%2\Y0V".8RRV@'M3T033);
M&8_=D1<B.S ?U^;C_SEYXY<,U0N1'82J5X>JUYHGT\>"GBOR;U!EP'/8(E.-
M]V$KS[&6VT5U2Q70@ZR\9&-(V%:WV.W7=ON_9W<M!:6$X&;;Y+65Y%BO_?^>
M[=->\^D^KVV<M]JXX_KA9*'H=>,Y;1QJ XH9;++22G2LE9(L# ^\!&$O;K83
M!K_>^*#5T'=7S-"^L#4J*LY@20?5T*X;A(5]U]?N72]0E2\VO*543:00-DWJ
MT7>-[WCKRL=&H&+K[T4@/HV?^O?WRIT,U=)5@9HNX%5NRI*@'JTKS4M77ST9
M']L*U)51OVC*\I4>_"6G"U[@@B@IH^C"565%6':,+%Q1=2\-E6BNF5(5C<I.
MH.\+*<VN8Q>HZ_+13U!+ P04    " !.A:16BPM,%>(#  "3$   &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,RYX;6S%6&UOVS80_BL'=2A:H(E>_)[:!F+'
M78,UJ!>W'89A'QCK;!.A1(VD[1C8CQ])R;+ER=H2",B76*3N'C[/Z4C>I;_E
MXE&N$!4\12R6 V>E5'+ENG*^PHC(2YY@K-\LN(B(TD.Q=&4BD(36*6)NX'EM
M-R(T=H9].S<5PSY?*T9CG J0ZR@B8C="QK<#QW?V$_=TN5)FPAWV$[+$&:KO
MR53HD9NCA#3"6%(>@\#%P+GVK\9^VSA8BQ\4M_+H&8R4!\X?S> V'#B>880,
MY\I $/VSP3$R9I TC[\R4"=?TS@>/^_1/UGQ6LP#D3CF[#<:JM7 Z3H0XH*L
MF;KGV\^8"6H9O#EGTOZ%;6;K.3!?2\6CS%DSB&B<_I*G+!!'#AJGW"'('()3
MA^89AT;FT+!"4V96U@U19-@7? O"6&LT\V!C8[VU&AJ;SSA30K^EVD\-9]^^
MCG_Y_/7+S>1^]O9--_ ['V'RZ_?;;[_#!<QTTH1KAL 7\(E0 3\(6]O1)$H8
MWR'"3/'Y(TS78K[2P80I(S&\NT%%*)/O-<1/X()<$8&R[RK-UZSJSC-NHY1;
M<(9; ^YXK%82)G&(8='?U3ISL<%>["BH!+PCXA(:_@<(O*!1PF?\_]V#"CJ-
M//8-B]<X%WL3EXN1CEL(8Q[IG2F)S>UK(4B\1+U;%#SLX-AN2G9V^GI+1 A_
M?-&0<*LPDG^6Q3==OUF^OCDAKF1"YCAP]!$@46S0&;Y]X[>]CV7!J0FL$*IF
M'JIF%?KPAFYHB'$(.XHL+).:^O>LOSF[-D.O[VZ.^5=9%$BU<E*M2E*3V71:
M1J72Z[E1KPFL(+"="VR_<H*VZPQ536"%4'7R4'6J<^$IT1>3UK_A3,>(4;4K
MT]OY=PY>]CHGB5IFU"E/U6Y.KUM)[Y[*QXN%T <VC15J^0H$4?C!7"DT6D=E
M7%-$WR_P\)K=W@G=<CNO7<ZXES/NO9 Q>3K'N%?*I!6<$"XW\QM^.6/?.]RE
M7B7GG_6N,#GPCL80<L:(D)"@2"_ ]Z478 K8/J+2.F&;F72/32Z;P1FN1_>^
M_Y^'%_P-=^>_?S7 <S=G76A%N<%!;O#*1UE&H*YPU816#->A,O$K;_/#<::W
M7J1W(.Q0)W.I[&J@-D2VABO5^!+7HJ!#_>!7%Q#[=#]_>%0#//O[U816E'NH
M3/S6:Z=[K55.76C%<!WJ'+^R-GA.NE<#!6<]QR_Q3.6X1^U=A&)INUX)<[Z.
M5=K\Y+-Y9WUM^\F3^9'IN&W;>(!)VW7=VBQI+('A0D/J<D-_#Y%VP.E \<0V
MD0]<Z9;4/JZ0A"B,@7Z_X%SM!V:!_/\0PW\ 4$L#!!0    ( $Z%I%;#HF+/
M*@,  ' *   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;*U66V_:,!3^
M*U96351JR8W[(%*Y3)VT=@C:[=E-#+'FV)GM0/?O9SLA#2AD/, #L4_.]^5\
MQ\?V&>\9_RUBA"1X3P@5$RN6,AW9M@ACE$#19BFBZLV&\01*->5;6Z0<P<B
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MJU3RO+W))Y*EID-X8U+U&V88JY80<>V@WF\8DX>)_D#99 ;_ %!+ P04
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MJ2D+T32UH;II96P']#?5K/:F;/M5NE[%'DOU9:ZG(TP?:H7>2IJSA>DO\L8
MIA[AZJ2J^/(S9Q-14#OY@Q,.>F3%\Z:E9$\Z&Y3*6 >H]+U'*A4;;T9^2U+=
MTX5:E=,BQSVW3M#SOUWG"154$KYI6M?^,:_RJQW'G;>R;)XJNX:='NN7_[&;
M;)^"R>043)Y$379/P61Z B8[;_;4?(G)Z/A-QL>YVT%]7-LX$VZ=")NH!R?O
MOO\#SOA\G=0;S1E73-2]*<LR*IX=#+6\(B/]9^F6OAZ?T9S,N;IOP+Z_;G^G
M&9L7:3/J%A:B'K5N?X/I14ES[->YF,CH@F;#NBLG(]/T=$-GK3] V$5NS,>-
M8!R+N1' L#R8 XQC65B>_VD^770^%L.\=9U(%^5T48YEN9"A^6)YW)Q4?]PS
M3=,X3A)L18=#IX,AMFY) C]N-<P;,+ \D.EE:XWO-EXA^^L V]-]%8+-%*]$
M;*;X6@/B7C=@I*E[M[$\P,!V :L=R._. S7EYL0Q["KF#;N#<21-,01JT5VC
M28*L3@)?]_Y@=TD<IZD; <SM((XQ!.Y&',$<@ <,B6/S'MQY'P6K]U2P_E_M
MX ]02P,$%     @ 3H6D5I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2
MN6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>
M:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEF
MM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;
M&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ
M8K3^-8+)#^Q^ %!+ P04    " !.A:1603Z,R D$  "M'P  #P   'AL+W=O
M<FMB;V]K+GAM;,6978^;.!1 _XK%4_=A-^%CINVHJ<0DS S:#&2!&6GWI7*"
M,[$*.#(FL^VO7T.2UK1PU9>[>0(,,@?;W'-M?W@5\O-:B,_DW[*HZIFU4VI_
M,YG4FQTK:?V'V+-*W]D*65*E+^7+I-Y+1O-ZQY@JBXDSG5Y/2LHKZ^.'<UTK
M.3$OA&(;Q46E"]N"9\Y>Z^_WVTMRX#5?\X*K+S.K.R^814I>\9)_9?G,FEJD
MWHG7!R'Y5U$I6J0;*8IB9MG'&\],*K[YJ3AM(3.ZKKL21=<)U2 SZWJJ*]QR
M6:ONB:Y^JAD/3#]\O&J4N..%8G)!%;N7HMGSZJ6M1G_%Q/B,KAW.QV,CWLA?
M:4:QW?(-6XA-4[)*'=M1LJ(%K.H=W]<6J6C)9M9<')ALOT>_(,R/WZ8TE-%2
M\H;K&S+,.SQ,E"IG5<UR<DL+6FT8Z=JO-N@<@,ZY#!UYLZ*250:D"T"Z_Q>D
M/JM%P7/-D9.TQ2E[D!X Z5T0\I-C0%X!D%>7A'0-R&L \AH7,D[N_2C\Q\_"
M.")^M"!I>!^%=^'<CS+BSPW(MP#D6US(NS#RHWGH+TD8I5GR]!A$66J@O0/0
MWN&BW?I+C1:0]"$(,C*/'U=Q] /=>X#N/?(0C*/G(,G"VZ4F#*(P3D@49X%)
M9T^A<#W%YGM\#+.N.[O!IWFS,+H/=&?W(4&G($LES>+YGP_Q<A$DZ2<2_/44
M9G^;;)!1;&2E1'K0+>,T):L@T6/03P*3#-*(C>R1)'@.HJ<>#B0,&]D88)SK
M&<.&E&$C.V,PTI$W.NLK6/V;20DYPT:6QEC0.X&:F) U;&1MC$6_ 4S((#:R
M0H;BRV"70R*QD4WR<Z 90G0@F3C(,CE%G$$NR!\.LC_@T&/F@0XX.4%6R7#H
M^9VD35E2^<7$A+SB('ME##.B4NJG34S(-PZR;\8PYSM:O;#>A!3RC7,1WYPZ
MO:=%!Q*.@RP<&+/W"T'"<9"%,^K%X_ T,2'A.!>:L[3#4Y1[$Q-2CH.L' !S
MP;;FG^Y"VG&1M0-@!G4O(+F0A5QD"T&=KF.2B0E9R$6V$(!YUZC&Q 07R;!7
MR493R\Y#)B9D(1=[G6P4,]6UYR8F9"$7>Z4,PNQ9R(4LY");:#!1_Y9Y'$Q,
MR$(NLH5&,$]Y'#$Q(0NYEYCVG#'[G0Y9R$6V$(QIIAX>9"$/V4)CF.UOWO3F
MNAYD(>\":VG?,'N=[D$6\I M!&/V.AVRD(=LH8%)^3&%:U3[L(D);M8@6V@0
MTZ\4SWG1]#(D#[*0AVRA\_K!][^&B"U)V(%5#2-K$Q.RD(=L(0/S%-%-2G.>
M[D$6\CH+3<[;P[G.J"N61_H5M2[?T&*SDJ0]'->XO:MV^6G;%,5<E\754M#\
MO-M\WBG_^!]02P,$%     @ 3H6D5KDCVC>R 0  5!P  !H   !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<\W9.V["0!2%X:T@+R##?4!"%%*EH8W8@ 7#
M0P%L>28*[#X("CA6BC1H3F7-6+[^JT_6^.TS[NJ\;0YILVW3X+C?'=*TVN3<
MOH:0%INXK]-3T\;#^<ZJZ?9U/B^[=6CKQ5>]CD&'PW'H[F=4[V_W,P?S4QO_
M,[%9K;:+^-$LOO?QD/\8''Z:[BMM8LS58%YWZYBG53CN;MLI7"[R=)Y<#6;+
M:=7-EE*%TD$*05H^R"#(R@<Y!'GYH!$$C<H'C2%H7#[H&8*>RP>]0-!+^: )
M!$W*!\D091P2)/6P)M!:D&LA\%H0;"$06Y!L(3!;$&TA4%N0;2%P6Q!N(9!;
MD&XAL%L0;R'06U%O)=!;46\ET%M[']L$>BOJK01Z*^JM!'HKZJT$>BOJK01Z
M*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z6^^PA$!O0[V-0&]#O8U
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $Z%I%:2A1SV[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $Z%
MI%:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 3H6D5LN2AH#?!0  XQX  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $Z%
MI%9)W "/R08   \>   8              " @2(.  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !.A:16H1/>;_<"  !9"@  &
M        @($A%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 3H6D5F*#56Y]!@  MA\  !@              ("!3A@  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $Z%I%:1K7W<508  %,H   8
M              " @0$?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !.A:16LXJR*(\'  "9(0  &               @(&,)0  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 3H6D5DY%JI"2#0
MU"(  !@              ("!42T  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( $Z%I%:\"'? K0L  $0A   8              " @1D[
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !.A:16P0\E
M2 ,+  "N&P  &               @('\1@  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 3H6D5H?+KE$'"P  U1X  !D
M ("!-5(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !.
MA:16,<Q"S7(&  !,#P  &0              @(%S70  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $Z%I%9% VBR_ H  "T?   9
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M970Q-BYX;6Q02P$"% ,4    " !.A:16_?"^,#L%   !#0  &0
M    @('JB0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M $Z%I%9\7Z8#6@,  ,D'   9              " @5R/  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 3H6D5D3*WJ5'!0  20\  !D
M             ("![9(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !.A:16O1);Z<4#  !I"0  &0              @(%KF   >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $Z%I%:08JL$'P,
M '0'   9              " @6><  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 3H6D5K=E3X:R P  !!0  !D              ("!
MO9\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !.A:16
M<[_FV1<(  ",/@  &0              @(&FHP  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( $Z%I%;8[?Q^8P(  +L&   9
M      " @?2K  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 3H6D5F.2CG7" @  .08  !D              ("!CJX  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !.A:16?%ADH\8%  !_'P
M&0              @(&'L0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( $Z%I%;XXR!1B (  (H%   9              " @82W  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 3H6D5L4_WP2(
M"   @5   !D              ("!0[H  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !.A:16G;4W=ZH"  #\!@  &0
M@($"PP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $Z%
MI%;I/"11 P0  +<0   9              " @>/%  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 3H6D5@G%>ZP# P  S@D  !D
M         ("!'<H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !.A:16]Y;!JQL#   >"   &0              @(%7S0  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $Z%I%8[R&D?R@(  %$)
M   9              " @:G0  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ 3H6D5I-?QUG\!   L1P  !D              ("!JM,
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !.A:16U=I<
MM<L"  !6"   &0              @('=V   >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( $Z%I%93.%2*]P(   P)   9
M  " @=_;  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M3H6D5A.9->Z!!@  ^S(  !D              ("!#=\  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !.A:16Y&$L15(#  #;"@  &0
M            @('%Y0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( $Z%I%;.Z^I^.P,  -4*   9              " @4[I  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 3H6D5OB0GF2@!
M*14  !D              ("!P.P  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !.A:16;^(!+YL#  #D#@  &0              @(&7
M\0  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $Z%I%;V
M;'*K@@,  *,+   9              " @6GU  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ 3H6D5HL+3!7B P  DQ   !D
M     ("!(OD  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $Z%I%8ULJH'5 ,  +@5   -              "
M 3<+ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ 3H6D5I>*NQS     $P(
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9>&UL4$L%!@     W #< ^ X  *<7 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>157</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - CONVERTIBLE SENIOR NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/REVENUE</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - FINANCIAL INSTRUMENTS - Changes in estimated fair value of contingent consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Changes in estimated fair value of contingent consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - BALANCE SHEET COMPONENTS - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - BALANCE SHEET COMPONENTS - Definite-lived Intangible Assets from Business Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Definite-lived Intangible Assets from Business Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - BALANCE SHEET COMPONENTS - Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - CONVERTIBLE SENIOR NOTES (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - CONVERTIBLE SENIOR NOTES (Schedule of Net Carrying Amount) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Schedule of Net Carrying Amount) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - CONVERTIBLE SENIOR NOTES (Schedule of Interest Expense) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Schedule of Interest Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - STOCKHOLDERS??? EQUITY - Summary of Time Based Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Summary of Time Based Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - STOCKHOLDERS??? EQUITY - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - STOCKHOLDERS??? EQUITY - Summary of RSUs and PSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Summary of RSUs and PSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - NET LOSS PER SHARE - Computation of Basic and Diluted Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Computation of Basic and Diluted Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - NET LOSS PER SHARE - Antidilutive Shares Excluded from Computation of Diluted Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Antidilutive Shares Excluded from Computation of Diluted Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - REVENUE - Schedule of Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails</Role>
      <ShortName>REVENUE - Schedule of Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pacb-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - REVENUE - Summary of Revenue by Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails</Role>
      <ShortName>REVENUE - Summary of Revenue by Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: pacb:StandardProductWarrantyPeriod, us-gaap:DebtInstrumentConvertibleConversionRatio1 -  pacb-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="pacb-20230331.htm">pacb-20230331.htm</File>
    <File>pacb-20230331.xsd</File>
    <File>pacb-20230331_cal.xml</File>
    <File>pacb-20230331_def.xml</File>
    <File>pacb-20230331_lab.xml</File>
    <File>pacb-20230331_pre.xml</File>
    <File>pacb-20230331x10qxexx311.htm</File>
    <File>pacb-20230331x10qxexx312.htm</File>
    <File>pacb-20230331x10qxexx321.htm</File>
    <File>pacb-20230331x10qxexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pacb-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="621">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pacb-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 621,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 157,
   "dts": {
    "calculationLink": {
     "local": [
      "pacb-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pacb-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pacb-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pacb-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pacb-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pacb-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 430,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://www.pacificbiosciences.com/20230331": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 17,
   "keyStandard": 249,
   "memberCustom": 18,
   "memberStandard": 34,
   "nsprefix": "pacb",
   "nsuri": "http://www.pacificbiosciences.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.pacificbiosciences.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - CONVERTIBLE SENIOR NOTES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES",
     "shortName": "CONVERTIBLE SENIOR NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - NET LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - REVENUE",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.pacificbiosciences.com/role/REVENUE",
     "shortName": "REVENUE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "15",
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables",
     "shortName": "CONVERTIBLE SENIOR NOTES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.pacificbiosciences.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - NET LOSS PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - REVENUE (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.pacificbiosciences.com/role/REVENUETables",
     "shortName": "REVENUE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib74a70bcb48d4df6a79ecde68ca7040d_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib74a70bcb48d4df6a79ecde68ca7040d_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "iab42dea2b5104f92933733e4ae8b828c_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "iab42dea2b5104f92933733e4ae8b828c_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ie27fe1fa4ecc4067a7d326349cbf168c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - FINANCIAL INSTRUMENTS - Changes in estimated fair value of contingent consideration (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Changes in estimated fair value of contingent consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ie27fe1fa4ecc4067a7d326349cbf168c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i36c2bb89833b4cfcb9dcbf700eebd5b0_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i36c2bb89833b4cfcb9dcbf700eebd5b0_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - BALANCE SHEET COMPONENTS - Components of Inventory (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Components of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - BALANCE SHEET COMPONENTS - Definite-lived Intangible Assets from Business Acquisitions (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Definite-lived Intangible Assets from Business Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ie27fe1fa4ecc4067a7d326349cbf168c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ie27fe1fa4ecc4067a7d326349cbf168c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - BALANCE SHEET COMPONENTS - Future Principal Payments (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Future Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "id3026c43f5474b3aaf648b1b685a4b02_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i2a4563e98c524b29afa46ed0121d04a2_I20210216",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - CONVERTIBLE SENIOR NOTES (Narrative) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
     "shortName": "CONVERTIBLE SENIOR NOTES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i2a4563e98c524b29afa46ed0121d04a2_I20210216",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - CONVERTIBLE SENIOR NOTES (Schedule of Net Carrying Amount) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
     "shortName": "CONVERTIBLE SENIOR NOTES (Schedule of Net Carrying Amount) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ib7391dc7425a48d1a68d124321e865b5_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - CONVERTIBLE SENIOR NOTES (Schedule of Interest Expense) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
     "shortName": "CONVERTIBLE SENIOR NOTES (Schedule of Interest Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pacb:PublicOfferingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i2af2b19b6b09479ea48c4083c6bd418c_D20230131-20230131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pacb:PublicOfferingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i638e0be2cf05429d9d48a17c3ad3afc4_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Summary of Time Based Options (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Summary of Time Based Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i638e0be2cf05429d9d48a17c3ad3afc4_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i3d55f5d1f2ab4ed397287f639f4978b7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i3d55f5d1f2ab4ed397287f639f4978b7_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i557fdaad292c4b3fb9316667a1bba49e_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Summary of RSUs and PSUs Activity (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Summary of RSUs and PSUs Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i557fdaad292c4b3fb9316667a1bba49e_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Options (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i87cda0291620443e8aecca5e2324bb78_D20220101-20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i3bc3bdef43ea4a9388d2b6618aa1605c_D20230101-20230331",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - NET LOSS PER SHARE - Computation of Basic and Diluted Earnings per Share (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails",
     "shortName": "NET LOSS PER SHARE - Computation of Basic and Diluted Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ia7a1b740447c43f8a9ab44e87fa30129_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - NET LOSS PER SHARE - Antidilutive Shares Excluded from Computation of Diluted Earnings per Share (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails",
     "shortName": "NET LOSS PER SHARE - Antidilutive Shares Excluded from Computation of Diluted Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ia7a1b740447c43f8a9ab44e87fa30129_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - REVENUE - Schedule of Revenue by Geographic Location (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails",
     "shortName": "REVENUE - Schedule of Revenue by Geographic Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "icb8e95a9d8854d71946cebeffe0b0fb3_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - REVENUE - Summary of Revenue by Category (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails",
     "shortName": "REVENUE - Summary of Revenue by Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "ibf52ec5feb514b609a102b910f6fa20e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i0c88663c018943f9969c82d3e25f57bc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i0c88663c018943f9969c82d3e25f57bc_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - FINANCIAL INSTRUMENTS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - BALANCE SHEET COMPONENTS",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230331.htm",
      "contextRef": "i771ebf8299794c3cb53f7fd659514061_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 56,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pacb_BalanceSheetComponentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Components [Line Items]",
        "label": "Balance Sheet Components [Line Items]",
        "terseLabel": "Balance Sheet Components [Line Items]"
       }
      }
     },
     "localname": "BalanceSheetComponentsLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_ConsumableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumable [Member]",
        "label": "Consumable [Member]",
        "terseLabel": "Consumable revenue"
       }
      }
     },
     "localname": "ConsumableMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes [Member]",
        "label": "Convertible Senior Notes [Member]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One",
        "label": "Customer One [Member]",
        "terseLabel": "One Customer"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Two",
        "label": "Customer Two [Member]",
        "terseLabel": "Two Customers"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_DebtConversionTermsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion Terms One",
        "label": "Debt Conversion Terms One [Member]",
        "terseLabel": "Debt Conversion Terms One"
       }
      }
     },
     "localname": "DebtConversionTermsOneMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_DebtConversionTermsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion Terms Two",
        "label": "Debt Conversion Terms Two [Member]",
        "terseLabel": "Debt Conversion Terms Two"
       }
      }
     },
     "localname": "DebtConversionTermsTwoMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_DebtInstrumentAdditionalInterestInEventOfDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Additional Interest in the Event of Default",
        "label": "Debt Instrument, Additional Interest in the Event of Default",
        "terseLabel": "Additional interest in the event of default"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalInterestInEventOfDefault",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Terms Of Conversion",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTermsOfConversionAxis",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Terms Of Conversion",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTermsOfConversionDomain",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_DebtInstrumentDebtDefaultCalendarDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Debt Default, Calendar Days",
        "label": "Debt Instrument, Debt Default, Calendar Days",
        "terseLabel": "Debt instrument, debt default, calendar days"
       }
      }
     },
     "localname": "DebtInstrumentDebtDefaultCalendarDays",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_DebtInstrumentInterestInTheEventOfDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest in the Event of Default",
        "label": "Debt Instrument, Interest in the Event of Default",
        "terseLabel": "Debt instrument, interest in the event of default"
       }
      }
     },
     "localname": "DebtInstrumentInterestInTheEventOfDefault",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Consecutive Trading Days",
        "label": "Debt Instrument, Redemption Price, Consecutive Trading Days",
        "terseLabel": "Debt redemption, consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPriceConsecutiveTradingDays",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage of Conversion Price",
        "label": "Debt Instrument, Redemption Price, Percentage of Conversion Price",
        "terseLabel": "Debt redemption, percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfConversionPrice",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_DebtInstrumentRedemptionPriceTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Trading Days",
        "label": "Debt Instrument, Redemption Price, Trading Days",
        "terseLabel": "Debt redemption, trading days"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPriceTradingDays",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_DebtInstrumentTermLoanElectiveOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Term Loan, Elective Option",
        "label": "Debt Instrument, Term Loan, Elective Option",
        "terseLabel": "Debt instrument, term loan, elective option"
       }
      }
     },
     "localname": "DebtInstrumentTermLoanElectiveOption",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_DomesticCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Customers [Member]",
        "label": "Domestic Customers [Member]",
        "terseLabel": "Domestic Customers"
       }
      }
     },
     "localname": "DomesticCustomersMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Equity Incentive Plan [Member]",
        "label": "Equity Incentive Plan2020 [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_FinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Line Items]",
        "label": "Financial Instruments [Line Items]",
        "terseLabel": "Financial Instruments [Line Items]"
       }
      }
     },
     "localname": "FinancialInstrumentsLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_FinancialInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Table]",
        "label": "Financial Instruments [Table]",
        "terseLabel": "Financial Instruments [Table]"
       }
      }
     },
     "localname": "FinancialInstrumentsTable",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_IncomeLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Loss per Share Abstract",
        "label": "Income Loss per Share Abstrct",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "IncomeLossPerShareAbstract",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_InstrumentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument [Member]",
        "label": "Instrument [Member]",
        "terseLabel": "Instrument revenue"
       }
      }
     },
     "localname": "InstrumentMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_InvitaeCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invitae Corporation [Member]",
        "label": "Invitae Corporation [Member]",
        "terseLabel": "Invitae Corporation"
       }
      }
     },
     "localname": "InvitaeCorporationMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_OfferingShareAmountMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Share Amount Maximum",
        "label": "Offering Share Amount Maximum",
        "terseLabel": "Offering share amount maximum (in dollars per share)"
       }
      }
     },
     "localname": "OfferingShareAmountMaximum",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pacb_OmniomeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omniome, Inc. (\u201cOmniome\u201d), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy.",
        "label": "Omniome Inc [Member]",
        "terseLabel": "Omniome, Inc"
       }
      }
     },
     "localname": "OmniomeIncMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock [Member]",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering",
        "label": "Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering",
        "terseLabel": "Percentage commission of gross proceeds on sale of common stock under at-the-market offering"
       }
      }
     },
     "localname": "PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_PercentageOfFeeToPrepayDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fee of the outstanding debt to prepay the debt.",
        "label": "Percentage of Fee to Prepay Debt",
        "terseLabel": "Percentage of fee to prepay debt"
       }
      }
     },
     "localname": "PercentageOfFeeToPrepayDebt",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity, net of issuance costs.",
        "label": "Proceeds from Issuance of Common Stock, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering, Option to Purchase Additional Shares, Period",
        "label": "Public Offering, Option to Purchase Additional Shares, Period",
        "terseLabel": "Public offering, option to purchase additional shares, period"
       }
      }
     },
     "localname": "PublicOfferingOptionToPurchaseAdditionalSharesPeriod",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering, Option to Purchase Additional Shares, Shares",
        "label": "Public Offering, Option to Purchase Additional Shares, Shares",
        "terseLabel": "Public offering, option to purchase additional shares (in shares)"
       }
      }
     },
     "localname": "PublicOfferingOptionToPurchaseAdditionalSharesShares",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pacb_PublicOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering, Shares",
        "label": "Public Offering, Shares",
        "terseLabel": "Public offering (in shares)"
       }
      }
     },
     "localname": "PublicOfferingShares",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pacb_ScheduleOfBalanceSheetComponentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Balance Sheet Components [Table]",
        "label": "Schedule of Balance Sheet Components [Table]",
        "terseLabel": "Schedule of Balance Sheet Components [Table]"
       }
      }
     },
     "localname": "ScheduleOfBalanceSheetComponentsTable",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_ScheduleOfInterestExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Interest Expense [Table Text Block]",
        "label": "Schedule of Interest Expense [Table Text Block]",
        "terseLabel": "Schedule of Interest Expense"
       }
      }
     },
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pacb_ServiceAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service and Other [Member]",
        "label": "Service And Other [Member]",
        "terseLabel": "Service and other revenue"
       }
      }
     },
     "localname": "ServiceAndOtherMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_ShelfOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Offering",
        "label": "Shelf Offering [Member]",
        "terseLabel": "Shelf Offering"
       }
      }
     },
     "localname": "ShelfOfferingMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_StandardProductWarrantyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standard Product Warranty, Period",
        "label": "Standard Product Warranty, Period",
        "terseLabel": "Standard product warranty, period"
       }
      }
     },
     "localname": "StandardProductWarrantyPeriod",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pacb_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pacb_SupplementalBalanceSheetComponentsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Components Disclosure [Abstract]",
        "label": "Balance Sheet Components [Abstract]",
        "terseLabel": "Balance Sheet Components [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetComponentsDisclosureAbstract",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "xbrltype": "stringItemType"
    },
    "pacb_TermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loans",
        "label": "Term Loans [Member]",
        "terseLabel": "Term Loans"
       }
      }
     },
     "localname": "TermLoansMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_TimeBasedRestrictedStockUnitsRsusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-Based Restricted Stock Units (RSUs) [Member]",
        "label": "Time Based Restricted Stock Units Rsus [Member]",
        "terseLabel": "RSUs with time-based vesting"
       }
      }
     },
     "localname": "TimeBasedRestrictedStockUnitsRsusMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pacb_TimeBasedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-based stock option",
        "label": "Time Based Stock Option [Member]",
        "terseLabel": "Time-based stock option"
       }
      }
     },
     "localname": "TimeBasedStockOptionMember",
     "nsuri": "http://www.pacificbiosciences.com/20230331",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AmericasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continents of North and South America.",
        "label": "Americas [Member]",
        "terseLabel": "Americas"
       }
      }
     },
     "localname": "AmericasMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region of Asia Pacific.",
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia-Pacific"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Future Principal Payments, Fiscal Year Maturity"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r252",
      "r525",
      "r586",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r280",
      "r282",
      "r283",
      "r284",
      "r357",
      "r461",
      "r475",
      "r495",
      "r496",
      "r522",
      "r535",
      "r540",
      "r585",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r280",
      "r282",
      "r283",
      "r284",
      "r357",
      "r461",
      "r475",
      "r495",
      "r496",
      "r522",
      "r535",
      "r540",
      "r585",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r252",
      "r525",
      "r586",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r249",
      "r463",
      "r523",
      "r538",
      "r581",
      "r582",
      "r586",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r249",
      "r463",
      "r523",
      "r538",
      "r581",
      "r582",
      "r586",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r280",
      "r282",
      "r283",
      "r284",
      "r350",
      "r357",
      "r384",
      "r385",
      "r386",
      "r437",
      "r461",
      "r475",
      "r495",
      "r496",
      "r522",
      "r535",
      "r540",
      "r580",
      "r585",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r280",
      "r282",
      "r283",
      "r284",
      "r350",
      "r357",
      "r384",
      "r385",
      "r386",
      "r437",
      "r461",
      "r475",
      "r495",
      "r496",
      "r522",
      "r535",
      "r540",
      "r580",
      "r585",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r250",
      "r251",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r524",
      "r539",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Segment, Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r250",
      "r251",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r498",
      "r524",
      "r539",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r537"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r186",
      "r471",
      "r480",
      "r481"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r27",
      "r30",
      "r128",
      "r430",
      "r476",
      "r477",
      "r552",
      "r553",
      "r554",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r537"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r564",
      "r565",
      "r566",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r114",
      "r115",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r35",
      "r319",
      "r426",
      "r559"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r319",
      "r426",
      "r520",
      "r521",
      "r559"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r51",
      "r78",
      "r83"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r147",
      "r165",
      "r184",
      "r203",
      "r240",
      "r243",
      "r247",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r404",
      "r406",
      "r418",
      "r537",
      "r583",
      "r584",
      "r594"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r178",
      "r188",
      "r203",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r404",
      "r406",
      "r418",
      "r537",
      "r583",
      "r584",
      "r594"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r570",
      "r571",
      "r604"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r401",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r117",
      "r118",
      "r401",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r403",
      "r558"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in the estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r122",
      "r123",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r122",
      "r124"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Debt instrument, stated interest rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "terseLabel": "Short term debt acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt",
        "terseLabel": "Long-term debt acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r53",
      "r180",
      "r507"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents at end of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r54",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r48",
      "r53",
      "r55"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r48",
      "r140"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r587",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r154",
      "r172"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r564",
      "r565",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r537"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Authorized 1,000,000 shares; issued and outstanding 249,803 and 226,505 shares at March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r31",
      "r190",
      "r192",
      "r197",
      "r467",
      "r472"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r58",
      "r59",
      "r138",
      "r139",
      "r252",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r58",
      "r59",
      "r138",
      "r139",
      "r252",
      "r482",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r58",
      "r59",
      "r138",
      "r139",
      "r252",
      "r485",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r58",
      "r59",
      "r138",
      "r139",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r58",
      "r59",
      "r138",
      "r139",
      "r252",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r332",
      "r333",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r332",
      "r333",
      "r346"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r332",
      "r333",
      "r346"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Fair value of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r95",
      "r297",
      "r298",
      "r309",
      "r310",
      "r311",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Shares issuable upon conversion of convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible senior notes, net, non-current"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r530",
      "r532",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r555",
      "r556"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r37",
      "r203",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r418",
      "r583"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "totalLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue [Abstract]",
        "terseLabel": "Cost of Revenue:"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r57",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r202",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r313",
      "r320",
      "r321",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "CONVERTIBLE SENIOR NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r148",
      "r149",
      "r163",
      "r205",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r427",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r5",
      "r149",
      "r163",
      "r324"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r96",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r22",
      "r99",
      "r100",
      "r102",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r142",
      "r144",
      "r297",
      "r427",
      "r518",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount of notes"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r21",
      "r142",
      "r327",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r21",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r205",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r427",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r23",
      "r99",
      "r101",
      "r102",
      "r103",
      "r141",
      "r142",
      "r144",
      "r162",
      "r205",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r427",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r143",
      "r309",
      "r325",
      "r518",
      "r519"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Short- and long-term debt"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r51",
      "r86"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r345",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Revenue by Category"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r361",
      "r389",
      "r390",
      "r391",
      "r395",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "Europe, Middle East and Africa"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r198",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r219",
      "r221",
      "r223",
      "r224",
      "r225",
      "r229",
      "r410",
      "r411",
      "r468",
      "r473",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net (loss) income per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]",
        "terseLabel": "Weighted average shares outstanding used in calculating net loss per share:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r198",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r221",
      "r223",
      "r224",
      "r225",
      "r229",
      "r410",
      "r411",
      "r468",
      "r473",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net (loss) income per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]"
       }
      }
     },
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98",
      "r176",
      "r193",
      "r194",
      "r195",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r231",
      "r258",
      "r331",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r409",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r430",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r412",
      "r413",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r130",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r311",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r413",
      "r434",
      "r435",
      "r436",
      "r518",
      "r519",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r311",
      "r351",
      "r356",
      "r413",
      "r434",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r311",
      "r351",
      "r356",
      "r413",
      "r435",
      "r518",
      "r519",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r311",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r413",
      "r436",
      "r518",
      "r519",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r133",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in the Estimated Fair Value of Contingent Consideration Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinestimatedfairvalueofcontingentconsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r311",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r434",
      "r435",
      "r436",
      "r518",
      "r519",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r322",
      "r330",
      "r408",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r515",
      "r573",
      "r574",
      "r575",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated Useful Life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r182",
      "r274"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r82",
      "r465"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r79",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r82",
      "r464"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposition of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r181",
      "r268",
      "r466",
      "r516",
      "r537",
      "r578",
      "r579"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r51",
      "r269",
      "r270",
      "r271",
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r36",
      "r203",
      "r240",
      "r242",
      "r246",
      "r248",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r418",
      "r514",
      "r583"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r33",
      "r145",
      "r155",
      "r174",
      "r240",
      "r242",
      "r246",
      "r248",
      "r469",
      "r514"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before expense (benefit) from income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r204",
      "r217",
      "r218",
      "r239",
      "r396",
      "r399",
      "r400",
      "r474"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Expense (benefit) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r462",
      "r558"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r558",
      "r593"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r143",
      "r157",
      "r196",
      "r238",
      "r425"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r39",
      "r317",
      "r328",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest expense",
        "verboseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r41",
      "r318",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r75",
      "r509"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r187",
      "r508",
      "r537"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventory, net",
        "verboseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails",
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r75",
      "r511"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Purchased materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r75",
      "r510"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory provision"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Accretion of discount and amortization of premium on marketable securities, net"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments:"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Investments:"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r18",
      "r203",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r405",
      "r406",
      "r407",
      "r418",
      "r513",
      "r583",
      "r594",
      "r595"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r150",
      "r170",
      "r537",
      "r562",
      "r576",
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r179",
      "r203",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r405",
      "r406",
      "r407",
      "r418",
      "r537",
      "r583",
      "r594",
      "r595"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r5",
      "r149",
      "r167",
      "r310",
      "r326",
      "r518",
      "r519"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r93",
      "r205",
      "r315"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long term debt, excluding current maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r23",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDisclosures": {
     "auth_ref": [
      "r278",
      "r279",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
        "label": "Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "LossContingencyDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]"
       }
      }
     },
     "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r48",
      "r49",
      "r52"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r34",
      "r52",
      "r156",
      "r173",
      "r177",
      "r189",
      "r191",
      "r195",
      "r203",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r222",
      "r240",
      "r242",
      "r246",
      "r248",
      "r257",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r411",
      "r418",
      "r514",
      "r583"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expense"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expense:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r240",
      "r242",
      "r246",
      "r248",
      "r514"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r125",
      "r126",
      "r127"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on investments",
        "verboseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r537"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities, current"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities, non-current"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based stock options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in share)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r537"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Authorized 50,000 shares; No shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under equity offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r45",
      "r112"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock from equity plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r66",
      "r199",
      "r200"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r42",
      "r66",
      "r199"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductWarrantyAccrual": {
     "auth_ref": [
      "r90",
      "r91",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Standard and Extended Product Warranty Accrual",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "negatedTerseLabel": "Repairs and replacements"
       }
      }
     },
     "localname": "ProductWarrantyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualWarrantiesIssued": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.",
        "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued",
        "terseLabel": "Additions charged to cost of product revenue"
       }
      }
     },
     "localname": "ProductWarrantyAccrualWarrantiesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r87",
      "r171",
      "r470",
      "r537"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Notes payable principal payoff"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r116",
      "r175",
      "r602"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r53",
      "r55",
      "r146",
      "r168",
      "r180"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash at end of period"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r53",
      "r55",
      "r484"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r547",
      "r560"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Short-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r484",
      "r548",
      "r560"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r104",
      "r169",
      "r479",
      "r481",
      "r537"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r176",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r258",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r409",
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r236",
      "r237",
      "r241",
      "r244",
      "r245",
      "r249",
      "r250",
      "r252",
      "r344",
      "r345",
      "r463"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/REVENUESummaryofRevenuebyCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r343",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographic Location"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "verboseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r252",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r117",
      "r118",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefinitelivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r23",
      "r99",
      "r101",
      "r102",
      "r103",
      "r141",
      "r142",
      "r144",
      "r162",
      "r518",
      "r520",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Net Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Computation of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r110",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Definite-lived Intangible Assets from Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r13",
      "r14",
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Components of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "terseLabel": "Changes in Reserve for Product Warranties"
       }
      }
     },
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r32",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/REVENUEScheduleofRevenuebyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r358",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Time-Based RSUs Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r105",
      "r106",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated Future Amortization Expense of Acquisition-Related Intangible Assets With Definite Lives"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Sales, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Sales, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending (in shares)",
        "periodStartLabel": "Outstanding, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending, outstanding (in dollars per share)",
        "periodStartLabel": "Beginning, outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average exercise price",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock remain available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending (in shares)",
        "periodStartLabel": "Outstanding, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending, outstanding (in dollars per share)",
        "periodStartLabel": "Beginning, outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r2",
      "r148",
      "r166",
      "r537"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r151",
      "r152",
      "r164",
      "r549"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r26",
      "r98",
      "r176",
      "r193",
      "r194",
      "r195",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r231",
      "r258",
      "r331",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r409",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r430",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r231",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Equity Awards"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedfromComputationofDilutedEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock in conjunction with equity plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r98",
      "r104",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofTimeBasedOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r98",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r104",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock in conjunction with equity plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r65",
      "r537",
      "r562",
      "r576",
      "r592"
     ],
     "calculation": {
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets",
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "BALANCE SHEET COMPONENTS"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r322",
      "r330",
      "r408",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r573",
      "r574",
      "r575",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Fair Value, Option, Eligible Item or Group [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government &amp; agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r220",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r219",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageRateOfTimeDepositsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Rate of Time Deposits [Abstract]",
        "verboseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "WeightedAverageRateOfTimeDepositsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/subtopic&trid=2127163",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/subtopic&trid=2127197",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r542": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r543": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r544": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r545": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r546": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(2))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001299130-23-000048-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001299130-23-000048-xbrl.zip
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M.62C".'+#[L;3Q[-2%6*)%D>O0<[5E8%1B7CQKM$I![J)R5TUD8SAP3',IK
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MP>?M;F=WT/6?QZ__XZ*T-W&)>4J" J?3>2YTT,R1E Q10EM-%5X8T:R%4.2
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MUBFA. 635%12NCDP[=F1X'1F;<F)#<H $F>^'TSF=C;OD]4J8#L/?/\[$KR
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MG.$E@"Y?@,_5_VMIJ_'ZGDTG90/+35&[Y:NVK_IT4]T[)VT4NF6!MOQ 8!+
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MK[D#+I'3VP$SFL>&U^:;&8DY9D9B7IF1F$=F).:8&8E;S.@9*4JM8F.SQL9
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M&1UF,>=^S<FK-:MB+ MHQ&.,L51&_&Q&?"N!LV.>"TM1<"JOY@B"C(0?3(?
M"8L$6SXT8JE_>J?K[&THF3U6<<_AF"I$,8T#,M>]F@ICGH Q=Q*>,B<\D=ZB
MJ#@0A:@(<H$Y))3-N0:3]-$NK5:QAX4TSTD=@JF"#A.RW5L50P%(J64>.2DU
MX@%^,S9AQ!764D47?2!Y[87A.8HYS%^EKZ?N)_W%MI)-8-MHA2IC0Y7S.UE
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MD)0[+8,E7"?'54Q.J1@#(](S8QP)#=M;)R3=VYYC>]1I*C6U*&@-;"\DA9S
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MY !2G[ U"DDE N+* ONGG",!DYHP=HK8DO/S-J.+YU-WX<MQ'[+W.)+X+'-
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MX'/;.;5G@XU_S<("8,+TH,^/5R.0-Q9(M;%Y4*;1 _U_.U..[G!&-N?G^ *
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M?DD%A^,:O-W<V?[W L"Q8UW6#7K](D]$#3D5"\QS-G(PK'6S\K7PV5%O<%+
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ME>[M]<LAJ)R;VBV7V1TH.S#GDW84Y42'<O%^CV,5;?Q.:*.+H,V<Q-)I:OS
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MY)$CY@O#K1;#W<XD*4NV+-FR9,N2+4NVZ)%%CYS3(Q<,^10<-4IR1#43B,=
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MZ*0$&FH:#GI7.0Q=]'8RBE5G-)K$X?2V?0L*;'8RUJ-6C0<5C%DW^R4.AO$
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MOP-\WT]C6=E?O@"<.HJA8J151X5D+KW24;^R8[ 5?>PYL [/#0-]#MOM_YG
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MWA%:M-WEN'06]L1$%,0X$9#S')1>'"2R,AD0K<8HHJ,'Y.8RBA=SR19]MV&
M;19>B[Y["VPN[/#XB#&+%'EG)>+6@RV:7:\D16%CM-K:D'=XFE1\:TE'6NMW
M4]W(W9S=P=AV[^,HWP/NZ)=$UTL=D"<N#I95 J $<3Z4M+B0_%H%%[!V&$6N
M'5A?C")C64+)6XE%,H1P6@=QBF47CFUT68#"EH4MEV[M/@!=EO#0^R?0^8T?
M3(AC0BM$D\E1\%PB+:A!A*>@B6*)RZQLM\02#RD6ZBS4^?2ILUG,6<).E\N2
M\YMP.+N%$E=(B)@SWR2'+,\U5A@76C*9**-UT"G0:5$S"U<6KGSTZE/%*']
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MWH]9PH./B;7D&H.P6!.Y,!)\/AB1"MS<M</G9)"J:NAYYUYXHKZY*PZ,I=0
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MGL-1#C@XE7K[*)5Q%:11D5)/A:$D<T:HEZL0NA7L;N)*KR)=CT"UV:XI/H3
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MIZ"8:TFL2PW12Y_&]&EK]&DO?7H_+3&I& J(*(,TIQ<3G7S@*S_6OZ_7FN"
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MUQ:IB#GB@1JD%5/(9E()+QWATJ;&Q1+/I7J\"]!<F63UK07AY:6!S-MG<=F
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MWF_N7NY=[O&=YGZL-_<NZH<'E& !SJ)%,2,<<:D94E8)T(W48QY26K>8;7K
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M5*81%XGM 5N#,O#A9<S CZ?LPT>EUC 1<\=KOS]&^$>X=8]-\)2I@A4 O04
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MOJ=/7KY]73[Y%MZT5,5*1;IFJX'%DK$5U*)((N#XP*B\KP[G*)^3S4^0LHV
M#,9-\)3](U(KBAP!?T7^/$=.4>0?1-8%H\LS8"+K--]H[?N'@]-+X-]YI09
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MGPA8.2 T&[1F/76WGL;!,#JP5%5:YL+)J*$0[A#]D\P)@DW<271T6Y&@8Z
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M7FUM+ETI<^ZKG"%'<A1H6"K?8%&CJ114!*;Z>/MW50$4/3>85IB"(\+LU[Q
M?2EKV% OX?H &66)PA>Q=VCLO<3B9G$BB6<5X!%+89J0J-NT5$7O@Q5<*K8>
M*-.Q0OYP'POF$-G$_?T&Q#A\]P>L'IF".L1EWZ4]_ )ZP<B:1BC'=O*WW^JE
M$M_\"G8&+_@;D*>IMCHB\SRS7;N9'&JFB,N&*J4H@TCH]*.UXWTO?QV=C,ZG
MD\EX]*+!_5[^"A^U&)\!^4NV4$>WC=RF!3[AU7MF$*Z2U'[6?(SZ;HPUGNBO
M2O*@7_F((&\,(LASKT,0_/3IRU]?O7G^+5RH%0<\K<FT;94W[21_L<@!C+5
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M_J!@3V;(JJM=>QP:UNV?=9O5^DQ,>O&"45O;V@O*^Z/*!K5.XE1\)'Y9/ W
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M,+D,EJI88%/:ES:5S(<J+-.<&B49B!V[ARS\WQN%(E)K5(\"W*:UP%LZAH[
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M*-:$I-4NI]\;>L5: EYM)Z(&>+6=QY>9SI6/Z$!@=+68MK()HL5ZLM-&Q*L
M=A89X+K@9@X1YMXP]V']1I65URZT7<CBEZZ@-&OF^S@4-:^#+E=J-//G&[<;
MQ61C0:"#8Z,Y!G<S(5\MJGF+;S1'NJL.+KRE$"XR9=)M%J)CWV?BU#J'V45#
MV0J6SE*5@R3"G<4NW95U706YC;,T]?Q4C9^L<(O]+K:,G.?Z-K=:UOJGT&ZH
M=/7+VW?!2YVF\-05 G:FP:M7W[UZI8,KJM2'C]_JZR0/J9K?IT_[RS#X:_)S
MPE]AM;_%#F"8%:_8UE 1>\V\DE>_L$.Z-&T3TT%2PEW0DBG^TU02(0Y&*IY"
M_:%9'BG%,K&!4G&[AZ=!O6YPV[(<[TU=D+Y@S#"Z79Z,O;4#\EW4Q.UHA JI
M%8V8@ES+APZ A$$F3)VXJ8HVV E;*!,,<.)F88A_NX57$]R+";9-N#AGHEE'
MP@;%@A I9+0N\F1 #EEB5E.=%J9)P%Y1KVJ/FWFM@(6H$]NOAT^S-&\G;XH)
MDS/\1BQ%R%*\Q(*(DCQ-*3E(^3F<:V8J"+BE,!]W>W]8_> 4#JE0=\ )]D6V
M--],P<OWR.=V6_A%(=9.1DO%E1"KI%HUJKDS<AX1E$+C%<TA6PV549(Q'BJA
MD[ICH39VO'&[CML##19Y5GJ\2XX 7DV(%E>,WD22,=+LH&(,HH)!@+"=5IUQ
M)2I!FN#\$5^I,*1ED6X\J("\W2(:)FJ.(<E 2-<BTQH8QWZ48-?J;N/*9EF?
MC3\W86)D\\C/Q[L$^UCF\^H&Y55K>PP-@0(:L2Z:8!2$$IP1DL$0@:7>)K1,
MD:=I7C/7P;;<@O;1 )T5\>!56'LPNCX0BH=>T*H5]+!T;3,]>&)1Y"1^,+C*
M',F[T$UPVK9\KA%&_[^Z.5/6:41G1VBM;70?V%Q,Q^+&@>86["1K4X ?:UP]
M[%?K2=N?T-T4TZ0<)VF*43NY9KB+;?I %$8-:97ZRWMI=V 7MN;ESZB%G^,D
MP&NW=;9MMO9':DZ?J;GK0A#"\DSKS$Z_-=W=UPZ?XBU@WATR^ ]:KKCGU/./
M6!X-O4ET&I<6;)..QAF>#J_2,T8;,VDQ$[YHH;U#L%Q#$7+S0K<=P;4JC+SQ
M+SW'_H98@@SO5:A'\/5[^?K?KWXD&(/1L]$E6"MP]Q'0%JX;99+0KG6@43LD
M9\+V@LEE>4W+XX<M7LLVKV_1NK#^ILSWQ:BUDQVU@&X1H34.!&S>8R^AP61P
M%U&NX8[NGXQ593>3V)7W=@GIVI17?QHWNSTDS@?RO N1>0M(I9L-^=N$I]O@
M(P1U8TZ!CWD'I$GY 'CGHT(TN;/;;$->M21+4EK-F^F_!-$R#-X8!X!<7N:^
M_O7L$E%;V#.N"+2-/U.0NG4/\[L#KZ3KHM;H:R-EDN@87;8H @2\%]-Y<1FO
M,LG=)8_1ZV*A,G-UD-->@1D>JR(VGSTE/_+)LU=7K^EOHV??&N2P&\W)&"EB
MM</WS5<2^\G:X.YD]0B\._JH& &$]4V[CS37VF#0)<;3T$/OVG3!<9\N^)6D
M"W[^(,M."66T0(<1R5D#,3&." 8D>5V7J(C\*_,3Q*TSU8I9.PC?;:I.J!IN
M=%N*T$ Y)!=BEXIAH 31R<IP0UV0EJ9!MGU-ZAIE^'U]F<-9UV]#?OCY8YY=
MJ8LB+\JVFR9 &]!\V!AE$Z4-I52,4$3&+) USW2E@DJ7C#LG08D9*1D1J^5$
MFQ6"8XEL@A5^ES?4:0'7"R59P^B8"&5E;5:&T;-65U.ARPM1X*RO!@2EKZE[
M+^-ME^G+S"U*%*Y&/",.IXDFCV#_!,L,E"[^)]07&?@_I!/Q &;=$]:,-^Z$
MDH#E4 +Q1^A&(Y*\AL7%+,^\X(BL15L#K6-H<G>A?/81ZJ_0#V'69]<"O\D%
M.U,1<%4:S"DSJTT1Y)TCF#0/1TS-8,IYMML',6?WAU6CCTY->[7+*V"M\ <Y
MNAO69.A;DL8 %C\*CLO(M<8,)F1PN#9((6AB"2:M-3L06Y6 S]Q'1*(>YQ,M
M:%?(DQ$9*81M83X*#6O#ED.8F[JQV, MUMB-7FJ=?^U0K6$>+>=(A[.=KKE@
MUS%\K&E77^:@G.*EH"WV=J;.O!UP[L2&ARA5") ]-X%36:]G_EE^S4Z;;OSB
MUF'>[A@S!QIN6V,[H5D>W!_G$*_CGM&JU[?AYAH0:D/FSBRALE-3(&8B$^Z*
M.%KU\KL;3C8FF9 L9&/Y[!.W^ R@H =Y_'=!F(O/,4:##AO1>-B6KDS4Z876
M\)2CZ+J_7FM HPNT'84ST,2L1,:$^B+1! ))]]X;P*LU,Q1TEXN0L7X+P?L%
M%0XL) JL-=(WF,#('W WHR75E)BUH]E0D,K]&Y!D5</)Z7.XW8[*CGR#N^29
M=8=:ORY!M)I4%SPPDG)>P,"/#3@=:"M*P+[:.SF *G3#G])$;-]N0F1DS:ZF
M&/*.\([H90M,>4:XWU["LTE1QJ."#863 J+BI)=]Q/#=RQ>H4R,^&<[VSI])
M+@EGN_)./^27=K?]V^H%YU1%R1C"RRP#\\VM;F#X%D?& 5DAO=\L0]_Y;UCH
M5L3?^*%;?FPXR+_!V2,3L+BIVF;DH"+5A'!?%)I72UOS*KL&$:=M/PO, 5LQ
M)J?P\TJ)$?"W.M/!>,KXG,%3O%O&_<6#!#]Z[WENWF,<8U3V@[XS@NY:887L
M@!! &YC\-J#14N^59TH-T![CO("!- ]8@R;L<3\PCRKT8<.M62:I;LI4%K,[
MF,>M2PEMVH /TEO ?:% LM8Q]OS#(UE+O"[)2G+JD=/.C-WQ:CQ_;C73ZB4A
MS/"6M=J .O>(D4D8A=S (]6DV=FF/S@W,QV,<62Y_R3W\"'WHRKLME$Q<Y24
MY#%U9]D^+(&.%WA F!*G*;?G.W3;T373?)9B!9@TCM#):E87; [.\Y:K@'IZ
MNN9%MYX@L5$IZW"0R^8$*9/4)0R:,.@]QP8FBE"X=-0NK<LX<*EWJ/F]:/5^
M>+PEZ2F?$_^=Q,*%B!0(%8V,:.0\_C1>TC8\56B5@7;&DOO..7\+)YS$_M2X
M21)!1"O7%.CN:T'Z$*>Y:$=;C#T.%)>P(&_3O3PG4:NR@9M@7=^8_VD%KTO:
MY/LU\&FA0X-Z>LLF?]O*F@7!^[M!X4;?$4]8VD>%WJ(X<8A@8E(FT17Z82AI
ME!QZU&;5AG6M"J*;BIV\H[T(:V$W+#L_!&NBJR(C[+4VD3)_S?"9F;BJ.&X[
M\!L0M7M(&19G^RQXK ZNC-$FDTQ<61&0O:DK)8>8UN]9WQ"INTS6DOWA]UXA
MY0(T\67(*2ATQ;H3_,*&D;/#QG'Q$51:,DO^TM^+ZFYP9M+5?=DMR($U@/:'
M(Q3:&/'BI?!B+;VM_(=[)JQ@)IUJDZ>I-LP""7AAM8*YCP]W:]V6#=>2OCM;
M-K593>A?2E'D_48NQ)]=+A56F;K%M#5#.QVVP>_C/&CH. =)17<Y0'>VV;:I
MWB9SJ&HF483DP;=Y2X75L:TG&P3@#D>)#<^&ABW@&<B+6#%NYGV&8@F!FJ:L
M+4$B4-Z_HKI0X!2VN_?62UWJHM%!MCV4"/XNFMR6+].Z8HVU@ *!=R*Q7(]*
M6TVS& ^[J)NB7(R\W>ILNSU5.TTI[*/3+CH]Z:/3?73Z8W/'';Y^IS=BLBLW
M#K]->NTI[-!>:ON3;?QN9CF%Q,"-%P34.7*;BB;G1\8_5YNJEM[?Y8+<(X@F
MC[K=)=GD=J^9;6<2GST[)"0;O#,Q,TAQ!,GRPP9NICT:MC_C!,F&NF*BHSI;
M(K^_JX\E,?EY'M6E\=^)YSK/6CY#G!W.DO>SD0W9G+!33[A-G$F_7Z>8=>Z%
MMG  #)]1]-:4"G;.,VQHW"UMVWC6_:3ECGYL[^YP,[?-+?0)D(#CS$X_-ZZ9
M#(N;LE3QCN,C7[K0LNTB;S)(LL;$Y8<97)(!5B/BZ=REE)@PA(TV1KBU::IW
MS8<S'>R#;'C1SF]31^(%:[L<\YZ^:WKO4A5F79C$Z&;+AULJ75[3QWY&,)D#
MWD,-;1D+9_$NH'&V(]$XW+$![A'L:R98?9O&&_.B411BBT],875IRT#X AJ?
M6%YXDVQVZ&NS#-A'(&#NWND5?;EL=C(@"N\8?3-\EW5!_@I.0>DR,IJ5(R4S
MQ9L"MG& _:D["HN4#7EX19Q>PK];+:_)6PA;U^)JZS+T>'H=I[N'87>GV-M.
M6VC)K7LP[3]BS=\_L^ 0#;8'A,CO+FA$6VP)Y@@<O%XGE(^_Q9SAT"B1G/+W
M!U[F_D%NXZV:76/3&D4<ML+8R/SM4!'N)364-HGP<[=EKA^[V65*_I>-A!O<
MU4X.0PN+ B1B/)!US^G_GGWJYFE #M0D&O1#B1> Z5=R173%OCGJ]HY.2CBE
M%<=YK*@EK?3!5!7Z.NF6YMG,RRK7Q#ZP=-!LI56M5R -J6TG9O9EYG 6F""9
MV<)O2JHLT)EJ;X3) BV+>EU)J2-7#"Y5DKGA_>+G)BL_SGO1JCLT45Y;4IE8
M#:EU:7QABG8*[RS?%^?Q]VL4[WMM0D.7)L5!$A7D%2(J6ZFA[<,RS8-WK,]D
MG=+R//]U7EA'&$C:.3KQX468$,S!-,:ZRTT0#:4@ZF<HM+I3\-K5]$WG&PQ8
MSC=./>(2V4"4//^='$ 3IY:)&K%^Z17N9^@0VW)G62YG_%T.I(24^H("B+XN
MA.HZ!5:J#9\@W6_>=!+WI%P;.]+GB,V;C4;B7(OSV>2L% O:YYF.L(,V)=[>
M !W(K3?*A0;3CG1#>^JT\:Y-H^VC[E*(^3*W$K)VF P/*8L9!B\TY]12PB12
M*_RBQAIN_Z"%I-*<\YKHC J]H(@=[_9J5=NBF() RE#OM/$R^KHR.(PS'.HF
M=(GG*\0_AUE1J5[6DDEB3_):;_+B/:5SFY@?NT^)W6,N,4W1.<^%.YI\[.U:
MOR5NF<]NY5 '\#X9[[WHP:A< ZM2A<>R<X+X4\)_+9>W<V>N@YGXYB=TAF :
MAIU*O*CYC=RFS@/?JB'\KDTS(1OR&!LKM^ZCL;H:EU>^DXP">WJPB2!Z9C76
M]1^?R'AG*CY]V4XZ%=V+6)*P5GF,X+D-+N2!RSJ=P;ICS/9YF$8"V="J(]SZ
MA6M41.YU)'D1&*20H'FJG5&88]# -VVQ#* =H\TYLJ :/!&F@>X,M+N,D\6]
M.06#7"Z7O)A!FLB/3TK54F]H;NP2D'GM0LJR*I>3<==2$+B];'8KM=K8^IOL
M949U>G42KV "O0_4IX/ B@SAF\[;;M?D,2_!"S2\S0SG3SA74CR,*V:O%?H(
MR/1UQ2W6SWE[ >S17:*?KE&3PIB$JZ#>ND^8P8AY(%:Q:"41&#\/)A6*7]=0
M3=YJ:-S$),.PU"+-9Y@9"6-B W'YI4\S!64PXL$6&VO[<$[ G#%_\0OCJT)H
M# \1P',+P=2C(K<O\G-!#-J&\7&5HN0A"JB,'ZDUFL:<[P@_I, >_15+EJ3V
MR"@FGE3"]!ZJ=<JNDR+/)!S,WE02N@S90>J,6I=21F0.PG9-=",29FBRJE/@
M;T8XA;:P*S8>"ZHTBA$!A&ZGJ4W ]$%TTIN\M1+[4EN04SS$YA%U4D5#0HGK
MCL6L#UAA',9KS)ID_/$=B#<-)4F(B]%UVE$"CEA:25BBVM8N3:928UP:A3FJ
ME"#*>1=7BM+RK,/:%-.9T#,[EF.-6BT1J(CMW6HE9]<X\(M2PY2Q',K Z1C2
MHIG7A0LBDR7_H?(2$]SVDLL:X4/1I:>HVQDK:J@QK7+&YBE)#J6HNFQ  8LB
M!"S61FUUI7X)MMFMDD5-NF[Y7J_1"URNMMQQ"6IZ*N54GKQ$IF"&Y6OBG;KI
M;VYM7\_N#1M(<"Y+2Q?2P:U<X^E8T\E1%<,+&$'D,1ENHLX!%SQ$9Q8T' 8?
MGT%_?1'M:1_1[B/:G]Y]?.7'.YSTI, H<#3.- PJK5:66SH7C)?E[P>2&'+!
M*J [%<VC4^-^ZX#F*>^]P1RP>P.[0T#GM-]@7^MY\-,'4*')@'U-1D(!GQ<8
M[H.5O1X&?]49:$949; F*:\]S+?@"@2-)GBY$9<9G(0FC0D/X\=B&/P"C%[I
M-/AKG;T'_0JT\0*X/R8P58FD8_T(VA\-,AGQ(#Q;GM_/UE]BYG=5PSX&?QD&
M?T]6]YC9^*)C9CS&WX?!"U5@.71K1L_K!:8[GF]/Y[6E-#.=7Q286?_&W=*@
M<NV:CZGXX,F,AL'?X+O@)SB-M/4;?L]+9Y*:%[G!9'JC,R[M:*SLC4:A_C,8
MIUBH2\L2F"WW^U\4EI[PCQ'Q!XM*D6C^C;C'743RW'5ML<N&<]7 I'Y&+U^Q
M<]WXJA'OX\@Y"U\N"?: =:(7N2IBHI6_Y<LL^!EI)D5?9+8'W1W?A;<1E!L"
M[Z*:+@[!^G?;ST@MK'MJILN*$[[Q+P9>$14Y@6@..S):MZO\3+*'Z]$MM=)Z
M30F*8"))Y85I,42)0>^S_";5\4+;1'7!SG/19S8';-$%IHZ+.Y!<T4TG#.MB
M\"]*3*<I6']$V-TCF#12&_:.6<54<:QC ]KH%XO!WB-5(U=-&%W"6%JV*]$*
M)+J4,#1\)&RDFL>QQ@Z59"[^V\J8!C.WJ!-3:&1PC0W,1ULFKHC"><$"NI#[
M^$9>R;VW:6A<4E$$W!-L&L XDWP WAL>4ZS0T477K#[QRXGL@9F D:B*I-LI
MU &3VH4@?4.E:YP2=&./3VY?^W0E($%+253AJLK\:$8+(!YS14!(H=7)2<E2
M'X$Q C:0W US&I7 %-L"IU:,8T$6EAV;RJKB:R6^1X(8;5><,.\P&D<#<(;-
M9+A(&V/+"]3;[;LA_7S([J.=J*D8.;=YS[<6FZT\%V5L?F^]A_"N:PHZ8Z"'
M3,C@>2:=?F"ZP#-JBTV/&5%405>GJG!<"3=ED5QKUQ*&RZ[9,+<J&?F8=S!G
M]%B(-2PN@1O=\*RY,C9?]16&$KKS,267^=I_$ Z?T#=I55POR=Y.PJ0A)XH)
MM\\3]!ZXGC7B&=74#8?2VUP>%*L^N[1LXQ1I A#5:SEY+\;.SA=S^N_UQI,I
M4OO3\'YC71Z-TX)&4A51@5Q"<@X0?-T\T0T@8#MZ=]70BMO5&8'J^D]($(G\
MT>U$HNY+3WZJCE36/H^H8;LX]YE'&1[ LU52=)9P?--> 6,?\A$U:,><+F'V
MM5C,CI'L63>)4$I%=E2(,ZF%#0$.A-B@/H%K(N5"9PO8!-)$.(C>I';)1W Z
M3(O*R8=)+_01\V\IH=N*N3>J#=VB?'UAD:OT".WDUX3'P%YH@X/>YDB,W2&E
M2(CB<R_*(6]R$Y/+G'-BW;5,E)DG1:2WBZ6.Q@\%7Z(%#NL0\TW2O2NP W%@
M?;5\RHWBSV52-&2)HT]O?J^I'#2&XT',B(; $\W_"L[K9T3?1S@X,)(WP7.0
M=80A!6(?63 L^K^2^X=R1SSV1K/-&'"]*;'@)GB%<E:V44["-MQQ*^4'WT)J
M-0_+K6PZ>7_KG%K&"]\]^)4 K$7:]:J!N46*@V*>>6.,$(&$\+]I;1ZG.5!V
M/NGA6;#0%(DR@4]_2^R"]0<%!O5,>>E_OF/?FB!LR(O8@2_0I*:IL0_ SRBP
M@M?^V"D2G%EG<ZQ\?Q*\O3:KQ: )?R1C *WRRS%]IJ6<=N%&^_+<'K78,3MN
M&$4.(I'?21[CMN5$J7!*URJMB8^Y6+13_E1E%62"-VE!Q  31N<+<5%5XAGB
M6]!"<G.77D;<C"A?-TZ^*A+*Z^,O,4@C\>1KLJ^I@I$42XPMX40YI&$GB@43
M?V#<;K1X/_]V!<_:'"TV]FU/I<#V2)KI32X>&-*G\]3>-D\]QC<!D==B$G-U
M/0-'HNI%*51I'16<]D+9"Y(-T6IV92%PJ'V!%XJG<T8!9P#21*X27Z[ICH%$
M26*XW=9X+X%;*8))D.CF[J4:)&$B&[:!#$P,GPT63X".B^;[C2IBB0D:;X=C
M*KZ$+CC@MJV+AE8[H+W,85>0GWF_%6<'E8U4E,Q'B!.(V,"9_7Z9O9S(W?7J
M%B6THQ+$P:^W:S^E@L$+X&'#@)MJZ5+@]]1TMUG!3C0".>90I)33X=M*D@>"
M6C5:JK1@T7>B[$F!BKV ? 1L"7J,@D4"'&C%V9@9IJ0D]!=,'I*D$I.UC1%C
MF!GEU5 ^IF>0MW;!\\;_:W@UQ-!NLI#(\#I/$_8S-85''OQU,'KA*8C72:D,
M.HLE(^(:RJ2A43>ZN>=[$V5A+ND4J4A=!A;"G]!T7*7-,IDE6]"X=#R=F@/F
MN6:T5<0&F@J3-J&$<I>631C;+OFUSI!4)-O3$@JO+2ELVH^)L):[TEY!6E'6
M#_QL%6"97;IQ *=^7X%MN=,!R"'@O0Y;RN-M2JI$Q'6]PU?CZFA(L@CHDML*
M05AB+019+?<Y,H01$ *OZ5S"RJG9ZON9,Y[C%7_DA?C-K0.!++EG"75R![T;
M>VEV9E#;="TO44RNLN4KCL7"1'$N]NXUF2OU19V+W=V'Y&U(_K0/R?<A^8]M
M"_MJE-0/=&DP#+#1<J997M( O-S3Q_'(E)\&/,U'U( .T8GR@%) XU817S/A
M/;&WO^IH"F6*W. )30F]059'J4;/290T$ H4!O!L:8 S8\5I(Z=#;A.$LRH]
MQ)(=*?.V(,>!3)EFJ18=,S8F1>"9.EMXSIY""^(<S'E-2[$X-(TB]MM070Z1
M1NX7G]YUK!ZB;<*'.D!PREF:E$O,-":@-2P-OMKU&R/QJ>&0E*-@FB \R:X@
M+/8G3;"L"S'^_ +\?*M!%Q\EA[P<L$$#>4Q@#RK3(ZMI"/N]&:2Y0H?'D1P0
MJ-V''1?#8+)1%FGJD_#.G<R%!W-DL7%?K'%/)99<]4"BRO-VF?UH=.(D-UQN
M>6(3<E8,:;5F3 0P&PML:E N%6O]>"?)Q;6]"#=O\M[ -F.%.YPYA2A9A=^*
MC#=\VS:AE.V!)F!&V(VDW$U#.)^:W6B*"I@TES4TW'_./'"PK]X.^_*O%EA(
MXR8,_31PY8.CB%#+"W8K.J:V1A<]4%A-'E_,75>+# @)!YLEN9N\5+XOBL06
M,WA^2LH09AD[#/Z:WVCR[?D^?P_$GNG;0R8S+MC2Y#3<!Q+J7H!L/A[D[:.[
M1H_M3KJ6=R*5>?>/C61N3^+NW]$QUG?W;H3;/&*T/X$H&M>8[F,DA6@N*N!2
M8XSD_#CM*&[K8&"A'>Z!R&S"7HAJU )&9T3)R)CK[DLWW1OC=6R*?*^TB&I#
M;((=)\6SXV('RK"T;T%2U8)PNH6LXI,^;&6Q8:<+Y8(PIB7+BEMU).?1:BA%
M4J:ZQ?WOW^F7_6@E2*1V,@N5FB78^(B]H^W6&%L((^W"1=O#4+PYI/]0OE6^
MKK <):$R. +<A8$49BCDNX3=,'AC,U6\3FNV%YWD7*R  3="#%XC^, V&.S2
M1HSLLXS2\T'Q(/C[=G-[B[7?2/8PN+&V,LD4)LXV-L#6"/HTT\4\J9D""R\&
MY,2.MV"&Z<M&QIJH'B8IV!3H>/DD/L^U'6LUK]2QA[K"7$_#[&WTJQ'P^O_9
M>Q<>1ZHL6_BO6.B./I BDWH #8WF2KR:KF_HADL5C:X^75V%[7!F4':$)\+.
MQ/SZ[^RU'V>?$Q'.3+J@2..19J9(V_$XCWWV8^VU^FI'*S(6',7MNMJ7P2SM
MJJCC#*^*=N:4N1DRUPZN94Y<ZK*1M4/_.E8V-L]V9)V@S6KT K+J^1D7;;?$
M^F>Z8VW 9:_^5#4P_GFO\*NKS-=>'IJ2FW;873AV*G''*3=*"62AGX6EL'A-
M@7M&35GDOP'!KV1]Z01P<SL]HY0 WK(C"!AEQ,>)2K@X/?[]+F>?Q>8W[R_Y
M!'!718*U$25R!Z[ Y@-@XW65-PB::#$/;-["1H$ 4[X-X@-(M,7:0#I!R+O+
MP%J!#=G9*&],C&$TC,*[[XZZ<%Y8IV!^A&&2=/:02O<\S[I_5"W4%Q K%#"D
M]2_8OT[EQ-AJ^H=3:,N,E>;7*3-*E$<F9[W=<\6\;7QE<W#N>KD5%Z$A9!F.
M0&3QN)RA-3;RJZHK4A,' 8^1!V,<$A^EX"6-WGYX%L8 :SWY*/8H!\BH1])9
M#F)22.I(+$N]KGTO? 2TBVC]1:IZ$2>8B'727?%C=8P^G/YWOUTJ6'F221R_
MUGQ>$H%&9/;=).)RTX1A,->6&8; .5VX"62,P*"6[4QI(; \$CIV%^"?;E/X
MBZ/I,P1>8FKZX'P VI(KP=5W.?$\MEJ@NJTI_FR0J$D2;IXK@Q;4@JP+LB%)
M/J(%0E6>>(H5>41H*P8-J1];KQ(XM=J]>7!VR->2 B?Y61>Q[R3YN;N>E=4G
MPEU]3B^J1"3/(T.H(0%B7S8 XIW,2X:J2FG1,T!+BI1;(S2"<+1_#K3,/@XZ
MVO\-+NLT,<^H0[R2;+>N6K3!-_\%C &L<@J#2F7 "3F_WS19^N<K*'YT+BB>
M"XJ_"[2[(Q/0-CGZRURYC.7.$4^I9\?%F/E%B"FJS7RM$3J[, R*W3'/L8\J
MLU]DS$S*&\%> %F^L'/I_X@JV+@ZV\@!EKZ"A,_P=$UWC:G"ZK5H]U(* 7)9
MP8UTL3:E:."G.6]4! @\+T^F&'#BCLBW":U'IK57-T(*P<Z\2W#MFSK$KVX-
M04_O$"=<A>.V';']9C/(D)2F'"->U%]J>@LH9[=6K=XRIG#4-N$_4> N+2<3
M']H$P+7CA9;HH@2%!@&&L^6)X')!D&+&L/(&L.VCF''W;'+GY%I)^=Y("$WH
M2'.WJ'F'TZ#9V?-9#LK7VA#V5[-#N^>1, ENOG0?:Z7SRO/&(&9@SL9BAOPQ
M+_$\H8Q0*FY4JAEURPL*'PY#7C6+'2WH:"7$./)L\XKYRUTR26/:MLM1YTZ\
M:N?E%%6(*4/Z,T,C*HB>?SQEZU,<WU#9D%,,6ND.$TTK=RXD@)R 41;>D>45
ML1ON$:*E2R*@IKIJ=TB;S&LF+W(TCY;U'7,._ZVY"2-<J*%F0 @F"IC?Y(N:
M4;8N#6F7=,MH0(F)OC8_^NFP9['=M"B*)WL$FE@_6.N]>!2K3B18Q2%GWTG2
MU!V"<4M'<U&90:,$3&Z6)<?T/9%5+2]D1&7,C C-#788K67;]?GH50<("V!2
M1<S-T).^!B3#R&2BCG=4?^-"LO\F'3E^_2'AIR_>^+#9M-^D-S0W2FND#!!$
MF1DTZ0CN411:I4W8@=<BU=U<<7Z ES;W1HQ<:J*BI*O4TY;G#T9#?/'KUW.^
M!H]JW9:*' U+N.WJGK0(J/++"91P@M&_0$36-JO@?O'"U%_=EIV_?@A4;ZE_
M@U@R2WSQ55G?EDUA-3^R$FY:Y?D-?#DR(F/22(A2!Y,J2QXA>;M/,^=X@#3Y
M:;TZTC&_"M$R>W'@[AOI^4_'WS#8=[93<E%!O^XZ/NE)<Z;-01PZW=M]TNV<
M=Y)PNH&0(VUZK[QY5N=]XU#)R7RUR;K1<W^\U279//L=UJ\>HHR#8;/"J/F.
MZHO:H:,P$.$B+%(V;]=/;\B5AQ%2G_FC[\L?/2 )%FY)Z$ (66K"E&S!E;7;
M66M;3UU@4KM@>AK'+.NZE1A$9-U&.9&[Z>N81]^BA*PTD['?;JRS<<#"NBF)
M;CDLB2^]\J#TP^'UY%6Q+%#K$4I[[H!J5]Y.B[0A'J50$LKL<UT#B:N[7BNP
M+=G 75F#YT0\#/@48Z^%[^D7-/TXLN"V9<\XSS;)=?935+6C>ITI]ZPO FK>
M3@5)&<!6:&*S-_&/56TCS\HR(F)%'MUDKH /V:IA1F:7SMAY/U$&H>V4'E-"
M"#T/+7>0Y+N'6T4]/^>>M4+K>;57$TA%G('@^.]%ILU+]6VP:6?MGF^,49OL
M<L:6FI/9DI9 NY98'*J-7,E-:4'C5SS9?8ZT"6=Z!>%+C\ +?A^]WP^OJ>NK
M*EQI?,";SP<-^X$<Q.\41,OL27P;N(R%'$+A?86\98=$,/M\,K[HB65$E>+$
MA(>EM4#684[,-#ELO6>;,8.%&=%-UHNGCI/$G4"F4^9E-5AIPR )=5(YEZ?>
M2PCK831M-^;P:C2MSAMXTXPHA?Y_,9:OU+8W)PVMR1/950)GF('S8B5/BDKL
MXK!8\]:5D+:EDD+E-$T=H95V^$?R7 [9V+L?!D(.]1#N?-&N+G#/7.0I3!;W
M\^ITT,0HA[+$?08;%)MCOKO8'T02<0IO+1P<[+9B>&Z:/Y^DA:1@.V[RX4SP
MAO0M9(B#PPLLPM,60V=^2%F3N1>7X+;KZ/2@FG[M+P]1,5:8P?6'1!W3E!QV
MQN QKE"HUP.&'X$596=$J[=VUA=1J9G5.@I:<,0-ON4BW9]83&/[C7_24PYU
M:5@%!L;)>A$\C^D^GE[XDC1FSB<%-5+_&OB4JP@N,*R/5\O@WN'V-FFOA+X&
M'[G?ANMWZ#F'<(8_+@MMQS)1#=Q&.)"S4]%ZER5.4?2@7QN @U-CLI5[^5=:
M39Z2(F(G3_-\XV6.,<X/2LW((Z%JJ=D(P<JZ]"?+%:K&N\@P'T85=&+;;$G;
M+8PDPFP3-&;T3[7L8^V<Z"+@+GB^ I^M/Q+3G(O%5BS^R[E8?"X6OVG+.\@F
M3N7AB@Q !W8J=V).2P\>2Q\,E-?'L\1"$S+,OK#@)FHQVK4F@4R&8"S0#7D1
M;/=^DY>*W;$"'TDP4<-\IS:%.4P1F%48>)W&NP]4M!P;D3'\SJ,\^Q\.5QC4
MP@@_&H(^KN7FIT4.Q4]$H&/B(=91DVC *!\C5""'!2.X<S%] BIPD#=FZ/$)
M!.29A.8B^< W>*")\5'.[%U>W3AXU#ITU?UF\H[$,[^-8%<MBOC<$SMVF3XZ
M301'<4FIXVAA8ZS7P'7 9DM!7;%$*-H3:L%73&6?_$P//*HQQOBQ3(P+X#6=
MJ*\4XPM-%K@@D=P_Y6XQ@QY^H95UJWNEC^40'Y+E\" $,-HL^-\E!\\66J\$
M.\P,LB0,R'GIJ 'L.W8*#Q]II8BGZ))Q3Y>^,>"A2]6HYR#C#L^XK'K4/@]U
MM5[ZRA'G(7?;O780'Y^)5$3;W2E]1)V92&VP8J:"NU?%^/ Z*+AO]"N7(8KG
M_4-%8TDI4%]40U")(JX%7ANG9UI>J43ET=;+.RLF?>N:7)(C1M'_NZBWEI\*
MDF?A-$/L:E?3P";(GS\42]JM+9K'W%E+,C4O7\Z^Z]KPZ!L#$BS!*CAS=FR@
MW>0$]-K;;%W*\C^RBQ%<SR]D47(J!ALZ7(UQ6]K:%]/NJ@KU1V(I9Q3XVV H
M5SVJ#K[RKY$2U;JD$(@)Q?^^)SRVUDU>O/P6N4Y_(K'##-:NL-;!LCO^560\
MFFR9LE;+XKJEWU%8[W$BD9F##NA][[1AN6'H/KO/>#)'%R4G'.0;0ON?DIVN
MF+R415%)#$Q+O'9 1C399-\U90D798JY=[71(T@2%B*80*NE^GAR! J2#L(!
M5*2LM^3/W -R1]#\-XY^2YLYP7YO\=62TN:O/<.SGZ]AN,61$9:I=A4=ILK4
M$].N#K-OQ/;SD!RVE&U%HE_JNNFEPK\,EF/34,">6EF-,U#)^:VI.8 ZT_H8
M$S;LNXQ44OI(1LO[^CX<AV1-PS0C7*FXO9;$6Y)BK[4*OZ1BG-%H)C( HX*\
M2B^KZQ'1J=+()L*^<DE]1Z+53_FE_.&8M>RE>-HT!*-W3@_$@ENR-3)RX9(,
M10+2RV(DW2'C"LVQ.CEU"$5IPC0,'V.90KJ#/A^USM/XHD?I1CTP]OZ^W-9+
M7I_-54[VTR1]BAGE<N1(T6P&&FX3?TO+:&'5KR':6"763":I2-9DWJP56Y_#
MVNC:&\])@IP*L9;QEUH@2:44\"AG[TY8OA$8C!4 .II,/LT\SW-"7"X-T04Q
MIT*GTT,<4C(VMC+<#QV3+4KV%!^%9":63-E+CZB@Y(SO?<BY)$L!YD'F-G-R
MXQK1WI-)6J1RN81)91RN/*(4)E:9#^23H+S<DH9"SHN6C6)HQY<7N4;]R >:
MRU(:!^YH#5;%^? WRO$-,#FGFTHZ2D0=7HX3'!?\=;:(@S9KPQ#'\(+YPHVM
M9Z*/N;-O:'"Y/G@Z!DOD*-V4Q^HH6;V;RWM,DPSHU!/=01X\4[':NT0&9S\T
MB:_ALR,1ZX!4,17%X SE;(6<(LE)>QAOD!!X)(^<M\>F+';9^3B).QI/QK]9
MMA^M7RZ#8]I0#EU&\Q@TA];+T63U\6EYC-;X@6<I@7)[8 Y6CKJN'\%>I."X
M=&Y\=KLPDOE-"9%&='P3C<.FM$I+Y#(:,42TPR?)/S1EX6B9$:KH@R4H'M^#
MEW=N/\K9O1-@+8.:\N<E "//<A&W?6\'$,T?PJUZY_30039AM?1M5RUK(7 ^
MMGKN209V?$%=G@OLL<#^\;G ?BZP_Q9.NAIHHZ3?M3O$KG!1\5+.MMRQN;ES
M EF&C%#.*%\8=QE[/^+]<4KWP4:IM* "IP#S"_/393EK0#OS'XPQ:Q)-9OC]
M%JPRK@*A(#8BO-LWXK&@OWHBBT4YS"3*U @3B9>=8)FD.[?<$$8R*\B&@ZN]
M97(DG\S,H$P><F8T-HF_9LI\BC7U3NVFM.CTUI/<*A)5ZPI]-7X8YS1<=OQ>
MSG[4))TJRN+L=9,@N-K9LMR5G$!:'\S[?/!:2Q96Q,2K@F1^XW@#E_23E6-/
MYKIKI)_3? AWN=8]KN18*0OMW@@OX%8RWEC%@*@'A#TB#F*]/D[!K;@4!!-V
MQ)8RSMF%U4_L]AGGV,-&4M"CQ.Z23O)@B/.M=IJ.DE@L'1+OO]S+PKD4 0@#
MA"GSCGXQH;.Q'-XPF+0;B()7I!)N$C4R!R M''5/ 89\DFI95)8GZ+69ITHC
M1ER2')]TQR8TR;.NG1/+<GAP]2*SW9(&RX V;*JP2Y;&>)DTD5C-'85V<5*9
M_5_Z'. *%@8#W[6D)X*,N:8[&"EE$6B/2Z.C5MID&;A$FJS"FQ3)1J%)"Y&R
MNJT;U+=#Y"UW$50\)64D"/PTMJWR5R2O[L^"0<=1Q<QH.^Q6:^#Q.!N*6]R*
M<^O ;]35D=%:U\'JRU#)EM6,M#2!$:Q JV&3?(M^G1^E.4>W!HUE0G*.TMX#
M77\F41F-#ATMU=BY4RBDCT9'7EH*54(VL9L-R$_&^FL?!H1+<7"/TAX^,"WP
MPJI$ND"7K#@W9J92=MU4H#6I\Z!@N&$R&[<WX2;I1NQYF^6\.S+92<H0ARX7
M8D\U=>[()#0W[<98M &B+&EFNB<&NV]7N]M2',/!R ]&ULCO1S!8/TX1[]ZG
M"/W6"LZQ5IZ^:.+ORH&0VTAGSSS0+_P0M"%AG*B:/\)WK;?,?L7<UJ*V'9U(
MOOL0^6S'1W &9^N2E"!7 D9#A-,='K#%-+5<*2LG]P7C6?@;P*T%OT%J I-6
MX,YDJ[9A/G8.JH?#A/EL$>D(D;OQK<56DL(DC;)1JE*M^3_KP[U:U+# R$]8
M'URCVF,<]GL [4KF*7%%Q)AUB%QRBH6?E$CQ2_I]QWCC#=B+]7J_0>OKYU^_
MF'TMTKRS=X$W>MVTMW X_Q$^"Q?X ILSS)Y^[[T"/MDF^&W?_O/5[)O=\K*8
M?=\NKH-;^SE!?AN1L_A?-=G)R]FW&1\>2]L2P2W920T;Y:!6?9<?UN12V4V+
MV5="11QND13'7X8+@!WZ:Y,8_D?2&1EO')G*$-M>!4-.O9]-N:E\9%,(X>M^
M3E76'2LC["HXYWMF3J8RXF%&4<2J78<'*I2C)R[BZ[I7U9-4KE9O:XY:$64K
MBR1>BFV*U+PH9$%XMA0LZZO)[@@M5*T&U@T_<Z#K(>&L,1BS-12^;\G<%(;8
M(N(HA7?SG]]7EEA__83]F9('3<4!BK2^)92V"45KPPUP6NV-\Z?M+]:QTF];
M?36KLE#Z)-H9NQX%$")"0<>M0B^27$*1X::MR(ZCQNJ#$MAQ<O^4K1&9 V6C
MBK-@U#**LI: ,VPX67Q2F$UT*J+G.P";H)Q6N  ?5 ("SXJG3:9=4=S+U*F%
M,A8 VM7ULBZE>YY"PQ#5WEZW&\MYK>JU4!VNJ<6)'4BJ;$-=8T7[A4V1# "4
M9+^LF2(GV,M]MS/.3_MS&)TO@Z^B?BOG.8C9'0SJ*J^"2[U(&'A>@8$G6.%-
M#2E;XXW[.Z40^&[AXE\U5VNX+.%_?[0.,OEJ]G#AZ\%$-F':-T4PFX20/US&
MH8I/ID,1QH&J;S)8^_XACW#/^Q>\W":&NAC.7_C%MS^'KR]G_PPGSI9LP*MD
M>808\'+VKFC.TLO1'T1Q]KW"9AG]_Y-O^."Y)>YU[E,(UP0YVF'VTWZI%'B4
M_VZ;B_3=ZN8F;(2E]L[LFXI\W47EXDZI$50@[.$!2C5H '3H]J1KLPHC*4V"
M(=A08,>^696U8X4!MM>_O(![Y>1CH!))$-4]K3P-6;FCNMM=\I%/E5>WZ\>W
M[8A[0JO<0*+ND9@U0H'9 UF9E ['$!!R0C%_C8V:BE9X  W11.V[A&#<JT\,
M42F"H)F"08TZM[]%#B=K9CPS@__[M>A/SK7H<RWZ[;3:)M >0_$G2A^:L/%H
MN#$EARPY?7H.Z;<I*DJ[QE)C?Q^]455Y?I#HG_,E<SR?U*4'D^M/ JU+=T,
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M43[&<GWH51#MIB)BR5Z8RTOR.[9ACOJDP *B8$M^[-K%Z]DMYSKYH<\8 ,,
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MQ)2TQ"VT(PJ,[-7#H.T[VF&$HBAFW^R;,)H4B_YO&E;J-IK;L26S0F.E[\B
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M&CI99?S_\K7F5X>U /JPD$,NIKKTR6[J=JTR!/) "K/*DZFP-TE&]=CRM;H
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MA\6O/@_VH$,"W4B>]3[\K6:F#3&]S=Y-O=SK?U-"D:M#P*1*)R__MM#+Z\9
MQ;U9A2V[T^[D]"62Q^4:O/3%++FD+JH096]9<;H88X(DZ5SUBY*-'%V1"# 8
M(+F[KK)%X=U4?6+=P7?/BRE[ME+""D- _FGZ1G+'=![H'G2@BJ"+_#DKJ$8X
MD+Y95&)U\:KVFCHXBDWANK5.VQ3A0!B8Y)%$;32)@YNXYJ;(5KIXG/156)-M
M0U]#!)'\=TX0+6")JJ-3?J\%8("K3 T5#=X8//42R=<-TT0S.V]O*J]%=6Q
M4%I6F(:/3@44$C%=6'&FD0(GH;,E* \ILBWF:5J_6$J+R/3."N<$,.0P*'/H
M>N;5W.&$#J$(L+!TN\DC*2FM)S0V5&-5B0@JI+O<?OA%OSKD%F+1U7"+$#);
M=3S6_!?KJD1PI"M^&>Y]\-*S_76]U1+SKR_DX&)[511N5^%HYSF]G/TC!,*M
M1FYHG^:F3T:GF3X&#ZG7-&RSMCK7OD<<-1MZO_RH]MV89%:"T0H+A1 FZP,'
M@M=5>5,#(H )H?3\*T0H\#!6_A""&J%K?$S7B.U [DVOJ).;ODV=;2$ZF(%V
MJ*IXR_#K(7D-YT' ,'+T?5US+RI9HG:-UG(AP%(^K#A07F-RWBYK%=2RPT](
M* SX5B[;[<YKA(]Z1Z.SR@_HB@9U-3!&]6I6A4=<2"^?J0D$X].D^\'%GCI&
M2=5V69=730@X :V%Q2<0/Y%@PMV#@>ZWA*;4)(#X M#UH@(!<P>D==J3\]&^
MS90$0<(??33,'F?N2@P9&#<KAI6-.F:]5GL$"V,7KS@6K\G$15X%J08YQ4)V
MZ"!%,-CC#K#GE5>#]Q5M&V!8!_9!)IZ09I5M6QM5L9V=XQ1'HI8XC-M+/Q0K
MT(H88))^ FI[Y /Y<.CV6^ZE2'$KWH.-^UJP+PIMRFBBW G'(PEB^F@SV1_J
M=P[R(HD])SKHJXA._M%$4R?&CH>!&T7N#<X1T"UR9GHBE<MRFP;:^>PIU1SS
MS"4>?9F>AZI1)Q1=SC9<[\-&_J-0+<YNZG#.OHT>D\P:*JPW,]WCG'QV'#%V
MU:0^/!YL (&]S0HLSC_S*&"+Y6*VWDD J@]6P0?S*:_)9[*.]U1ODFS)OFL>
M2,.F#@@ZJ<[%X#=0#/[X7 P^%X-_GV)PAF83MV^<-LKEE<))Q41,:[(KZ$GP
M)$E_:UN.!K_L]E?!>8U<$UZ7=1EN1<96TB0^-/2^M2)PJH@(%V1PM=9T%,%D
M?#)*0S"X%H3MNRE%_Y>]:__F*T2X:OF-#6Y0U^%$"MOF7OP>[3WI-,@;M=Q2
M&A,7>GZX*[S+_1#-]/P9 +J#/F-K_PY.U[Q:2YHA?&73"O[5CCEX,TWXIG8%
M?O_#M\9,G+:!T95I"<6K$T[_JA$Q,_2&+:WW<P\):+#;AB?F91]7S(ZE++N1
M77$Y^[M1E/ED53%S2E1YXXKFB#P@+-+S"U+6J=A'-$'RA'LL8FOM<'O:;>1[
M[UH=TK]]^5ELM)0"M_P-B5RW"WWL'I_#LD6<GD2U-$/YANBJL.W>Y@M"ED%A
M:Z P \)9J'X6YKW0)U/ILQS09TV(>8)R6??H-(DJ;A1:$^VD(HX'CV3W9B!C
MOAQA'JH-E[29BX<-$3-%Z&IFTZ=U]%)Y::@ .112]6-^M:^7;.T:>G4WE$DX
MD/J>0VTH,Z=**TG7TDWGLZ4,Z&YO2?!P3D<IS79<A;P?=,%\\^6KWC;AU!;:
MC]0X?]*4B,]+CAY',0E]YQG Y8_8^@D88]]'"$A>>'+M^AG#%+4"7)A&UZ66
M!^G>"36E2_G:K!>*[1[1_ L+TT^BQI(L<LOM!OZA9)LDVUZM2G*=^2&//BB?
MLZ0,GV:09;'WZ,!ZL?);* F&\IP7=Q-(D3GV^B6WS^@H[YJIXM_I6XG6)C]:
M!1J\,Y%NA2:H$/28.G;,>8P]=>\?6[0-DK+[K9GH,0/==CQ]TU>3^D924J"J
MDJ?%A_M1&5<5]QL7F3_B1TB6M_-$KLMN@\X_WQ_KG"Z FD63Y^YQ*+B'2_!H
ML/))NR!59C31U&BC'KU2)=@G;3^7U_;YW*A.+OY<]EV4)L1'M.BXT]R83#&9
M5EK;<:RY^N7 30)XNI)4\5'E>"X&V)+ATUHO/> +.[C;1FR;"@;JC8G1GB!.
M8?R%!9?,.4'5RP5J(^$1-@;V.#U?\)68GT%50?E<4SUXJG9UE:8/(V6;)L)3
MWRS-QDJAU\XSA]+40[H-!@3=5'2BI8[=LR=//X@.AS3[[V[;V;(+L7D\GY?M
M0DKJ#"'CI3MRHA-4"#5L*G%=,-7.JBLWU6W;O=9VB;V4M.AY='NP+5!/-A81
MU4M"?Q29>^1F2:L(= !ZBG,Y;/*IM5*(RJ?#8RVKL&RQE%E7BI]%Q^-6&B#Q
M2J@(]B1]0.C#L)3"T\]:,&F$B8\OZ7%=VZZZD)TNHD(T M?A!U5W02,D0S#B
M(F/[ ^]9;IR?MN>2>'BZ"]Z(;#IARP@YP(GVL) &;GX,&,1L\8/A5 G+X"]Q
M&91-T])!+?C36M&;9I]QIJT3[PV<0388X4SC%^/3R.:2D79V'F!.:43XR\&-
MD#LA+-9:^'8?AGRA)6') 5-7M2.VBK?&7TMJ0T26F[+K7[3-5<?1:-[38C+$
M2:D,Z3;POE(]$BRD3..U<_M:-LMMR7C$=<6<,.BQY0CI2KE?PC+E8R&V^T4W
M6LM;/$N,!6#Z"4AC4!A";93$?-O+-@/=::OMZI2^I-/),TP7-%G6).D?&[%C
M5W&<)OA*<7@797=3701W2D':.C42QC,#OC-6A.D!6E"D,$ASP,U*7-?X)!L6
M>>&N),">/V%EOH5(7:N#IW=(?-9G6T,7(]#@2L@UV,?L=ML?(YI79UD\%\[Z
MU+M^EL*J^!#X+&JU^95/CE!*L-KM02WU6CH[1_9XO6(,/\TQ# .QMQ8*HS/I
M'] #Y4D#L$01;L=\>U,&2+(>(XWL$E;X;-.F#=XD'*6.X#G>K<%PUK!6&HGV
M3"<#GVM!-F]G^^T:F@7T#54@U.!6G2@J1!"95('OFH6)>07^I@('>!MEF10Z
M"G"C,@&D]8<0,6_X]ZZN$FM[7\1R'DJ!0J;@+C%Z&,%5W<2&NY6O\[>=((6<
M!$'\Z1"8%Z='>FW <RM1%'K-E\S$3W?U%9RV<[9OHB<8T(=1V@=7&ATI\0Z3
M)C[LTTAZ<-.P@!4 ;?YN$1>LYHDGTJUXVK1IR(TK6[%%V7FW;>84I3 HDLQR
MI76OQB")'Q$C$J )(I/" N 8EH0GWREYB2I+D,MS\;I>O"8"/JY:AS] 5((^
MIDL6_E'#^MD+*FJ^EWT2(MG@]"M9C/PI&/H;<ND9EAA6(DT.?_3=]:$/?A8Q
M;)4']L)>[IN>^,MFGRU20K5@;)I@>8DLXC#P&42I H<LKARA(U;-G@8H9+YS
M8G%/\$Q)X3;P[)X/'/R_P7W[6MTW.?Z_S'(YP2_\%Q6T9U_&1?^=&NYO)+M&
MF^)[S1O^$);'M\WZ<*D.!/GDYB56FVUP0,++]*E7(H82[C$Z*UJJ QFU4=IN
MP\=,3:"V#9O *NSI/<<3X3/&A8;-O'6\03T^);/0-D:D:*01EIU'^I4#B<S!
M[1D;RKGKJJO6AYG7]\$5T,%!WXM$/RZR)_!-DF,U\X%$*\;@7$BV0O(GYT+R
MN9#\IHTC>7B:$654)[H,Q4.ATZ'Z.1BIG1#G9)D-2Q<6+M4;CZ)N(HE>CQFQ
M'.GHT^C'2BRB5<5@6.0<HZ%)CLS734M> F<^+(WM*H02C_HOB!R%!>5CY8Y<
M<2Q]+9\SO0VNP(Y[*8,G,P^7Z8T@-+Z@.!-MAZ9(=IX(]K=&6^Y5V8F%E8>,
M:::J QA4$J/VJ ,JBC(9%Y^FNHD:SD8LIUR:R>LG.E8GYS&$4_ZS_16)>CU[
M\NP)NPI?5@2^5*#WWSD0!X4LX'8OE<WQW7?^_O>7[[SG$D;A>%N(A@HA2/7\
MC-M$0+QKTX> BTUN0)SN8=:,8\W@C%*!!ZF-1751@D5ZPR6U$*5RD,KNKZ8^
MBGO]1I(<4EGWS9 29-#SN:=2Z3X1!PI#^,_@KJ-S* SBTV(6AD5:F&DX/R<Z
MIR2N!N<V7+$R]QG(H5]VX@JYF9EMV[ *#S;6^(5_5=QTV59]K!Z4^J.VX5?D
M?%ZP/S3!9#U@Z;R5(W)RVLZ\[R27=GJK_AN7\QA1E>&4+VH<+2OPZG'P__3#
M%(CK'*^ITR)8*F:9YL3A[! .CCZ/Q/]%#P[2K<^()P\Y@JJDCR^JY54U>_&O
M+UZ%C1@#Y\^X78X6V.Q=NL([__KLFQ=?TM_?><^RZ&1-*3N"#!\@QK<S.B>N
MZ& B23<)AR)Q8;(4<FP452W"NTB$H!#7:!N1DBK4W0]6DQY;0C1F<*/&]+0^
M+4E\)(54#SH_;&V,05^Y1#+1DBR:QMR6O9*FV5!P%IG3163A=^G'(">31F+9
M&QVU<FF'&Y(M,%2\Y=NKKMQ0S\$B7(\LUX!?XL6.E9'A'B"?DZ?5&*P20_&E
M!.@QQ.>[BQ'4'('/_TB54;HZ4C*'!&O%*(\,K7MZV]=5^)WLYWW@2+/^>@17
M--KP0@&AK7CG QEN$,6M_98P0CK4FJ!7YHP<KC?F4UG[2K7GRR_@F5S(V11A
M?5D"3 \CI%YR)AO#$3#0;VGT6!&88,CG8@*+P*S; _2",4N/(Q1BVX%.D>!
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M!E" /<2N4HS)/&&RS'1K<Q+42'U="7@HC,</1&%MB:FOI57@RW)7$@/AKF)
M@\-/:6[JZR^_B]6UR#JTI%\J5V6*B0.%.!]285#:0UX#+)@KDX:LVG&!)/F4
MW:K_NIQ]'IS5*HR1\;0\?>*>0"YB,I&,L)T2^MU%A<.8SOVE[)94))1^) ';
M+:XIR2R8'P>02?L0M2T*5&3!@/,(T@- P$0 QH?%6EA9;\M>*6$B;TO",9;N
MB;-1>*PO,VD4$"M@?_LM^C<Q"E_P4@[;41GI0+X3%SQ^KJ0WAHN5&,&[A*F(
M^E"ZTCCWN;I'#_$MN3O8'?HXG_4D2? %ARCGI7D:2]- 2-FAH]B'L53'>>Y/
M8^[-8IC?$+DO5^5-BRK"NEV@\"UELO/<G\;<)ZDY JZ&0R%X-W-B3!7DRH[_
M8]&U?7_!$:HCHS@OA--8"!J!,+!P0?))G/,KP%-)#7-,+3\CU]4 Q2X9@I*E
M2BEEJ4GU@P'UH>8Z /MG*@6DCK<^!&.769SA;&I.9(6Y%#-2DNO"'-/"\M=X
MPHBO$ES72 CG$]Z26_>!-+R5(L<!36F=JSBH,>S #&HO!/.61)8'B:IS85"Z
M1,H"5CL!=D[9*I5/B#LS)I.<5-!QWL?.,$W3"I&H<BK'Q.U_A1^$QXXHT#3,
MC[B2KOJYWJ71NS /7%5MG CTWEG$S/@)IH_2;R208X(74N6).MY*C32R!#3]
M_+;$K/[PN@L_K)1F JS^%J$HM-&+S\:HQ:$(2Q%,4ARBWM@ B-^3E%695_D0
M:=GMSD;F-(S,MD43"V]9Z4NFFA> .N@TJWQ5C:N@/27BNJL*NF@$S%IT0D/K
MLU=Q\:7ER_/2.8VE,ZCL<+<>=7CLRO"1Y&S1.>6/FEC)!!+KO!I.;S5L)1%.
M/H3KUBRBPULP(62[V M>;U?!X]US>I@Z4XG^.EQ?/&?T\K&GS"V"XS\1VJ](
MS1L\(?$TEC62S^(ECTB57PZ7XONH'/X!*[,O5F!JI:I&V_FF8Q2Q6Z)M[PL&
M6%*Y/-6G6U8BT.%[H2+S!S#!FVHI4 9<C&(<2<9'X>)]D]*_KFJ9(E.I+";
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MHD _3L[B^D4&'4+G*LS)K#P?$,W *T"PIMC@$V&]@@^@1J/5BLZL\Q(XC27
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M*"/G.DWYZ*53QP0;N\P#<BR<4R88G>09P45I[*[;5&U/;)EV?VV"KN8#UE*
MF 9#O(G0[31,RET"/T6T,<C%DW3W5-N-:MERY_M4"S/S]SUD4A2X53EQ>B+D
MOT.B(K!$;.-)Q85NQ8)OZ'L(*0@QXH8>92MBKAZ5S5()^=8%DD\'AB(L,8 Q
M:$:$P8*>K&2$ACL%9RX:-_Z?TM_YP6/7\U=[R6;.=G@H6[ES&W7L2SIK'+SS
M$$W&UF4T-6QAMB;*LMD"K^Z9M/KY TV;75(6Y@.VCR;<PMU0"C'WX1YS2 '(
M O7%3TX]JIKMR-G&4TFZ 0VU^SU(R7CZM)W&B9'J1":8DL.A6OON;^V?A22N
M<5?F$2!OO'*$WS9?GI5(MSBIK%:!<,M,ZO!,6-!]\M"=NCH_'>:I>'C8B/NB
MS*++BMI B_JXM:V$=2U=O23T&MR7G$?\25X[6RZ\R?$'>5U"9$D )(I8'+7X
MSPXR<5U/P= -XQTOQ<,[7V^8$EH)SC#'!VS=@&K30N3DII=%>Q&H&WB-\??M
MEYFWGH;/TLC6MF8^SV 0XWR=<[ +DZZ+O<YP42T9S&EP3$ &]YYCO-25/*Y.
MRF4'FQB;@T'G8LBS9R<<5YAERFKW"S*W%!5-%L&(WWP98+%]RK9!EF "MN\1
MV-TE4"AI3G:ZS(@"7*_9KEKW+@GY$>Z8T.B=B_J2\R/>30FP8C(JY'CHHF-F
M;ECY!.^A"<BDZYF(SVCNZTLO-1P*9R!;/_%O1J'N\URXP:=2@R+?IUI$HTYE
M G)\Y1:OE(<("%ZU*#+["OJTW8>=%:W99P%T8#51_*!U#)X2ABWQR"=F6?=/
M@]FBRFY(_9,3#C5Q@43H:1-5?#(]!9HRC-T\(_ Y[RD-*#Q9-NT2]>5Z="IE
MVD?[CW2-3M/F+'5&?>_-59FCJH?JI=L_4%KPZ"1**_FU6;<%UTF<LS 719E[
M&RHZ>YZV"[T1QA8Z%6"V0%/IY3+#I[>7\[0UOG=$@'B-4QQ;0E^>(_YT\G_8
M1;>U^RQGZP2?U^\SIL+[M ,8<L^"8:7-B4:X<3P0,PW?T3^PH[ MPW9=36GT
M]L3OP48E%^X0EVOXD"TN-,<DXU0')H_RV !EIWR78]13#0]#<+@R=QPME6*X
M.P5$^BU'9EMI!V\9(;RY+E'K\W)GJVY",\[-A/X4DQ;>RB7<Z$K\CN-<Q.2I
M.KW%SA7I3D$-P6B9GQ=MZ9N(/8P%DA=0"0AL5SJG=9IG@,' /XQ*!0M?A@3-
M+#)S^%;+G.H\AU>VCK?8/'O_K('N];7FZ"<>7.::!QTS*H%X>/V+O<]M<H!F
M-E+(6;>4I0S#;#*.>3#B"ZG E.+#\\J0)C7YA.F;Q?(1B8#)LLB3+UNI9>0\
M"9GT6@S6",EXRF//A>UB3@6+0",9=@BT*]Z&NTW,TX:2B4O\;NPDW\R/.2.2
MR&[7HGS5&:$69==,/?=0%F:AH($Q4I)U7XTSY).+FE0I?V\QER04<\*$MY#Q
MQ31[!FDC)NT@Y]Y/KI"F 7I@:'#_(K]S.9X<1:I%Q.>[]T1KVY>J""\]%6T#
M&2"=P *)Z2:J^I*F'7KRD&6]G@#8:Z?(C-Z_UOGZ2N!/=R7P70G\X_L?+\(D
M)^!41.&8[(AAR= ("JEX]91)_"8706NU^<2//$7B4'XS,.XB";SSH:]V0"$]
M/&_F=?\Z:ROPZ]]]K_Q%7LY;\9PEY*8XAQ-E%.<@6 +B"YZ/02#X=%74F^)B
M#($ F\MHA@\!" !Y'),,!0LNK/G=[S#"&7(L8,Y:\5^KD;-=9!+IZO!HYEHA
M'!J QF57*G%-4D)/<C9ONBRG+MR"$01S@/L##:=A< %7C!+GA#E'R$FRS]?Y
MG IE\@C(C%IMLZPJOA\59EHUG7&AU[EO$_+(LIP,/IX3A9/$%+O@3V0"%\-&
MR& D"7G3*L1,8<'X^F8!I2H?3P.4*3IXX @.+JG1B,Z!?#D7D[F'T!(WC23,
M%Y=U\TX)^C&"[3*G(C(M>T4CBGFFFUML",S%TCTQ)OHQ+\Z2LC]N%]WFD@OA
MY+V>$>^A^=1%FDXR]NKIGFP"E<_2R3L,DY6!X0!C\F)2&5]WK0ZE)]Z;.J0Z
MN!^BI4KX(B)"H8S4;,XTP%ZG^'5]Q1,'R875!("L;3KB\X?Y>@H#-76JU1EY
M-J+!W,)2".WKD?+/7N/9+F3O*YG=<R$;CLH>O,-:!@\1/VW)LPUE9I:F#1@Y
M0B,WV"'WHP_O=7+B>'0LB):.AE:WG1S<*DNU?5O*AA .X&K1XCHO4SX\!><H
M[7QMVE%\"7E'=_1I4"Y!IN<%HB0 ?2?I4D 8O#F+]%TN:'1W -WRS=;JUPG-
MXO:MN50"X?F:))599,CBG,+ Q*7.4*KUF4L/S]P@[935G(TM 83Q4U,T96;F
MBI@"C)-)=W!)TC"PHR@S*?BV$"5.BZ.LZ12:<Q\:)R_-$A,@D^A\F$8)$'.Q
MX$HZ.N$R4MMR8*66:8+2"^DK>"G!M/EXV?;<U8W_*J6\67\NZGY213]@#*K'
M6 H]%;):=H%H=D!.V5/*NN7^F4V;9\"7L;61.6\AY%JS?I<7.:1:\\G_6@J-
MV2PMM;0E38(:22:!@#9*2KIOL0;'FJZ5D>V;T"E.O*5E2;AR>DYJ^WYYZ7NA
M7U62*V:(2R_Z1//UH>SL7O\BG;<FGC0I$C,1\YK.@VCNKY[A ?SXP&!@3!J?
MEO5E: 1!4I5?%Z_G5;ML:921YI62/Q[&</I;1@ZG:^8P6&=[&B6/7%,E>%;(
M1#D;7_!2 ALO$P U31WC%,(LV B<8+0XY9:6!";:RO6_KB,-"@3SGS![>=FT
M>8\:R54[L7HF!>4\EXKR'^_9O[(.8Z]*3-0+GI.O27<SP^[B?>-2S700\\R.
MNM<B'F_$$#3JD.(\(GE9Q;2 +K'WZ%Z:A24 E:0R!B7+^9H(9":>K_:*D,3F
MQL)(:)1S'4)8_ZJ6"GQR<Q2J[ ,1G$:#9 ' 6@2P^CAPJ_2 !#9 \?]C\]CO
M]HO[3#[DA?L?6+5U7WQ&AU4FZ&5=Y[S/\5:_6;!SY.[N 99UP;7W/>^VUXV>
M["RN:X6QKVJKU'L7>T,6R[TR+:I3RJE3B"LJ +9N*^)8K%E7%[13A?L:QJ,K
M7IJ?&34C*HXN2XY5BPJQJ1>'<$'M(D2?&"6\G3^ ^D!+"GN&$$@>R/PJ'),(
M'&)82J5WZ4SB7&1[L:QQ8(>=FA4+D>L%H+33!0^T;FABZ'(A]XSVB#AHW&D\
MCWI#C87D_6"J&HY,^K6K=^C=%NL1\&;.2C/40V=[Y7B@#ILWQG'C5X49!UR%
MIW5C/%X&YXP=(K<Y0Q<L,&TO>F4>3@I<DLQCL)-<7?B0*4A!XTHIS_,@<-9O
MWO#8^S$)>QV<NRC#X+?::B*[-AR<;WX C^D^RY5)\3SW!(;2>>>.Y83Z:#.J
M5 #8[I\"Q\\?N'"6U:V+C[,>T5'KSN1,L4B"VWC3Z5>I*VHRP;MO? >%Z4.#
MAL"WU=H-;I+PSDD\E_ 614?T+'0I3(IFLIP!<,(LOSUZ,&)-HJ7JSQ$DA+58
M4H5&! W!!/OVE')@%6KLQ.VWF1>Q)WAL(D$<7#>?<OAG[H/EC3_$<B%-U^6F
M$B.X@F%B7+#3>H#14/Z $SQU8K(5ZQF)X()%F)*AY>4AWK*R01'J"KN?Q8V,
M27Q"2#&1<4*31A,R,^Z?U *+#-YH+6LOJYW5#22?=WJ1^+'%1>2*NI3,KMVT
M\&C)2&*Y.369L\PPML<.DT:1#M@?Q#U='#[K> .*)I65TPZ;,'? -PL@#A0N
M./3"$PB+@\3B3/% V:U>L??U0U;F\+8WY5"$+$)CZ6[LY:DDZ*G/18D0P*G3
M1DS\: LI4*HCX+%>9.@K'K*A9'R#$;,D=J^/$&WM$YU1@7@I7[!RT/+@>!2:
MQR0K!13KPG3M "G/'0.2PA ?-$S+!1!FH2XX#W?P+16;7"Y>*9[/+BQTJ,*W
M-7V7G$X_:U4@O;SPW6?U;09FHJY2?+S/O1ZF[THQ6\U5G WMUR_KZ=$^R!"'
M<NXKRQ@^91Z)F[W(PWF;4]3)2(541J@SC6JWNO[/G-*0E>E5B7R-@?QIG #U
MG>B +/".>'][5X+6$O23_5T)>E>"ON]$AN$]$'/#"!CA; @,'HJ9)<V6%Q(G
MRB1U1$#^KWXBDE904<@R/L1\4$"3<D9-8:U*=EZ9D@S:9M]+EQTY&+FE+H6U
M9</D;9&J_,3VTDIAL_!3"<CI"54RNK-Q<M3YXGA56FJU;U9*/?ZQ)47#Q=;I
MDNK$;1XFU9O^OY*B+'6>0J<B2TM^18Z4$G"4N5D7+(#35DQ:),Z9%&8-\BI>
M3.UNLU'%O,EGQ7)F2=T:/ZJD+?29^3DSAK+AH%+V?B]<.QX 46L15?H\]6%O
M0_;=5TP?:*$=R(QW4JI;>7!NF<C^)P.QA62A7)D*50 -QC!QX2XRI:S@UB2,
M152\*&=AJ<S66R-AD:%M<E[XN=;L*^FUZ%2:0I\5)5,'DQ8!@8@8Q;DGF=;^
MN^Q2.(/VU@,HG?'(M\AU&U*YI9[>S73B<BVGZRR'OBE.^6O +*OJ$0%G*5"9
ME:2@SE:^%U[B#OCQ6RF;]Y;D5VE5BG4KGE1X2]:JE#H&*1FACM*$1-E@>>"&
M*7J3D.>'&1IC>&U-H;ZL.!\I'1^ES#.A=2C?Q^/F.?TTF-JGMX8"-3G^9#C)
MWPM]([WPGA3)>JX_KFQ02=;%O=Q@B6Q=4!R&WXSU1F(5A\Y6Z>_H-C!P[<G&
MT0XG-HGX_H3-,= [FF -$M(ET@]53@&5\7H:Y+C%'AL6L0UW:N.7;HKSNJF)
M2@#Z@B8G2;\/IL:5TM?0'8EDR\NR^G&_/<_-E'YZ3Y%(6U86[R@)@/"6=M]P
M>&DEGDK>;9[CZ@):%HJZ7C7M?2IG?IWYUS <CTB%D (I);P,W"P,&^9 W;E6
M=M'IJ>S?<F30%!F&UTA3W"K4T ?N3#OHPJW@*M_64;BE:^!.&./W'JSVC;IJ
M$G\^U^VY/R.1NQ5Z$.C+YP+)((G$U8_1M^TDY)5?=\.I^MS)8;KTI9I7<L_?
M@8+#U$8HK43[T^LY4O1UPQX,-=2Z7W#+K/L,>G" & 2\=5;'K]5VHY)  (T9
M9T9.!>>H%G1?*>MA.BTB!IZFQ$$$:#[.W1LN<H[?WA<9:3.>:9NL=^ST/9D3
M]$HW(^D0>H1*GG_&1%!*ZJ/0(_-IY:/)!37Z40)TJDYZDDZ1&530(J+A$(<&
MI#O.BP%VE&.*8R>][C/GQ(=]/A$521RJ?H3F\<FS,.&'[Q>""56J,NJ7-):Y
ML%L?@TGDB59MUWMD^*2GQE1#S]Q!_?G@20HR3H\/HLO\+:V69*H/DM'A_B%Q
MOQKX';6EGLO(+'JAT, O+8_V*4(W-JG_D*K'1^;M)K)L7MG@-]Q!Y3_")3JT
MQ?QUNW#=,6>6<&:^V$,)-I![>::G?K?Z=WU)>23>EHF3X-)PK-*_O?=T/9'U
M%EM):@--5.Y.:9@GK4^!MPKP4MJ[$$^#G4!J T-/6;2#]S'.B# =D)4L+NHZ
M0S@.%8&*90="FMC'&A$0]5SNYS3F;\3N0/E3$I#$;B7B *JR<R79?J1GXBU+
M.!J1W2KXXW'R=NUXQ!USGA+6"Q_35L0">Q01"-/;+X#L9OWHT]#V["@9,H,!
MBZJ8%7\&C2@N9=1CSNVJJ?!1A*O*Z46\)8(;P5?%<76R,_&\P_YMT+6&\A^1
MD+F[$1^8[>XS,Y8,JW,K-DO?XA]%X]PJFD6F.F;T*QKIW.(<\*W)G0C*JLOQ
M_4Q9!ZA=VS/5#*SU,9EG9W?,W?ZVK/+UF_'7(LTX>)-E:>[PQR*]Z'N70W-Y
M^DZ_]KW9/8ZE?#!9+J);K;HW\MN27M+AP2V.@UD]T1,J:QH<Y3<5>J1_Y1(]
M#Z*]T:/1CU_7E[W;>12>C!_EK8D*AO9WPXVCS7T\'IV&MVVE0B4,,' Y[-A)
M,;XBK:3D.\WON(9P,SS>YW0)BZ[:$.^?=FQ'33Y^=*;<4A#&H-=5H%/$# D*
M4^D2!J96M8W9YPNO&,*2=%YDRKZC_<?21PM0F&%)=&OM7!S6TBE,%< Y^05W
MQ'@_,HJ?W"TU_$#0P&'\8"02%2.-9\*YU;B5UI>+'Y[#'G5YV#4BU;DLSV'!
MYH83@S;IY]P9ZPLGD)J%/:$!TN(;T-(]8WHA_2=/N?_TB3=0/[\^>68LE.>N
MZ8^'*<K-4D*:X;3!>##H1;;;(A>FQC'N9ETN^-&MB'_[KJHO*Q)K>31QB=R+
MKW\[FKNJ)TWRUEPP]AF=-"/CAZP&R#CG%ZL6V1$< 6U4P[^TZ=0M/;]?/8A!
MV/!8$LQ[!B9EKB#Q!2PA0 H0^7:XM=&^WCAE.MEX%\)FNEAAQHQ"BK;?^%Q>
M?S@]D)4<;'>SGR9)H:\;]EOSFP.I&Y"2Z#YX8D?YGL:97/>GO]-RU>:*>UAU
M6BF\KMK5KWW]^F!7O][5K^_;Z/A$G&+@G-:HE^=(H5(+6X2N46T89]@Y\] #
M9?.9>0MW[+9+F#9A3K;?!4L.0!N#R".@]_6([I!D"7A5%'B1: 2-103G[@4O
MASIR/X#Y)J#E 70R4'UV::5.@#&UQ7Q9,E?9$(09;$\ ,9M'U]T)KQ#!"Z.G
MNQ74#X0Q'3R?.HBU36/= >!GY_K 84EB_R<\\N]!HB@9\5+IY>GICMT)@/V1
MWR%6[W++>$K7T6_LH;N'\EF,F3NES"&2L3 *\[QQ="2+=(HV7PH[)!:.I_+(
M$]#-?T9[VZD0! L06@CWV,T.\ 4)&BQ SCP-R'7<=J#KF/W_9\[B-56^:G7T
ME?)6ZZ4VMY'VLY4_/.][C>>-B4ZG/"(A8@4VU*"=.32^2"?%2E\0,6V@\0'C
MCW%/89G.LTXQ:ND"36V%"E0_RH?:#9K F=I-%JJD*)&U2>STMP#V/ '2\I2&
MCV"8_>N2&,;GSO.QFTE9Q.!J=K.??9%B=U)7:/P-2 <LX]!6V2T%&J?UHWUZ
M>C04LKW!0;[A4Y<ZEYNJ5N_K\GT'=8!#IE4I=&N;HB$GQ"/$*:+BH \Y2#9R
M6#?GSC+\Z2<8,!0H"5%1)[-GWB!$0MC"1F=+^XXD#FW.TW--ECBKD!K$;%RM
M#'&]UA [F1.\0_2^#+GB$((AM[,Z<[H@M,69DV2JI%5FH$T@!2<(7=R<)6#M
MT ,.OT6Q8.Z14N;E%+FA4*3M5%'N!EZZ<TT2)ENA+KWXET',OX?WDR9*S\BS
ME3\]%;HO6\LF=L$T!(8SXNZ+5#*CJO$IPTV#'&]6SE]O*=@ S0]5".-\H$O>
MY_)I7?HKE][9B9I^HBZF,B4X/I\(G]$*EZ:H6>H;$?H@[NZ-F>/M^<70@B0@
MOMT;75)XG9C*BWO*_[_,S@5*]SE%<!OM_&U9[3V8LYTT2R>KGNO)8$4@^+4.
M8V'9$M2C,#^3BZ3]8V;^2%"T(9V)NE3 U/2.";$B[^,7 DQ4P6VX9,J@*N\0
M24B16)N6Z>35 =R#P[W<SJV]!O' Q+&TH/6$CNUY4R_G.-U^#!5<'B&85:Y9
M3['(A!U7V)*BI6"@]4XY6&$OZC(+LZ_">C>=R8_3>H*66F("Z1,BOH 1(\W%
MOCS]J\]K!OLFDU)0?>XZ0D*V#C\N%](+6UN;4_I^V>361X@(VMTUU=MQ=S=W
MC08.$H>M)Q>)O^<'0N3YP@92D65'H"S[8R#8F5O#!DG&=[DL[O\);A(SA1O%
M%)*14QXW[5G7)W4SQ[BPT<0MSI\Y1ICA!&((0-#OT7ZX"^;0ON[+W.=/U!C3
MVH\D8O8IMA'/:_=-C%X%5+]NHO9]]B]:6#/F*YFD<X#M@AMBCO)%"/\HY4P]
MY;J@B5)VC?ZUE)PQ#C.0944572^\MA$FCPITYHWF(R7F06D):/L$XJ=C=#L$
M0V;03"<>7-=%&Z=OQ<<D4DORLV4E:FQ(3\4^(T]2!0$81=^D;7I$$K^UTL52
M@[ !&#3Q4J.(*B!X+:*#JV%M+H*$"@?8>3&AYWI=+]ZLK:5[#S2T-B="RZ)#
M@((;AIYG06U%+XG3:.:Q<'#&>ZNG!!D:[R6W3J"*R3LJ_;71D0,%/I>=F!LF
MK*GBG>,K>4H](!U:RNM/5\+]:HXLT;J9VR1KEJW/0S$D<Z(F>;"1-F:OL;5^
M0DNV^]V=?C=+";FQMZCG/S[I'6?_22_S]96.#H=+1_2X1?:?WUQ?X7CZ_3>[
M>M.VUYO,$3HXW'2&[MUG7PN^#FGW7R_RV>AP_+__U\&3_9_6__N/JB%7=@%(
MSJF"&E\Z,^8<)J'LTES?']Q;<L))@?:#M<C'CUJP K_555\Z_69GTAVA;[9E
MEX\&=_E%#EJET1_.FW>[6A54O/";^Y5LY-'6;.2CP8W\E9" IQS.O @^]/;L
MX,)D/#]@+Y]LS5X^'MS+-XC036%U>W;Q@\[AT[Z]<\\RV7/O11'0C^UR1A/O
M?OHB-_3)X(:^O,)@VYN>1O?L"S@8WO\EVO(]U!/F;?ZC_H^?7+ \+]/5CP6
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MWOI@_V#\^K?3FU2AMO0-_^_SM[\0/Q7&=XU>U),EVJV^91X,^>=,_SFK<Q[
MG<[G.8^YH2^^)@E-F=(-K&\4-1+_-(;S4'<Z;K-(S[D9BT@<LTP8'_TU0%2'
M+^K]_G(?"[]S\+8D"_MIC_7I\<]WDJ[M>$-[FGY/KWC<S4LF+"$4+PUU3/UQ
MOX^%V%G0+<FD?=IC=OSLEP=L/:\Y9L=I.1&JA=$O1?6.1HU\V*';V;:=;;O^
MT+UX^>KKM6TO\BGX8N[MS.T,W<[077_F?GGV_.LU=+^D9WG9[FS<UI^W[;
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M>.VN2KFB<B]\GMIDL:8OG>O@^4B;8DLJEB'R>HAH#0,9'3.* R^F7C#;NK?
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M:)-HH@X[F-5^'T6/&A4-A=U))0:QV$\3G,+V!1V2M0V=S]S4^0/@C/:@1 Y
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M],-EI.@D_==Y?X3YYO04^MGY&>:Y0WCM!V^&@\^?<'16'UYZB3@J(DJZKW,
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M?;^65#*OD5"JF.*-A,SX=(Z<!!^\!XTV^A*X,':U.MCE:QR@=]JY H?MI7]
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M_RZMJHHMZB/- /\?M*WK;4_WZ??W[4W>_KE-CUN>A"S%"MU!H4XR1(Q.<*9
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MV\*/:(?#W_52#_[Y_.DO4$L#!!0    ( $Z%I%;U9*.V?1L  $,<   4
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M\3/0!@$P #"P,/Q'@/\I#(QT&UG9V#DXN>@*K7P (P,3$R,ST[]6TU?CZ>L
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MNL[SOMF)V MZC:]FHF]QQYP^#(JBFO)YA%Q3$'W;P[1G1UO\'U!+ P04
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MF.,SD*_6D0Y?U6?K- #G?+<ZWG21(>"3X*(^B[K+,R9:8>E,!B26<0("BB.
M@B@%)$U3 /TD(2SDBI<N2 ]PLM^I,=!64.])2WJE3V[.1:M?!+P9!0T Y\ \
M=) ,H 7M70WM\(D S@(U2!: T[V^8@J LU!TQ_^??[WG*791B*/5ZV=)@ 1C
M&(&014290Y0#+ 4#H8S") Q1X,?$)G+I9$]6'#1"%-,7W8='*G&]QWJ!X!XI
M/:DO.I\[(PPM,38\#7:!W- GO)6,.]XN6SD=GM>>@\+5&>S)?L8]5SVG[L%9
MZ=D7!O)!+$XYC#29(7]>YE)DI9*D>+^HTT?NN8VL<T=6_#;#C(9"0@Y$["<
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M==E%SO#BLR\>0U]V&D-A?\%Y3&57EYH[;8][D7E,K8/+RZ,/]<["JC<,E6'
M!7_S\FLA^/O%[9/(2:EK0+$R>ZX"268!H@1S7ZA%/5&S6! "2 Q]D,! _1ZE
M<1A8.3J8=STUSP>=5Y+IG>^JJ.JQ>,NUS![9"&V==M-T',PX81AT!R8,#6QU
MI+ 66U_%??]KC?(/WD9X[_H\S'UR=UHBYBZQIVG'8V?]M 3D2$I0VQ;ZT=BF
MQ0^"J!4^([1*K/%VE>O\KC/&4N3'6+$6#Z#Z'XM!*D4$(M]/ GU_Y*>QC0'2
MW=W4+)+MM)EK<;UY(V^5:9[5,MNQU1FXS1C*'8@#L](6OTI2M6]9RWKEO3T#
MGS4+F:'BB'G.=#8JVY@IOL\PAF]=FE1GDSY!Y,\9$R<NU>NR#%5T[2?!EO>+
M[!]5_:EL6==-J?(JS**$!I$O(P EQ(J,0@PP34,022I($A*&(JM:O(-(.34.
M:R=?V698J?5LG'7H@5?/IE)&$RF_5;>YO?0JA9OT*[8W/H-\'(971:\]Y$/?
M,777H;I:EQRN"Z"\)4^9,OJU3NO,!V>']((T.@- [CR!CDL97REUS@ PGTZ:
M,T1G_0.AMMD;]FNU[&=F(VI+CC$#+"4^0"$E@.J[_(1 $?F!,GE]JZ7$IO/)
MK1"KQT>2OZQOI:_JC:2.=7]6LFNW3LT5[Q?/HB@KOS?[."GC<3%C\:'0'IB<
M#8I5#9K0K ]L#N.GC+L>/8C*%I1CD536;?1CN?>+NWS)1%%\$H50;S]<+_@[
M??VP?-)S<QUIG@HD<0A!Q ,!D!_I##*A!%@D"25"8(&MMNU&O4Z-U][K.,1*
M:F\M=L5D+<'MF,P,>S,*<X[HP-QE .8 MY%6*#FB*K,^1^4H*QCVR<GNY1[.
MYYUQI&^7"YU/3Z?6^I(3GBWNWY&78H9)$K/4CZLB8FHKCP*0A@D"%'-?8HQ2
M:I:5L*\ 4^.JRC3(-Y)?>6PKME?6<GM<"6[A>]UG7+K):PRTQ[#!NJ/66SIX
MC1+>N^&AMW"&'W@(1G*1'V(H[)SG+\"QTZ6^3[OC.=I?H/6.^_TE[5QZK'QA
MRL;ZR%#Z@D<Q1@!'(@:(!1*D*": ^8+%(2)J4(-^Y\DNQ)O:$M4^2'96 ^FR
M\V,G7X'MP?'88SOTB?$K#.L%9\@NT7=^>.Q$N%<Z-78)[.GC8J>]]/2P-*SB
M_:FNX*UKOW_YNOSRD"]7]P\_*[DWSI\SJE;]- Z$VKL0 A"$7"T@(0>A%*'/
M:.B+V&H!<2?:U!:/=ROA$:EZ\I8+X;THP;VR%MN3FFST;RS/E1V.H]D2\#JC
M\_IGTE=>H]O+YEJXN3_\K-14*\?ZGY5I7JJG&_V;\;Y5X]U@X&D0/(W+3AX?
MA[ZMSD?(E6.L.\'&]:IU#NB!2Z[['D8N@G@ZV\,LH%B&D9^"A$<!0($.Z0G"
M1*T/E"=II"OF^K.%N-<3ZLL(10]/BVK$2&G-2 <"#\=..TF%>A75&&1861(2
MQ!+ 9) "A$D$2!KJ:/ XPC'A89QLAO7/-*+_5PZFX?;OE09H.LF=+LKM-(%2
MD^<'XK5K2G9(.*T$3/TA=E8ETJ"K?F; A^7B7JULC]KZ^*CP:ARSL4@"SF+%
M]E*JG9YD5.WT) 34CP/U7R(XM_(7.M[-U'9M6DI/=?3H<27G55,.2]OVC<#>
MX\9 LV/R$S";D?'EX W,IUI H"6LBCA<->=G&K?&O=K[Y3QNUM38#8LC=CO1
MR:@$U:WH/L><>;HG36PC06:8B!#Y0@ _0C% D,0@A3X$DE+*(D98"B.;\+Y6
MVU:$,%KFXE88C.6L;Z%F.-7[83'T_#8 P'[Z'JKJ:LZV6AYWHAZJ=# [CSQB
M-R6+O-QF\?F;6-[GY.DA8V1>1]#',61^&(,84K5P!R(!A'*U5R-2QG$:B5 8
M.9IT]C*U=;LMGU4L?3>6W5/6&4(#3UX;<(PGL9'R7=-9-=":RNIOVVG<W?8H
M$]I(O?74-GMXY%.Z#]E"O%<B%;-44"*B4 ") @80"Q.01HH1"$Y8@B.><#O?
MV,M%FAI]7'P<X/VN=?,JY6PO]R\?X(%/='H-V]0/<,Q&;+S3F@.07_MP9BO0
MG^,LY@! 9T<OARWW\!G6&[(/2[(H&J?Y"*4QC_T0<!'X "&& 8V9KSB:))&?
MRC1B1N<KQQJ?&KU6!P.5?!8>I?N =9/<I3 ,3%=;!,['#)R'PL)Q]@)(1G**
M-?@X['Q<3ZC<Z;^Z_\YXOJDGI-WQ.SWUC-,\3G6XXTZFE4U68DZY8 3Z@(2,
M Q1""%*!(L!2**3 80(39&-!VHLP-4JK(D9EE<VX<A',UJ*[3NO4-2QF=M^P
M8 ],G&?2/&V4:*5Y&B2]='\0A\W\U"7 %#) &0!DF G*I*6^$:;K0._W"[9\
M%$J Z\=E7F;_:)PRUR5,KQ?\+A>/V>IQEA#*PEAB( 05 *61 !23!% !HS1D
M21 F@9U'1 \IIN?Q<,U8+M9^TGQ=I%=[SI&6+OH?GVH5//6W1Y+_(<HJ"KQH
M^>4MA'6TJOTXFE'H4&,S5B3K6GJO%O_*4PI4^4]VAN1=>[P:-5Q&MO;&T%F<
MJ[T$(T>]]H;H, :V?U-]ZX<LV1_OBV(E^#LUAQ?WM7="Y:GX47RM_J6821CQ
M,(@Y\.-$ B1]KFQ*&@&9,#^.@A#&B5U&*Y->IV8\:JFT:YB>=&IP'M7T*[0>
MM2GYZT*!_E6Q8"D6WMV*SC-6Y28I7[Q;*856LB)'_7:V;HGII#*V=4A,!LSP
M;-'U, Q]?%C!70OLU1)OBO(UF<>5V/4##F\\K6!R5JW$I,^1RY98P'!8O\3F
MY7Y<ME=?25LU*S)OS@2+&4QD ",$ ?01!H@A"5). @"#5/M()2CBHH>7<W>O
M/8R],1R6/XDGDN5UQJ1</,W54SU2)IT!W(R$'. W<KTY#=K--\7S>F.[7S?-
M:Q2X\MX)957K=*Q25T)I]'''2F:X.:*C,YV-RD-FBN\3D.%;/>X(?LX6:C'/
MR'P;9%YL;_G\!--0$@Y8E";*=$(<I"1E (4R4=I#$H?$^,:@LZNIV4L;85O)
M$XH>5ZX&(!O<,CB#;F"6&1$UBPL)9^B-=#UQ 8IVUQ9&P'1>8G2W,-Z5AI$F
M.Q<<9F_T+4KWMMIB579C=<%;W*[*0B_!RGB<01SA*($,L*HT'2<^P+ZO,V2B
M-"(I"6!L5(3*K+NI,6LML5>+[%4R7]4^$X77$MNV3%TGXMT4ZQ['@6GV4@A[
M%*XS0>:"\G6=S8]<Q,Y$U<-2=D9O75C0[A=ED:_R>K.S^>7_S$2N,\Z]O%L^
MDDPMA3$6).(4<!HJ3B%( ,R8#]) LI3[.$*ID<W6J_>ID<TV -[;2.K]7LMJ
MZ31G-PIFV\?!L!W:SCL&J]Y9?KS^^WEX^]?+LX')=04]H[Y?IZ:>#2PGJ^Q9
M-=+WC$M(D>>"MVBR/E:;04H)H1$'DJ,((,HAH#R"(,21,I6XB+COV[#6Z:ZF
M1E$;2>L#^:LF:KLZ9V_'<5N&<7=@;7JTY0+!@8EH"]ZN%50+ZO*\ZAP8SLZJ
M3G8T\CG5.84/SZC.OF&_FWK7[+AU/<%9&/$XXBP%(@T41R2A!"24/A )E S+
M@"5F=;+V&YX:(ZQEJVI3FN^#=K ZO^/IB\# ,]I,>:L=S#%->^U5=AH:;5=R
M3/SV_N/HO_=;H-]J:19E7AUP?<J*/]Z(!7O0SC*-6<O#D*94QB#Q8[6Y8&J%
MQEPDP"=JTQ$'(I;0:G-QKL.I3<T=>3TML+>1N.>^XBSF9LNU2R0'GN*7@6B]
M=ILBXV@%/]O=J.NXJ?+[J[GQ>SV/-+)%5HH/V;-VLRS5QY'1N;@N"E$6OY#_
M6N9OYZ0H/JIOJ)D#?@ %320$<9#&ND8W4KSC4X"#!"I""B(BA=6AAEW_4Z.A
M6GQ0R>]M%?!J#70N0:6#5RGA:2WZ'GE8CI+AH<=PV ]_O>48=ONCD'[@N3H,
ML>Q]W..0?M <'(CT;&;D6.O:/:]U>75;/HC\RP-9-&F;/BXK?TS!?Q/9_8/Z
M\_I9Y.1>_$V[$.@DHMO4K (RSA!D@/@ZN0K"$E 1I0#+"";,3P0/T>RI\GGZ
M7)*\-./8*:AF0Q[["@['(V_$?;985$Z5R^TM0774PY?S.<D+3PG3Z]AG"J#/
M4!"30/"H#OQ'<12#E/(84.FGDOL"BY@VW]/-8NCLC:_Z-:W5&_(ND/_W_9#,
M#(HIB#HA*\5!HLG&][OM?E)!XY4*FVT:R@T\5]X:(*]!R*L@JI)5#Y*%>DIC
M_MII$URJ].=(O## (#I+W3"$;/V+]>J8F_E27^QMZ[^BU$\YU F5J53+<R12
MH/;0%$!$_0@&$5/KMVU=WB/]3&W3_/;VX]]O/GUY_^;#C??YYN/[VT_>Q]LO
M-Y_M*^T> ]5LJ7( U=#G[[I6P59$[_?!JN1VX."P(.ZQ7D:O?=NAZK$RMUV/
M]SW8+TI=%OQ9+%9B$\S/8A[%!!. DCA0QCH,08K3 ,22Q5"$ OK0B@B.]C(Y
M&E!"ZCBV1LR_VI[6'P/2](C^0G@&/Y??06:0I :=&#@[@3_6Q\C'[AUJ'IZU
M=SULGZBSB18IKA?\L\B?,R:*YH!6II PA 4(8KTQ#X6R 2 , (_]-)$$4P1#
MTT2=)WN9VH1?!SE5Q71J22W/P[M![9[\SJ :>/+W0LDJ=>=9%"Y(W7FZ[=%2
M=YY5KYVZ\_S#?2,//C^(^5QO6<CB948E9%&0<+6BQQB@F/L )X2"A.' #UF<
MI-#HVNQX\U.;Z(U;?"6BU\AH&T:P U_WS+X<E(&GM!4>/6("CJE]00S 3G,C
M^_P?4^70Q__H4WT3 -7QM>LXV_>+*JA3\';Z]H &/$EX @((?66D8PG20(0@
M29)44(95RU:WWB:=3FU2-Q)ZXIL^A+'-<&8$LYGU[AJ\@2?_6ESO^[7 /^A2
M06LX!\FN;P.1LP0[!EV.G%'''(3#%#H6[_8]%'P6\^63SM3 'A;+^?+^Y9,^
MAEPG^D1<QHP'&,!$'PSP* (4(P@B)I)0!Q#Y#-H=#G;V-S6ZV8CK;>6U/2#L
M!MCTH- 9;(,?&!XBYM6RGD\\V^/@T @79P>(W;V-?)!HI/KA@:+9:[T=^?;#
MJ*LR%C+PF: 1T94;N?I?&@,,F0 0";4I\25&OET4XO%^ID8?QT+WK8J#G,/5
MC#T<H#4P:_0!JH^S7!<,[ISBCO8RMO-;EZI'G-PZ'W=&!L6QNS(11U$:AB'
MJ2:'&!&@OA*N&"*DB B.211=2 ['^IT<6;S_>/WQ[?OK#][[CY^_?/KUEYN/
M7RQO(TT1[TT;E^+X"C12#']]:0G4<$1SM-?7)IXN* R(J//UGEZV9"Z*YH+E
MHR@;2SP-(^9#ZH,@B2. 1"0!@9(!$@C&$LQA$EC9*$=[F1KI5$*NK_BJK+R6
M?H%'H33CEXL!&IA-UA>?K6@DYQN83@Q<>9(=[6-<UZXN-0]\K3H?[A\U?+?V
MP=5>53/&$,.(4! Q'&BO9 HHCGU 2!2'<2PP8L:7(4=[F-I4WX32UE)Z2LS*
M(=,^I'@7R//7(A?#,_29A2TRO>*-CVI_4>#Q;HNC1R ?5>A8*/+Q!UU&R-3Y
M!:Y7Y<,RS_XA>)7!NLH\4'M9WJGQ+FZ^B9QEA;C+,R8^:<?-#YO\@0%#E 8I
M48N_CP&* K4;B6 "((O3% 8)3A.K<\YAQ)P:I=0^X_3 MWR3>&.KJK?2NM9Y
M.1J7<:]25Y?JKA7V*HV]2F7GY0PO_D(,;9I7'_>!N?)HF,#6#?JJ&=M+1M61
M][\KT ?UY[]8R EXZ+L"VLSGWEEO/=(CU[40UC40ZOZ^+._4W'I08EYSGNG?
MD'DM8[WLS7B8"C]. B Y(0 1C '!4:0,S83@5.(8AT;'6[TEF-JJT5246&Y*
M22SKY:!<>D^-(A[9:-(DP+KRZA ZBXS!O4:KF^9'&8.!&;R!?UO)XW8#_UH'
M;ZM$LY)?-;;QT/!;Y'$>>AA&2N\\S'#897Z^!,K.A-"]&AXO3_0E>N^DC[ZH
MH7X;H3H'P2P-0LXIC8'$H5"K2R !93P&, X8%"@.28QFY;(D<[.-2]VLU9*Q
M:7RX2?)%]^&12C:[W4 #DYGU;J_\P%Q]W:VQM:6\JZ CR[9I=%1+=%>1?<MQ
M[U]=Q$MN@GM"*J6?I@%09*=O*Y5-EV(& ::Q3$A$*92R?[CD5,.D#N( SP<#
MV8!J-CTOAVKH@T1[E"Z,E1PH9NI$)Z\8*7DN:NK,T_THX(;D.B^+7K"KE7M+
M BE,PP@A (5:<%&21( F$@/():<$"APD1C4;SG4T-1I8RZG-S]H4[<T$)[$U
MXP(7B W,!OW LB:$<T@XHH23W8Q*"N>4W:>%L\_WCM=8/HK/:F]8G7I^T(.D
M\T%HG[R8A4&<RA10&"@#(4TPP F'($EC*: 4L916[DP=?4V-'FI1O8VLWEK8
M7DZ/72";D80CZ ;FB=ZH]8G(.(>'NT",DSV-'7]Q3N4C81=G7[FP=$N]0;E>
MM",YFHH+_';Q2=<@UP<)ZH&/RT6^_NL;4F3%%UVF?.O*1P/(_%@R$&.(=!9T
M"E(_BD' $AC@2$0Q27K5=W$FXM1(ZO/J\9'D+SJU0:UC%>3<TM);J^F1LI6M
M2A>*)]Y&<:]2M6?1&'?C;T:$KSNJ _-G:XC:54NN6F-5%:-I*>3]7FGC#>,.
M.AC8KHO8N!/P=2K=. ?X9#D<]SWUN'YL<@.H3JHD8HVS)<$PI4($ &.N[,TP
MX@#':BU@"4F#$+.0A-CX?O%H%Y-C\"8AA9[5RRH185Y["UK<3AW'TN#V[V*$
M!F;#-3A*P"9+XUFO55-T+"[G+D9II-NW]J=DB);=U5HG$)UW9\??'.]RK%/R
MG=NO[B=[7F\MRHQG\U69/8O/FD\KRKWYQN8K+OC/2E3M%+*JOX];N;_/?_-R
MO(%J\QC%21R*) 9IH/.@1$@"+$*L=NB"8<XX3OW4QF8>4-:I46];4F\K:J_]
M_9!#;'C?-XV!&_H2L=^8V5\N#H^FJQO+ 24=]QIT>,@/[E9'Z+)G/4F1RV7^
M2!1RM9_%VFQ!, X"$@+I0PD0\Q- @SA2GT4J.4=^DEH6DSS>S]2HNB5FXZ)=
M591LO.TL3RY.86O&LPX0&Y@C6Q*N?=?=!WN=@<%5S<@3O8Q;,+);U8-JD6<>
M[VE#'F3+>:OVY6I3,9/(%RCD ? Y10"E/@4T0A0D<8JE]M-EL56LY\F>ID8*
ME^7/.@VHH;WE J:AK:7#E%A77B.F0UOI'!*N+)V3_8QKIYQ3]\#*./O"0 66
MBE.)_)MT_>O(@N+]HG;CW$O;OQ-Y,..Q$ E)?("KC)M4_40B&0&?!E0FDJ9"
M&F78?1WQIT9>:^'X."5MW'X*9@PYW0$>^MC2H$Q-<:9.S:82S08$G>.PAN%(
M39K="+41B]$,,H9CE9UQ*_P$PM>&'ACK4C+#2-%OO?PHRK>D>+C+E\^9VMZ_
M>?FUT(40FSPMB_MKIK;Q==[4-(A%0)4Y[9,T4C9U@ ".40"".$8\)2P11-I$
M(IAW;;5.C1"MH"3WF!+=>VIDU[PEUW)[9".XW8)E,19FB\TP" ^\4&APM=3>
M70O<[[7DBNQ_\#;">]?G8;:F=GO$'-&R1<>C4JH](/MTV*.%OCZ;RD8517E3
M;WVUP_@LD#A$,9$@"-) YZ5, 0UA#,*0PL!/TXA).5.L2I?FWIH'O=A,GG9?
M0WH<UD*NCP&N/*[DM/7./(23(X01D0+X7.HR0E2 E,0!T,D_481@PF!JLP1<
M".9XD6G9'J"70VG&X!<"-#!5;SZSF_5G]J[K,^OASGI2>V=NK(<]C.R^>E+%
M0[?5TX]>XN7^85D4];7.HLP6JRJ^5=F9E2GZ1LAE+NKGOI!O^AZHS(GJ0[%W
M_E+E6_BH%%5O*J553_=K(6=AB&/.401XS)%.^IGHHL"*?B6F$0D@]65B1Q6#
MR3HURM%*>K329LTWWO=4+(3,RA\\_0TI/JI<RDNM9A^G^V'&W)33)C&2@W-C
M-4+?:SV;0=NJZFUU70]T\WRE;E5JMZ6>M];/=:3 H(/@--)@&$E?(5)A4,B/
M1SH,VV7/<WI]5?VPG*LWBKJ$[B8^D/HI@:$(@4]0#)"/*$BY'P+&12+#6(8X
MLDO5=K*KJ9U_MR7]Y[_@ ";_ZHE*8LN3[]/@&IY2.X%LZ!/EEI#_LJYA?EV6
M>4979>7]KU.LD+Q.->\^+O,\2*Z.;$]W-.[QZEF%#XY"S[_1TQ4H%T\DXXTI
MO'9,K9WXUU?689SZG!$..$8^0%QM5@FC 9!Q0B"1DH6^U=V<09]3(Y1&Y(TW
M0,NCGM42]\JY8H*^&=$XQG1@QEG#V8C;<BJO)1[ C\ "(%?N108]CNMJ9 [!
M@=N1Q:L]79 >EWF9_:-QAMP<:NH:OSJ:2&>L6*X693'C,$@2B@5( X8!DCP&
ME$D)8A@+14VI0()9>209=CPU2FK+K4,T]<&DQQMIJQFUO4AA6AE+#R;3\3#C
MIR%0'IBD]@&N<M:\+XI5Y?M825[!O)'=H=.3)5JN?*!,NQW7)<H2C ,/*=OW
MW:3 V48>8Y1"Y@<<!%C?G2#B@S0*?!!ADDAE2!$27Y0#9[(!Y!]OOG@?;C]_
M]NYN/GF?_^?UIYO+,M_8!G,[ 6I@ECF6^V:08.NS8 R4_N:50I_/JGLN <ZE
M@<BZ7/DOY+^6^=M542X?U72KXJV8@!+'+ *8$P@0Y!C@T!<@A$BDT"=4ID:'
M,L>;GQH#K(6S"GL[@5SWG+\<CX$GNBD4QA.[6^.NV:S>;,UD];?M+#[1Z"A3
MMUNA]7P]\U3/4U3V(/AJ+F[E<8>R5MKT0J<YJ#W1E"WX6/]N+]>('\8!CP@'
M81Q2M>*K^4W#, ",IV'"L,!18)7ZTJUX4R.)M7;:R&YGD9'>S>/3?/DBQ$XU
M#,N-C..A-3SW?;4!&_JLN#56'0[&.^-UY6U4]%HZ#II:9I@!<'4.[5:X<<^N
M!P'VX+Q[F%YZ+@ZKIZ=YY7!,YF_(O(Z]$Z*51;78\@.*F0@(2P'$D:+^4*0
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M S@<L5]73Z/REH'*^XQC\DK?0[)KSM674[Q5/][F7Y9?%S.$ ^CK-+<QQ2%
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M(HFD )A"71Q)_42(ST$"20*9( &61@ES;#J=&OUN9*[RB6\RG:S%-KFZ[#\
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M%!'?*D[F;(]3(^&U>-Y3+9]MJMES )N1J5/8!J;)M:S>]VMI?] .+!L@[\X
MV2,WK2$XSE+5GNMOY,RUANH?)K(U?;%GTH2U ?J+:EU9G_K 4\?\_;I84IT.
M6W?Q?O&T*HM/0NN:S;/J/%3_=97GV>+^#2FR8A,:6+6EC,= 1EPQ$J5"  2A
M #B@&,1!3 B),,>1F-7>PY]+DI=FO#2(K#:3<E_BX>;G&W&?+1;ZY)?6]>,L
M<S$,,JH)2C +* 5I$&"U)4 88"A3D*A_"#'4Z3F#9E1O%OQ/-:9K>0>\;ZX/
M\B<TG&:KVJL/T, KX?88Y<IKJ5@'KK>5]&HMO5TUK[R-GEZE:"O&O6[68>J.
M(8?"56:/060<-_''D# ?Y 49M#-'+IS;BS(XBQ,6BH1(D(J@2M(L $&^!#01
MDE/",3;+L6C2V=3V&;M^A[D2]DK'0#7B7NBUV0;9\$#;$71#GV$?>&M>>7?G
M4;O<4?,('$,Y:;:[>ET'S2-*GW7.//;.R)%.==[)6WG->56,E,SK+(G7J_)A
MF6?_$'S&HS01C/H@E:%B'B8AH!(3 !,N_03'F)%PE."F\[).C;BVDNJCZDW)
M02^O2QYQ3R[S.A^E+@P^?M23P>B;4>)$QG1@1G40VU3KJ\_!6]]&DYATJ_,$
M0IG,!^:UHY<,)/US!"R90^XL1LFBRWX+TUV^Y"M6_D:T+.7+-6/YBLQGV*=8
M(#\"/HD)0 DCRI"5" 0QA(0BP@6/[ ^JCG<VT9.F^D!"1_73S:%3S]C^$R"'
M1 8P$A%(PC %2*8I()#Y( PC1 4GDOO0]MS(%<3#'_RT +X@;<():,U6Q<O!
M&GI!TWZNB@8J5Y>;;Z4"2B]9M=C>6FZO$=S=JM0-C*,%Y40GHZX%W8KNT_B9
MIR^LBZE3H18/@O]MN>1[U6$3'"91K$Q\S!@#*&48T$#1A6((+N-(4$FL'&4-
M^IR:J;Z6U+O7HO8LFMD!L>E=IE/@!K_-W%3@W<!7"3Q&"=[S"+FNOMG1X^N4
MXSP/P<GZG :O]J.;ZV>2S?7IZ<_+_#.9BVVR>>W?_PLIF[]]5O;.7#1_?WE'
M2C'S<<(H0@PHFP4"%/$04(Y"P"+)@D1RS'0(Z;(D<S,6ZB^*%3EM!!INHGW1
M?=AQT@7C8$95XZ [,(/M5:NX\C9: ;G,@=;KREO+KOYU7A&4J VF6K/-/WM:
MM[9_L#O2NQQK1UQX@2"C4N3E@.TSIX,6>Q)J*TW]K=Q/8C_C?A '241 D"B#
M#3$I 6$H #YF,58V79!@86.Z=7<W-:NM+:VV-[)MA0=2"6Q)FMU8&Q*C,P0'
M)K]]\/;+8SBTVLPP<452W9V-2T1&BA^0C=E;_0CEAN3ZL*FX$_GZ4#!C,Y]
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M-"JYG%=XGT,,WNA[947*:AM>7<?.&"=IFHH8^#+0Z?L3KJPA" %/I.8&D>+
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M[3VCX"\?,K<=E'$'8F#J.5KK;Q>C=E6/R=5V4 9M 1X.VE A]Y<K-&XX?C
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MZ\"SU-Z(;@V,C(5O(P?MKZV=46.H;8O^TQ_5&/\<[>(-=_9&?S86AZR",>"
MA"J8,82*X];6&!#D@S(<0\KJ'4A@)#^P'_71VR]JJ?1\,Q.:QT3&$#".S,2A
M&3*K!/-/B<VDD2/!*?9JU7!"SM1HOSEZ_HE7^OT<V3?&?/8E/6S8#U\^/X6O
M\TG_I:@-?Y1OD3$J;H_M?ZJU#!B!?0:'< ?R1Z6,?>+>9>J1(_7.R_U885UL
M9E_5HV6H7]7JL6#?GN:"+9HNP;'*$B830!AD $,E 5&2 (725,193,W_7#BA
M4\K4&*%6U#88V:GJV92Y&]9N*@@&UM '"U[P.#. D_E=W[]Y0.O;-__:???=
MSQ[EJW<RK_GFW2Z^-.6UKHSZ#V;S #>OV_KS>]F2(I-,Z!@!G2.[J%0<4&9<
M!2Z1CN,$X81X!5+[*C UGJC*^:_M*O"+6JOBNXKTJHB:ZKVU-=[K0>]Q<7,L
MAD1[Q-W&/71?=WT^1DI4]4,O>%JJH_AW2D+U ^=TRJGG<_J66J]C$,OXBGM6
MW!5?-S;PN#R@N5=%&7(QB[&"G! $<FWS^IF"@-M@-IY+E$K*M!!>90S=Q$Z-
M[+9:-]&#WUC3G<G&5LG58L&*=616K56<E6>8E>-8N%%=>(0')K@=N'7TE='9
MO,I1I75]D&OTKJ*R0I:#]P$J6)UX)Z$C%Y#W >*PLKS7W9=LVY3/M>[@=J>7
M9(ICHA*0<*(!5C0!'&EFSWIQ)A.AN-L2[8R<J?%1O0NQU=-E.]8+5Y_MFHO0
M&F>[Q@NHGKLU)V$(NEMS*.4==FM.FGI\M^;TY3W7;D=+<K3JN/SRNKND+O-R
M_1<K9%VPXU?K5JUOE_=E-';9SF8FA8),$P4RS3* =<+,\B[E -(T9BG+TY0R
MK^5=>!VG1D*EBF:"[AU=/L0X.BX'WW=TAEXQMJH<M>UKESJR1WQ'JR%9*YLZ
M2.NKJ+*TS%8K;;VJVH8%7%L.-Q2AEI\#:#CN"G4XB \6L0.*ZAMA(LO*OFQQ
MS^;R=OF!?9MOV*(NB"HRE$F-*(AUF@ <4T/[4FN@.!2*" D9\5K>=DJ;&H'O
ME(VLML!\Y+6^OC$<71"[!F,$ F[PJ(I3F W1%L0%E&"1#5VR1@Y1<##[,-;
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M&2?$C.QD=!M[Z&.<N?ZR(\=RSW==UI.IMW^;UU@*29B&&.2$YF;Y(5) ),X
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M*B%K?Y\6-GX1\+.&'ZT&?OZN?F32:CE2]3F]?MD\K0J;%#<C6<Q8FG- !64
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MC&E"$PASY=0=R$78U C-*EF%KMF_J)VZGM%K7?BZL5@HU(9>]S6 E7]I:3I
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MPQ?^8/4UO 7W;'6\:[!\O:Q2])]6"W/_^J9LF3##*H]U2@D092OC).& 9D0
ME$,M>!JG&'&?'I/G!'K-%B/TG:SR3A8[K<L0Y'5+[V:OL^HQX=G)^!S\;K-
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M3# *Y^VX_6VB<&JU_R^+PGD[&.-'X>S)]YOYUL5F=OVLBKE@C1NG=$QPGFG
MN6VVD>82,(8%$"0E&%)$1.94[/#PT5.;/1KMW&:)(U!U\_AE  S,M(UB ;W9
MT_9V,92YJ\5.YE\[9CKRP%&XX[0AS=?=<468PO.&#N;B;O.DBH_SM5BLUB]F
M\+=%W'B,8P4Y!T@@"3#-.>"(YR"!)(XEX;F 7FM9+^E3^XK_H>:/3W9SG7U7
M!7M4567!=;1ZV:PW;%F6]GVQCL)\&0FV$"\+0\'F9\N^U0C[C5DFF4XPA4!
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M)!ZE,E<Y 7EFPRW37 ,*809(BA+$(%<8.K5X._KTJ='S3C^_)-;CT'43X\6
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ME5<,7$8#1F1F1,#@<;^E?^UUVRF^XV/+W877R:)_]3U]#O-/N#EO=5YIQU,
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M?7S&]3218WV-F7TZ:U]_[$':;#_ R2%[;MM4HM610Q)^$^TIB#)$T#QPK41
MXUIG"AVBY_;U$Q"2]=%R\]J\B7'?X7(SU&@23.;HZWKDOEXXL@P^TZ(,V48T
MPIO"6ENR[2@;^UBJ,7(>/J!JHIX._*SK7)V.S7IVLOZ\6$[_&_,DN"2-EQY0
MU^$GI7#PQFN2FD%=QV9)^="DB/W!=I.BL<^S#@JRO=31*;A>KU8GQ$F),A6!
M=6**C;1,<H @&0.FJKL:;9'V$, ZI6;LTZX10+6#&CH%U-4A?RIP7RC: 2]2
M 46Q+43-(F3M'(FHCA)NG2'U"$EC'VV- *U=%=(!OJY<+-R[P1NO-,DG01::
M-GBA:SOJ+$%KSG,V3BG3^CAU"[+&/M8:&&>M%=,7UF[M\[5QC=-:@,VZFF4C
M(;*H0/O &4DK%?O0//$],;:3SS7@F=?AL+67(GK$U-DVCYPG)Q-"DJZ>M0@-
M&ZY$R?630JNCM;=U#RGC)E8='DL[**!''%W=TX5!:;7CX&QRH*)TX J7F^0P
M5A*+.3<?SK/O\.K!DJH.CZA=5?$3S2*LI8Z+V337/?Y"P*M%.:OXH)^&FK%X
MY3ZUWJ3N=;2ZXRN'.G9M(8%&1[*G5]471%R"VG$=//-0,'E04D@(1EG(3 67
MC'8BM,ZLO(>4_>\:SQ[X<5/1@4A!B[<95,BU/DT'B*H@%.\5"X%'90<;Z?AQ
MZZJ:P0Y26^C[]@7CSA(><3=<+=>U,7L^26N*.'#Y=9KPV??I:I(HG"";GD$(
M"FT53PI\(<ON%3IK(A=D>+=!"+W@"CKHNTMDW/?N3@[9=]#CHJ%0^P#%YD[S
ME(/5R\5QF,XGL>BL33" )3+:Z9,%GV4$:;0E)C1NV=QL.V3<)F <>+31Z6V
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MZ56^UF'^:4K,7'C6OR\6^=MT-KO!HC6Z8(H*;$@)5"H%?+8.7+*E&&F*2V9
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MRH=8(+*(H!)+M>U*!F988DY$+6YV'=VI$_'%"T=L6-UVR]I=C#WH_@RR!BD
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M3T4VN]T8S$5__NP-N9.O/OS[JU<?7QS]\>[H;:O^ZUL^N;%[O L_>SJWFWY
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M':)EHTG:,*7D:AAH;5ITI%,Q!@Y"%I>MH CC;FS5'"\]Q.2'2_@)R.S![@Y
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MR>-W571\8@L+:(($AH+X%RW%^X8'"$(;7DHH++9>W[SUX7K*P@Z!N%9R.0W
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M&[<EZD2G-W2H0P=#YI1U:,^94R(C)A8E%%>KG+,4$)U0(+1C5CL9H]"]:-2
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M*&LD!*\EV%@')B<I4S][U%\]MWK10](11Y9]+V@?IA2P*!G)1 A(K&[5S+R
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MAAD10TY/^3KW_N31Q7ZHI.:MV#:VS.EZ75Y^KM9Q<WBE4(;H/= I%2AO-+A
M5ZH@]C ?."\Q;B7SNS]YO SD #(_B&T=!.L;EER52B)/R4@.S&@&2H=:JD;A
M6T9?!_0J-*ZURWWK .,E(]M"XW#NCFT.KB[#65ZU_5Z59LL8'9(94XX@K7CM
M)H]*0V!,>2ZR3O')F/?A'S_.EHB!#,/A#.S .CS@1%^GEB3C7B7,Y"(9^D,D
M/RG2[X%(BOSIJ%"GULVM3YUIW/QR\[!C$%%T *U]$HNX<KZY@E)2(1+)J7(L
M>L!0= BVZ.):3P0YN2QQ6YPTR ;O(K3AL\&;OU'_4+<K_N__]?\!4$L#!!0
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MV>4KM[.*O_ZBF+NR=OY?4$L#!!0    ( $Z%I%::?^L.>P@  $XG   <
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MW'=I'7<#/14;WVJM(FE31WTUA(\0SMQL#OG&YUW%7_>EF?WF[>P_4$L#!!0
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M,FXG721I3HS K>\E=ZFP$\"_.T)FF(^%WCY2QWAL;'[HLT=SK;_VV.].XW\
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M+3(P,C,P,S,Q+FAT;5!+ 0(4 Q0    ( $Z%I%; &"!(5@X  .F-   1
M          "  0I; @!P86-B+3(P,C,P,S,Q+GAS9%!+ 0(4 Q0    ( $Z%
MI%8-E7O>=!T  &,= 0 5              "  8]I @!P86-B+3(P,C,P,S,Q
M7V-A;"YX;6Q02P$"% ,4    " !.A:16)&R5R-A2  !R"P0 %0
M    @ $VAP( <&%C8BTR,#(S,#,S,5]D968N>&UL4$L! A0#%     @ 3H6D
M5O5DH[9]&P  0QP  !0              ( !0=H" '!A8V(M,C R,S S,S%?
M9S$N:G!G4$L! A0#%     @ 3H6D5C6..(4#R0  JV ( !4
M ( !\/4" '!A8V(M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( $Z%I%::
M8<2AK'P  "O0!0 5              "  2:_ P!P86-B+3(P,C,P,S,Q7W!R
M92YX;6Q02P$"% ,4    " !.A:163@S_W'@(   -)P  '
M@ $%/ 0 <&%C8BTR,#(S,#,S,7@Q,'%X97AX,S$Q+FAT;5!+ 0(4 Q0    (
M $Z%I%::?^L.>P@  $XG   <              "  ;=$! !P86-B+3(P,C,P
M,S,Q>#$P<7AE>'@S,3(N:'1M4$L! A0#%     @ 3H6D5@)J(R@2!0  TA(
M !P              ( !;$T$ '!A8V(M,C R,S S,S%X,3!Q>&5X>#,R,2YH
M=&U02P$"% ,4    " !.A:16::Y*N <%  "7$P  '               @ &X
M4@0 <&%C8BTR,#(S,#,S,7@Q,'%X97AX,S(R+FAT;5!+!08     "P + /0"
(  #Y5P0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
